1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Information

  • Patent Application
  • 20180251437
  • Publication Number
    20180251437
  • Date Filed
    July 27, 2016
    8 years ago
  • Date Published
    September 06, 2018
    6 years ago
Abstract
The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.
Description
TECHNICAL FIELD

The present invention relates to 1,3,4-oxadiazole sulfonamide derivative compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof; uses thereof for the preparation of therapeutic medicaments; methods of treating diseases using the same; pharmaceutical compositions comprising the same; and methods for preparing the same.


BACKGROUND ART

Post-translational modifications such as acetylation are very crucial regulatory modules at the heart of biological processes in the cells and are tightly regulated by a multitude of enzymes. Histones are the chief protein components of chromatin and act as spools around which DNA strands. Also, the balance of histone acetylation and deacetylation is a critical role in the regulation of gene expression.


Histone deacetylases (HDACs) are enzymes that remove acetyl groups from lysine residues on histone proteins of chromatin, and are known to be associated with gene silencing and induce cell cycle arrest, angiogenic inhibition, immune regulation, cell death, etc. (Hassig et al., Curr. Opin. Chem. Biol. 1997, 1, 300-308). In addition, it was reported that the inhibition of enzymatic function of HDACs induces the apoptosis of cancer cells in vivo by reducing the activity of cancer cell survival-associated factors and activating cancer cell apoptosis-associated factors (Warrell et al, J. Natl. Cancer Inst. 1998, 90, 1621-1625).


In humans, 18 HDACs have been identified and are subdivided into four classes based on their homology to yeast HDACs. Among them, 11 HDACs use zinc as a cofactor and can be divided into three groups: Class I (HDAC1, 2, 3 and 8), Class II (IIa: HDAC4, 5, 7 and 9; IIb: HDAC6 and 10), Class IV (HDAC 11). Additionally, 7 HDACs of Class III (SIRT 1-7) require NAD+ instead of zinc as a cofactor (Bolden et al., Nat. Rev. Drug Discov. 2006, 5(9), 769-784).


Various HDAC inhibitors are in preclinical or clinical development, but to date, only non-selective HDAC inhibitors have been identified as anticancer agents, and only vorinostat (SAHA) and romidepsin (FK228) have been approved for the treatment of cutaneous T-cell lymphoma. However, non-selective HDAC inhibitors are known to cause side effects such as fatigue and nausea, generally at high doses (Piekarz et al., Pharmaceuticals 2010, 3, 2751-2767). Such side effects have been reported to be due to the inhibition of class I HDACs. Due to such side effects, the use of non-selective HDAC inhibitors in the development of drugs other than anticancer drugs has been limited (Witt et al., Cancer Letters, 2009, 277, 8-21).


Meanwhile, it was reported that the selective inhibition of class II HDACs would not show toxicity shown in the inhibition of class I HDACs. Also, when selective HDAC inhibitors are developed, side effects such as toxicity, which are caused by the non-selective HDAC inhibition, can be overcome. Thus, selective HDAC inhibitors have potential to be developed as therapeutic agents effective for the treatment of various diseases (Matthias et al., Mol. Cell. Biol. 2008, 28, 1688-1701).


It is known that HDAC6, a member of Class IIb HDACs, is present mainly in the cytoplasm and is involved in the deacetylation of a number of non-histone substrates (HSP90, cortactin, etc.), including tubulin, (Yao et al., Mol. Cell 2005, 18, 601-607). HDAC6 has two catalytic domains, and the zinc finger domain of C-terminal can bind to ubiquitinated proteins. It is known that HDAC6 has a number of non-histone proteins as substrates, and thus plays an important role in various diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders (Santo et al., Blood 2012 119: 2579-258; Vishwakarma et al., International Immunopharmacology 2013, 16, 72-78; Hu et al., J. Neurol. Sci. 2011, 304, 1-8).


The common structural characteristic of various HDAC inhibitors is a structure consisting of a cap group, a linker and a zinc-binding group (ZBG), as shown in the following Vorinostat structure. Many researchers have conducted studies on enzyme inhibitory activity and selectivity by structurally modifying the cap group and the linker Among these groups, the zinc-binding group is known to play a more important role in enzyme inhibitory activity and selectivity (Wiest et al., J. Org. Chem. 2013 78: 5051-5065; Methot et al., Bioorg. Med. Chem. Lett. 2008, 18, 973-978).




embedded image


The zinc-binding group is generally a hydroxamic acid or benzamide derivative. Herein, the hydroxamic acid derivative exhibits a potent HDAC inhibitory effect, but has problems of low bioavailability and severe off-target activity. In addition, the benzamide derivative has a problem in that it can produce toxic metabolites in vivo, because it contains aniline (Woster et al., Med. Chem. Commun. 2015, online publication).


Accordingly, there is a need for the development of selective HDAC 6 inhibitors for treatment of diseases such as cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders, which have a zinc-binding group with improved bioavailability and, at the same time, cause no side effects, unlike non-selective inhibitors that cause side effects.


DISCLOSURE OF INVENTION
Technical Problem

It is an object of the present invention to provide 1,3,4-oxadiazole sulfonamide derivative compounds having selective HDAC6 inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof.


Another object of the present invention is to provide pharmaceutical compositions containing 1,3,4-oxadiazole sulfonamide derivative compounds having selective HDAC6 inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof.


Still another object of the present invention is to provide methods for preparing the novel compounds.


Still another object of the present invention is to provide pharmaceutical compositions for prevention or treatment of HDAC6 activity-associated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities, which contain the above compound.


Still another object of the present invention is to provide the use of the compounds for the preparation of therapeutic medicaments against HDAC6 activity-associated diseases.


Yet another object of the present invention is to provide methods for treating HDAC6 activity-associated diseases, which comprise administering a therapeutically effective amount of the pharmaceutical compositions containing the compounds.


Solution to Problem

The present inventors have discovered 1,3,4-oxadiazole sulfonamide derivative compounds, which have histone deacetylase 6 (HDAC6) inhibitory activity, and have found that these compounds can be used for the inhibition or treatment of histone deacetylase 6 (HDAC6) activity-associated diseases, thereby completing the present invention.


1,3,4-Oxadiazole Sulfonamide Derivative Compounds


To achieve the above objects, the present invention provides an 1,3,4-oxadiazole sulfonamide derivative compound represented by the following formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:




embedded image


wherein R1 is —CX2H or —CX3;


R2 is —(C1-C4 alkyl), —(C1-C4 alkyl)-O(C1-C4 alkyl), —(C1-C4)—C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-O—C(═O)—(C1-C4 alkyl), —(C1-C4 alkyl)-NRARB, —(C1-C4 alkyl)-aryl, —(C1-C4 alkyl)-heteroaryl, -aryl, -heteroaryl,




embedded image


wherein at least one H of the —(C1-C4 alkyl), —(C1-C4 alkyl)-O(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-O—C(═O)—(C1-C4 alkyl) or —(C1-C4 alkyl)-NRARB may be substituted with —X or —OH,


at least one H of the —(C1-C4 alkyl)-aryl, —(C1-C4 alkyl)heteroaryl, -aryl or -heteroaryl may be substituted with —X, —OH, —O(C1-C4 alkyl), —(C1-C4 alkyl), —CF3, —CF2H, —(C1-C4 alkyl)-OH, —C(═O)—(C1-C4 alkyl), —C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—(C1-C4 alkyl), —C(═O)—CF3 or —C(═O)—CF2H, and


at least one H of




embedded image


may be substituted with —X, —OH, —O(C1-C4 alkyl), —NRARB, —CN, —(C1-C4 alkyl), —CF3, —CF2H, —(C1-C4 alkyl)-OH, —(C1-C4 alkyl)-NRARB, —C(═O)—(C1-C4 alkyl), —C(═O)—CF3, —C(═O)—CF2H, —C(═O)—NRARB, —C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—(C1-C4 alkyl), —(C1-C4 alkyl)-OC(═O)—CF2H, —(C3-C6 heterocycloalkyl), —(C1-C4 alkyl)-aryl, aryl or heteroaryl, wherein at least one H of the —(C1-C4 alkyl)-aryl, aryl or heteroaryl may be substituted with —X, —OH, —O(C1-C4 alkyl) or —(C1-C4 alkyl);


R3 is —H, —(C1-C4 alkyl), —(C1-C4 alkyl)-0(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl), -aryl, -heteroaryl,




embedded image


wherein at least one H of the —(C1-C4 alkyl), —(C1-C4 alkyl)-O(C1-C4 alkyl) or —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl) may be substituted with —X or —OH,


at least one H of the -aryl or -heteroaryl may be substituted with —X, —OH, —O(C1-C4 alkyl), —(C1-C4 alkyl), —CF3, —CF2H, —(C1-C4 alkyl)-OH, —C(═O)—(C1-C4 alkyl), —C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—(C1-C4 alkyl), —C(═O)—CF3, —C(═O)—CF2H,




embedded image


at least one H of




embedded image


may be substituted with —X, —OH, —O(C1-C4 alkyl), —(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —C(═O)—O(C1-C4 alkyl) or —(C3-C6 heterocycloalkyl);


R4 is —CX2H or —CX3;


L1 to L4 are each independently —C(0-C2 alkyl)-;


Z1 to Z8 are each independently N or CRZ, wherein at least three of Z1 to Z4 or Z5 to Z8 may not be simultaneously N, and RZ is —H, —X or —O(C1-C4 alkyl);


Z9 and Z10 are each independently N or S;


Y1 to Y3 are each independently —CH2—, —NRC—, —O— or —S(═O)2—;


Y4 to Y7 are each independently —CH2—, —NRD— or —O—;


Y8 is —C(═O), —CH2— or —NRE—;


Y9 and Y10 are each independently —NRF— or —S(═O)2—;


RA and RB are each independently —H, —(C1-C4 alkyl), —(C1-C4 alkyl)-aryl, —C(═O)—CF2H or —C(═O)—O(C1-C4 alkyl);


RC to RE are each independently —H, —(C1-C4 alkyl), —(C1-C4 alkyl)-OH, —(C1-C4 alkyl)-O—(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —C(═O)—O(C1-C4 alkyl), —C(═O)—(C3-C7 cycloalkyl), —(C1-C4 alkyl)-C(═O)—(C2-C6 heterocycloalkyl), —S(═O)2—(C1-C4 alkyl), —(C1-C4 alkyl) aryl, —C(2-C4 alkenyl)-aryl, —(C1-C4 alkyl)-heteroaryl, -aryl, -heteroaryl,




embedded image


wherein at least one H of the —(C1-C4 alkyl)-aryl, —C(2-C4 alkenyl)-aryl, —(C1-C4 alkyl)-heteroaryl, -aryl, -heteroaryl,




embedded image


may be substituted with —X, —OH, —O(C1-C4 alkyl), —(C1-C4 alkyl) or —CF3;


Y11 is —CH2—, —NRF—or —O—;


RF is —(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl)-OH, —C(═O)—(C3 C7 cycloalkyl) or —S(═O)2—(C1-C4 alkyl);



custom-character is a single bond or a double bond, provided that custom-character is a double bond, Y1 or Y2 is —CH—;


a to e are each independently an integer of 0, 1, 2 or 3, provided that a and b may not be simultaneously 0, and c and d may not be simultaneously 0; and


X is F, Cl, Br or I.


According to preferable embodiment of the present invention,


R1 is —CX2H or —CX3;


R2 is —(C1-C4 alkyl), —(C1-C4 alkyl)-O(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-O—C(═O)—(C1-C4 alkyl), —(C1-C4 alkyl)-NRARB, —(C1-C4




embedded image


wherein at least one H of the —(C1-C4 alkyl), —(C1-C4 alkyl)-O(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-O—C(═O)—(C1-C4 alkyl) or —(C1-C4 alkyl)-NRARB may be substituted with —X or —OH,


at least one H of the —(C1-C4 alkyl)-heteroaryl, -aryl or -heteroaryl may be substituted with —O(C1-C4 alkyl), —(C1-C4 alkyl) or —(C1-C4 alkyl)-OH, and


at least one H of




embedded image


may be substituted with —X, —OH, —NRARB, —CN, —(C1-C4 alkyl), —(C1-C4 alkyl)-OH, —(C1-C4 alkyl)-NRARB, —C(═O)-NRARB, —C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—(C1-C4 alkyl), —(C1-C4 alkyl)-OC(═O)—CF2H, —(C3-C6 heterocycloalkyl), —(C1-C4 alkyl)-aryl, -aryl or -heteroaryl, wherein at least one H of the —(C1-C4 alkyl)-aryl, -aryl or -heteroaryl may be substituted with —X, —OH, —O(C1-C4 alkyl) or —(C1-C4 alkyl);


R3 is —H, —(C1-C4 alkyl), -aryl, -heteroaryl,




embedded image


wherein at least one H of the —(C1-C4 alkyl) may be substituted with —X or —OH,


at least one H of the -aryl or -heteroaryl may be substituted with —X, —O(C1-C4 alkyl), —(C1-C4 alkyl), —CF3, —C(═O)—(C1-C4 alkyl),




embedded image


and


at least and H of




embedded image


may be substituted with —(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —C(═O)—O(C1-C4 alkyl) or —(C3-C6 heterocycloalkyl);


R4 is —CX2H or —CX3;


L1 to L4 are each independently —(C0-C2 alkyl)-;


Z1 to Z8 are each independently N or CRZ, wherein at least three of Z1 to Z4 or Z5 to Z8 may not be simultaneously N, and RZ is —H, —X or —O(C1-C4 alkyl);


Z9 and Z10 are each independently N or S;


Y1 to Y3 are each independently —CH2—, —NRC—, —O— or —S(═O)2—;


Y4 to Y7 are each independently —CH2—, —NRD— or —O—;


Y8 is —C(═O), —CH2— or —NRE—;


Y9 and Y10 are each independently —NRF— or —S(═O)2—;


RA and RB are each independently —H, —(C1-C4 alkyl), —(C1-C4 alkyl)-aryl, —C(═O)—CF2H or —C(═O)—O(C1-C4 alkyl);


RC to RE are each independently —H, —(C1-C4 alkyl), —(C1-C4 alkyl)-OH, —(C1-C4 alkyl)-O—(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —C(═O)—O(C1-C4 alkyl), —C(═O)—(C3-C7 cycloalkyl), —(C1-C4 alkyl)-C(═O)—(C2-C6 heterocycloalkyl), —S(═O)2-(C1-C4 alkyl), —(C1-C4




embedded image


wherein at least one H of the —(C1-C4 alkyl)-aryl, —C(2-C4 alkenyl)-aryl, —(C1-C4 alkyl)-heteroaryl, -aryl, -heteroaryl,




embedded image


may be substituted with —X, —OH, —O(C1-C4 alkyl), —(C1-C4 alkyl) or —CF3;


Y11 is —CH2—, —NRF— or —O—;


RF is —(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl)-OH, —C(═O)—(C3-C7 cycloalkyl) or —S(═O)2—(C1-C4 alkyl);



custom-character is a single bond or a double bond, provided that custom-character is a double bond, Y1 or Y2 is —CH—;


a to e are each independently an integer of 0, 1, 2 or 3, provided that a and b may not be simultaneously 0, and c and d may not be simultaneously 0; and


X is F, Cl, Br or I.


According to more preferable embodiment of the present invention,


R1 is —CX2H;


R2 is —(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-NRARB, -heteroaryl,




embedded image


wherein at least one H of the —(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl) or —(C1-C4 alkyl)-NRARB may be substituted with —X or —OH,


at least one H of the -heteroaryl may be substituted with —O(C1-C4 alkyl), —(C1-C4 alkyl) or —(C1-C4 alkyl)-OH, and


at least one H of




embedded image


may be substituted with —(C1-C4 alkyl) or —(C1-C4 alkyl)-OH;




embedded image


wherein at least one H of the -aryl or -heteroaryl may be substituted with —X, —O(C1-C4 alkyl), —(C1-C4 alkyl), —CF3 or —C(═O)—(C1-C4 alkyl), and


at least one H of




embedded image


may be substituted with —(C1-C4 alkyl);


L1 and L3 are each independently —C(0 alkyl)-;


L2 is —C(1 alkyl)-;


Z1 to Z4 are each independently N or CRZ, wherein at least two of Z1 to Z4 may not be simultaneously N, and RZ is —H or X;


Y1 is —NRC—, —O— or —S(═O)2—;


Y2 is —CH2— or —NRC—;


Y6 and Y7 are each independently —O—;


Y8 is —CH2—;


RA and RB are each independently —(C1-C4 alkyl);


RC is —(C1-C4 alkyl), —(C1-C4 alkyl)-OH, —C(═O)—(C1-C4 alkyl), —S(═O)2—(C1-C4 alkyl) or




embedded image


wherein at least one H of




embedded image


may be substituted with —(C1-C4 alkyl);


Y11 is —NRF— or —O—;


RF is —(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl)-OH or —S(═O)2—(C1-C4 alkyl);



custom-character is a single bond;


a, b and e are each independently an integer of 0, 1 or 2, provided that a and b may not be simultaneously 0; and


X is F, Cl, Br or I.


According to particularly preferable embodiment of the present invention,


R1 is —CF2H;


R2 is —(C1-C4 alkyl), —(C1-C4 alkyl)-NRARB,




embedded image


wherein at least one H of the —(C1-C4 alkyl) or —(C1-C4 alkyl)-NRARB may be substituted with —X or OH, and


at least one H of




embedded image


may be substituted with —(C1-C4 alkyl);


R3 is -aryl or -heteroaryl,


wherein at least one H of the -aryl or -heteroaryl may be substituted with —X or —C(1-C4 alkyl);


L1 and L3 are each independently —(C0 alkyl)-;


L2 is —(C1 alkyl)-;


Z1 to Z4 are each independently N or CRZ, wherein at least two of Z1 to Z4 may not be simultaneously N, and RZ is H or X;


Y1 is —NRC—, —O— or —S(═O)2—;


Y2 is —NRC—;


RA and RB are each independently —(C1-C4 alkyl);


RC is —(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —S(═O)2—(C1-C4 alkyl) or




embedded image


wherein at least one H of




embedded image


may be substituted with —(C1-C4 alkyl);


Y11 is —NRF— or —O—;


RF is —(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl), —C(═O)—(C1-C4 alkyl)-OH or —S(═O)2—(C1-C4 alkyl);



custom-character is a single bond;


a, b and e are each independently an integer of 0, 1 or 2, provided that a and b may not be simultaneously 0; and


X is F, Cl or Br.


The specific compounds represented by formula I are shown in Table 1 below:











TABLE 1





Ex.
Comp.
Structure

















1
11044


embedded image







2
11045


embedded image







3
11078


embedded image







4
11088


embedded image







5
1089


embedded image







6
11120


embedded image







7
11121


embedded image







8
11128


embedded image







9
11129


embedded image







10
11133


embedded image







11
11151


embedded image







12
11152


embedded image







13
11153


embedded image







14
11154


embedded image







15
11155


embedded image







16
11156


embedded image







17
11167


embedded image







18
11168


embedded image







19
11169


embedded image







20
11170


embedded image







21
11171


embedded image







22
11172


embedded image







23
11173


embedded image







24
11174


embedded image







25
11175


embedded image







26
11176


embedded image







27
11177


embedded image







28
11178


embedded image







29
11179


embedded image







30
11180


embedded image







31
11181


embedded image







32
11182


embedded image







33
11183


embedded image







34
11184


embedded image







35
11186


embedded image







36
11190


embedded image







37
11191


embedded image







38
11192


embedded image







39
11193


embedded image







40
11194


embedded image







41
11195


embedded image







42
11196


embedded image







43
11197


embedded image







44
11216


embedded image







45
11217


embedded image







46
11218


embedded image







47
11219


embedded image







48
11220


embedded image







49
11221


embedded image







50
11222


embedded image







51
11225


embedded image







52
11226


embedded image







53
11227


embedded image







54
11229


embedded image







55
11230


embedded image







56
11231


embedded image







57
11248


embedded image







58
11249


embedded image







59
11250


embedded image







60
11251


embedded image







61
11252


embedded image







62
11253


embedded image







63
11254


embedded image







64
11255


embedded image







65
11256


embedded image







66
11271


embedded image







67
11272


embedded image







68
11273


embedded image







69
11274


embedded image







70
11275


embedded image







71
11276


embedded image







72
11277


embedded image







73
11278


embedded image







74
11279


embedded image







75
11280


embedded image







76
11281


embedded image







77
11282


embedded image







78
11283


embedded image







79
11284


embedded image







80
11287


embedded image







81
11288


embedded image







82
11289


embedded image







83
11290


embedded image







84
11291


embedded image







85
11292


embedded image







86
11323


embedded image







87
11324


embedded image







88
11338


embedded image







89
11345


embedded image







90
11346


embedded image







91
11347


embedded image







92
11348


embedded image







93
11350


embedded image







94
11351


embedded image







95
11352


embedded image







96
11353


embedded image







97
11354


embedded image







98
11355


embedded image







99
11366


embedded image







100
11367


embedded image







101
11368


embedded image







102
11372


embedded image







103
11373


embedded image







104
11377


embedded image







105
11386


embedded image







106
11387


embedded image







107
11388


embedded image







108
11389


embedded image







109
11390


embedded image







110
11392


embedded image







111
11402


embedded image







112
11403


embedded image







113
11404


embedded image







114
11405


embedded image







115
11406


embedded image







116
11411


embedded image







117
11412


embedded image







118
11426


embedded image







119
11427


embedded image







120
11428


embedded image







121
11429


embedded image







122
11430


embedded image







123
11431


embedded image







124
11432


embedded image







125
11433


embedded image







126
11447


embedded image







127
11448


embedded image







128
11451


embedded image







129
11452


embedded image







130
11460


embedded image







131
11461


embedded image







132
11462


embedded image







133
11463


embedded image







134
11497


embedded image







135
11501


embedded image







136
11502


embedded image







137
11503


embedded image







138
11504


embedded image







139
11505


embedded image







140
11506


embedded image







141
11507


embedded image







142
11508


embedded image







143
11514


embedded image







144
11518


embedded image







145
11520


embedded image







146
11521


embedded image







147
11522


embedded image







148
11539


embedded image







149
11540


embedded image







150
11541


embedded image







151
11552


embedded image







152
11553


embedded image







153
11554


embedded image







154
11564


embedded image







155
11565


embedded image







156
11566


embedded image







157
11567


embedded image







158
11573


embedded image







159
11582


embedded image







160
11583


embedded image







161
11588


embedded image







162
11589


embedded image







163
11605


embedded image







164
11606


embedded image







165
11625


embedded image







166
11628


embedded image







167
11629


embedded image







168
11630


embedded image







169
11631


embedded image







170
11632


embedded image







171
11633


embedded image







172
11634


embedded image







173
11636


embedded image







174
11637


embedded image







175
11638


embedded image







176
11639


embedded image







177
11645


embedded image







178
11646


embedded image







179
11647


embedded image







180
11648


embedded image







181
11655


embedded image







182
11656


embedded image







183
11657


embedded image







184
11658


embedded image







185
11663


embedded image







186
11665


embedded image







187
11668


embedded image







188
11669


embedded image







189
11675


embedded image







190
11676


embedded image







191
11677


embedded image







192
11678


embedded image







193
11679


embedded image







194
11680


embedded image







195
11681


embedded image







196
11682


embedded image







197
11683


embedded image







198
11684


embedded image







199
11685


embedded image







200
11686


embedded image







201
11687


embedded image







202
11688


embedded image







203
11689


embedded image







204
11690


embedded image







205
11691


embedded image







206
11692


embedded image







207
11693


embedded image







208
11694


embedded image







209
11695


embedded image







210
11696


embedded image







211
11697


embedded image







212
11698


embedded image







213
11699


embedded image







214
11700


embedded image







215
11705


embedded image







216
11706


embedded image







217
11707


embedded image







218
11708


embedded image







219
11709


embedded image







220
11710


embedded image







221
11711


embedded image







222
11712


embedded image







223
11717


embedded image







224
11718


embedded image







225
11719


embedded image







226
11721


embedded image







227
11722


embedded image







228
11723


embedded image







229
11724


embedded image







230
11725


embedded image







231
11726


embedded image







232
11727


embedded image







233
11728


embedded image







234
11729


embedded image







235
11730


embedded image







236
11731


embedded image







237
11732


embedded image







238
11733


embedded image







239
11734


embedded image







240
11735


embedded image







241
11736


embedded image







242
11737


embedded image







243
11738


embedded image







244
11739


embedded image







245
11740


embedded image







246
11741


embedded image







247
11742


embedded image







248
11743


embedded image







249
11744


embedded image







250
11745


embedded image







251
11746


embedded image







252
11747


embedded image







253
11748


embedded image







254
11749


embedded image







255
11750


embedded image







256
11751


embedded image







257
11752


embedded image







258
11753


embedded image







259
11754


embedded image







260
11755


embedded image







261
11756


embedded image







262
11757


embedded image







263
11758


embedded image







264
11759


embedded image







265
11760


embedded image







266
11761


embedded image







267
11762


embedded image







268
11763


embedded image







269
11764


embedded image







270
11765


embedded image







271
11766


embedded image







272
11767


embedded image







273
11768


embedded image







274
11769


embedded image







275
11770


embedded image







276
11771


embedded image







277
11772


embedded image







278
11773


embedded image







279
11774


embedded image







280
11775


embedded image







281
11776


embedded image







282
11777


embedded image







283
11778


embedded image







284
11779


embedded image







285
11780


embedded image







286
11781


embedded image







287
11782


embedded image







288
11783


embedded image







289
11784


embedded image







290
11785


embedded image







291
11786


embedded image







292
11790


embedded image







293
11791


embedded image







294
11792


embedded image







295
11793


embedded image







296
11794


embedded image







297
11795


embedded image







298
11796


embedded image







299
11797


embedded image







300
11798


embedded image







301
11799


embedded image







302
11800


embedded image







303
11801


embedded image







304
11802


embedded image







305
11803


embedded image







306
11804


embedded image







307
11805


embedded image







308
11806


embedded image







309
11807


embedded image







310
11808


embedded image







311
11809


embedded image







312
11810


embedded image







313
11811


embedded image







314
11812


embedded image







315
11813


embedded image







316
11814


embedded image







317
11815


embedded image







318
11816


embedded image







319
11817


embedded image







320
11818


embedded image







321
11819


embedded image







322
11820


embedded image







323
11821


embedded image







324
11822


embedded image







325
11836


embedded image







326
11837


embedded image







327
11838


embedded image







328
11839


embedded image







329
11840


embedded image







330
11841


embedded image







331
11842


embedded image







332
11843


embedded image







333
11844


embedded image







334
11845


embedded image







335
11847


embedded image







336
11848


embedded image







337
11849


embedded image











Preferably, the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof may be selected from the group consisting of compounds 11154, 11156, 11168, 11170, 11171, 11172, 11176, 11178, 11182, 11191, 11193, 11197, 11217, 11225, 11227, 11231, 11254, 11256, 11276, 11284, 11287, 11289, 11324, 11345, 11346, 11350, 11352, 11353, 11354, 11355, 11366, 11367, 11368, 11372, 11373, 11377, 11390, 11411, 11412, 11426, 11428, 11433, 11447, 11448, 11451, 11452, 11460, 11461, 11462, 11463, 11497, 11501, 11502, 11503, 11504, 11505, 11506, 11507, 11508, 11521, 11522, 11539, 11540, 11541, 11552, 11553, 11554, 11564, 11582, 11583, 11637, 11638, 11646, 11647, 11665, 11679, 11680, 11681, 11682, 11683, 11684, 11685, 11721, 11777, 11781, 11782, 11803, 11806, 11809 and 11837. More preferably, the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof may be selected from the group consisting of compounds 11154, 11170, 11172, 11178, 11182, 11191, 11197, 11217, 11256, 11350, 11352, 11354, 11355, 11366, 11367, 11368, 11372, 11373, 11390, 11411, 11412, 11426, 11428, 11433, 11447, 11451, 11452, 11460, 11461, 11462, 11463, 11497, 11501, 11502, 11503, 11504, 11505, 11506, 11507, 11521, 11540, 11541, 11552, 11553, 11637, 11646, 11665, 11681, 11683, 11684, 11685 and 11781.


As used herein, the term “pharmaceutically acceptable salt” means any salt that is generally used in the pharmaceutical field. Examples of the pharmaceutically acceptable salt include, but are not limited to, salts with inorganic ions such as calcium, potassium, sodium or magnesium ions, salts with inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid or sulfuric acid, salts with organic acids such as acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid or the like, salts with sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or naphthalenesulfonic acid, salts with amino acids such as glycine, arginine or lysine, and salts with amines such as trimethylamine, triethylamine, ammonia, pyridine or picoline.


In the present invention, preferred salts include salts with hydrochloric acid, phosphoric acid, sulfuric acid, trifluoroacetic acid, citric acid, bromic acid, maleic acid, tartaric acid or the like, and preferred examples of such compounds include compounds 11172 as disclosed herein.


The compounds represented by formula I may contain one or more asymmetrical carbon atoms, and thus may exist in the form of racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers. The compounds of formula I can be separated into such isomers by methods known in the art, for example, column chromatography or HPLC. Alternatively, stereoisomers of the compounds of formula I may be synthesized by stereospecific synthesis using optically pure starting materials and/or reagents of known configuration.


Methods for Preparation of 1,3,4-Oxadiazole Sulfonamide Derivative Compounds


The present invention provides methods for the preparation of the 1,3,4-oxadiazole sulfonamide derivative compounds presented by formula I, streoisomers thereof, or pharmaceutically acceptable salts thereof.


Preferred methods for the preparation of the 1,3,4-oxadiazole sulfonamide derivative compounds presented by formula I, stereoisomers thereof, or pharmaceutically acceptable salts thereof are as shown in reaction schemes 1 to 25 below, and also include modifications obvious to those skilled in the art.




embedded image


As shown in reaction scheme 1 above, the ester moiety of a compound of formula 1-1 is substituted with hydrazine to prepare a compound of formula 1-2, which is then reacted with trifluoroacetic anhydride or difluoroacetic anhydride to prepare a compound of formula 1-3. Then, the prepared compound of formula 1-3 is reacted with 1-methoxy-N-triethylammoniosulfonyl-methaneimidate (Burgess reagent) to yield a compound of formula 1-4 which has an oxadiazole structure. Then, the compound of formula 1-4 is deprotected, thereby preparing an intermediate of formula 1-5.




embedded image


As shown in reaction scheme 2 above, the ester moiety of a compound of formula 2-1 is substituted with hydrazine to prepare a compound of formula 2-2, which is then reacted with trifluoroacetic anhydride or difluoroacetic anhydride to prepare a compound of formula 2-3. Next, the compound of formula 2-3 is reacted with 1-methoxy-N-triethylammoniosulfonyl-methaneimidate (Burgess reagent) to yield a compound of formula 2-4 which has an oxadiazole structure. Then, the methyl group of the compound of formula 2-4 is halogenated, thereby preparing an intermediate of formula 2-5.




embedded image


Reaction scheme 3 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 3-1 is reacted with an amine to yield a compound of formula 3-2, which is then reacted with a compound of formula 2-5 under a basic condition, thereby preparing a compound of formula 3-3.


Compounds that are prepared according to reaction scheme 3 are compounds 11229, 11230, 11231, 11252, 11253, 11254, 11287, 11288, 11289, 11290, 11291, 11292, 11747, 11748, 11749, 11774, 11775 and 11776.




embedded image


Reaction scheme 4 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 1-5 is reacted with any of various sulfonyl chloride compounds (formula 3-1) to yield a compound of formula 4-1, which is then subjected to a substitution reaction with R3-L2-X, thereby preparing a compound of formula 3-3.


Compounds that are prepared according to reaction scheme 4 are compounds 11078, 11121 and 11222.




embedded image


Reaction scheme 5 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 5-1 is subjected to a reductive amination reaction with an amine compound to yield a compound of formula 5-2, which is then reacted with any of various sulfonyl chloride compounds (formula 3-1) to yield a compound of formula 5-4. Alternatively, a compound of formula 3-2 is subjected to a substitution reaction with a compound of formula 5-3 under a basic condition to yield the compound of formula 5-4. Then, the compound of formula 5-4 is reacted with hydrazine to yield a compound of formula 5-5. Next, the compound of formula 5-5 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 3-3 which has an oxadiazole structure. Compounds that are prepared according to reaction scheme 5 above are compounds 11120, 11151, 11152, 11153, 11154, 11155, 11167, 11168, 11173, 11174, 11196, 11197, 11216, 11217, 11218, 11225, 11226, 11227, 11255, 11256, 11271, 11272, 11323, 11324, 11338, 11345, 11346, 11347, 11348, 11350, 11351, 11354, 11355, 11366, 11390, 11411, 11412, 11428, 11429, 11430, 11431, 11432, 11433, 11504, 11505, 11506, 11520, 11521, 11522, 11539, 11540, 11541, 11628, 11636, 11668, 11669, 11739, 11740, 11741, 11742, 11743, 11744, 11745, 11746 and 11750.


In addition, a compound of formula 5-6, which has no oxadiazole structure, is reacted with 1-methoxy-N-triethylammoniosulfonyl-methaneimidate (Burgess reagent) to yield a compound of formula 3-3, which has an oxadiazole structure. Compounds that are prepared according to this reaction scheme are compounds 11044, 11045, 11088, 11089, 11128, 11129, 11133, 11156, 11169, 11170, 11171, 11172, 11175, 11176, 11177, 11178, 11179, 11180, 11181, 11182, 11183, 11184, 11190, 11191, 11192, 11193, 11194, 11195, 11219, 11220, 11221, 11248, 11249, 11250, 11251, 11273, 11274, 11275, 11276, 11277, 11278, 11279, 11280, 11281, 11282, 11283, 11284, 11352, 11353, 11460, 11461, 11462, 11463, 11497, 11507 and 11508.




embedded image


Reaction scheme 6 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 6-1 is subjected to a reductive amination reaction with a compound of formula 5-1 to yield a compound of formula 6-2, which is then reacted with any of various sulfonyl chloride compounds (formula 3-1), thereby preparing a compound of formula 6-3. The compound of formula 6-3 is reacted with hydrazine to yield a compound of formula 6-4, which is then reacted with trifluoroacetic anhydride or difluoroacetic anhydride to yield a compound of formula 6-5, which has an oxadiazole structure.


A compound that is prepared according to reaction scheme 6 above is compound 11186.




embedded image


embedded image


Reaction scheme 7 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 7-1 is reacted with any of various amine compounds to yield a compound of formula 7-2, which is then subjected to a substitution reaction with a compound of formula 5-1, thereby preparing a compound of formula 7-3. The protecting group of the compound of formula 7-3 is removed, thereby preparing a compound of formula 7-4. The compound of formula 7-4 is subjected to a reductive amination reaction or a substitution reaction, thereby preparing a compound of formula 7-5. The compound of formula 7-5 is reacted with hydrazine to yield a compound of formula 7-6, which is then reacted with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 7-7, which has an oxadiazole structure.


Compounds that are prepared according to reaction scheme 7 above are compounds 11367, 11368, 11372, 11373, 11377, 11426, 11501, 11625, 11637, 11638, 11639 and 11794.




embedded image


embedded image


Reaction scheme 8 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 7-4 is subjected to a reductive amination reaction, a substitution reaction or an amide coupling reaction to yield a compound of formula 8-1, which is then reacted with hydrazine, thereby preparing a compound of formula 8-2. Then, the compound of formula 8-2 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride to yield a compound of formula 8-3 or formula 8-4. Next, the compound of formula 8-3 is subjected to a cyclization reaction using a base and a good leaving group, thereby preparing the compound of formula 8-4. The prepared compound of formula 8-4 is deprotected to yield a compound of formula 8-5, which is then subjected to a reductive amination reaction or a substitution reaction, thereby preparing a compound of formula 8-6.


Compounds that are prepared according to reaction scheme 8 above are compounds 1 1447, 11448, 11451, 11452, 11837, 11838 and 11839.




embedded image


Reaction scheme 9 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 8-1 is deprotected to yield a compound of formula 9-1, which is then subjected to a substitution reaction, thereby preparing a compound of formula 9-2. Next, the compound of formula 9-2 is reacted with hydrazine to yield a compound of formula 9-3, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 8-6.


Compounds that are prepared according to reaction scheme 9 above are compounds 11502 and 11503.




embedded image


embedded image


Reaction scheme 10 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 10-1 is subjected to a substitution reaction with a compound of formula 10-2 to yield a compound of formula 10-3, and the nitro group of the compound of formula 10-3 is reduced with zinc, thereby preparing a compound of formula 10-4. Next, the compound of formula 10-4 is reacted with any of various sulfonyl chloride compounds (formula 3-1) to obtain a compound of formula 10-5, which is then subjected to a substitution reaction with a compound of formula 5-1, thereby preparing a compound of formula 10-7. Next, the compound of formula 10-7 is deprotected and subjected to a reductive amination reaction, a substitution reaction or an amide coupling reaction to yield a compound of formula 10-8, which is then reacted with hydrazine to yield a compound of formula 10-9. Next, the compound of formula 10-9 is subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 10-10.


Compounds that are prepared according to reaction scheme 10 above are compounds 11386, 11387, 11388, 11402, 11403, 11404, 11405 and 11406.




embedded image


Reaction scheme 11 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 9-1 is subjected to a substitution reaction with a compound of formula 11-2 to yield a compound of formula 11-3, and the nitro group of the compound of formula 11-3 is reduced with zinc to yield a compound of formula 11-4. Next, the compound of formula 11-4 is reacted with any of various sulfonyl chloride compounds (formula 3-1) to yield a compound of formula 11-5, which is then subjected to a substitution reaction with a compound of formula 5-1, thereby preparing a compound of formula 11-6. The compound of formula 11-6 is reacted with hydrazine to yield a compound of formula 11-7, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic acid, thereby preparing a compound of formula 11-8.


A compound that is prepared according to reaction scheme 11 above is compound 11392.




embedded image


embedded image


Reaction scheme 12 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 12-1 is subjected to a substitution reaction with any of various sulfonyl chloride compounds (formula 3-1) to yield a compound of formula 12-2, which is then subjected to a Suzuki coupling reaction with boron ester, thereby preparing a compound of formula 12-3. The compound of formula 12-3 is subjected to a reduction reaction in the presence of palladium and hydrogen to yield a compound of formula 12-4, which is then subjected to a substitution reaction with a compound of formula 5-1, thereby preparing a compound of formula 12-5. The compound of formula 12-5 is deprotected, and then subjected to a reductive amination reaction with an amine, thereby preparing a compound of formula 12-7. Next, the compound of formula 12-7 is reacted with hydrazine to yield a compound of formula 12-8, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 12-9.


A compound that is prepared according to reaction scheme 12 above is compound 11427.




embedded image


Reaction scheme 13 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a protecting group is introduced into a compound of formula 13-1 to yield a compound of formula 13-2, and the benzonitrile group of the compound of formula 13-2 is substituted with hydroxybenzimide in the presence of hydroxylamine and a base to yield a compound of formula 13-3. Then, the prepared compound of formula 13-3 is subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride to yield a compound of formula 13-4. Next, the compound of formula 13-4 is deprotected to yield a compound of formula 13-5, which is then subjected to a substitution reaction with any of various sulfonyl chloride compounds (formula 3-1), thereby preparing a compound of formula 13-6. The compound of formula 13-6 is subjected to a substitution reaction with a compound of formula 2-5 under a basic condition to yield a compound of formula 13-7. When the oxadiazole ring is open, the compound of formula 13-7 is subjected to a cyclization reaction using a good leaving group under a basic condition, thereby preparing a compound of formula 13-8.


A compound that is prepared according to reaction scheme 13 above is compound 11389.




embedded image


Reaction scheme 14 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, the methyl group of a compound of formula 2-1 is halogenated to yield a compound of formula 5-1, which is then subjected to a substitution reaction with any of various sulfonamide compounds (formula 3-2), thereby preparing a compound of formula 5-4. Next, the compound of formula 5-4 is reacted with hydrazine to yield a compound of formula 5-5, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic acid, thereby preparing a compound of formula 3-3.


Compounds that are prepared according to reaction scheme 14 above are compounds 11518, 11564, 11565, 11566, 11567, 11573, 11605 and 11606.




embedded image


Reaction scheme 15 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 15-1 is subjected to a substitution reaction any of various primary amine compounds to yield a compound of formula 15-2 or formula 15-3, which is then subjected to a substitution reaction with a compound of formula 5-1, thereby preparing a compound of formula 15-4 or 15-5. The prepared compound is reacted with an amine compound (formula 10-2) to yield a compound of formula 15-6, which is then reacted with hydrazine, thereby preparing a compound of formula 15-7. Next, the prepared compound is subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 15-8.


Compounds that are prepared according to reaction scheme 15 above are compounds 11514, 11588, 11589, 11629, 11630, 11631. 11632, 11645, 11647, 11655, 11657, 11658, 11663, 11675, 11676, 11677, 11678, 11679, 11685, 11700, 11705, 11706, 11707, 11708, 11709, 11710, 11711, 11717, 11718, 11719, 11721, 11722, 11723, 11724 and 11786.




embedded image


Reaction scheme 16 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 15-6 is deprotected to yield a compound of formula 16-1, which is then subjected to a reductive amination reaction or a substitution reaction, thereby preparing a compound of formula 16-2. Next, the prepared compound is reacted with hydrazine to yield a compound of formula 16-3, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 16-4.


Compounds that are prepared according to reaction scheme 16 above are compounds 11552, 11553, 11554, 11583, 11648 and 11656.




embedded image


Reaction scheme 17 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 16-1 is subjected to a reductive amination reaction with a ketone compound to yield a compound of formula 17-1 which is then deprotected to yield a compound of formula 17-2. Then, the prepared compound is subjected to a substitution reaction to yield a compound of formula 17-3. The compound of formula 17-3 is reacted with hydrazine to yield a compound of formula 17-4, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 17-5.


A compound that is prepared according to reaction scheme 17 above is compound 11582.




embedded image


Reaction scheme 18 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 15-8 is deprotected to yield a compound of formula 18-1, which is then subjected to a substitution reaction, thereby synthesizing a compound of formula 18-2.


Compounds that are prepared according to reaction scheme 18 above are compounds 11633 and 11634.




embedded image


Reaction scheme 19 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 15-6 is subjected to a reductive amination reaction with aldehyde to yield a compound of formula 19-1. The prepared compound of formula 19-1 is reacted with hydrazine to yield a compound of formula 19-2, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 19-3.


Compounds that are prepared according to reaction scheme 19 above are compounds 11646 and 11665.




embedded image


Reaction scheme 20 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 20-1 is reacted with hydrazine to yield a compound of formula 20-5, which is then subjected to a cyclization reaction to yield a compound of formula 20-3. The prepared compound of formula 20-3 is brominated to yield a compound of formula 20-6. Alternatively, acyl chloride of formula 20-4 is used to yield the compound of formula 20-6. Meanwhile, a compound of formula 14-1 is subjected to a substitution reaction with any of various primary amine compounds to yield a compound of formula 14-3, which is then subjected to a substitution reaction with the compound of formula 20-6 to yield a compound of formula 20-7. Then, the prepared compound is reacted with an amine compound (formula 14-6), thereby preparing a compound of formula 20-8.


Compounds that are prepared according to reaction scheme 20 above are compounds 11737, 11738, 11751, 11752, 11753, 11754, 11755, 11756, 11757, 11758, 11759, 11760, 11761, 11762, 11763, 11764, 11765, 11766, 11767, 11768, 11769, 11770, 11771, 11772, 11773, 11795, 11796, 11797, 11798, 11799, 11800, 11801, 11802, 11803, 11804, 11805, 11806, 11807, 11808, 11809, 11810, 11811, 11812, 11813, 11814, 11815, 11816, 11817, 11818, 11819, 11820, 11821, 11822, 11842, 11843, 11844, 11845, 11847, 11848 and 11849.




embedded image


Reaction scheme 21 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 21-1 is reacted with hydrazine to yield a compound of formula 21-2, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 21-4. The prepared compound of formula 21-4 is deprotected to yield a compound of formula 21-5, which is then subjected to a reductive amination reaction or a substitution reaction, thereby preparing a compound of formula 21-6.


Compounds that are prepared according to reaction scheme 21 above are compounds 11680, 11681, 11682, 11683, 11684, 11686, 11687, 11688, 11689, 11690, 11691, 11692, 11693, 11694, 11695, 11696, 11697, 11698, 11699, 11725, 11726, 11727, 11728, 11790, 11791, 11792 and 11793.




embedded image


Reaction scheme 22 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 22-1 is subjected to a reductive amination reaction to yield a compound of formula 22-2, which is then deprotected, thereby preparing a compound of formula 22-3. The prepared compound of formula 22-3 is subjected to a reductive amination reaction or a substitution reaction, thereby preparing a compound of formula 22-4.


Compounds that are prepared according to reaction scheme 22 above are compounds 11777, 11778, 11779, 11780, 11781, 11782, 11783, 11784, 11785 and 11836.




embedded image


Reaction scheme 23 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 23-1 is subjected to a reductive amination reaction to yield a compound of formula 23-2, and the hydroxyl group of the compound of formula 23-1 is substituted with fluoride to yield a compound of formula 23-3. The prepared compound of formula 23-3 is reacted with hydrazine to yield a compound of formula 23-4, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 23-5.


Compounds that are prepared according to reaction scheme 23 above are compounds 11840 and 11841.




embedded image


embedded image


Reaction scheme 24 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 24-1 is subjected sequentially to a substitution reaction with a compound of formula 3-1 and a substitution reaction with a compound of formula 5-1 to obtain a compound of formula 24-3, which is then reacted with hydrazine to yield a compound of formula 24-4. Then, the prepared compound of formula 24-4 is subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride to yield a compound of formula 24-5, which is then deprotected, thereby preparing a compound of formula 24-6. Then, the prepared compound of formula 24-6 is subjected to a reductive amination reaction or a substitution reaction, thereby preparing a compound of formula 24-7.


Compounds that are prepared according to reaction scheme 24 above are compounds 11729, 11730, 11731, 11732, 11733, 11734, 11735 and 11736.




embedded image


embedded image


Reaction scheme 25 above shows a general method for synthesis of compounds having a sulfonamide structure. As shown therein, a compound of formula 25-1 is subjected sequentially to a substitution reaction with a compound of formula 3-1 and a substitution reaction with a compound of formula 5-1 to obtain a compound of formula 25-3. The compound of formula 25-4 is subjected to a reductive amination reaction or a substitution reaction to yield a compound of formula 25-5. Then, the compound of formula 25-5 is reacted with hydrazine to yield a compound of formula 25-6, which is then subjected to a cyclization reaction with trifluoroacetic anhydride or difluoroacetic anhydride, thereby preparing a compound of formula 25-7.


A compound that is prepared according to reaction scheme 25 above is compound 11712.


Compositions Comprising 1,3,4-Oxadiazole Sulfonamide Derivative Compounds, the Use Thereof and the Method of Treating Diseases


The present invention provides a pharmaceutical composition for preventing or treating histone deacetylase 6 (HDAC6) activity-associated diseases, which contains, as an active ingredient, a compound represented by the following formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:




embedded image


wherein formula I is as defined above.


The pharmaceutical composition according to the present invention exhibits a remarkable effect on the prevention or treatment of histone deacetylase 6 (HDAC6) activity-associated diseases by selectively inhibiting histone deacetylase 6 (HDAC6).


The histone deacetylase 6 (HDAC6) activity-associated diseases include infectious diseases such as prion disease; neoplasms such as benign tumor(e.g. myelodysplastic syndrome) or malignant tumor(e.g. multiple myeloma, lymphoma, leukemia, lung cancer, rectal cancer, colon cancer, prostate cancer, urothelial carcinoma, breast cancer, melanoma, skin cancer, liver cancer, brain cancer, gastric cancer, ovarian cancer, pancreatic cancer, head and neck cancer, oral cancer, or glioma); endocrine, nutritional and metabolic diseases such as Wilson's disease, amyloidosis or diabetes; mental and behavioral disorders such as depression or Rett's syndrome, and the like; neurological diseases such as atrophy of central nervous system (e.g. Huntington's disease, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA)), neurodegenerative disease (e.g. Alzheimer's disease), movement disorder (e.g. Parkinson's disease), neuropathy (e.g. hereditary neuropathy (Charcot-Marie-Tooth disease), sporadic neuropathy, inflammatory neuropathy, drug-induced neuropathy), motor neuron diseases (amyotrophic lateral sclerosis (ALS)), or demyelinating diseases of the central nervous system (e.g. multiple sclerosis (MS)), and the like; diseases of the eye and adnexa, such as uveitis; cardiovascular diseases such as atrial fibrillation or stroke and the like; respiratory diseases such as asthma; digestive diseases such as alcoholic liver disease, inflammatory bowel disease, Crohn's disease or ulcerative bowel disease, and the like; diseases of the skin and subcutaneous tissue, such as psoriasis; diseases of the musculoskeletal system and connective tissue, such as rheumatoid arthritis, osteoarthritis or systemic lupus erythematosus (SLE), and the like; or congenital malformations, deformations and chromosomal abnormalities, such as autosomal dominant polycystic kidney disease, as well as disorders or diseases associated with the abnormal function of histone deacetylase.


The pharmaceutically acceptable salt is as described above with respect to a pharmaceutically acceptable salt of the compound represented by formula I according to the present invention.


For administration, the pharmaceutical composition according to the present invention may further contain at least one pharmaceutically acceptable carrier in addition to the compound of formula I, an isomer thereof or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable carrier that is used in the present invention may be at least one of physiological saline, sterile water, Ringer solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of two or more thereof. If necessary, the composition may contain other conventional additives such as an antioxidant, a buffer or a bacteriostatic agent. In addition, the composition can be formulated into injectable formulations such as solutions, suspensions, turbid fluid, etc, pills, capsules, granules or tablets using a diluent, a dispersing agent, a surfactant, a binder and a lubricant. Thus, the composition of the present invention may be in the form of patches, liquids, pills, capsules, granules, tablets, suppositories, etc. These formulations can be prepared either by conventional methods that are used for formulation in the art or by the method disclosed in Remington's Pharmaceutical Science (the latest edition), Mack Publishing Company, Easton Pa.


The pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) depending on the intended use. The dose of the pharmaceutical composition varies depending on the patient's weight, age, sex, health conditions and diet, the time of administration, the mode of administration, excretion rate, the severity of the disease, and the like. The daily dose of the compound of formula I according to the present invention may be about 1 to 1000 mg/kg, preferably 5 to 100 mg/kg, and may be administered once to several times a day.


The pharmaceutical composition of the present invention may further contain, in addition to the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, one or more active ingredients that exhibit medicinal efficacy identical or similar thereto.


The present invention also provides a method for preventing or treating a histone deacetylase-mediated disease, which comprises administering a therapeutically effective amount of the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.


As used herein, the term “therapeutically effective amount” refers to the amount of the compound represented by formula I, which is effective for the prevention or treatment of histone deacetylase 6 activity-associated diseases.


The present invention also provides a method of selectively inhibiting HDAC6, which comprises administering the compound of formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof to mammals including humans.


The method of preventing or treating histone deacetylase 6 activity-associated disease according to the present invention includes inhibiting or averting the disease as well as addressing the disease itself, prior to the onset of symptoms by administering the compound represented by formula I. In the management of diseases, the magnitude of a prophylactic or therapeutic dose of a particular active ingredient will vary with the nature and severity of the disease or condition, and may also vary according to the route by which the active ingredient is administered. The dose and the dose frequency will also vary according to the age, body weight, and response of the individual patient. Suitable dosing regimens can be readily selected by those skilled in the art with due consideration of such factors. In addition, the method of preventing or treating histone deacetylase 6 activity-associated disease according to the present invention may further comprise administering a therapeutically effective amount of an additional active agent helpful for the treatment of the disease together with the compound represented by formula I, in which the additional active agent can exhibit a synergistic effect with the compound of formula I or an assistant effect.


The present invention is also intended to provide the use of the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating histone deacetylase 6 activity-associated disease. For the preparation of the medicament, the compound represented by formula I may be mixed with a pharmaceutically acceptable adjuvant, diluent, carrier or the like, and combined with other active agents such that the active ingredients can have synergistic effects.


The particulars mentioned in the use, composition and treatment method of the present invention may be appropriately combined unless contradictory to one another.


Advantageous Effects of Invention

The compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof can selectively inhibit HDAC6, and thus exhibit excellent effects on the prevention or treatment of histone deacetylase 6 activity-associated diseases.







MODE FOR THE INVENTION

Hereinafter, preferred examples will be presented to assist in the understanding of the present invention. However, these examples are provided only for a better understanding of the present invention and are not intended to limit the scope of the present invention.


Preparation of 1,3,4-Oxadiazole Sulfonamide Derivative Compounds


Specific methods for preparing the compounds of formula I are as follows.


EXAMPLE 1
Compound 11044: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide
[Step 1] N-(pyridin-2-ylmethyl)methanesulfonamide



embedded image


A solution of pyridin-2-ylmethanamine (1.000 g, 9.247 mmol), pyridine (0.821 mL, 10.172 mmol) and methanesulfonyl chloride (0.865 mL, 11.097 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. The precipitates were collected by filtration, washed by dichloromethane, and dried to give N-(pyridin-2-ylmethyl)methanesulfonamide as brown solid (1.050 g, 61.0%).


[Step 2] Methyl 3-fluoro-4-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(pyridin-2-ylmethyl)methanesulfonamide (0.300 g, 1.611 mmol), NaH (60.00%, 0.077 g, 1.933 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.438 g, 1.772 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethylacetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)benzoate as white solid (0.290 g, 51.1%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)benzoate (0.400 g, 1.135 mmol) and hydrazine hydrate (0.568 g, 11.351 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide, 0.370 g, 92.5%, yellow solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide (0.370 g, 1.050 mmol), trifluoroacetic anhydride (TFAA, 0.131 mL, 0.945 mmol) and triethylamine (TEA, 0.220 mL, 1.575 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethy-lacetate/hexane=0% to 40%) to give N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide as yellow solid (0.350 g, 74.3%).


[Step 5] Compound 11044



embedded image


A solution of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide (0.350 g, 0.781 mmol) and Burgess reagent (1-methoxy-N-triethylammoniosulfonyl-methanimidate, 0.279 g, 1.171 mmol) in tetrahydrofuran (10 mL) was stirred at 150° C. for 30 min, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethylacetate/hexane=0% to 30%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide as yellow solid (0.095 g, 28.3%).



1H NMR (400 MHz, CDCl3) δ 8.62-8.55 (m, 1H), 7.90 (dd, 1H, J=8.1, 1.7 Hz), 7.81-7.72 (m, 2H), 7.72-7.66 (m, 1H), 7.34-7.21 (m, 3H), 4.65 (s, 2H), 4.57 (s, 2H), 3.07 (s, 3H); LRMS (ES) m/z 431.1 (M++1).


EXAMPLE 2
Compound 11045: N-(pyridin-2-ylmethyl)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] methyl 4-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(pyridin-2-ylmethyl)methanesulfonamide (0.300 g, 1.611 mmol), NaH (60.00%, 0.077 g, 1.933 mmol) and methyl 4-(bromomethyl)benzoate (0.406 g, 1.772 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl4-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)benzoate as yellow solid (0.270 g, 50.1%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)benzoate (0.420 g, 1.256 mmol) and hydrazine hydrate (0.629 g, 12.560 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide, 0.330 g, 78.6%, yellow solid).


[Step 3] N-(pyridin-2-ylmethyl)-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-2-ylmethyl)methanesulfonamide (0.332 g, 0.993 mmol), TFAA (0.124 mL, 0.894 mmol) and TEA (0.208 mL, 1.489 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(pyridin-2-ylmethyl)-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide as yellow solid (0.330 g, 77.2%).


[Step 4] Compound 11045



embedded image


A mixture of N-(pyridin-2-ylmethyl)-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide (0.330 g, 0.767 mmol) and Burgess reagent (0.274 g, 1.150 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(pyridin-2-ylmethyl)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.100 g, 31.6%).



1H NMR (400 MHz, CDCl3) δ 8.62-8.56 (m, 1H), 8.10-8.03 (m, 2H), 7.76-7.67 (m, 1H), 7.60-7.53 (m, 2H), 7.34-7.25 (m, 2H), 4.58 (s, 4H), 3.04 (s, 3H); LRMS (ES) m/z 413.1 (M++1).


EXAMPLE 3
Compound 11078, 4-methoxy-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)benzenesulfonamide
[Step 1] tert-butyl (4-(hydrazinecarbonyl)benzyl)carbamate



embedded image


A mixture of methyl 4-(((tert-butoxycarbonyl)amino)methyl)benzoate (10.000 g, 37.692 mmol) and hydrazine monohydrate (9.661 g, 301.534 mmol) in ethanol (20 mL) prepared at the ambient temperature was heated at reflux for 20 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The precipitates were collected by filtration, washed by water, and dried to give tert-butyl (4-(hydrazinecarbonyl)benzyl)carbamate as white solid (9.800 g, 98.0%).


[Step 2] tert-butyl (4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)carbamate



embedded image


TEA (3.396 mL, 24.500 mmol) was added to a solution of tert-butyl (4-(hydrazinecarbonyl)benzyl)carbamate (5.000 g, 18.846 mmol) in dichloromethane (20 mL) at 0° C., and the mixture was stirred at the same temperature. The reaction mixture was treated with TFAA (2.760 mL, 20.730 mmol), and stirred for additional 3 hr at the room temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (tert-butyl (4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)carbamate, 6.000 g, 88.1%, white solid).


[Step 3] tert-butyl (4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)carbamate



embedded image


A mixture of tert-butyl 4-(2-(2,2,2-trifluoroacetyl)hydrazinecarbonyl)benzylcarbamate (6.990 g, 19.346 mmol) and Burgess reagent (7.438 g, 29.019 mmol) in tetrahydrofuran (25 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 80 g cartridge; ethyl acetate/hexane=0% to 20%) to give tert-butyl 4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzylcarbamate as white solid (4.500 g, 67.8%).


[Step 4] (4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)phenyl)methanamine hydrochloride



embedded image


A solution of tert-butyl (4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)carbamate (3.760 g, 10.953 mmol) in dichloromethane (20 mL) was mixed with HCl (4.00 M solution , 3.012 mL, 12.048 mmol) at the room temperature. The reaction mixture was stirred at the same temperature for 8 hr. The precipitates were collected by filtration, washed by dichloromethane, and dried to give (4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)phenyl)methanamine hydrochloride as white solid (2.800 g, 91.4%).


[Step 5] Compound 11078



embedded image


A solution of (4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)phenyl)methanamine hydrochloride (0.050 g, 0.179 mmol), 4-methoxybenzene-1-sulfonyl chloride (0.041 g, 0.197 mmol) and pyridine (0.017 g, 0.215 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 20 min. Then, aqueous 1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 10%) to give 4-methoxy-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)benzenesulfonamide as white solid (0.065 g, 87.9%).



1H NMR (400 MHz, DMSO-d6) δ 8.20 (s, 1H), 8.06-8.01 (m, 2H), 7.81-7.72 (m, 2H), 7.58-7.53 (m, 2H), 7.17-7.09 (m, 2H), 4.11 (s, 2H), 3.86 (d, 3H, J=0.9 Hz); LRMS (ES) m/z 414.0 (M++1).


EXAMPLE 4
Compound 11088: N-(pyridin-3-yl)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-(pyridin-3-yl)methanesulfonamide



embedded image


A solution of pyridin-3-amine (3.000 g, 31.874 mmol), pyridine (2.830 mL, 35.062 mmol) and methanesulfonyl chloride (4.381 g, 38.249 mmol) in dichloromethane (80 mL) was stirred at the room temperature for 12 hr. The precipitates were collected by filtration, washed by dichloromethane, and dried to give N-(pyridin-3-yl)methanesulfonamide as yellow solid (3.200 g, 58.3%).


[Step 2] methyl 4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(pyridin-3-yl)methanesulfonamide (0.400 g, 2.323 mmol), NaH (60.00%, 0.111 g, 2.787 mmol) and methyl 4-(bromomethyl)benzoate (0.585 g, 2.555 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.210 g, 28.2%).


[Step 3] N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate (0.210 g, 0.656 mmol) and hydrazine hydrate (0.328 g, 6.555 mmol) in ethanol (10 mL) was stirred at 120° C. for 1 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide, 0.150 g, 71.4%, yellow solid).


[Step 4] N-(pyridin-3-yl)-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide (0.150 g, 0.468 mmol), trifluoroacetic anhydride (0.059 mL, 0.421 mmol) and triethylamine (0.098 mL, 0.702 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(pyridin-3-yl)-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide as yellow oil (0.110 g, 56.4%).


[Step 5] Compound 11088



embedded image


A mixture of N-(pyridin-3-yl)-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide (0.110 g, 0.264 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.094 g, 0.396 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(pyridin-3-yl)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.073 g, 69.4%).



1H NMR (400 MHz, CDCl3) δ 9.07 (s, 1H), 8.59 (s, 1H), 8.08 (d, 2H, J=8.3 Hz), 7.97 (d, 1H, J=8.5 Hz), 7.55 (d, 3H, J=8.1 Hz), 5.15 (s, 2H), 3.15 (s, 3H); LRMS (ES) m/z 399.19 (M++1).


EXAMPLE 5
Compound 11089: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)methanesulfonamide
[Step 1] methyl 3-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(pyridin-3-yl)methanesulfonamide (0.400 g, 2.323 mmol), NaH (60.00%, 0.111 g, 2.787 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.631 g, 2.555 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate as white solid (0.250 g, 31.8%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate (0.250 g, 0.739 mmol) and hydrazine hydrate (0.370 g, 7.389 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide, 0.200 g, 80.0%, yellow solid).


[Step 3] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide (0.200 g, 0.591 mmol), trifluoroacetic anhydride (0.074 mL, 0.532 mmol) and triethylamine (0.124 mL, 0.887 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide as yellow oil (0.130 g, 50.6%).


[Step 4] Compound 11089



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide (0.130 g, 0.299 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.107 g, 0.449 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)methane sulfonamide as yellow solid (0.091 g, 73.0%).



1H NMR (400 MHz, CDCl3) δ 8.70 (s, 1H), 8.58 (d, 1H, J=4.7 Hz), 7.91 (dd, 1H, J=8.0, 1.5 Hz), 7.81-7.73 (m, 2H), 7.69 (t, 1H, J=7.6 Hz), 7.40 (dd, 1H, J=8.3, 4.8 Hz), 5.09 (s, 2H), 3.09 (s, 3H); LRMS (ES) m/z 416.9 (M++1).


EXAMPLE 6
Compound 11120: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(pyridin-3-yl)methanesulfonamide
[Step 1] methyl 3-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(pyridin-3-yl)methanesulfonamide (0.800 g, 4.646 mmol), sodium hydride (60.00%, 0.223 g, 5.575 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (1.263 g, 5.110 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.740 g, 47.1%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate (0.740 g, 2.187 mmol) and hydrazine hydrate (1.095 g, 21.871 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide, 0.610 g, 82.4%, yellow solid).


[Step 3] Compound 11120



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide (0.080 g, 0.236 mmol), difluoroacetic anhydride (0.031 mL, 0.284 mmol) and triethylamine (0.066 mL, 0.473 mmol) in dichloromethane (1 mL) was stirred at the room temperature for 1 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(pyridin-3-yl)methanesulfonamide as white solid (0.041 g, 43.5%).



1H NMR (400 MHz, CDCl3) δ 8.92 (s, 1H), 8.65-8.59 (m, 1H), 8.02-7.95 (m, 1H), 7.92 (dd, 1H, J=8.0, 1.7 Hz), 7.78 (dd, 1H, J=10.0, 1.7 Hz), 7.67 (t, 1H, J=7.6 Hz), 7.59 (dd, 1H, J=8.4, 5.1 Hz), 7.06 (s, 0.2H), 6.93 (s, 0.4H), 6.80 (s, 0.2H), 5.13 (s, 2H), 3.13 (s, 3H); LRMS (ES) m/z 399.1 (M++1).


EXAMPLE 7
Compound 11121: N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide



embedded image


Triethylamine (0.032 mL, 0.232 mmol) was added to a solution of (4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)phenyl)methanamine hydrochloride (0.050 g, 0.179 mmol) in dichloromethane (2 mL) at the room temperature and the mixture was stirred at the same temperature for 10 min. The reaction mixture was treated with methanesulfonyl chloride (0.015 mL, 0.197 mmol), and stirred for additional 5 hr at the same temperature. Then, saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.055 g, 95.7%).



1H NMR (400 MHz, DMSO-d6) δ 8.17-8.07 (m, 2H), 7.77 (s, 1H), 7.66 (d, 2H, J=8.2 Hz), 4.32 (d, 2H, J=3.6 Hz), 2.96 (s, 3H); LRMS (ES) m/z 320.19 (M+−1).


EXAMPLE 8
Compound 11128: N-(pyridin-2-ylmethyl)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] methyl 6-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of N-(pyridin-2-ylmethyl)methanesulfonamide (0.300 g, 1.611 mmol), sodium hydride (60.00%, 0.077 g, 1.933 mmol) and methyl 6-(bromomethyl)nicotinate (0.408 g, 1.772 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)nicotinate as yellow solid (0.290 g, 53.7%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(pyridin-2-ylmethyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(pyridin-2-ylmethyl)methylsulfonamido)methyl)nicotinate (0.290 g, 0.865 mmol) and hydrazine hydrate (0.433 g, 8.647 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(pyridin-2-ylmethyl)methanesulfonamide, 0.110 g, 37.9%, white solid).


[Step 3] N-(pyridin-2-ylmethyl)-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(pyridin-2-ylmethyl)methanesulfonamide (0.110 g, 0.328 mmol), trifluoroacetic anhydride (0.041 mL, 0.295 mmol) and triethylamine (0.069 mL, 0.492 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(pyridin-2-ylmethyl)-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide as yellow oil (0.091 g, 64.3%).


[Step 4] Compound 11128



embedded image


A mixture of N-(pyridin-2-ylmethyl)-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.091 g, 0.211 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.075 g, 0.316 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(pyridin-2-ylmethyl)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.021 g, 24.1%).



1H NMR (400 MHz, CDCl3) δ 9.27 (dd, 1H, J=2.2, 0.9 Hz), 8.61-8.54 (m, 1H), 8.43-8.35 (m, 1H), 7.76 (t, 1H, J=7.8 Hz), 7.67 (dd, 1H, J=8.2, 0.8 Hz), 7.46 (d, 1H, J=7.9 Hz), 7.29 (s, 1H), 4.73 (s, 2H), 4.67 (s, 2H), 3.16 (s, 3H); LRMS (ES) m/z 414.3 (M++1).


EXAMPLE 9
Compound 11129: N-(2-methoxy-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)methanesulfonamide
[Step 1] methyl 3-methoxy-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(pyridin-3-yl)methanesulfonamide (0.500 g, 2.904 mmol), sodium hydride (60.00%, 0.139 g, 3.484 mmol) and methyl 4-(bromomethyl)-3-methoxybenzoate (0.828 g, 3.194 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-methoxy-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.117 g, 11.5%).


[Step 2] N-(4-(hydrazinecarbonyl)-2-methoxybenzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A mixture of methyl 3-methoxy-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate (0.117 g, 0.334 mmol) and hydrazine hydrate (0.167 g, 3.339 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)-2-methoxybenzyl)-N-(pyridin-3-yl)methanesulfonamide, 0.100 g, 85.5%, yellow oil).


[Step 3] N-(2-methoxy-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A solution of N-(4-(hydrazinecarbonyl)-2-methoxybenzyl)-N-(pyridin-3-yl)methanesulfonamide (0.100 g, 0.285 mmol), trifluoroacetic anhydride (0.036 mL, 0.257 mmol) and triethylamine (0.059 mL, 0.428 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(2-methoxy-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide as yellow oil (0.090 g, 70.6%).


[Step 4] Compound 11129



embedded image


A mixture of N-(2-methoxy-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide (0.090 g, 0.202 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.072 g, 0.302 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(2-methoxy-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)methanesulfonamide as white solid (0.036 g, 41.7%).



1H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 8.56 (d, 1H, J=5.1 Hz), 8.01 (d, 1H, J=8.5 Hz), 7.67 (dd, 1H, J=7.9, 1.6 Hz), 7.61-7.52 (m, 3H), 5.08 (s, 2H), 3.90 (s, 3H), 3.09 (s, 3H); LRMS (ES) m/z 429.3 (M++1).


EXAMPLE 10
Compound 11133: N-(3-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)methanesulfonamide
[Step 1] methyl 2-fluoro-4-((pyridin-3-ylamino)methyl)benzoate



embedded image


Methyl 2-fluoro-4-formylbenzoate (1.490 g, 8.181 mmol) and AcOH (0.501 mL, 8.181 mmol) were added to a solution of pyridin-3-amine (0.700 g, 7.437 mmol) in dichloromethane (20 mL) at the room temperature, and the mixture was stirred at the same temperature for 1 hr. The reaction mixture was treated with Na(OAc)3BH (3.153 g, 14.875 mmol), and stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 2-fluoro-4-((pyridin-3-ylamino)methyl)benzoate as yellow oil (0.500 g, 25.8%).


[Step 2] methyl 2-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 2-fluoro-4-((pyridin-3-ylamino)methyl)benzoate (0.500 g, 1.921 mmol), pyridine (0.171 mL, 2.113 mmol) and methanesulfonyl chloride (0.180 mL, 2.305 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 2-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.160 g, 24.6%).


[Step 3] N-(3-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A mixture of methyl 2-fluoro-4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate (0.160 g, 0.473 mmol) and hydrazine hydrate (0.237 g, 4.729 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide, 0.109 g, 68.1%, yellow oil).


[Step 4] N-(3-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A solution of N-(3-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide (0.109 g, 0.322 mmol), trifluoroacetic anhydride (0.040 mL, 0.290 mmol) and triethylamine (0.067 mL, 0.483 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-(3-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide as yellow oil (0.071 g, 50.7%).


[Step 5] Compound 11133



embedded image


A mixture of N-(3-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide (0.071 g, 0.163 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.058 g, 0.245 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)methanesulfonamide as yellow oil (0.031 g, 45.6%).



1H NMR (400 MHz, CDCl3) δ 9.24 (s, 1H), 8.60 (d, 1H, J=5.1 Hz), 8.13-8.02 (m, 2H), 7.67-7.54 (m, 1H), 7.37 (d, 2H, J=9.3 Hz), 5.19 (s, 2H), 3.16 (s, 3H); LRMS (ES) m/z 417.1 (M++1).


EXAMPLE 11
Compound 11151: N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)pyridine-3-sulfonamide
[Step 1] N-phenylpyridine-4-sulfonamide



embedded image


A solution of aniline (0.200 g, 2.147 mmol) and Pyridine (0.260 mL, 3.221 mmol) in dichloromethane (6 mL) was mixed with pyridine-4-sulfonyl chloride hydrochloride (0.483 g, 2.255 mmol) at the room temperature, and the reaction mixture was stirred at the same temperature for 10 hr. Then, saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-phenylpyridine-4-sulfonamide as yellow solid (0.250 g, 49.7%).


[Step 2] methyl 4-((N-phenylpyridine-3-sulfonamido)methyl)benzoate



embedded image


Sodium hydride (60.00%, 0.082 g, 2.049 mmol) was added to a solution of N-phenylpyridine-3-sulfonamide (0.400 g, 1.707 mmol) in N,N-dimethylformide (8 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with methyl 4-(bromomethyl)benzoate (0.430 g, 1.878 mmol), and stirred for additional 8 hr at the room temperature. Then, saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 4-((N-phenylpyridine-3-sulfonamido)methyl)benzoate as white solid (0.380 g, 58.2%).


[Step 3] N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpyridine-3-sulfonamide



embedded image


A mixture of methyl 4-((N-phenylpyridine-3-sulfonamido)methyl)benzoate (0.330 g, 0.863 mmol) and hydrazine hydrate (0.138 g, 4.315 mmol) in ethanol (6 mL) was heated at reflux for 16 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure. The precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpyridine-3-sulfonamide as white solid (0.320 g, 97.0%).


[Step 4] Compound 11151



embedded image


Triethylamine (0.075 mL, 0.544 mmol) was added to a solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpyridine-3-sulfonamide (0.160 g, 0.418 mmol) in tetrahydrofuran (8 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with trifluoroacetic anhydride (0.061 mL, 0.460 mmol), heated at reflux for 14 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)pyridine-3-sulfonamide as white solid (0.150 g, 77.9%).



1H NMR (400 MHz, DMSO-d6) δ 8.95 (dd, 1H, J=4.9, 1.6 Hz), 8.84 (dd, 1H, J=2.4, 0.8 Hz), 8.10 (ddd, 1H, J=8.1, 2.4, 1.6 Hz), 8.06-7.99 (m, 2H), 7.73 (ddd, 1H, J=8.1, 4.9, 0.8 Hz), 7.66-7.54 (m, 2H), 7.38-7.24 (m, 3H), 7.21-7.12 (m, 2H), 5.04 (s, 2H); LRMS (ES) m/z 462.0 (M++1).


EXAMPLE 12
Compound 11152: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpyridine-3-sulfonamide



embedded image


Triethylamine (0.075 mL, 0.544 mmol) was added to a solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpyridine-3-sulfonamide (0.160 g, 0.418 mmol) in tetrahydrofuran (8 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.050 mL, 0.460 mmol), heated at reflux for 14 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpyridine-3-sulfonamide as white solid (0.140 g, 75.6%).



1H NMR (400 MHz, DMSO-d6) δ 8.95 (dd, 1H, J=4.9, 1.6 Hz), 8.84 (dd, 1H, J=2.3, 0.8 Hz), 8.09 (ddd, 1H, J=8.1, 2.4, 1.6 Hz), 8.06-7.96 (m, 2H), 7.78-7.66 (m, 1H), 7.64-7.53 (m, 3H), 7.43 (s, OH), 7.38-7.26 (m, 3H), 7.21-7.12 (m, 2H), 5.03 (s, 2H); LRMS (ES) m/z 444.0 (M++1).


EXAMPLE 13
Compound 11153: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethanesulfonamide
[Step 1] methyl 3-fluoro-4-((N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of ethanesulfonyl chloride (0.219 mL, 2.314 mmol), N,N-dimethylpyridin-4-amine (DMAP, 0.071 g, 0.579 mmol) and pyridine (0.233 mL, 2.893 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 30 min, and then mixed with methyl 3-fluoro-4-((phenylamino)methyl)benzoate (0.500 g, 1.928 mmol). The reaction mixture was heated at reflux for 5 hr, cooled down to the room temperature to terminate the reaction. Then, saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 25%) to give methyl 3-fluoro-4-((N-phenylethylsulfonamido)methyl)benzoate as white solid (0.450 g, 66.4%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylethanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-phenylethylsulfonamido)methyl)benzoate (0.450 g, 1.281 mmol) and hydrazine hydrate (0.205 g, 6.403 mmol) in ethanol (8 mL) was heated at reflux for 16 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The precipitates were collected by filtration, washed by water, and dried to give N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylethanesulfonamide as white solid (0.420 g, 93.3%).


[Step 3] Compound 11153



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylethanesulfonamide (0.080 g, 0.228 mmol) and triethylamine (0.041 mL, 0.296 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with trifluoroacetic anhydride (0.033 mL, 0.250 mmol). The reaction mixture was heated at reflux for 6 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethanesulfonamide as white solid (0.075 g, 76.7%).



1H NMR (400 MHz, DMSO-d6) δ 7.91 (dd, 1H, J=8.0, 1.7 Hz), 7.84 (dd, 1H, J=10.1, 1.7 Hz), 7.71 (t, 1H, J=7.7 Hz), 7.51-7.43 (m, 2H), 7.44-7.30 (m, 3H), 5.11 (s, 2H), 3.31 (q, 2H, J=7.3 Hz), 1.33 (t, 3H, J=7.3 Hz); LRMS (ES) m/z 430.0 (M++1).


EXAMPLE 14
Compound 11154: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylethanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylethanesulfonamide (0.080 g, 0.228 mmol) and triethylamine (0.041 mL, 0.296 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with 2,2-difluoroacetic anhydride (0.030 mL, 0.273 mmol). The reaction mixture was heated at reflux for 3 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylethanesulfonamide as white solid (0.065 g, 69.4%).



1H NMR (400 MHz, DMSO-d6) δ 7.88 (dd, 1H, J=8.0, 1.7 Hz), 7.80 (dd, 1H, J=10.2, 1.7 Hz), 7.75-7.67 (m, 1H), 7.58-7.40 (m, 3H), 7.39 (dd, 2H, J=8.5, 6.9 Hz), 7.34-7.27 (m, 1H), 5.10 (s, 2H), 3.30 (q, 2H, J=7.4 Hz), 1.33 (t, 3H, J=7.3 Hz); LRMS (ES) m/z 412.3 (M++1).


EXAMPLE 15
Compound 11155: N-(3-fluorophenyl)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)pyridine-3-sulfonamide
[Step 1] N-(3-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)pyridine-3-sulfonamide



embedded image


A mixture of methyl 4-((N-(3-fluorophenyl)pyridine-3-sulfonamido)methyl)benzoate (0.300 g, 0.749 mmol) and hydrazine hydrate (0.120 g, 3.746 mmol) in ethanol (6 mL) prepared at the ambient temperature was heated at reflux for 16 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred at the ambient temperature. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(3-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)pyridine-3-sulfonamide as white solid (0.290 g, 96.7%).


[Step 2] Compound 11155



embedded image


A solution of N-(3-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)pyridine-3-sulfonamide (0.100 g, 0.250 mmol) and triethylamine (0.045 mL, 0.325 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with trifluoroacetic anhydride (0.037 mL, 0.275 mmol). The reaction mixture was heated at reflux for 3 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-fluorophenyl)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)pyridine-3-sulfonamide as white solid (0.060 g, 50.2%).



1H NMR (400 MHz, DMSO-d6) δ 8.97 (dd, 1H, J=4.9, 1.6 Hz), 8.87 (dd, 1H, J=2.4, 0.8 Hz), 8.11 (ddd, 1H, J=8.1, 2.4, 1.6 Hz), 8.05-7.95 (m, 2H), 7.74 (ddd, 1H, J=8.1, 4.9, 0.8 Hz), 7.69 (s, 0.2H), 7.62-7.57 (m, 2H), 7.56 (s, 0.5H), 7.43 (s, 0.2H), 7.37 (dd, 1H, J=8.2, 6.6 Hz), 7.21-7.11 (m, 2H), 7.07 (ddd, 1H, J=8.1, 2.0, 1.0 Hz), 5.04 (s, 2H); LRMS (ES) m/z 477.2 (M+−1).


EXAMPLE 16
Compound 11156: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide



embedded image


A solution of N-(3-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)pyridine-3-sulfonamide (0.100 g, 0.250 mmol) and triethylamine (0.045 mL, 0.325 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with 2,2-difluoroacetic anhydride (0.033 mL, 0.300 mmol). The reaction mixture was heated at reflux for 3 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide as white solid (0.080 g, 67.0%).


[Step 2] Compound 11156



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide (0.080 g, 0.167 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.035 g, 0.201 mmol) in tetrahydrofuran (2 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide as white solid (0.055 g, 71.4%).



1H NMR (400 MHz, DMSO-d6) δ 8.97 (dd, 1H, J=4.9, 1.5 Hz), 8.87 (d, 1H, J=2.3 Hz), 8.11 (ddd, 1H, J=8.1, 2.4, 1.6 Hz), 8.08-7.97 (m, 2H), 7.74 (ddd, 1H, J=8.0, 4.9, 0.8 Hz), 7.60 (d, 2H, J=8.2 Hz), 7.37 (td, 1H, J=8.1, 6.6 Hz), 7.22-7.10 (m, 2H), 7.10-7.02 (m, 1H), 5.05 (s, 2H); LRMS (ES) m/z 462.0 (M++1).


EXAMPLE 17
Compound 11167: N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-phenylmethanesulfonamide



embedded image


A solution of aniline (3.000 g, 32.213 mmol), pyridine (2.860 mL, 35.434 mmol) and methanesulfonyl chloride (3.012 mL, 38.656 mmol) in dichloromethane (80 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-phenylmethanesulfonamide, 4.100 g, 74.3%, white solid).


[Step 2] methyl 4-((N-phenylmethylsulfonamido)methyl)benzoate



embedded image


A solution of N-phenylmethanesulfonamide (0.800 g, 4.673 mmol), sodium hydride (60.00%, 0.224 g, 5.607 mmol) and methyl 4-(bromomethyl)benzoate (1.177 g, 5.140 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 4-((N-phenylmethylsulfonamido)methyl)benzoate as white solid (0.700 g, 46.9%).


[Step 3] N-(4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide



embedded image


A mixture of methyl 4-((N-phenylmethylsulfonamido)methyl)benzoate (0.700 g, 2.192 mmol) and hydrazine hydrate (1.097 g, 21.917 mmol) in dichloromethane (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide, 0.430 g, 61.4%, yellow oil).


[Step 4] Compound 11167



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide (0.200 g, 0.626 mmol), trifluoroacetic anhydride (0.096 mL, 0.689 mmol) and triethylamine (0.175 mL, 1.252 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.140 g, 56.3%).



1H NMR (400 MHz, CDCl3) δ 8.09-8.01 (m, 2H), 7.54-7.47 (m, 2H), 7.42-7.26 (m, 5H), 4.97 (s, 2H), 3.01 (s, 3H); LRMS (ES) m/z 398.1 (M++1).


EXAMPLE 18
Compound 11168: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylmethanesulfonamide



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide (0.200 g, 0.626 mmol), difluoroacetic anhydride (0.075 mL, 0.689 mmol) and triethylamine (0.131 mL, 0.939 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylmethanesulfonamide as white solid (0.110 g, 46.3%).



1H NMR (400 MHz, CDCl3) δ 8.08-7.97 (m, 2H), 7.53-7.45 (m, 2H), 7.44-7.26 (m, 5H), 7.05 (s, 0.2H), 6.92 (s, 0.5H), 6.79 (s, 0.2H), 4.96 (s, 2H), 3.01 (s, 3H); LRMS (ES) m/z 380.0 (M++1).


EXAMPLE 19
Compound 11169: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylmethanesulfonamide
[Step 1] methyl 3-fluoro-4-((N-phenylmethylsulfonamido)methyl)benzoate



embedded image


A solution of N-phenylmethanesulfonamide (0.800 g, 4.673 mmol), sodium hydride (60.00%, 0.224 g, 5.607 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (1.270 g, 5.140 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 3-fluoro-4-((N-phenylmethylsulfonamido)methyl)benzoate as yellow solid (0.752 g, 47.7%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-phenylmethylsulfonamido)methyl)benzoate (0.752 g, 2.229 mmol) and hydrazine hydrate (1.116 g, 22.290 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide, 0.700 g, 93.1%, yellow oil).


[Step 3] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylmethanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide (0.200 g, 0.593 mmol), trifluoroacetic anhydride (0.091 mL, 0.652 mmol) and triethylamine (0.124 mL, 0.889 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylmethanesulfonamide, 0.150 g, 58.4%, yellow oil).


[Step 4] Compound 11169



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylmethanesulfonamide (0.150 g, 0.346 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.124 g, 0.519 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylmethanesulfonamide as white solid (0.091 g, 63.3%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.1, 1.7 Hz), 7.75 (dd, 1H, J=9.8, 1.6 Hz), 7.71 (t, 1H, J=7.6 Hz), 7.42-7.29 (m, 5H), 5.05 (s, 2H), 3.03 (s, 3H); LRMS (ES) m/z 416.3 (M++1).


EXAMPLE 20
Compound 11170: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylmethanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-phenylmethanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide (0.200 g, 0.593 mmol), difluoroacetic anhydride (0.071 mL, 0.652 mmol) and triethylamine (0.124 mL, 0.889 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-phenylmethane sulfonamide, 0.110 g, 44.7%, yellow oil).


[Step 2] Compound 11170



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-phenylmethanesulfonamide (0.110 g, 0.254 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.091 g, 0.381 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylmethanesulfonamide as white solid (0.071 g, 70.4%).



1H NMR (400 MHz, CDCl3) δ 7.88 (d, 1H, J=8.3 Hz), 7.75 (d, 1H, J=10.0 Hz), 7.68 (t, 1H, J=7.7 Hz), 7.42-7.29 (m, 5H), 7.05 (s, 0.2H), 6.92 (s, 0.5H), 6.79 (s, 0.2H), 5.04 (s, 2H), 3.03 (s, 3H); LRMS (ES) m/z 398.5 (M++1).


EXAMPLE 21
Compound 11171: N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] methyl 6-((N-phenylmethylsulfonamido)methyl)nicotinate



embedded image


A solution of N-phenylmethanesulfonamide (0.800 g, 4.673 mmol), sodium hydride (60.00%, 0.224 g, 5.607 mmol) and methyl 6-(bromomethyl)nicotinate (1.182 g, 5.140 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-((N-phenylmethylsulfonamido)methyl)nicotinate as yellow solid (0.323 g, 21.6%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide



embedded image


A mixture of methyl 6-((N-phenylmethylsulfonamido)methyl)nicotinate (0.323 g, 1.008 mmol) and hydrazine hydrate (0.505 g, 10.082 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide, 0.300 g, 92.9%, yellow oil).


[Step 3] N-phenyl-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide (0.100 g, 0.312 mmol), trifluoroacetic anhydride (0.048 mL, 0.343 mmol) and triethylamine (0.065 mL, 0.468 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried (anhydrous MgSO4), filtered, and concentrated in vacuo. The title compound was used without further purification (N-phenyl-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide, 0.083 g, 63.9%, yellow oil).


[Step 4] Compound 11171



embedded image


A mixture of N-phenyl-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.083 g, 0.199 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.071 g, 0.299 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as yellow solid (0.053 g, 66.7%).



1H NMR (400 MHz, CDCl3) δ 9.25 (dd, 1H, J=2.3, 0.8 Hz), 8.40 (dd, 1H, J=8.3, 2.3 Hz), 7.76 (dd, 1H, J=8.2, 0.8 Hz), 7.46-7.34 (m, 4H), 7.35-7.29 (m, 1H), 5.18 (s, 2H), 3.08 (s, 3H); LRMS (ES) m/z 399.3 (M++1).


EXAMPLE 22
Compound 11172: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide
[Step 1] N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide (0.100 g, 0.312 mmol), difluoroacetic anhydride (0.037 mL, 0.343 mmol) and triethylamine (0.065 mL, 0.468 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide, 0.083 g, 66.7%, yellow oil).


[Step 2] Compound 11172



embedded image


A mixture of N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide (0.083 g, 0.208 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.074 g, 0.313 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide as yellow solid (0.043 g, 54.3%).



1H NMR (400 MHz, CDCl3) δ 9.25 (dd, 1H, J=2.2, 0.9 Hz), 8.40 (dd, 1H, J=8.3, 2.2 Hz), 7.74 (dd, 1H, J=8.1, 0.8 Hz), 7.49-7.29 (m, 5H), 7.08 (s, 0.2H), 6.95 (s, 0.5H), 6.82 (s, 0.2H), 5.17 (s, 2H), 3.09 (s, 3H); LRMS (ES) m/z 381.2 (M++1).


[Step 3] Compound 11172 HCl Salt



embedded image


A solution of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide (0.026 g, 0.068 mmol) and hydrogen chloride (1.00 M solution in EtOAc, 0.075 mL, 0.075 mmol) in ethyl acetate (2 mL) was stirred at the room temperature for 1 hr. The precipitates were collected by filtration, washed by ethyl acetate, and dried to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylmethanesulfonamide hydrochloride as white solid (0.028 g, 98.3%).


EXAMPLE 23
Compound 11173: N-phenyl-N-((6-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)methyl)methanesulfonamide
[Step 1] methyl 5-((phenylamino)methyl)picolinate



embedded image


Methyl 5-formylpicolinate (0.975 g, 5.906 mmol) and acetic acid (0.338 mL, 5.906 mmol) were added to a solution of aniline (0.500 g, 5.369 mmol) in dichloromethane (20 mL) at the room temperature, and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with sodium triacetoxyborohydride (2.276 g, 10.738 mmol), stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 5-((phenylamino)methyl)picolinate as yello solid (0.672 g, 51.7%).


[Step 2] methyl 5-((N-phenylmethylsulfonamido)methyl)picolinate



embedded image


A solution of methyl 5-((phenylamino)methyl)picolinate (0.672 g, 2.774 mmol), triethylamine (0.773 mL, 5.547 mmol) and methanesulfonyl chloride (0.259 mL, 3.328 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 5-((N-phenylmethylsulfonamido)methyl)picolinate as yellow oil (0.620 g, 69.8%).


[Step 3] N-((6-(hydrazinecarbonyl)pyridin-3-yl)methyl)-N-phenylmethanesulfonamide



embedded image


A mixture of methyl 5-((N-phenylmethylsulfonamido)methyl)picolinate (0.620 g, 1.935 mmol) and hydrazine hydrate (0.969 g, 19.353 mmol) in dichloromethane (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((6-(hydrazinecarbonyl)pyridin-3-yl)methyl)-N-phenylmethanesulfonamide, 0.590 g, 95.2%, yellow oil).


[Step 4] Compound 11173



embedded image


A solution of N-((6-(hydrazinecarbonyl)pyridin-3-yl)methyl)-N-phenylmethanesulfonamide (0.200 g, 0.624 mmol), trifluoroacetic anhydride (0.096 mL, 0.687 mmol) and triethylamine (0.131 mL, 0.936 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-phenyl-N-((6-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)methyl)methanesulfonamide as yellow solid (0.100 g, 40.2%).



1H NMR (400 MHz, CDCl3) δ 8.67-8.60 (m, 1H), 8.31-8.24 (m, 1H), 8.04-7.96 (m, 1H), 7.45-7.24 (m, 5H), 5.01 (s, 2H), 3.03 (s, 3H); LRMS (ES) m/z 399.0 (M++1).


EXAMPLE 24
Compound 11174: N-((6-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)methyl)-N-phenylmethanesulfonamide



embedded image


A solution of N-((6-(hydrazinecarbonyl)pyridin-3-yl)methyl)-N-phenylmethanesulfonamide (0.200 g, 0.624 mmol), difluoroacetic anhydride (0.075 mL, 0.687 mmol) and triethylamine (0.131 mL, 0.936 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-((6-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)methyl)-N-phenylmethanesulfonamide as yellow solid (0.110 g, 46.3%).



1H NMR (400 MHz, CDCl3) δ 8.63 (dd, 1H, J=2.2, 0.8 Hz), 8.25 (d, 1H, J=8.1, 0.8 Hz), 8.02-7.95 (m, 1H), 7.41-7.29 (m, 5H), 7.07 (s, 0.2H), 6.94 (s, 0.5H), 6.81 (s, 0.2H), 5.01 (s, 2H), 3.03 (s, 3H); LRMS (ES) m/z 381.3 (M++1).


EXAMPLE 25
Compound 11175: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide
[Step 1] N-(3-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of 3-(trifluoromethyl)aniline (1.000 g, 6.206 mmol), pyridine (0.551 mL, 6.827 mmol) and methanesulfonyl chloride (0.580 mL, 7.447 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-(trifluoromethyl)phenyl)methanesulfonamide, 1.050 g, 70.7%, yellow oil).


[Step 2] methyl 3-fluoro-4-((N-(3-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(3-(trifluoromethyl)phenyl)methanesulfonamide (0.500 g, 2.090 mmol), sodium hydride (60.00%, 0.100 g, 2.508 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.568 g, 2.299 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(3-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate as yellow solid (0.600 g, 70.8%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(3-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate (0.665 g, 1.641 mmol) and hydrazine hydrate (0.821 g, 16.405 mmol) in dichloromethane (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide, 0.520 g, 78.2%, yellow oil).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide (0.200 g, 0.493 mmol), trifluoroacetic anhydride (0.075 mL, 0.543 mmol) and triethylamine (0.103 mL, 0.740 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide, 0.140 g, 56.6%, white solid).


[Step 5] Compound 11175



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide (0.140 g, 0.279 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.100 g, 0.419 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide as yellow solid (0.094 g, 69.6%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dt, 1H, J=8.1, 4.0 Hz), 7.81-7.72 (m, 1H), 7.68 (t, 1H, J=7.6 Hz), 7.63-7.56 (m, 2H), 7.56-7.45 (m, 2H), 5.07 (s, 2H), 3.06 (s, 3H); LRMS (ES) m/z 484.3 (M++1).


EXAMPLE 26
Compound 11176: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide (0.200 g, 0.493 mmol), difluoroacetic anhydride (0.059 mL, 0.543 mmol) and triethylamine (0.103 mL, 0.740 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide, 0.130 g, 54.5%, white solid).


[Step 2] Compound 11176



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide (0.130 g, 0.269 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.096 g, 0.403 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide as yellow solid (0.094 g, 75.1%).



1H NMR (400 MHz, CDCl3) δ 7.90 (dd, 1H, J=8.0, 1.7 Hz), 7.76 (dd, 1H, J=9.9, 1.7 Hz), 7.66 (t, 1H, J=7.6 Hz), 7.61-7.55 (m, 2H), 7.55-7.45 (m, 2H), 7.05 (s, 0.2H), 6.92 (s, 0.4H), 6.79 (s, 0.2H), 5.06 (s, 2H), 3.05 (s, 3H); LRMS (ES) m/z 466.2 (M++1).


EXAMPLE 27
Compound 11177: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)methanesulfonamide
[Step 1] N-(m-tolyl)methanesulfonamide



embedded image


A solution of m-toluidine hydrochloride (1.000 g, 6.963 mmol), pyridine (0.618 mL, 7.660 mmol) and methanesulfonyl chloride (0.651 mL, 8.356 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(m-tolyl)methanesulfonamide, 1.100 g, 85.3%, white solid).


[Step 2] methyl 3-fluoro-4-((N-(m-tolyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(m-tolyl)methanesulfonamide (0.500 g, 2.699 mmol), sodium hydride (60.00%, 0.130 g, 3.239 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.734 g, 2.969 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(m-tolyl)methylsulfonamido)methyl)benzoate as yellow solid (0.630 g, 66.4%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(m-tolyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(m-tolyl)methylsulfonamido)methyl)benzoate (0.630 g, 1.793 mmol) and hydrazine hydrate (0.898 g, 17.929 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(m-tolyl)methanesulfonamide, 0.590 g, 93.7%, yellow oil).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(m-tolyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(m-tolyl)methanesulfonamide (0.200 g, 0.569 mmol), trifluoroacetic anhydride (0.087 mL, 0.626 mmol) and triethylamine (0.119 mL, 0.854 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(m-tolyl)methanesulfonamide, 0.153 g, 60.1%, white solid).


[Step 5] Compound 11177



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(m-tolyl)methanesulfonamide (0.153 g, 0.342 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.122 g, 0.513 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)methanesulfonamide as yellow solid (0.100 g, 68.1%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.1, 1.7 Hz), 7.79-7.67 (m, 2H), 7.30-7.09 (m, 4H), 5.03 (s, 2H), 3.02 (s, 3H), 2.34 (s, 3H); LRMS (ES) m/z 430.0 (M++1).


EXAMPLE 28
Compound 11178: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(m-tolyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(m-tolyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(m-tolyl)methanesulfonamide (0.200 g, 0.569 mmol), difluoroacetic anhydride (0.068 mL, 0.626 mmol) and triethylamine (0.119 mL, 0.854 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(m-tolyl)methanesulfonamide, 0.130 g, 53.2%, white solid).


[Step 2] Compound 11178



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(m-tolyl)methanesulfonamide (0.130 g, 0.303 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.108 g, 0.454 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(m-tolyl)methanesulfonamide as yellow solid (0.091 g, 73.1%).



1H NMR (400 MHz, CDCl3) δ 7.92-7.83 (m, 1H), 7.79-7.64 (m, 2H), 7.25 (dd, 1H, J=15.9, 8.2 Hz), 7.19-7.08 (m, 3H), 7.05 (s, 0.2H), 6.92 (S, 0.5H), 6.79 (s, 0.2H), 5.02 (s, 2H), 3.02 (s, 3H), 2.34 (s, 3H); LRMS (ES) m/z 412.0 (M++1).


EXAMPLE 29
Compound 11179: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide
[Step 1] N-(3-methoxyphenyl)methanesulfonamide



embedded image


A solution of 3-methoxyaniline (1.000 g, 8.120 mmol), pyridine (0.721 mL, 8.931 mmol) and methanesulfonyl chloride (0.759 mL, 9.743 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-methoxyphenyl)methanesulfonamide, 0.920 g, 52.6%, yellow oil).


[Step 2] methyl 3-fluoro-4-((N-(3-methoxyphenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(3-methoxyphenyl)methanesulfonamide (0.700 g, 3.252 mmol), sodium hydride (60.00%, 0.156 g, 3.902 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.884 g, 3.577 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(3-methoxyphenyl)methylsulfonamido)methyl)benzoate as yellow solid (0.900 g, 75.3%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(3-methoxyphenyl)methylsulfonamido)methyl)benzoate (0.973 g, 2.648 mmol) and hydrazine hydrate (1.326 g, 26.484 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide, 0.830 g, 85.3%, yellow oil).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide (0.200 g, 0.544 mmol), trifluoroacetic anhydride (0.083 mL, 0.599 mmol) and triethylamine (0.114 mL, 0.817 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide, 0.140 g, 55.5%, yellow solid).


[Step 5] Compound 11179



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide (0.140 g, 0.302 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.108 g, 0.453 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide as white solid (0.100 g, 74.3%).



1H NMR (400 MHz, CDCl3) δ 7.90-7.82 (m, 1H), 7.79-7.65 (m, 2H), 7.31-7.20 (m, 1H), 6.96-6.80 (m, 3H), 5.03 (s, 2H), 3.77 (s, 3H), 3.02 (s, 3H); LRMS (ES) m/z 446.3 (M++1).


EXAMPLE 30
Compound 11180: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-methoxyphenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-methoxyphenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-methoxyphenyl)methanesulfonamide (0.200 g, 0.544 mmol), difluoroacetic anhydride (0.065 mL, 0.599 mmol) and triethylamine (0.114 mL, 0.817 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-methoxyphenyl)methanesulfonamide, 0.160 g, 66.0%, white solid).


[Step 2] Compound 11180



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-methoxyphenyl)methanesulfonamide (0.160 g, 0.359 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.128 g, 0.539 mmol) in dichloromethane (10 mL) was heated at 150° C. for 30 min under the microwaves, cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-methoxyphenyl)methanesulfonamide as white solid (0.120 g, 78.2%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=7.9, 1.7 Hz), 7.75 (dd, 1H, J=10.0, 1.7 Hz), 7.68 (t, 1H, J=7.6 Hz), 7.31-7.22 (m, 1H), 7.05 (s, 0.2H), 6.95-6.81 (m, 3H), 6.79 (s, 0.2H), 5.03 (s, 2H), 3.78 (d, 3H, J=0.6 Hz), 3.03 (d, 3H, J=0.5 Hz); LRMS (ES) m/z 428.1 (M++1).


EXAMPLE 31
Compound 11181: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)methanesulfonamide
[Step 1] N-(3-fluorophenyl)methanesulfonamide



embedded image


A solution of 3-fluoroaniline (0.800 g, 7.199 mmol), pyridine (0.639 mL, 7.919 mmol) and methanesulfonyl chloride (0.673 mL, 8.639 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-fluorophenyl)methanesulfonamide, 0.610 g, 44.8%, yellow oil).


[Step 2] methyl 3-fluoro-4-((N-(3-fluorophenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(3-fluorophenyl)methanesulfonamide (0.610 g, 3.224 mmol), sodium hydride (0.093 g, 3.869 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.876 g, 3.547 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (methyl 3-fluoro-4-((N-(3-fluorophenyl)methylsulfonamido)methyl)benzoate, 0.590 g, 51.5%, yellow oil).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(3-fluorophenyl)methylsulfonamido)methyl)benzoate (0.590 g, 1.660 mmol) and hydrazine hydrate (0.831 g, 16.603 mmol) in dichloromethane (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)methanesulfonamide, 0.500 g, 84.7%, yellow oil).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-fluorophenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)methanesulfonamide (0.200 g, 0.563 mmol), trifluoroacetic anhydride (0.086 mL, 0.619 mmol) and triethylamine (0.118 mL, 0.844 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-fluorophenyl)methanesulfonamide, 0.150 g, 59.0%, yellow solid).


[Step 5] Compound 11181



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(3-fluorophenyl)methanesulfonamide (0.150 g, 0.332 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.119 g, 0.498 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)methanesulfonamide as white solid (0.091 g, 63.2%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.1, 1.7 Hz), 7.77 (dd, 1H, J=9.8, 1.6 Hz), 7.68 (t, 1H, J=7.6 Hz), 7.39-7.30 (m, 1H), 7.18-6.99 (m, 3H), 5.04 (s, 2H), 3.05 (s, 3H); LRMS (ES) m/z 434.1 (M++1).


EXAMPLE 32
Compound 11182: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-fluorophenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)methanesulfonamide (0.200 g, 0.563 mmol), difluoroacetic anhydride (0.067 mL, 0.619 mmol) and triethylamine (0.118 mL, 0.844 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-fluorophenyl)methanesulfonamide, 0.150 g, 61.5%, white solid).


[Step 2] Compound 11182



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(3-fluorophenyl)methanesulfonamide (0.150 g, 0.346 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.124 g, 0.519 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)methanesulfonamide as white solid (0.089 g, 61.9%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.0, 1.7 Hz), 7.77 (dd, 1H, J=9.9, 1.7 Hz), 7.66 (t, 1H, J=7.6 Hz), 7.34 (td, 1H, J=8.2, 6.3 Hz), 7.18-6.98 (m, 3H), 6.92 (s, 0.5H), 6.79 (s, 0.2H), 5.03 (s, 2H), 3.04 (s, 3H); LRMS (ES) m/z 416.3 (M++1).


EXAMPLE 33
Compound 11183: N-(3-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylmethanesulfonamide
[Step 1] methyl 2-fluoro-4-((phenylamino)methyl)benzoate



embedded image


Methyl 2-fluoro-4-formylbenzoate (1.076 g, 5.906 mmol) and acetic acid (0.338 mL, 5.906 mmol) were added to a solution of aniline (0.500 g, 5.369 mmol) in dichloromethane (30 mL) at the room temperature, and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with sodium triacetoxyborohydride (2.276 g, 10.738 mmol), and stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 2-fluoro-4-((phenylamino)methyl)benzoate as colorless oil (1.000 g, 71.8%).


[Step 2] methyl 2-fluoro-4-((N-phenylmethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 2-fluoro-4-((phenylamino)methyl)benzoate (0.540 g, 2.083 mmol), triethylamine (0.581 mL, 4.165 mmol) and methanesulfonyl chloride (0.195 mL, 2.499 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 35%) to give methyl 2-fluoro-4-((N-phenylmethylsulfonamido)methyl)benzoate as yellow solid (0.600 g, 85.4%).


[Step 3] N-(3-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide



embedded image


A mixture of methyl 2-fluoro-4-((N-phenylmethylsulfonamido)methyl)benzoate (0.600 g, 1.778 mmol) and hydrazine hydrate (0.890 g, 17.785 mmol) in dichloromethane (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide, 0.520 g, 86.7%, yellow oil).


[Step 4] N-(3-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylmethanesulfonamide



embedded image


A solution of N-(3-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide (0.200 g, 0.593 mmol), trifluoroacetic anhydride (0.091 mL, 0.652 mmol) and triethylamine (0.124 mL, 0.889 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylmethanesulfonamide, 0.120 g, 46.7%, white solid).


[Step 5] Compound 11183



embedded image


A mixture of N-(3-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylmethanesulfonamide (0.120 g, 0.277 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.099 g, 0.415 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylmethanesulfonamide as white solid (0.079 g, 68.7%).



1H NMR (400 MHz, CDCl3) δ 8.05 (dd, 1H, J=8.2, 7.0 Hz), 7.46-7.25 (m, 7H), 4.96 (s, 2H), 3.02 (s, 3H); LRMS (ES) m/z 416.3 (M++1).


EXAMPLE 34
Compound 11184: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-3-fluorobenzyl)-N-phenylmethanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-3-fluorobenzyl)-N-phenylmethanesulfonamide



embedded image


A solution of N-(3-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylmethanesulfonamide (0.200 g, 0.593 mmol), difluoroacetic anhydride (0.071 mL, 0.652 mmol) and triethylamine (0.124 mL, 0.889 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-3-fluorobenzyl)-N-phenylmethanesulfonamide, 0.130 g, 52.8%, white solid).


[Step 2] Compound 11184



embedded image


A solution of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-3-fluorobenzyl)-N-phenylmethanesulfonamide (0.130 g, 0.313 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.112 g, 0.469 mmol) in tetrahydrofuran (10 mL) was stirred at 150° C. for 30 min, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-3-fluorobenzyl)-N-phenylmethanesulfonamide as white solid (0.096 g, 77.2%).



1H NMR (400 MHz, CDCl3) δ 8.04 (dd, 1H, J=8.2, 7.0 Hz), 7.45-7.28 (m, 6H), 7.06 (s, OH), 6.94 (s, OH), 6.81 (s, OH), 4.96 (s, 2H), 3.02 (s, 3H); LRMS (ES) m/z 398.3 (M++1).


EXAMPLE 35
Compound 11186: N,N-bis(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] dimethyl 4,4′-(azanediylbis(methylene))dibenzoate



embedded image


Acetic acid (0.099 mL, 1.731 mmol) was added to a solution of methyl 4-(aminomethyl)benzoate (0.260 g, 1.574 mmol) and methyl 4-formylbenzoate (0.284 g, 1.731 mmol) in dichloromethane (10 mL) at the room temperature, and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with sodium triacetoxyborohydride (0.667 g, 3.148 mmol), and stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give dimethyl 4,4′-(azanediylbis(methylene))dibenzoate as white solid (0.248 g, 50.3%).


[Step 2] dimethyl 4,4′-(((methylsulfonyl)azanediyl)bis(methylene))dibenzoate



embedded image


A solution of dimethyl 4,4′-(azanediylbis(methylene))dibenzoate (0.248 g, 0.791 mmol), triethylamine (0.165 mL, 1.187 mmol) and methanesulfonyl chloride (0.074 mL, 0.950 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give dimethyl 4,4′-(((methylsulfonyl)azanediyl)bis(methylene))dibenzoate as white solid (0.250 g, 80.7%).


[Step 3] N,N-bis(4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of dimethyl 4,4′-(((methylsulfonyl)azanediyl)bis(methylene))dibenzoate (0.250 g, 0.639 mmol) and hydrazine hydrate (0.320 g, 6.387 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N,N-bis(4-(hydrazinecarbonyl)benzyl)methanesulfonamide, 0.210 g, 84.0%, white solid).


[Step 4] Compound 11186



embedded image


A solution of N,N-bis(4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.100 g, 0.255 mmol), difluoroacetic anhydride (0.033 mL, 0.307 mmol) and triethylamine (0.071 mL, 0.511 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N,N-bis(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.079 g, 60.5%).



1H NMR (400 MHz, CDCl3) δ 8.10 (d, 4H, J=8.0 Hz), 7.48 (d, 4H, J=7.8 Hz), 7.07 (s, 0.3H), 6.94 (s, 0.8H), 6.81 (s, 0.4H), 4.49 (s, 4H), 2.96 (s, 3H); LRMS (ES) m/z 512.2 (M++1).


EXAMPLE 36
Compound 11190: N-(3-chlorophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-(3-chlorophenyl)methanesulfonamide



embedded image


A solution of 3-chloroaniline (0.500 g, 3.919 mmol), pyridine (0.348 mL, 4.311 mmol) and methanesulfonyl chloride (0.366 mL, 4.703 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chlorophenyl)methanesulfonamide, 0.700 g, 86.8%, yellow solid).


[Step 2] methyl 4-((N-(3-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of N-(3-chlorophenyl)methanesulfonamide (0.700 g, 3.404 mmol), sodium hydride (60.00%, 0.163 g, 4.084 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.925 g, 3.744 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-((N-(3-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate as yellow solid (0.640 g, 50.6%).


[Step 3] N-(3-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(3-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate (0.640 g, 1.721 mmol) and hydrazine hydrate (0.862 g, 17.213 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide, 0.570 g, 89.1%, white solid).


[Step 4] N-(3-chlorophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide



embedded image


A solution of N-(3-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.250 g, 0.672 mmol), trifluoroacetic anhydride (0.112 mL, 0.807 mmol) and triethylamine (0.187 mL, 1.345 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chlorophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide, 0.170 g, 54.0%, yellow solid).


[Step 5] Compound 11190



embedded image


A mixture of N-(3-chlorophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide (0.170 g, 0.363 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.130 g, 0.545 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(3-chlorophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.110 g, 67.3%).



1H NMR (400 MHz, CDCl3) δ 7.90 (dd, 1H, J=8.0, 1.7 Hz), 7.78 (dd, 1H, J=9.9, 1.7 Hz), 7.68 (t, 1H, J=7.6 Hz), 7.39-7.27 (m, 3H), 7.32-7.19 (m, 1H), 5.03 (s, 2H), 3.04 (s, 3H); LRMS (ES) m/z 450.2 (M++1).


EXAMPLE 37
Compound 11191: N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide
[Step 1] N-(3-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide



embedded image


A solution of N-(3-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.250 g, 0.672 mmol), difluoroacetic anhydride (0.088 mL, 0.807 mmol) and triethylamine (0.187 mL, 1.345 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide, 0.180 g, 59.5%, yellow solid).


[Step 2] Compound 11191



embedded image


A mixture of N-(3-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide (0.180 g, 0.400 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.143 g, 0.600 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as white solid (0.120 g, 69.4%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.0, 1.7 Hz), 7.76 (dd, 1H, J=10.0, 1.7 Hz), 7.65 (t, 1H, J=7.6 Hz), 7.39-7.18 (m, 4H), 7.05 (s, 0.2H), 6.93 (s, 0.5H), 6.80 (s, 0.2H), 5.02 (s, 2H), 3.04 (s, 3H); LRMS (ES) m/z 432.0 (M++1).


EXAMPLE 38
Compound 11192: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide
[Step 1] N-(4-methoxyphenyl)methanesulfonamide



embedded image


A solution of 4-methoxyaniline (0.600 g, 4.872 mmol), pyridine (0.424 g, 5.359 mmol) and methanesulfonyl chloride (0.670 g, 5.846 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-methoxyphenyl)methanesulfonamide, 0.840 g, 85.7%, yellow solid).


[Step 2] methyl 3-fluoro-4-((N-(4-methoxyphenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(4-methoxyphenyl)methanesulfonamide (1.000 g, 4.969 mmol), sodium hydride (60.00%, 0.239 g, 5.963 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (1.350 g, 5.466 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(4-methoxyphenyl)methylsulfonamido)methyl)benzoate as yellow solid (0.810 g, 44.4%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(4-methoxyphenyl)methylsulfonamido)methyl)benzoate (0.810 g, 2.205 mmol) and hydrazine hydrate (1.104 g, 22.047 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide, 0.700 g, 86.4%, white solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide (0.350 g, 0.953 mmol), trifluoroacetic anhydride (0.159 mL, 1.143 mmol) and triethylamine (0.264 mL, 1.905 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide, 0.250 g, 56.6%, yellow solid).


[Step 5] Compound 11192



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide (0.250 g, 0.539 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.193 g, 0.809 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide as yellow solid (0.190 g, 79.1%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.0, 1.8 Hz), 7.78-7.65 (m, 2H), 7.26-7.16 (m, 2H), 6.92-6.81 (m, 2H), 4.98 (s, 2H), 3.79 (s, 3H), 3.01 (s, 3H); LRMS (ES) m/z 446.2 (M++1).


EXAMPLE 39
Compound 11193: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4-methoxyphenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-methoxyphenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-methoxyphenyl)methanesulfonamide (0.350 g, 0.953 mmol), difluoroacetic anhydride (0.124 mL, 1.143 mmol) and triethylamine (0.264 mL, 1.905 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-methoxyphenyl)methanesulfonamide, 0.260 g, 61.3%, white solid).


[Step 2] Compound 11193



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-methoxyphenyl)methanesulfonamide (0.260 g, 0.584 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.209 g, 0.876 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4-methoxyphenyl)methanesulfonamide as yellow solid (0.180 g, 72.1%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.0, 1.7 Hz), 7.75 (dd, 1H, J=9.9, 1.7 Hz), 7.67 (dd, 1H, J=8.0, 7.3 Hz), 7.26-7.16 (m, 2H), 7.05 (s, 0.2H), 6.92 (s, 0.5H), 6.89-6.82 (m, 2H), 6.80 (s, 0.2H), 4.98 (s, 2H), 3.79 (s, 3H), 3.01 (s, 3H); LRMS (ES) m/z 428.3 (M++1).


EXAMPLE 40
Compound 11194: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide
[Step 1] N-(pyrimidin-5-yl)methanesulfonamide



embedded image


A solution of pyrimidin-5-amine (0.500 g, 5.257 mmol), pyridine (0.467 mL, 5.783 mmol) and methanesulfonyl chloride (0.492 mL, 6.308 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(pyrimidin-5-yl)methanesulfonamide as yellow solid (0.610 g, 67.0%).


[Step 2] methyl 3-fluoro-4-((N-(pyrimidin-5-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(pyrimidin-5-yl)methanesulfonamide (0.610 g, 3.522 mmol), sodium hydride (60.00%, 0.169 g, 4.227 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.957 g, 3.874 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(pyrimidin-5-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.590 g, 49.4%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(pyrimidin-5-yl)methylsulfonamido)methyl)benzoate (0.590 g, 1.739 mmol) and hydrazine hydrate (0.870 g, 17.387 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide, 0.520 g, 88.1%, white solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide (0.245 g, 0.722 mmol), trifluoroacetic anhydride (0.121 mL, 0.866 mmol) and triethylamine (0.200 mL, 1.444 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide, 0.180 g, 57.3%, yellow solid).


[Step 5] Compound 11194



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide (0.180 g, 0.413 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.148 g, 0.620 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide as yellow solid (0.090 g, 52.2%).



1H NMR (400 MHz, CDCl3) δ 9.14 (d, 1H, J=0.6 Hz), 8.73 (s, 2H), 7.94 (dd, 1H, J=8.1, 1.6 Hz), 7.81 (dd, 1H, J=9.8, 1.7 Hz), 7.68 (t, 1H, J=7.6 Hz), 5.07 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 418.3 (M++1).


EXAMPLE 41
Compound 11195: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(pyrimidin-5-yl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(pyrimidin5-5yl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide (0.245 g, 0.722 mmol), difluoroacetic anhydride (0.094 mL, 0.866 mmol) and triethylamine (0.200 mL, 1.444 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(pyrimidin5-5yl)methanesulfonamide, 0.170 g, 52.3%, yellow solid).


[Step 2] Compound 11195



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(pyrimidin-5-yl)methanesulfonamide (0.170 g, 0.407 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.146 g, 0.611 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(pyrimidin-5-yl)methanesulfonamide as yellow solid (0.100 g, 61.5%).



1H NMR (400 MHz, CDCl3) δ 9.12 (s, 1H), 8.70 (s, 2H), 7.91 (dd, 1H, J=8.1, 1.6 Hz), 7.78 (dd, 1H, J=10.0, 1.6 Hz), 7.64 (t, 1H, J=7.6 Hz), 7.04 (s, 0.04H), 6.91 (s, 0.06H), 6.78 (s, 0.2H), 5.04 (s, 2H), 3.08 (s, 3H); LRMS (ES) m/z 400.1 (M++1).


EXAMPLE 42
Compound 11196: N-(3-bromophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-(3-bromophenyl)methanesulfonamide



embedded image


A solution of 3-bromoaniline (1.000 g, 5.813 mmol), pyridine (0.516 mL, 6.394 mmol) and methanesulfonyl chloride (0.799 g, 6.976 mmol) in dichloromethane (50 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(3-bromophenyl)methanesulfonamide as white solid (1.100 g, 75.7%).


[Step 2] methyl 4-((N-(3-bromophenyl)methylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of N-(3-bromophenyl)methanesulfonamide (0.500 g, 1.999 mmol), sodium hydride (60.00%, 0.096 g, 2.399 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.543 g, 2.199 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-((N-(3-bromophenyl)methylsulfonamido)methyl)-3-fluorobenzoate as yellow solid (0.490 g, 58.9%).


[Step 3] N-(3-bromophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(3-bromophenyl)methylsulfonamido)methyl)-3-fluorobenzoate (0.490 g, 1.177 mmol) and hydrazine hydrate (0.589 g, 11.771 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-bromophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide, 0.400 g, 81.6%, white solid).


[Step 4] Compound 11196



embedded image


A solution of N-(3-bromophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.200 g, 0.480 mmol), trifluoroacetic anhydride (0.074 mL, 0.529 mmol) and triethylamine (0.100 mL, 0.721 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-bromophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.100 g, 42.1%).



1H NMR (400 MHz, CDCl3) δ 7.90 (dd, 1H, J=8.1, 1.7 Hz), 7.77 (dd, 1H, J=9.8, 1.6 Hz), 7.68 (dd, 1H, J=8.1, 7.2 Hz), 7.52 (t, 1H, J=1.9 Hz), 7.48-7.44 (m, 1H), 7.29-7.22 (m, 2H), 5.03 (s, 2H), 3.04 (s, 3H); LRMS (ES) m/z 496.2 (M++1).


EXAMPLE 43
Compound 11197: N-(3-bromophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide



embedded image


A solution of N-(3-bromophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.200 g, 0.480 mmol), difluoroacetic anhydride (0.057 mL, 0.529 mmol) and triethylamine (0.100 mL, 0.721 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-bromophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as yellow solid (0.130 g, 56.8%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.0, 1.6 Hz), 7.77 (dt, 1H, J=10.0, 1.3 Hz), 7.65 (t, 1H, J=7.6 Hz), 7.54-7.49 (m, 1H), 7.48-7.42 (m, 1H), 7.32-7.20 (m, 2H), 7.05 (s, 0.2H), 6.93 (s, 0.5H), 6.80 (s, 0.2H), 5.02 (s, 2H), 3.04 (s, 3H); LRMS (ES) m/z 478.2 (M++1).


EXAMPLE 44
Compound 11216: N-(3-fluorophenyl)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] methyl 6-(((3-fluorophenyl)amino)methyl)nicotinate



embedded image


Acetic acid (0.283 mL, 4.950 mmol) was added to a solution of 3-fluoroaniline (0.500 g, 4.500 mmol) and methyl 6-formylnicotinate (0.817 g, 4.950 mmol) in dichloromethane (20 mL) at the room temperature, and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with sodium triacetoxyborohydride (1.907 g, 8.999 mmol), and stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-(((3-fluorophenyl)amino)methyl)nicotinate as yellow oil (0.500 g, 42.7%).


[Step 2] methyl 6-((N-(3-fluorophenyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((3-fluorophenyl)amino)methyl)nicotinate (0.500 g, 1.921 mmol), pyridine (0.186 mL, 2.305 mmol), N,N-dimethylpyridin-4-amine (DMAP, 0.012 g, 0.096 mmol) and methanesulfonyl chloride (0.180 mL, 2.305 mmol) in dichloromethane (10 mL) was stirred at 50° C. for 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(3-fluorophenyl)methylsulfonamido)methyl)nicotinate as yellow solid (0.380 g, 58.5%).


[Step 3] N-(3-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(3-fluorophenyl)methylsulfonamido)methyl)nicotinate (0.380 g, 1.123 mmol) and hydrazine hydrate (0.562 g, 11.231 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide, 0.280 g, 73.7%, white solid).


[Step 4] Compound 11216



embedded image


A solution of N-(3-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.090 g, 0.266 mmol), trifluoroacetic anhydride (0.041 mL, 0.293 mmol) and triethylamine (0.055 mL, 0.399 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-fluorophenyl)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.043 g, 38.8%).



1H NMR (400 MHz, CDCl3) δ 9.27 (dd, 1H, J=2.3, 0.8 Hz), 8.41 (dd, 1H, J=8.2, 2.2 Hz), 7.73-7.66 (m, 1H), 7.38-7.31 (m, 1H), 7.26-7.17 (m, 2H), 7.07-6.97 (m, 1H), 5.16 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 417.3 (M++1).


EXAMPLE 45
Compound 11217: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3-fluorophenyl)methanesulfonamide



embedded image


A solution of N-(3-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.090 g, 0.266 mmol), difluoroacetic anhydride (0.032 mL, 0.293 mmol) and triethylamine (0.055 mL, 0.399 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3-fluorophenyl)methanesulfonamide as yellow solid (0.053 g, 50.0%).



1H NMR (400 MHz, CDCl3) δ 9.27 (dd, 1H, J=2.3, 0.9 Hz), 8.40 (dd, 1H, J=8.2, 2.2 Hz), 7.68 (dd, 1H, J=8.3, 0.8 Hz), 7.38-7.30 (m, 1H), 7.27-7.16 (m, 2H), 7.08 (s, 0.2H), 7.05-6.98 (m, 1H), 6.95 (s, 0.5H), 6.82 (s, 0.2H), 5.15 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 399.0 (M++1).


EXAMPLE 46
Compound 11218: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide
[Step 1] N-(2-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of 2-(trifluoromethyl)aniline (1.000 g, 6.206 mmol), pyridine (0.551 mL, 6.827 mmol) and methanesulfonyl chloride (0.580 mL, 7.447 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-(trifluoromethyl)phenyl)methanesulfonamide, 1.100 g, 74.1%, yellow solid).


[Step 2] methyl 3-fluoro-4-((N-(2-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(2-(trifluoromethyl)phenyl)methanesulfonamide (0.500 g, 2.090 mmol), sodium hydride (60.00%, 0.100 g, 2.508 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.568 g, 2.299 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(2-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate as yellow solid (0.610 g, 72.0%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(2-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate (0.610 g, 1.505 mmol) and hydrazine hydrate (0.753 g, 15.048 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide, 0.530 g, 86.9%, yellow solid).


[Step 4] Compound 11218



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide (0.265 g, 0.654 mmol), trifluoroacetic anhydride (0.100 mL, 0.719 mmol) and triethylamine (0.136 mL, 0.981 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide as white solid (0.190 g, 60.1%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.0, 1.7 Hz), 7.79-7.70 (m, 2H), 7.66-7.57 (m, 1H), 7.56-7.46 (m, 2H), 7.31-7.21 (m, 1H), 5.01 (dd, 1H, J=14.7, 1.5 Hz), 4.86 (d, 1H, J=14.7 Hz), 3.12 (s, 3H); LRMS (ES) m/z 484.2 (M++1).


EXAMPLE 47
Compound 11219: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide (0.270 g, 0.666 mmol), difluoroacetic anhydride (0.087 mL, 0.799 mmol) and TEA (0.185 mL, 1.332 mmol) in (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide, 0.192 g, 59.6%, yellow solid).


[Step 2] Compound 11219



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide (0.192 g, 0.397 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.142 g, 0.596 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2-(trifluoromethyl)phenyl)methanesulfonamide as yellow solid (0.110 g, 59.5%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.0, 1.7 Hz), 7.79-7.70 (m, 2H), 7.59 (t, 1H, J=7.6 Hz), 7.55-7.46 (m, 2H), 7.27-7.21 (m, 1H), 7.06 (s, 0.2H), 6.93 (s, 0.5H), 6.80 (s, 0.2H), 5.00 (dd, 1H, J=14.8, 1.4 Hz), 4.86 (d, 1H, J=14.6 Hz), 3.12 (s, 3H); LRMS (ES) m/z 466.2 (M++1).


EXAMPLE 48
Compound 11220: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide
[Step 1] N-(4-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of 4-(trifluoromethyl)aniline (1.000 g, 6.206 mmol), pyridine (0.551 mL, 6.827 mmol) and methanesulfonyl chloride (0.580 mL, 7.447 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(trifluoromethyl)phenyl)methanesulfonamide, 1.200 g, 80.8%, yellow oil).


[Step 2] methyl 3-fluoro-4-((N-(4-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(4-(trifluoromethyl)phenyl)methanesulfonamide (0.500 g, 2.090 mmol), sodium hydride (60.00%, 0.100 g, 2.508 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.568 g, 2.299 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(4-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate as white solid (0.630 g, 74.4%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of methyl 3-fluoro-4-((N-(4-(trifluoromethyl)phenyl)methylsulfonamido)methyl)benzoate (0.630 g, 1.554 mmol) and hydrazine hydrate (0.778 g, 15.542 mmol) in ethanol (10 mL) was stirred at 120° C. for 1 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide, 0.600 g, 95.2%, yellow solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide (0.240 g, 0.592 mmol), trifluoroacetic anhydride (0.091 mL, 0.651 mmol) and triethylamine (0.123 mL, 0.888 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide, 0.180 g, 60.6%, yellow solid).


[Step 5] Compound 11220



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide (0.180 g, 0.359 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.128 g, 0.539 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide as yellow solid (0.130 g, 74.9%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.1, 1.7 Hz), 7.78 (dd, 1H, J=9.8, 1.7 Hz), 7.72-7.60 (m, 3H), 7.52-7.45 (m, 2H), 5.09 (s, 2H), 3.05 (s, 3H); LRMS (ES) m/z 484.4 (M++1).


EXAMPLE 49
Compound 11221: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide (0.240 g, 0.592 mmol), difluoroacetic anhydride (0.077 mL, 0.710 mmol) and triethylamine (0.123 mL, 0.888 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide, 0.140 g, 48.9%, yellow solid).


[Step 2] Compound 11221



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide (0.140 g, 0.365 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.131 g, 0.548 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4-(trifluoromethyl)phenyl)methanesulfonamide as yellow solid (0.092 g, 54.1%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.1, 1.7 Hz), 7.77 (dd, 1H, J=10.0, 1.7 Hz), 7.70-7.60 (m, 3H), 7.52-7.44 (m, 2H), 7.05 (s, 0.2H), 6.92 (s, 0.5H), 6.79 (s, 0.2H), 5.08 (s, 2H), 3.05 (s, 3H); LRMS (ES) m/z 466.3 (M++1).


EXAMPLE 50
Compound 11222: N-butyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide



embedded image


Sodium hydride (60.00%, 0.016 g, 0.405 mmol) was added to a solution of N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide (0.100 g, 0.311 mmol) in N,N-dimethylformide (2 mL) at 0° C., and the mixture was stirred for 30 min. The reaction mixture was treated with 1-iodobutane (0.063 g, 0.342 mmol), and stirred at the same temperature for 30 min. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 25%) to give the crude product which was rechromatographed (SiO2, 4 g cartridge; acetonitrile/aqueous 1%-formic acid solution=5% to 50%) to give N-butyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.035 g, 29.8%).



1H NMR (400 MHz, CDCl3) δ 8.14-8.06 (m, 2H), 7.61-7.53 (m, 2H), 4.46 (s, 2H), 3.27-3.12 (m, 2H), 2.90 (s, 3H), 1.47 (ddt, 2H, J=9.3, 7.7, 3.4 Hz), 1.28-1.21 (m, 2H), 0.84 (t, 3H, J=7.3 Hz); LRMS (ES) m/z 378.3 (M++1).


EXAMPLE 51
Compound 11225: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide
[Step 1] N-(3-fluorophenyl)pyridine-3-sulfonamide



embedded image


Triethylamine (1.622 mL, 11.699 mmol) wa added to a solution of 3-fluoroaniline (1.000 g, 8.999 mmol) in dichloromethane (14 mL) at the room temperature, and the mixture was stirred at the same temperature for 10 min. The reaction mixture was treated with pyridine-3-sulfonyl chloride (1.758 g, 9.899 mmol), and stirred for additional 24 hr at the same temperature. The precipitates were collected by filtration, washed by diethylether, and dried to give N-(3-fluorophenyl)pyridine-3-sulfonamide as light yellow solid (1.900 g, 83.7%).


[Step 2] methyl 3-fluoro-4-((N-(3-fluorophenyl)pyridine-3-sulfonamido)methyl)benzoate



embedded image


Sodium hydride (60.00%, 0.076 g, 1.903 mmol) was added to a solution of N-(3-fluorophenyl)pyridine-3-sulfonamide (0.400 g, 1.586 mmol) in N,N-dimethylformide (6 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with methyl 4-(bromomethyl)-3-fluorobenzoate (0.411 g, 1.665 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(3-fluorophenyl)pyridine-3-sulfonamido)methyl)benzoate as white solid (0.250 g, 37.7%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(3-fluorophenyl)pyridine-3-sulfonamido)methyl)benzoate (0.250 g, 0.598 mmol) and hydrazine hydrate (0.057 g, 1.793 mmol) in ethanol (6 mL) prepared at the ambient temperature was heated at reflux for 24 hr, and cooled down to the ambient temperature. The reaction mixture was concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide as white solid (0.220 g, 88.0%).


[Step 4] Compound 11225



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide (0.040 g, 0.096 mmol) and triethylamine (0.017 mL, 0.124 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with 2,2-difluoroacetic anhydride (0.012 mL, 0.115 mmol). The reaction mixture was heated at reflux for 8 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)pyridine-3-sulfonamide as white solid (0.035 g, 76.5%).



1H NMR (400 MHz, DMSO-d6) δ 8.96 (dd, 1H, J=4.9, 1.6 Hz), 8.87 (dd, 1H, J=2.4, 0.8 Hz), 8.11 (ddd, 1H, J=8.1, 2.4, 1.6 Hz), 7.91-7.78 (m, 2H), 7.78-7.69 (m, 2H), 7.68 (s, 0.25H), 7.56 (s, 0.5H), 7.44 (s, 0.25H), 7.39 (td, 1H, J=8.2, 6.6 Hz), 7.24-7.11 (m, 2H), 7.06 (ddd, 1H, J=8.0, 2.0, 0.9 Hz), 5.08 (s, 2H); LRMS (ES) m/z 480.1 (M++1).


EXAMPLE 52
Compound 11226: N-(benzo[d][1,3]dioxol-5-yl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-(benzo[d][1,3]dioxol-5-yl)methanesulfonamide



embedded image


Triethylamine (1.314 mL, 9.479 mmol) was added to a solution of benzo[d][1,3]dioxol-5-amine (1.000 g, 7.292 mmol) in dichloromethane (14 mL) at the room temperature, and the mixture was stirred at the same temperature for 10 min. The reaction mixture was treated with methanesulfonyl chloride (0.621 mL, 8.021 mmol), and stirred for additional 24 hr at the same temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(benzo[d][1,3]dioxol-5-yl)methanesulfonamide, 1.400 g, 89.2%, light yellow solid).


[Step 2] methyl 4-((N-(benzo[d][1,3]dioxol-5-yl)methylsulfonamido)methyl)-3-fluorobenzoate



embedded image


Sodium hydride (60.00%, 0.067 g, 1.673 mmol) was added to a solution of N-(benzo[d][1,3]dioxol-5-yl)methanesulfonamide (0.300 g, 1.394 mmol) in N,N-dimethylformide (4 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with methyl 4-(bromomethyl)-3-fluorobenzoate (0.362 g, 1.464 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-((N-(benzo[d][1,3]dioxol-5-yl)methylsulfonamido)methyl)-3-fluorobenzoate as white solid (0.210 g, 39.5%).


[Step 3] N-(benzo[d][1,3]dioxol-5-yl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(benzo[d][1,3]dioxol-5-yl)methylsulfonamido)methyl)-3-fluorobenzoate (0.210 g, 0.551 mmol) and hydrazine hydrate (0.053 g, 1.652 mmol) in ethanol (6 mL) prepared at the ambient temperature was heated at reflux for 24 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(benzo[d][1,3]dioxol-5-yl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide as white solid (0.190 g, 90.5%).


[Step 4] Compound 11226



embedded image


A solution of N-(benzo[d][1,3]dioxol-5-yl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.055 g, 0.144 mmol) and triethylamine (0.026 mL, 0.187 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with trifluoroacetic anhydride (0.021 mL, 0.159 mmol). The reaction mixture was heated at reflux for 8 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(benzo[d][1,3]dioxol-5-yl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.040 g, 60.4%).



1H NMR (400 MHz, DMSO-d6) δ 7.98-7.80 (m, 2H), 7.72 (t, 1H, J=7.7 Hz), 6.99-6.86 (m, 2H), 6.06 (s, 2H), 4.99 (s, 2H), 3.15 (s, 3H); LRMS (ES) m/z 460.2 (M++1).


EXAMPLE 53
Compound 11227: N-(benzo[d][1,3]dioxol-5-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide



embedded image


A solution of N-(benzo[d][1,3]dioxol-5-yl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.055 g, 0.144 mmol) and triethylamine (0.026 mL, 0.187 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with 2,2-difluoroacetic anhydride (0.019 mL, 0.173 mmol). The reaction mixture was heated at reflux for 8 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(benzo[d][1,3]dioxol-5-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as white solid (0.035 g, 55.0%).



1H NMR (400 MHz, DMSO-d6) δ 7.90 (dd, 1H, J=8.0, 1.7 Hz), 7.82 (dd, 1H, J=10.3, 1.6 Hz), 7.71 (t, 1H, J=6.8 Hz), 7.69 (s, 0.25H), 7.57 (d, 0.5H), 7.44 (s, 0.25H), 7.10 (s, 1H), 6.96-6.85 (m, 2H), 6.06 (s, 2H), 4.98 (s, 2H), 3.14 (d, 3H, J=0.7 Hz); LRMS (ES) m/z 442.2 (M++1).


EXAMPLE 54
Compound 11229: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylcyclohexanesulfonamide
[Step 1] N-phenylcyclohexanesulfonamide



embedded image


A mixture of aniline (0.500 g, 5.369 mmol) and pyridine (0.520 mL, 6.443 mmol) in dichloromethane (10 mL) was treated at the room temperature with cyclohexanesulfonyl chloride (1.079 g, 5.906 mmol), and stirred at the same temperature for 5 min. The reaction mixture was stirred at the same temperature for additional 2 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 0.1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-phenylcyclohexanesulfonamide, 1.400 g, 109.0%, brown solid).


[Step 2] Compound 11229



embedded image


A mixture of 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.050 g, 0.154 mmol) and N-phenylcyclohexanesulfonamide (0.040 g, 0.169 mmol) in N,N-dimethylformide (10 mL) was treated at the room temperature with NaH (60.00%, 0.007 g, 0.185 mmol), and stirred at the same temperature for 5 min. The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylcyclohexanesulfonamide as white solid (0.070 g, 97.8%).



1H NMR (400 MHz, CDCl3) δ 7.88-7.86 (m, 1H), 7.74-7.69 (m, 2H), 7.35-7.27 (m, 5H), 6.91 (t, 1H, J=52.0 Hz), 5.08 (brs, 2H), 3.05-3.00 (m, 1H), 2.23-2.14 (m, 2H), 1.92 (m, 2H), 1.72-1.66 (m, 4H), 1.28-1.24 (m, 2H); LRMS (ES) m/z 466.30 (M++1).


EXAMPLE 55
Compound 11230: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylbutane-2-sulfonamide
[Step 1] N-phenylbutane-2-sulfonamide



embedded image


A mixture of aniline (0.078 mL, 0.859 mmol) and pyridine (0.083 mL, 1.031 mmol) in dichloromethane (10 mL) was treated at the room temperature with butane-2-sulfonyl chloride (0.148 g, 0.945 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 0.1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-phenylbutane-2-sulfonamide as yellow solid (0.160 g, 87.3%).


[Step 2] Compound 11230



embedded image


A solution of 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.050 g, 0.154 mmol) and N-phenylbutane-2-sulfonamide (0.036 g, 0.169 mmol) in dichloromethane (10 mL) was mixed at the room temperature with sodium hydride (60.00%, 0.007 g, 0.185 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 0.1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylbutane-2-sulfonamide as white solid (0.045 g, 64.0%).



1H NMR (400 MHz, CDCl3) δ 7.88-7.86 (m, 1H), 7.74-7.69 (m, 2H), 7.35-7.27 (m, 5H), 6.91 (t, 1H, J=52.0 Hz), 5.11-5.08 (m, 2H), 3.09-3.04 (m, 1H), 2.13-2.07 (m, 1H), 1.74-1.64 (m, 1H), 1.44 (d, 3H, J=8.0 Hz), 1.03 (t, 3H, J=8.0 Hz); LRMS (ES) m/z m/z 440.23 (M++1).


EXAMPLE 56
Compound 11231: methyl 2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylsulfamoyl)acetate
[Step 1] methyl 2-(N-phenylsulfamoyl)acetate



embedded image


A mixture of aniline (0.147 mL, 1.611 mmol) and pyridine (0.156 mL, 1.933 mmol) in dichloromethane (10 mL) was treated at the room temperature with methyl 2-(chlorosulfonyl)acetate (0.306 g, 1.772 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 0.1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification. (methyl 2-(N-phenylsulfamoyl)acetate, 0.300 g, 75.3%, brown solid).


[Step 2] Compound 11231



embedded image


A solution of 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.050 g, 0.154 mmol), methyl 2-(N-phenylsulfamoyl)acetate (0.039 g, 0.169 mmol) and sodium hydride (60.00%, 0.007 g, 0.185 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 0.1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give methyl 2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylsulfamoyl)acetate as light-yellow oil (0.035 g, 50.0%).



1H NMR (400 MHz, CDCl3) δ 7.89-7.87 (m, 1H), 7.72-7.66 (m, 2H), 7.47-7.45 (m, 2H), 7.40-7.28 (m, 3H), 6.91 (t, 1H, J=52.0 Hz), 5.12 (s, 2H), 4.07 (s, 2H), 3.87 (s, 3H); LRMS (ES) m/z 454.27 (M+−1).


EXAMPLE 57
Compound 11248: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(o-tolyl)methanesulfonamide
[Step 1] N-(o-tolyl)methanesulfonamide



embedded image


A solution of o-toluidine (1.000 g, 9.332 mmol), pyridine (0.829 mL, 10.265 mmol) and methanesulfonyl chloride (0.873 mL, 11.198 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(o-tolyl)methanesulfonamide, 0.910 g, 52.6%, yellow solid).


[Step 2] methyl 3-fluoro-4-((N-(o-tolyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(o-tolyl)methanesulfonamide (0.500 g, 2.699 mmol), sodium hydride (60.00%, 0.130 g, 3.239 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.734 g, 2.969 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(o-tolyl)methylsulfonamido)methyl)benzoate as yellow solid (0.610 g, 64.3%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(o-tolyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(o-tolyl)methylsulfonamido)methyl)benzoate (0.610 g, 1.736 mmol) and hydrazine hydrate (0.869 g, 17.360 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(o-tolyl)methanesulfonamide, 0.530 g, 86.9%, yellow solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(o-tolyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(o-tolyl)methanesulfonamide (0.260 g, 0.740 mmol), trifluoroacetic anhydride (0.113 mL, 0.814 mmol) and triethylamine (0.154 mL, 1.110 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(o-tolyl)methanesulfonamide, 0.190 g, 57.4%, yellow solid).


[Step 5] Compound 11248



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(o-tolyl)methanesulfonamide (0.190 g, 0.425 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.152 g, 0.637 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(o-tolyl)methanesulfonamide as white solid (0.100 g, 54.8%).



1H NMR (400 MHz, CDCl3) δ 7.85 (dd, 1H, J=8.1, 2.0 Hz), 7.80-7.72 (m, 1H), 7.61-7.51 (m, 1H), 7.28-7.15 (m, 4H), 4.92 (s, 2H), 3.07 (s, 3H), 2.23 (s, 3H); LRMS (ES) m/z 430.3 (M++1).


EXAMPLE 58
Compound 11249: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(o-tolyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(o-tolyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(o-tolyl)methanesulfonamide (0.260 g, 0.740 mmol), difluoroacetic anhydride (0.097 mL, 0.888 mmol) and triethylamine (0.205 mL, 1.480 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(o-tolyl)methanesulfonamide, 0.180 g, 56.7%, yellow solid).


[Step 2] Compound 11249



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(o-tolyl)methanesulfonamide (0.180 g, 0.419 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.150 g, 0.629 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(o-tolyl)methanesulfonamide as white solid (0.110 g, 63.8%).



1H NMR (400 MHz, CDCl3) δ 7.84 (dd, 1H, J=8.0, 1.7 Hz), 7.74 (dd, 1H, J=9.7, 1.7 Hz), 7.57-7.47 (m, 1H), 7.27-7.15 (m, 4H), 7.05 (s, 0.2H), 6.92 (s, 0.5H), 6.80 (s, 0.2H), 4.91 (s, 2H), 3.06 (s, 3H), 2.22 (s, 3H); LRMS (ES) m/z 412.3 (M++1).


EXAMPLE 59
Compound 11250: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide
[Step 1] N-(2-methoxyphenyl)methanesulfonamide



embedded image


A solution of 2-methoxyaniline (1.000 g, 8.120 mmol), pyridine (0.721 mL, 8.931 mmol) and methanesulfonyl chloride (0.759 mL, 9.743 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-methoxyphenyl)methanesulfonamide, 0.920 g, 56.3%, brown solid).


[Step 2] methyl 3-fluoro-4-((N-(2-methoxyphenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(2-methoxyphenyl)methanesulfonamide (0.500 g, 2.485 mmol), sodium hydride (60.00%, 0.119 g, 2.982 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.675 g, 2.733 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(2-methoxyphenyl)methylsulfonamido)methyl)benzoate as yellow solid (0.630 g, 69.0%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide



embedded image


A solution of methyl 3-fluoro-4-((N-(2-methoxyphenyl)methylsulfonamido)methyl)benzoate (0.630 g, 1.715 mmol) and hydrazine hydrate (0.858 g, 17.148 mmol) in ethanol (10 mL) was stirred at 120° C. for 1 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide, 0.520 g, 82.5%, yellow solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide (0.260 g, 0.708 mmol), trifluoroacetic anhydride (0.108 mL, 0.778 mmol) and triethylamine (0.147 mL, 1.062 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide, 0.210 g, 64.0%, yellow solid).


[Step 5] Compound 11250



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide (0.210 g, 0.453 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.162 g, 0.680 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide as white solid (0.130 g, 64.4%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.0, 1.8 Hz), 7.80-7.67 (m, 2H), 7.36-7.26 (m, 1H), 7.24-7.15 (m, 1H), 7.02-6.94 (m, 1H), 6.93-6.82 (m, 1H), 4.97 (s, 2H), 3.94 (d, 3H, J=0.9 Hz), 3.04 (d, 3H, J=1.0 Hz); LRMS (ES) m/z 446.0 (M++1).


EXAMPLE 60
Compound 11251: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2-methoxyphenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-methoxyphenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-methoxyphenyl)methanesulfonamide (0.260 g, 0.708 mmol), difluoroacetic anhydride (0.092 mL, 0.849 mmol) and triethylamine (0.196 mL, 1.415 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-methoxyphenyl)methanesulfonamide, 0.210 g, 66.6%, yellow solid).


[Step 2] Compound 11251



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-methoxyphenyl)methanesulfonamide (0.210 g, 0.471 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.169 g, 0.707 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2-methoxyphenyl)methanesulfonamide as white solid (0.126 g, 62.5%).



1H NMR (400 MHz, CDCl3) δ 7.91-7.83 (m, 1H), 7.77-7.66 (m, 2H), 7.36-7.26 (m, 1H), 7.22-7.15 (m, 1H), 7.05 (s, 0.2H), 7.00-6.94 (m, 1H), 6.92 (s, 0.5H), 6.91-6.83 (m, 1H), 6.79 (s, 0.2H), 4.97 (s, 2H), 3.94 (s, 3H), 3.04 (s, 3H); LRMS (ES) m/z 428.1 (M++1).


EXAMPLE 61
Compound 11252: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylpyridine-3-sulfonamide
[Step 1] N-phenylpyridine-3-sulfonamide



embedded image


A solution of pyridine-3-sulfonyl chloride (2.002 g, 11.275 mmol) and pyridine (1.274 g, 16.107 mmol) in dichloromethane (14 mL) was stirred at the room temperature for 20 min, and mixed with aniline (1.000 g, 10.738 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The title compound was used without further purification (N-phenylpyridine-3-sulfonamide, 2.300 g, 91.4%, orange solid).


[Step 2] 3-fluoro-4-methylbenzohydrazide



embedded image


A mixture of methyl 3-fluoro-4-methylbenzoate (10.000 g, 59.464 mmol) and hydrazine hydrate (9.526 g, 297.318 mmol) in ethanol (20 mL) prepared at the ambient temperature was heated at reflux for 16 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The precipitates were collected by filtration, washed by water, and dried to give 3-fluoro-4-methylbenzohydrazide as white solid (9.500 g, 95.0%).


[Step 3] N′-(2,2-difluoroacetyl)-3-fluoro-4-methylbenzohydrazide



embedded image


A solution of 3-fluoro-4-methylbenzohydrazide (4.000 g, 23.785 mmol) and triethylamine (4.286 mL, 30.921 mmol) in tetrahydrofuran (12 mL) was stirred at the room temperature for 10 min, and then mixed with 2,2-difluoroacetic anhydride (3.105 mL, 28.543 mmol). The reaction mixture was heated at reflux for 8 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 30%) to give N′-(2,2-difluoroacetyl)-3-fluoro-4-methylbenzohydrazide as white solid (4.900 g, 83.7%).


[Step 4] 2-(difluoromethyl)-5-(3-fluoro-4-methylphenyl)-1,3,4-oxadiazole



embedded image


A mixture of N′-(2,2-difluoroacetyl)-3-fluoro-4-methylbenzohydrazide (4.800 g, 19.497 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 3.563 g, 20.472 mmol) in tetrahydrofuran (25 mL) prepared at the ambient temperature was heated at reflux for 16 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 15%) to give 2-(difluoromethyl)-5-(3-fluoro-4-methylphenyl)-1,3,4-oxadiazole as white solid (2.830 g, 63.6%).


[Step 5] 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole



embedded image


A mixture of 2-(difluoromethyl)-5-(3-fluoro-4-methylphenyl)-1,3,4-oxadiazole (2.830 g, 12.403 mmol), 1-bromopyrrolidine-2,5-dione (NBS, 2.317 g, 13.023 mmol) and Azobisisobutyronitrile (AIBN, 0.102 g, 0.620 mmol) in dichloromethane (20 mL) prepared at the ambient temperature was heated at reflux for 24 hr, and cooled down to the ambient temperature. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 10%) to give 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole as white solid (2.900 g, 76.1%).


[Step 6] Compound 11252



embedded image


Sodium hydride (60.00%, 0.007 g, 0.179 mmol) was added to a solution of N-phenylpyridine-3-sulfonamide (0.035 g, 0.149 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.048 g, 0.157 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylpyridine-3-sulfonamide as white solid (0.055 g, 80.0%).



1H NMR (400 MHz, CDCl3) δ 8.94-8.85 (m, 2H), 7.96-7.84 (m, 2H), 7.74-7.66 (m, 2H), 7.52-7.46 (m, 1H), 7.35-7.24 (m, 3H), 7.05 (ddd, 2H, J=6.7, 3.1, 1.1 Hz), 7.04-6.76 (m, 1H), 4.95 (s, 2H); LRMS (ES) m/z 461.0 (M++1).


EXAMPLE 62
Compound 11253: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(6-(trifluoromethyl)pyridin-2-yl)pyridine-3-sulfonamide



embedded image


Sodium hydride (60.00%, 0.007 g, 0.178 mmol) was added to a solution of N-(6-(trifluoromethyl)pyridin-2-yl)pyridine-3-sulfonamide (0.045 g, 0.148 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(trifluoromethyl)-1,3,4-oxadiazole (0.051 g, 0.156 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(6-(trifluoromethyl)pyridin-2-yl)pyridine-3-sulfonamide as white solid (0.045 g, 55.4%).



1H NMR (400 MHz, CDCl3) δ 8.95 (d, 1H, J=2.4 Hz), 8.87 (dd, 1H, J=4.9, 1.6 Hz), 8.02 (dt, 1H, J=8.0, 2.0 Hz), 7.90 (t, 1H, J=7.9 Hz), 7.82 (dd, 1H, J=8.0, 1.7 Hz), 7.79-7.71 (m, 2H), 7.63 (t, 1H, J=7.6 Hz), 7.54-7.47 (m, 2H), 5.22 (s, 2H); LRMS (ES) m/z 546.18 (M+−1).


EXAMPLE 63
Compound 11254: N-(3-acetylphenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide
[Step 1] N-(3-acetylphenyl)methanesulfonamide



embedded image


Triethylamine (1.333 mL, 9.618 mmol) was added to a solution of 1-(3-aminophenyl)ethan-1-one (1.000 g, 7.398 mmol) in dichloromethane (14 mL) at the room temperature, and the mixture was stirred at the same temperature for 10 min. The reaction mixture was treated with methanesulfonyl chloride (0.630 mL, 8.138 mmol), and stirred for additional 24 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(3-acetylphenyl)methanesulfonamide as white solid (0.750 g, 47.5%).


[Step 2] Compound 11254



embedded image


Sodium hydride (60.00%, 0.007 g, 0.169 mmol) was added to a solution of N-(3-acetylphenyl)methanesulfonamide (0.030 g, 0.141 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.045 g, 0.148 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-acetylphenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as white solid (0.030 g, 48.5%).



1H NMR (400 MHz, CDCl3) δ 7.92 (t, 1H, J=1.9 Hz), 7.89-7.82 (m, 2H), 7.72 (dd, 1H, J=9.9, 1.7 Hz), 7.64 (t, 1H, J=7.6 Hz), 7.52 (ddd, 1H, J=8.0, 2.3, 1.2 Hz), 7.45 (t, 1H, J=7.8 Hz), 6.89 (t, 1H, J=51.7 Hz), 5.04 (s, 2H), 3.02 (s, 3H), 2.58 (s, 3H); LRMS (ES) m/z 438.16 (M+−1).


EXAMPLE 64
Compound 11255: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide
[Step 1] N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide



embedded image


Triethylamine (0.162 mL, 1.170 mmol) was added to a solution of aniline (0.100 g, 0.900 mmol) in dichloromethane (4 mL) at 0° C., and the mixture was stirred at the same temperature for 10 min. The reaction mixture was treated with tetrahydro-2H-thiopyran-4-sulfonyl chloride 1,1-dioxide (0.209 g, 0.900 mmol), and stirred for additional 25 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as white solid (0.250 g, 90.4%).


[Step 2] methyl 3-fluoro-4-(((N-(3-fluorophenyl)-1,1-dioxidotetrahydro-2H-thiopyran)-4-sulfonamido)methyl)benzoate



embedded image


Sodium hydride (60.00%, 0.041 g, 1.032 mmol) was added to a solution of N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide (0.244 g, 0.794 mmol) in N,N-dimethylformide (6 mL) at 0° C., and stirred at the same temperature for 20 min. The reaction mixture was treated with methyl 4-(bromomethyl)-3-fluorobenzoate (0.216 g, 0.873 mmol), and stirred at the same temperature for 20 min. Then, aqueous 1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-(((N-(3-fluorophenyl)-1,1-dioxidotetrahydro-2H-thiopyran)-4-sulfonamido)methyl)benzoate as colorlessness oil (0.220 g, 58.5%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide



embedded image


A mixture of methyl 3-fluoro-4-(((N-(3-fluorophenyl)-1,1-dioxidotetrahydro-2H-thiopyran)-4-sulfonamido)methyl)benzoate (0.220 g, 0.465 mmol) and hydrazine hydrate (0.074 g, 2.323 mmol) in ethanol (8 mL) prepared at the ambient temperature was heated at reflux for 18 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as white solid (0.200 g, 90.9%).


[Step 4] Compound 11255



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide (0.070 g, 0.148 mmol) and triethylamine (0.027 mL, 0.192 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with trifluoroacetic anhydride (0.022 mL, 0.163 mmol). The reaction mixture was heated at reflux for 16 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as white solid (0.065 g, 79.7%).



1H NMR (400 MHz, DMSO-d6) δ 7.93 (dd, 1H, J=8.0, 1.7 Hz), 7.85 (dd, 1H, J=10.1, 1.7 Hz), 7.68 (t, 1H, J=7.7 Hz), 7.51-7.39 (m, 2H), 7.35-7.30 (m, 1H), 7.22-7.15 (m, 1H), 5.18 (s, 2H), 3.76 (t, 1H, J=11.7 Hz), 3.51-3.43 (m, 2H), 3.37-3.29 (m, 2H), 3.23 (d, 2H, J=13.8 Hz), 2.18 (q, 2H, J=12.6 Hz); LRMS (ES) m/z 552.3 (M++1).


EXAMPLE 65
Compound 11256: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide (0.070 g, 0.148 mmol) and triethylamine (0.027 mL, 0.192 mmol) in tetrahydrofuran (2 mL) was stirred at the room temperature for 10 min, and then mixed with 2,2-difluoroacetic anhydride (0.019 mL, 0.177 mmol). The reaction mixture was heated at reflux for 16 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as white solid (0.070 g, 88.8%).



1H NMR (400 MHz, DMSO-d6) δ 7.90 (dd, 1H, J=8.0, 1.7 Hz), 7.82 (dd, 1H, J=10.1, 1.7 Hz), 7.68 (d, 1H, J=8.2 Hz), 7.65 (s, 0.25H), 7.56 (s, 0.5H), 7.49 (m, 0.25H), 7.49-7.37 (m, 2H), 7.33 (dd, 1H, J=8.2, 1.9 Hz), 7.19 (td, 1H, J=8.2, 2.2 Hz), 5.17 (s, 2H), 3.75 (t, 1H, J=11.8 Hz), 3.53-3.41 (m, 2H), 3.36-3.28 (m, 2H), 3.23 (d, 2H, J=13.6 Hz), 2.18 (q, 2H, J=12.6 Hz); LRMS (ES) m/z 534.3 (M++1).


EXAMPLE 66
Compound 11271: N-(4-chlorophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-(4-chlorophenyl)methanesulfonamide



embedded image


A solution of 4-chloroaniline (1.000 g, 7.839 mmol), pyridine (0.696 mL, 8.623 mmol) and methanesulfonyl chloride (0.733 mL, 9.407 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-chlorophenyl)methanesulfonamide, 0.950 g, 58.9%, brown solid).


[Step 2] methyl 4-((N-(4-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of N-(4-chlorophenyl)methanesulfonamide (0.500 g, 2.431 mmol), sodium hydride (60.00%, 0.117 g, 2.917 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.661 g, 2.674 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-((N-(4-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate as yellow solid (0.690 g, 76.3%).


[Step 3] N-(4-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(4-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate (0.690 g, 1.856 mmol) and hydrazine hydrate (0.929 g, 18.558 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide, 0.580 g, 84.1%, yellow solid).


[Step 4] Compound 11271



embedded image


A solution of N-(4-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.300 g, 0.807 mmol), trifluoroacetic anhydride (0.123 mL, 0.888 mmol) and triethylamine (0.169 mL, 1.210 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-chlorophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide, 0.120 g, 33.1%, white solid).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.0, 1.7 Hz), 7.76 (dd, 1H, J=9.8, 1.7 Hz), 7.67 (t, 1H, J=7.6 Hz), 7.38-7.29 (m, 2H), 7.31-7.22 (m, 2H), 5.01 (s, 2H), 3.02 (s, 3H); LRMS (ES) m/z 450.3 (M++1).


EXAMPLE 67
Compound 11272: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide
[Step 1] N-(5-fluoropyridin-3-yl)methanesulfonamide



embedded image


A solution of 5-fluoropyridin-3-amine (1.000 g, 8.920 mmol), pyridine (0.792 mL, 9.812 mmol) and methanesulfonyl chloride (0.834 mL, 10.704 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 5 hr. The precipitates were collected by filtration, washed by saturated aqueous dichloromethane solution, and dried to give N-(5-fluoropyridin-3-yl)methanesulfonamide as yellow solid (0.890 g, 52.5%).


[Step 2] methyl 3-fluoro-4-((N-(5-fluoropyridin-3-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(5-fluoropyridin-3-yl)methanesulfonamide (0.380 g, 1.998 mmol), sodium hydride (60.00%, 0.096 g, 2.398 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.543 g, 2.198 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(5-fluoropyridin-3-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.510 g, 71.6%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(5-fluoropyridin-3-yl)methylsulfonamido)methyl)benzoate (0.510 g, 1.431 mmol) and hydrazine hydrate (0.716 g, 14.312 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide, 0.440 g, 86.3%, yellow solid).


[Step 4] Compound 11272



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide (0.220 g, 0.617 mmol), trifluoroacetic anhydride (0.094 mL, 0.679 mmol) and triethylamine (0.129 mL, 0.926 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was obtained without further purification (N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide, 0.110 g, 41.0%, yellow solid).



1H NMR (400 MHz, CDCl3) δ 8.48-8.42 (m, 2H), 7.92 (dd, 1H, J=8.1, 1.7 Hz), 7.80 (dd, 1H, J=9.8, 1.7 Hz), 7.67 (t, 1H, J=7.6 Hz), 7.52-7.43 (m, 1H), 5.07 (s, 2H), 3.09 (s, 3H); LRMS (ES) m/z 435.1 (M++1).


EXAMPLE 68
Compound 11273: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-fluorophenyl)methanesulfonamide
[Step 1] N-(2-fluorophenyl)methanesulfonamide



embedded image


A solution of 2-fluoroaniline (1.000 g, 8.999 mmol), pyridine (0.799 mL, 9.899 mmol) and methanesulfonyl chloride (0.841 mL, 10.799 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluorophenyl)methanesulfonamide, 0.900 g, 52.9%, yellow solid).


[Step 2] methyl 3-fluoro-4-((N-(2-fluorophenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(2-fluorophenyl)methanesulfonamide (0.500 g, 2.643 mmol), sodium hydride (60.00%, 0.127 g, 3.171 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.718 g, 2.907 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(2-fluorophenyl)methylsulfonamido)methyl)benzoate as yellow solid (0.630 g, 67.1%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-fluorophenyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(2-fluorophenyl)methylsulfonamido)methyl)benzoate (0.680 g, 1.914 mmol) and hydrazine hydrate (0.958 g, 19.136 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-fluorophenyl)methanesulfonamide, 0.590 g, 86.8%, white solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(2-fluorophenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-fluorophenyl)methanesulfonamide (0.290 g, 0.816 mmol), trifluoroacetic anhydride (0.125 mL, 0.898 mmol) and triethylamine (0.170 mL, 1.224 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(2-fluorophenyl)methanesulfonamide, 0.210 g, 57.0%, yellow solid).


[Step 5] Compound 11273



embedded image


A solution of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(2-fluorophenyl)methanesulfonamide (0.210 g, 0.465 mmol) in tetrahydrofuran (10 mL) was treated with 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.166 g, 0.698 mmol), heated at 150° C. under the microwaves for 30 min, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-fluorophenyl)methanesulfonamide as yellow solid (0.150 g, 74.4%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.0, 1.7 Hz), 7.79-7.67 (m, 2H), 7.41-7.30 (m, 1H), 7.32-7.23 (m, 1H), 7.22-7.07 (m, 2H), 5.00 (s, 2H), 3.09 (s, 3H); LRMS (ES) m/z 434.0 (M++1).


EXAMPLE 69
Compound 11274: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-fluorophenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-fluorophenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(2-fluorophenyl)methanesulfonamide (0.290 g, 0.816 mmol), difluoroacetic anhydride (0.098 mL, 0.898 mmol) and triethylamine (0.170 mL, 1.224 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-fluorophenyl)methanesulfonamide, 0.200 g, 56.5%, yellow solid).


[Step 2] Compound 11274



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(2-fluorophenyl)methanesulfonamide (0.200 g, 0.461 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.165 g, 0.692 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-fluorophenyl)methanesulfonamide as yellow solid (0.110 g, 57.4%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.0, 1.7 Hz), 7.74 (dd, 1H, J=9.9, 1.6 Hz), 7.68 (t, 1H, J=7.6 Hz), 7.38-7.31 (m, 1H), 7.30-7.24 (m, 1H), 7.20-7.08 (m, 2H), 7.05 (s, 0.2H), 6.92 (s, 0.5H), 6.80 (s, 0.2H), 4.99 (s, 2H), 3.09 (s, 3H); LRMS (ES) m/z 416.3 (M++1).


EXAMPLE 70
Compound 11275: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(4-fluorophenyl)methanesulfonamide
[Step 1] N-(4-fluorophenyl)methanesulfonamide



embedded image


A solution of 4-fluoroaniline (1.000 g, 8.999 mmol), pyridine (0.799 mL, 9.899 mmol) and methanesulfonyl chloride (0.841 mL, 10.799 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-fluorophenyl)methanesulfonamide, 0.960 g, 56.4%, brown solid).


[Step 2] methyl 3-fluoro-4-((N-(4-fluorophenyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(4-fluorophenyl)methanesulfonamide (0.500 g, 2.643 mmol), sodium hydride (60.00%, 0.127 g, 3.171 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.718 g, 2.907 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(4-fluorophenyl)methylsulfonamido)methyl)benzoate as yellow solid (0.690 g, 73.5%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-fluorophenyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(4-fluorophenyl)methylsulfonamido)methyl)benzoate (0.690 g, 1.942 mmol) and hydrazine hydrate (0.972 g, 19.417 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-fluorophenyl)methanesulfonamide, 0.610 g, 88.4%, yellow solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-fluorophenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-fluorophenyl)methanesulfonamide (0.300 g, 0.844 mmol), trifluoroacetic anhydride (0.129 mL, 0.929 mmol) and triethylamine (0.176 mL, 1.266 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-fluorophenyl)methanesulfonamide, 0.210 g, 55.1%, yellow solid).


[Step 5] Compound 11275



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(4-fluorophenyl)methanesulfonamide (0.210 g, 0.465 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.166 g, 0.698 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(4-fluorophenyl)methanesulfonamide as white solid (0.140 g, 69.4%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.0, 1.7 Hz), 7.76 (dd, 1H, J=9.8, 1.6 Hz), 7.68 (t, 1H, J=7.6 Hz), 7.35-7.23 (m, 2H), 7.13-7.00 (m, 2H), 5.00 (s, 2H), 3.03 (s, 3H); LRMS (ES) m/z 434.2 (M++1).


EXAMPLE 71
Compound 11276: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4-fluorophenyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-fluorophenyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(4-fluorophenyl)methanesulfonamide (0.300 g, 0.844 mmol), difluoroacetic anhydride (0.101 mL, 0.929 mmol) and triethylamine (0.176 mL, 1.266 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-fluorophenyl)methanesulfonamide, 0.230 g, 62.9%, yellow solid).


[Step 2] Compound 11276



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-fluorophenyl)methanesulfonamide (0.230 g, 0.531 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.190 g, 0.796 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4-fluorophenyl)methanesulfonamide as yellow solid (0.140 g, 63.5%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.0, 1.7 Hz), 7.76 (dd, 1H, J=9.9, 1.7 Hz), 7.65 (t, 1H, J=7.6 Hz), 7.34-7.24 (m, 2H), 7.11-7.00 (m, 2H), 6.93 (s, 0.5H), 6.80 (s, 0.2H), 4.99 (s, 2H), 3.03 (s, 3H); LRMS (ES) m/z 416.3 (M++1).


EXAMPLE 72
Compound 11277: N-(4-bromophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-(4-bromophenyl)methanesulfonamide



embedded image


A solution of 4-bromoaniline (1.000 g, 5.813 mmol), pyridine (0.516 mL, 6.395 mmol) and methanesulfonyl chloride (0.544 mL, 6.976 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-bromophenyl)methanesulfonamide, 0.960 g, 66.0%, yellow solid).


[Step 2] methyl 4-((N-(4-bromophenyl)methylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of N-(4-bromophenyl)methanesulfonamide (0.500 g, 1.999 mmol), sodium hydride (60.00%, 0.096 g, 2.399 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.543 g, 2.199 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-((N-(4-bromophenyl)methylsulfonamido)methyl)-3-fluorobenzoate as yellow solid (0.680 g, 81.7%).


[Step 3] N-(4-bromophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(4-bromophenyl)methylsulfonamido)methyl)-3-fluorobenzoate (0.680 g, 1.634 mmol) and hydrazine hydrate (0.818 g, 16.336 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-bromophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide, 0.650 g, 95.6%, white solid).


[Step 4] N-(4-bromophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide



embedded image


A solution of N-(4-bromophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.290 g, 0.697 mmol), trifluoroacetic anhydride (0.108 mL, 0.766 mmol) and triethylamine (0.117 mL, 0.836 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-bromophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide, 0.258 g, 72.3%, yellow solid).


[Step 5] Compound 11277



embedded image


A solution of N-(4-bromophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide (0.290 g, 0.566 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.202 g, 0.849 mmol) in tetrahydrofuran (10 mL) was stirred at 150° C. for 30 min, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(4-bromophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as yellow solid (0.190 g, 67.9%).



1H NMR (400 MHz, CDCl3) δ 7.92-7.85 (m, 1H), 7.76 (dd, 1H, J=9.9, 1.7 Hz), 7.71-7.62 (m, 1H), 7.54-7.45 (m, 2H), 7.24-7.17 (m, 2H), 5.01 (s, 2H), 3.02 (s, 3H); LRMS (ES) m/z 496.2 (M++1).


EXAMPLE 73
Compound 11278: N-(4-bromophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide
[Step 1] N-(4-bromophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide



embedded image


A solution of N-(4-bromophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.300 g, 0.721 mmol), difluoroacetic anhydride (0.138 g, 0.793 mmol) and triethylamine (0.121 mL, 0.865 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-bromophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide, 0.240 g, 67.4%, yellow solid).


[Step 2] Compound 11278



embedded image


A mixture of N-(4-bromophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide (0.240 g, 0.486 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.174 g, 0.728 mmol) in dichloromethane (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-bromophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as white solid (0.150 g, 64.9%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.1, 1.7 Hz), 7.76 (dd, 1H, J=9.9, 1.7 Hz), 7.64 (t, 1H, J=7.6 Hz), 7.54-7.45 (m, 2H), 7.25-7.16 (m, 2H), 7.05 (s, 0.2H), 6.93 (s, 0.5H), 6.80 (s, 0.2H), 5.01 (s, 2H), 3.02 (s, 3H); LRMS (ES) m/z 476.2 (M++1).


EXAMPLE 74
Compound 11279: N-(2-chlorophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-(2-chlorophenyl)methanesulfonamide



embedded image


A solution of 2-chloroaniline (1.000 g, 7.839 mmol), pyridine (0.696 mL, 8.623 mmol) and methanesulfonyl chloride (0.733 mL, 9.407 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-chlorophenyl)methanesulfonamide, 0.940 g, 58.3%, yellow solid).


[Step 2] methyl 4-((N-(2-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of N-(2-chlorophenyl)methanesulfonamide (0.500 g, 2.431 mmol), sodium hydride (60.00%, 0.117 g, 2.917 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.661 g, 2.674 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-((N-(2-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate as yellow solid (0.640 g, 70.8%).


[Step 3] N-(2-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(2-chlorophenyl)methylsulfonamido)methyl)-3-fluorobenzoate (0.640 g, 1.721 mmol) and hydrazine hydrate (0.862 g, 17.213 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide, 0.580 g, 90.6%, yellow solid).


[Step 4] N-(2-chlorophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide



embedded image


A solution of N-(2-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.290 g, 0.780 mmol), trifluoroacetic anhydride (0.121 mL, 0.858 mmol) and triethylamine (0.130 mL, 0.936 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-chlorophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide, 0.200 g, 54.8%, yellow solid).


[Step 5] Compound 11279



embedded image


A mixture of N-(2-chlorophenyl)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)methanesulfonamide (0.200 g, 0.428 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.153 g, 0.641 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-chlorophenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as yellow solid (0.120 g, 65.0%).



1H NMR (400 MHz, CDCl3) δ 7.89 (dd, 1H, J=8.0, 1.7 Hz), 7.77-7.66 (m, 2H), 7.52-7.44 (m, 1H), 7.36-7.17 (m, 3H), 5.04 (s, 2H), 3.14 (s, 3H); LRMS (ES) m/z 450.0 (M++1).


EXAMPLE 75
Compound 11280: N-(2-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide
[Step 1] N-(2-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide



embedded image


A solution of N-(2-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.290 g, 0.780 mmol), difluoroacetic anhydride (0.093 mL, 0.858 mmol) and triethylamine (0.130 mL, 0.936 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide, 0.220 g, 62.7%, yellow solid).


[Step 2] Compound 11280



embedded image


A mixture of N-(2-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide (0.220 g, 0.489 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.175 g, 0.734 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as yellow solid (0.130 g, 61.6%).



1H NMR (400 MHz, CDCl3) δ 7.91-7.82 (m, 1H), 7.78-7.62 (m, 2H), 7.53-7.43 (m, 1H), 7.36-7.26 (m, 1H), 7.26-7.17 (m, 2H), 7.06 (s, 0.2H), 6.93 (s, 0.5H), 6.80 (s, 0.2H), 5.02 (s, 2H), 3.13 (s, 3H); LRMS (ES) m/z 432.2 (M++1).


EXAMPLE 76
Compound 11281: N-(4-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide
[Step 1] N-(4-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide



embedded image


A solution of N-(4-chlorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.300 g, 0.807 mmol), difluoroacetic anhydride (0.097 mL, 0.888 mmol) and triethylamine (0.135 mL, 0.968 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide, 0.240 g, 66.1%, yellow solid).


[Step 2] Compound 11281



embedded image


A mixture of N-(4-chlorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)methanesulfonamide (0.240 g, 0.534 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.191 g, 0.800 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as yellow solid (0.140 g, 60.8%).



1H NMR (400 MHz, CDCl3) δ 7.93-7.85 (m, 1H), 7.80-7.72 (m, 1H), 7.65 (t, 1H, J=7.7 Hz), 7.37-7.30 (m, 2H), 7.30-7.22 (m, 2H), 7.05 (s, 0.2H), 6.93 (s, 0.5H), 6.80 (s, 0.2H), 5.01 (s, 2H), 3.02 (s, 3H); LRMS (ES) m/z 432.2 (M++1).


EXAMPLE 77
Compound 11282: N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(p-tolyl)methanesulfonamide
[Step 1] N-(p-tolyl)methanesulfonamide



embedded image


A solution of p-toluidine (1.000 g, 9.332 mmol), pyridine (0.829 mL, 10.265 mmol) and methanesulfonyl chloride (0.873 mL, 11.198 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(p-tolyl)methanesulfonamide, 1.100 g, 63.6%, yellow solid).


[Step 2] methyl 3-fluoro-4-((N-(p-tolyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(p-tolyl)methanesulfonamide (0.500 g, 2.699 mmol), sodium hydride (60.00%, 0.130 g, 3.239 mmol) and methyl 4-(bromomethyl)-3-fluorobenzoate (0.734 g, 2.969 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-fluoro-4-((N-(p-tolyl)methylsulfonamido)methyl)benzoate as white solid (0.660 g, 69.6%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(p-tolyl)methanesulfonamide



embedded image


A mixture of methyl 3-fluoro-4-((N-(p-tolyl)methylsulfonamido)methyl)benzoate (0.660 g, 1.878 mmol) and hydrazine hydrate (0.940 g, 18.783 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(p-tolyl)methanesulfonamide, 0.540 g, 81.8%, white solid).


[Step 4] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(p-tolyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(p-tolyl)methanesulfonamide (0.270 g, 0.768 mmol), trifluoroacetic anhydride (0.118 mL, 0.845 mmol) and triethylamine (0.161 mL, 1.153 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(p-tolyl)methanesulfonamide, 0.190 g, 55.3%, white solid).


[Step 5] Compound 11282



embedded image


A mixture of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-(p-tolyl)methanesulfonamide (0.190 g, 0.425 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.152 g, 0.637 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(p-tolyl)methanesulfonamide as yellow solid (0.110 g, 60.3%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.0, 1.7 Hz), 7.79-7.65 (m, 2H), 7.25-7.08 (m, 4H), 5.02 (s, 2H), 3.01 (s, 3H), 2.33 (s, 3H); LRMS (ES) m/z 430.3 (M++1).


EXAMPLE 78
Compound 11283: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(p-tolyl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(p-tolyl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(p-tolyl)methanesulfonamide (0.270 g, 0.768 mmol), difluoroacetic anhydride (0.092 mL, 0.845 mmol) and triethylamine (0.129 mL, 0.922 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(p-tolyl)methanesulfonamide, 0.210 g, 63.6%, yellow solid).


[Step 2] Compound 11283



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(p-tolyl)methanesulfonamide (0.210 g, 0.489 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.175 g, 0.734 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(p-tolyl)methanesulfonamide as yellow solid (0.120 g, 59.6%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.1, 1.6 Hz), 7.74 (dd, 1H, J=9.9, 1.7 Hz), 7.68 (t, 1H, J=7.7 Hz), 7.25-7.12 (m, 4H), 7.05 (s, 0.2H), 6.92 (s, 0.5H), 6.79 (s, 0.2H), 5.01 (s, 2H), 3.01 (s, 3H), 2.33 (s, 3H); LRMS (ES) m/z 412.4 (M++1).


EXAMPLE 79
Compound 11284: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide
[Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide (0.220 g, 0.617 mmol), difluoroacetic anhydride (0.074 mL, 0.679 mmol) and triethylamine (0.129 mL, 0.926 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide as yellow solid (0.140 g, 52.2%).


[Step 2] Compound 11284



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide (0.140 g, 0.322 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.115 g, 0.483 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(5-fluoropyridin-3-yl)methanesulfonamide as yellow solid (0.086 g, 64.1%).



1H NMR (400 MHz, CDCl3) δ 8.46 (s, 2H), 7.92 (dd, 1H, J=8.1, 1.7 Hz), 7.80 (dd, 1H, J=9.8, 1.3 Hz), 7.65 (t, 1H, J=7.7 Hz), 7.54-7.43 (m, 1H), 7.06 (s, 0.2H), 6.93 (s, 0.5H), 6.80 (s, 0.2H), 5.07 (s, 2H), 3.09 (d, 3H, J=1.1 Hz); LRMS (ES) m/z 417.3 (M++1).


EXAMPLE 80
Compound 11287: methyl 3-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylsulfamoyl)propanoate
[Step 1] methyl 3-(N-phenylsulfamoyl)propanoate



embedded image


A solution of aniline (0.490 mL, 5.369 mmol) and pyridine (0.520 mL, 6.443 mmol) in dichloromethane (10 mL) was mixed at the room temperature with methyl 3-(chlorosulfonyl)propanoate (1.102 g, 5.906 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 0.1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (methyl 3-(N-phenylsulfamoyl)propanoate, 1.000 g, 71.3%, brown solid).


[Step 2] Compound 11287



embedded image


Sodium hydride (60.00%, 0.014 g, 0.345 mmol) was added to a solution of methyl 3-(N-phenylsulfamoyl)propanoate (0.070 g, 0.288 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.093 g, 0.302 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 3-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylsulfamoyl)propanoate as white solid (0.085 g, 62.9%).



1H NMR (400 MHz, DMSO-d6) δ 7.88 (dd, 1H, J=8.1, 1.7 Hz), 7.80 (dd, 1H, J=10.2, 1.7 Hz), 7.73-7.67 (m, 1H), 7.66 (s, 0.25H), 7.56 (s, 0.5H), 7.50 (s, 0.25H), 7.50-7.45 (m, 2H), 7.44-7.36 (m, 2H), 7.36-7.29 (m, 1H), 5.11 (s, 2H), 3.67 (s, 3H), 3.59 (t, 2H, J=7.4 Hz), 2.84 (t, 2H, J=7.4 Hz); LRMS (ES) m/z 470.2 (M++1).


EXAMPLE 81
Compound 11288: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-3-methoxy-N-phenylbutane-1-sulfonamide
[Step 1] 3-methoxy-2-methyl-N-phenylpropane-1-sulfonamide



embedded image


A solution of aniline (0.245 mL, 2.684 mmol) and pyridine (0.259 mL, 3.221 mmol) in dichloromethane (10 mL) was mixed at the room temperature with 3-methoxy-2-methylpropane-1-sulfonyl chloride (0.551 g, 2.953 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 0.1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (3-methoxy-2-methyl-N-phenylpropane-1-sulfonamide, 0.500 g, 76.5%, brown solid).


[Step 2] Compound 11288



embedded image


Sodium hydride (60.00%, 0.012 g, 0.296 mmol) was added to a solution of 3-methoxy-2-methyl-N-phenylpropane-1-sulfonamide (0.060 g, 0.247 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.080 g, 0.259 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-3-methoxy-N-phenylbutane-1-sulfonamide as white solid (0.045 g, 38.9%).



1H NMR (400 MHz, DMSO-d6) 400 MHz): δ 7.88 (dd, 1H, J=8.1, 1.7 Hz), 7.80 (dd, 1H, J=10.2, 1.7 Hz), 7.70 (d, 1H, J=8.0 Hz), 7.67 (s, 0.25H), 7.56 (s, 0.5H), 7.53-7.44 (m, 2H), 7.43 (s, 0.25H), 7.43-7.34 (m, 2H), 7.36-7.27 (m, 1H), 5.09 (s, 2H), 3.49-3.40 (m, 2H), 3.33-3.22 (m, 4H), 3.12 (dd, 1H, J=14.0, 8.2 Hz), 2.32 (tt, 1H, J=12.8, 6.1 Hz), 1.08 (d, 3H, J=6.8 Hz); LRMS (ES) m/z 468.17 (M+−1).


EXAMPLE 82
Compound 11289: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylpropane-1-sulfonamide
[Step 1] N-phenylpropane-1-sulfonamide



embedded image


A solution of aniline (0.490 mL, 5.369 mmol) and propane-1-sulfonyl chloride (0.628 g, 5.637 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 min, and mixed with triethylamine (1.497 mL, 10.738 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-phenylpropane-1-sulfonamide as light yellow oil (0.130 g, 12.2%).


[Step 2] Compound 11289



embedded image


Sodium hydride (60.00%, 0.011 g, 0.271 mmol) was added to a solution of N-phenylpropane-1-sulfonamide (0.045 g, 0.226 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.073 g, 0.237 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 15%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylpropane-1-sulfonamide as white solid (0.060 g, 62.5%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.1, 1.6 Hz), 7.77-7.65 (m, 2H), 7.41-7.27 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 5.06 (s, 2H), 3.17-2.99 (m, 2H), 2.06-1.83 (m, 2H), 1.09 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 424.32 (M+−1).


EXAMPLE 83
Compound 11290: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylbutane-1-sulfonamide
[Step 1] N-phenylbutane-1-sulfonamide



embedded image


A solution of aniline (0.490 mL, 5.369 mmol) and butane-1-sulfonyl chloride (0.883 g, 5.637 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 min, and mixed with triethylamine (1.497 mL, 10.738 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-phenylbutane-1-sulfonamide as light yellow oil (0.460 g, 40.2%).


[Step 2] Compound 11290



embedded image


Sodium hydride (60.00%, 0.010 g, 0.253 mmol) was added to a solution of N-phenylbutane-1-sulfonamide (0.045 g, 0.211 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.068 g, 0.222 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 15%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylbutane-1-sulfonamide as white solid (0.060 g, 64.7%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.0, 1.7 Hz), 7.78-7.63 (m, 2H), 7.42-7.25 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 5.06 (s, 2H), 3.15-3.03 (m, 2H), 1.98-1.79 (m, 2H), 1.48 (h, 2H, J=7.4 Hz), 0.97 (t, 3H, J=7.3 Hz); LRMS (ES) m/z 440.2 (M++1).


EXAMPLE 84
Compound 11291: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylcyclopropanesulfonamide
[Step 1] N-phenylcyclopropanesulfonamide



embedded image


A solution of Aniline (0.500 g, 5.369 mmol) and Et3N (1.630 g, 16.107 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 10 min, and mixed with cyclopropanesulfonyl chloride (1.510 g, 10.738 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-phenylcyclopropanesulfonamide as white solid (0.650 g, 61.4%).


[Step 2] Compound 11291



embedded image


Sodium hydride (60.00%, 0.011 g, 0.274 mmol) was added to a solution of N-phenylcyclopropanesulfonamide (0.045 g, 0.228 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.074 g, 0.240 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylcyclopropanesulfonamide as white solid (0.055 g, 56.9%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.1, 1.6 Hz), 7.76-7.65 (m, 2H), 7.41-7.26 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 5.07 (s, 2H), 2.51 (tt, 1H, J=8.0, 4.8 Hz), 1.18-1.11 (m, 2H), 1.06-0.98 (m, 2H); LRMS (ES) m/z 424.3 (M++1).


EXAMPLE 85
Compound 11292: N-cyclohexyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide
[Step 1] N-cyclohexylmethanesulfonamide



embedded image


A solution of methanesulfonyl chloride (0.858 mL, 11.091 mmol) and pyridine (1.221 mL, 15.124 mmol) in dichloromethane (16 mL) was stirred at the room temperature for 10 min, and mixed with cyclohexanamine (1.000 g, 10.083 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The title compound was used without further purification (N-cyclohexylmethanesulfonamide, 1.700 g, 95.1%, yellow solid).


[Step 2] Compound 11292



embedded image


Sodium hydride (60.00%, 0.014 g, 0.338 mmol) was added to a solution of N-cyclohexylmethanesulfonamide (0.050 g, 0.282 mmol) in N,N-dimethylformide (1 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.087 g, 0.282 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-cyclohexyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as light yellow oil (0.080 g, 70.3%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.2, 1.6 Hz), 7.84-7.72 (m, 2H), 6.91 (t, 1H, J=51.7 Hz), 4.49 (s, 2H), 3.74 (tt, 1H, J=11.3, 2.9 Hz), 2.94 (d, 3H, J=9.4 Hz), 1.87-1.66 (m, 4H), 1.66-1.52 (m, 1H), 1.31 (qt, 4H, J=12.6, 6.9 Hz), 1.01 (dt, 1H, J=9.5, 6.3 Hz); LRMS (ES) m/z 404.0 (M++1).


EXAMPLE 86
Compound 11323: N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide
[Step 1] methyl 6-((N-(3-(trifluoromethyl)phenyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of N-(3-(trifluoromethyl)phenyl)methanesulfonamide (0.500 g, 2.090 mmol), sodium hydride (60.00%, 0.100 g, 2.508 mmol) and methyl 6-(bromomethyl)nicotinate (0.529 g, 2.299 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-((N-(3-(trifluoromethyl)phenyl)methylsulfonamido)methyl)nicotinate as yellow solid (0.400 g, 49.3%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(3-(trifluoromethyl)phenyl)methylsulfonamido)methyl)nicotinate (0.400 g, 1.030 mmol) and hydrazine hydrate (0.516 g, 10.300 mmol) in ethanol (10 mL) was heated at 120° C. for 1 hr under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide, 0.300 g, 75.0%, yellow solid).


[Step 3] Compound 11323



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide (0.150 g, 0.386 mmol), trifluoroacetic anhydride (0.060 mL, 0.425 mmol) and triethylamine (0.081 mL, 0.579 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide as yellow solid (0.067 g, 37.2%).



1H NMR (400 MHz, CDCl3) δ 9.28 (dd, 1H, J=2.3, 0.8 Hz), 8.41 (dd, 1H, J=8.2, 2.2 Hz), 7.76-7.62 (m, 3H), 7.62-7.47 (m, 2H), 5.18 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 467.3 (M++1).


EXAMPLE 87
Compound 11324: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide



embedded image


A mixture of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide (0.150 g, 0.386 mmol), difluoroacetic anhydride (0.050 mL, 0.463 mmol) and triethylamine (0.081 mL, 0.579 mmol) in dichloromethane (10 mL) was heated at 150° C. for 30 min under the microwaves, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)methanesulfonamide as yellow solid (0.074 g, 42.7%).



1H NMR (400 MHz, CDCl3) δ 9.28 (dd, 1H, J=2.2, 0.9 Hz), 8.42 (dd, 1H, J=8.2, 2.2, 0.8 Hz), 7.73 (dq, 1H, J=3.0, 0.8 Hz), 7.70-7.62 (m, 2H), 7.62-7.45 (m, 2H), 7.08 (s, 0.2H), 6.95 (s, 0.5H), 6.83 (s, 0.2H), 5.18 (s, 2H), 3.10 (d, 3H, J=0.7 Hz); LRMS (ES) m/z 449.3 (M++1).


EXAMPLE 88
Compound 11338: tert-butyl 4-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methylsulfonamido)piperidine-1-carboxylate
[Step 1] tert-butyl 4-(methylsulfonamido)piperidine-1-carboxylate



embedded image


A solution of methanesulfonyl chloride (0.425 mL, 5.492 mmol) and pyridine (0.605 mL, 7.490 mmol) in dichloromethane (14 mL) was stirred at the room temperature for 20 min, and mixed with tert-butyl 4-aminopiperidine-1-carboxylate (1.000 g, 4.993 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The title compound was used without further purification (tert-butyl 4-(methylsulfonamido)piperidine-1-carboxylate, 1.300 g, 93.5%, white solid).


[Step 2] tert-butyl 4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)methylsulfonamido)piperidine-1-carboxylate



embedded image


Sodium hydride (60.00%, 0.172 g, 4.311 mmol) was added to a solution of tert-butyl 4-(methylsulfonamido)piperidine-1-carboxylate (1.000 g, 3.592 mmol) in N,N-dimethylformide (8 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with methyl 4-(bromomethyl)-3-fluorobenzoate (0.932 g, 3.772 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give tert-butyl 4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)methylsulfonamido)piperidine-1-carboxylate as white solid (1.200 g, 75.1%).


[Step 3] tert-butyl 4-(N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methylsulfonamido)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)methylsulfonamido)piperidine-1-carboxylate (1.200 g, 2.700 mmol) and hydrazine hydrate (0.394 mL, 8.099 mmol) in ethanol (10 mL) prepared at the ambient temperature was heated at reflux for 24 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The title compound was used without further purification (tert-butyl 4-(N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methylsulfonamido)piperidine-1-carboxylate, 1.100 g, 91.7%, white solid).


[Step 4] Compound 11338



embedded image


Triethylamine (0.122 mL, 0.877 mmol) was added to a solution of tert-butyl 4-(N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)methylsulfonamido)piperidine-1-carboxylate (0.300 g, 0.675 mmol) in dichloromethane (8 mL) at the room temperature, and the mixture was stirred for 20 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.088 mL, 0.810 mmol), heated at reflux for 16 hr, and cooled down to the room temperature to terminate the reaction. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give tert-butyl 4-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methylsulfonamido)piperidine-1-carboxylate as light yellow oil (0.280 g, 82.2%).



1H NMR (400 MHz, CDCl3) δ 7.91 (dd, 1H, J=8.2, 1.6 Hz), 7.83-7.77 (m, 2H), 6.92 (t, 1H, J=51.7 Hz), 4.50 (s, 2H), 4.11 (q, 2H, J=7.2 Hz), 3.92 (tt, 1H, J=12.1, 3.8 Hz), 2.94 (s, 3H), 2.71 (t, 2H, J=12.8 Hz), 1.70 (t, 2H, J=13.6 Hz), 1.64-1.48 (m, 2H), 1.42 (s, 9H); LRMS (ES) m/z 405.33 (M++1).


EXAMPLE 89
Compound 11345: N-(benzo[d][1,3]dioxol-5-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] methyl 6-((benzo[d][1,3]dioxol-5-ylamino)methyl)nicotinate



embedded image


Acetic acid (0.150 mL, 2.625 mmol) was added to a solution of benzo[d][1,3]dioxol-5-amine (0.300 g, 2.188 mmol) and methyl 6-formylnicotinate (0.379 g, 2.297 mmol) in dichloromethane (10 mL) at the room temperature, and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with sodium triacetoxyborohydride (0.927 g, 4.375 mmol), and stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((benzo[d][1,3]dioxol-5-ylamino)methyl)nicotinate as yellow solid (0.492 g, 78.6%).


[Step 2] methyl 6-((N-(benzo[d][1,3]dioxol-5-yl)methylsulfonamido)methyl)nicotinate



embedded image


A mixture of methyl 6-((benzo[d][1,3]dioxol-5-ylamino)methyl)nicotinate (0.490 g, 1.712 mmol), triethylamine (0.477 mL, 3.423 mmol) and methanesulfonyl chloride (0.160 mL, 2.054 mmol) in dichloromethane (10 mL) prepared at the ambient temperature was heated at reflux for 15 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 6-((N-(benzo[d][1,3]dioxol-5-yl)methylsulfonamido)methyl)nicotinate as brown oil (0.216 g, 34.6%).


[Step 3] N-(benzo[d][1,3]dioxol-5-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(benzo[d][1,3]dioxol-5-yl)methylsulfonamido)methyl)nicotinate (0.216 g, 0.593 mmol) and hydrazine hydrate (50.00% solution, 0.165 mL, 1.778 mmol) in ethanol (10 mL) was stirred at the ambient temperature for 1 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(benzo[d][1,3]dioxol-5-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide, 0.131 g, 60.6%, white foamy solid).


[Step 4] Compound 11345



embedded image


A mixture of N-(benzo[d][1,3]dioxol-5-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.135 g, 0.371 mmol), difluoroacetic anhydride (0.060 mL, 0.556 mmol) and triethylamine (0.155 mL, 1.112 mmol) in dichloromethane (5 mL) prepared at the ambient temperature was heated at reflux for 36 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=10% to 50%) to give N-(benzo[d][1,3]dioxol-5-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as brown solid (0.097 g, 61.7%).



1H NMR (400 MHz, CDCl3) δ 9.23 (d, 1H, J=2.2 Hz), 8.37 (dd, 1H, J=8.2, 2.2 Hz), 7.67 (d, 1H, J=8.2 Hz), 7.26 (s, 0.4H), 7.06 (s, 0.2H), 6.93 (s, 0.5H), 6.88-6.76 (m, 2H), 6.72 (d, 1H, J=8.2 Hz), 5.96 (s, 2H), 5.04 (s, 2H), 3.06 (s, 3H); LRMS (ES) m/z 425.24 (M++1).


EXAMPLE 90
Compound 11346: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(4-methoxyphenyl)methanesulfonamide
[Step 1] methyl 6-(((4-methoxyphenyl)amino)methyl)nicotinate



embedded image


Acetic acid (0.167 mL, 2.923 mmol) was added to a solution of 4-methoxyaniline (0.300 g, 2.436 mmol) and methyl 6-formylnicotinate (0.422 g, 2.558 mmol) in dichloromethane (10 mL) at the room temperature, and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with sodium triacetoxyborohydride (1.033 g, 4.872 mmol), and stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-(((4-methoxyphenyl)amino)methyl)nicotinate as yellow solid (0.537 g, 81.0%).


[Step 2] methyl 6-((N-(4-methoxyphenyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((4-methoxyphenyl)amino)methyl)nicotinate (0.530 g, 1.946 mmol), triethylamine (0.543 mL, 3.893 mmol) and methanesulfonyl chloride (0.182 mL, 2.336 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 6-((N-(4-methoxyphenyl)methylsulfonamido)methyl)nicotinate as pale brown solid (0.305 g, 44.7%).


[Step 3] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(4-methoxyphenyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(4-methoxyphenyl)methylsulfonamido)methyl)nicotinate (0.305 g, 0.870 mmol) and hydrazine hydrate (50.00% solution , 0.242 mL, 2.611 mmol) in ethanol (10 mL) was stirred at the ambient temperature for 1 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(4-methoxyphenyl)methanesulfonamide as white solid (0.282 g, 92.5%)


[Step 4] Compound 11346



embedded image


A mixture of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(4-methoxyphenyl)methanesulfonamide (0.282 g, 0.805 mmol), difluoroacetic anhydride (0.131 mL, 1.207 mmol) and triethylamine (0.337 mL, 2.414 mmol) in dichloromethane (5 mL) was heated at reflux for 36 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=10% to 50%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(4-methoxyphenyl)methanesulfonamide as brown solid (0.228 g, 69.0%).



1H NMR (400 MHz, CDCl3) δ 9.22 (dd, 1H, J=2.2, 0.9 Hz), 8.37 (dd, 1H, J=8.3, 2.2 Hz), 7.71 (d, 1H, J=8.2 Hz), 7.34-7.21 (m, 2H), 7.06 (s, 0.2H), 6.93 (s, 0.4H), 6.88-6.81 (m, 2H), 6.80 (s, 0.2H), 5.08 (s, 2H), 3.76 (s, 3H), 3.05 (s, 3H); LRMS (ES) m/z 411.28 (M++1).


EXAMPLE 91
Compound 11347: N-(5-bromopyridin-2-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] Methyl 4-((N-(5-bromopyridin-2-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of methanesulfonyl chloride (0.106 mL, 1.370 mmol), N,N-dimethylpyridin-4-amine (DMAP, 0.046 g, 0.374 mmol) and pyridine (0.151 mL, 1.868 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 20 min, and then mixed with methyl 4-(((5-bromopyridin-2-yl)amino)methyl)benzoate (0.400 g, 1.245 mmol). The reaction mixture was heated at reflux for 24 hr, and cooled down to the room temperature to terminate the reaction. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 15%) to give methyl 4-((N-(5-bromopyridin-2-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.350 g, 70.4%).


[Step 2] N-(5-bromopyridin-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(5-bromopyridin-2-yl)methylsulfonamido)methyl)benzoate (0.350 g, 0.877 mmol) and hydrazine hydrate (0.084 g, 2.630 mmol) in ethanol (8 mL) prepared at the ambient temperature was heated at reflux for 24 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(5-bromopyridin-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide as white solid (0.290 g, 82.9%).


[Step 3] Compound 11347



embedded image


Triethylamine (0.032 mL, 0.234 mmol) was added to a solution of N-(5-bromopyridin-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.072 g, 0.180 mmol) in tetrahydrofuran (1 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.024 mL, 0.216 mmol), heated at reflux for 6 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give the crude product which was rechromatographed (SiO2 plate, 20×20×1 mm; ethyl acetate/hexane=30%) to give N-(5-bromopyridin-2-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.035 g, 42.3%).



1H NMR (400 MHz, CDCl3) δ 8.39-8.31 (m, 1H), 8.08-7.99 (m, 2H), 7.61 (dd, 1H, J=8.7, 2.6 Hz), 7.56-7.46 (m, 2H), 7.32-7.26 (m, 2H), 6.89 (t, 1H, J=51.7 Hz), 5.16 (s, 2H), 3.07 (s, 3H); LRMS (ES) m/z 461.1 (M++1).


EXAMPLE 92
Compound 11348: N-(5-chloropyridin-2-yl)-N-(4-(5-(difluoromethyl-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] methyl 4-((N-(5-chloropyridin-2-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of methanesulfonyl chloride (0.123 mL, 1.590 mmol), N,N-dimethylpyridin-4-amine (DMAP, 0.053 g, 0.434 mmol) and pyridine (0.175 mL, 2.168 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 20 min, and then mixed with methyl 4-(((5-chloropyridin-2-yl)amino)methyl)benzoate (0.400 g, 1.446 mmol). The reaction mixture was heated at reflux for 24 hr, and cooled down to the room temperature to terminate the reaction. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 15%) to give methyl 4-((N-(5-chloropyridin-2-yl)methylsulfonamido)methyl)benzoate as white solid (0.320 g, 62.4%).


[Step 2] N-(5-chloropyridin-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A mixture of methyl 4-((N-(5-chloropyridin-2-yl)methylsulfonamido)methyl)benzoate (0.320 g, 0.902 mmol) and hydrazine hydrate (0.087 g, 2.706 mmol) in ethanol (8 mL) prepared at the ambient temperature was heated at reflux for 24 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(5-chloropyridin-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide as white solid (0.280 g, 87.5%).


[Step 3] Compound 11348



embedded image


N-(5-chloropyridin-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.074 g, 0.207 mmol) in tetrahydrofuran (1 mL) was stirred for 10 min at the room temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.027 mL, 0.249 mml), and heated at reflux for 6 hr. The reaction mixture was cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(5-chloropyridin-2-yl)-N-(4-(5-(difluoromethyl-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.030 g, 34.9%).



1H NMR (400 MHz, CDCl3) δ 8.48 (dd, 1H, J=2.6, 0.7 Hz), 8.09-8.00 (m, 2H), 7.77 (ddd, 1H, J=8.6, 2.5, 0.6 Hz), 7.54 (d, 2H, J=8.2 Hz), 7.30-7.27 (m, 1H), 6.92 (t, 1H, J=51.7 Hz), 5.19 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 415.2 (M++1).


EXAMPLE 93
Compound 11350: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide
[Step 1] N-phenyltetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide



embedded image


Triethylamine (0.193 mL, 1.396 mmol) was added to a solution of aniline (0.100 g, 1.074 mmol) in dichloromethane (6 mL) at 0° C., and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with tetrahydro-2H-thiopyran-4-sulfonyl chloride 1,1-dioxide (0.250 g, 1.074 mmol), and stirred for additional 16 hr at the room temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-phenyltetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide, 0.310 g, 99.8%, white solid).


[Step 2] methyl 6-(((1,1-dioxido-N-phenyltetrahydro-2H-thiopyran)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.125 g, 0.544 mmol) and potassium iodide (0.017 g, 0.104 mmol) in N,N-dimethylformide (2 mL) was stirred at the room temperature for 20 min, and mixed with N-phenyltetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide (0.150 g, 0.518 mmol) and potassium carbonate (0.086 g, 0.622 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 60%) to give methyl 6-(((1,1-dioxido-N-phenyltetrahydro-2H-thiopyran)-4-sulfonamido)methyl)nicotinate as white solid (0.200 g, 87.9%).


[Step 3] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide



embedded image


A mixture of methyl 6-(((1,1-dioxido-N-phenyltetrahydro-2H-thiopyran)-4-sulfonamido)methyl)nicotinate (0.200 g, 0.456 mmol) and hydrazine hydrate (0.067 mL, 1.368 mmol) in ethanol (4 mL) prepared at the ambient temperature was heated at reflux for 16 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The precipitates were collected by filtration, washed by water, and dried to give N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as white solid (0.180 g, 90.0%).


[Step 4] Compound 11350



embedded image


Triethylamine (0.057 mL, 0.410 mmol) was added to a solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide (0.090 g, 0.205 mmol) in tetrahydrofuran (1 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.033 mL, 0.308 mmol), heated at reflux for 6 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as white solid (0.070 g, 68.4%)



1H NMR (400 MHz, CDCl3) δ 9.24 (d, 1H, J=2.1 Hz), 8.37 (dd, 1H, J=8.2, 2.2 Hz), 7.59 (d, 1H, J=8.2 Hz), 7.45-7.28 (m, 5H), 6.95 (t, 1H, J=51.6 Hz), 5.16 (s, 2H), 3.45 (p, 1H, J=6.3 Hz), 3.41-3.28 (m, 2H), 3.05-2.94 (m, 2H), 2.64 (q, 4H, J=6.3 Hz); LRMS (ES) m/z 499.3 (M++1).


EXAMPLE 94
Compound 11351: N-cyclohexyl-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] Methyl 6-((N-cyclohexylmethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.164 g, 0.711 mmol) and potassium iodide (0.022 g, 0.135 mmol) in N,N-dimethylformide (2 mL) was stirred at the room temperature for 20 min, and mixed with N-cyclohexylmethanesulfonamide (0.120 g, 0.677 mmol) and potassium carbonate (0.112 g, 0.812 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-cyclohexylmethylsulfonamido)methyl)nicotinate as white solid (0.210 g, 95.0%).


[Step 2] N-cyclohexyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-cyclohexylmethylsulfonamido)methyl)nicotinate (0.210 g, 0.643 mmol) and hydrazine hydrate (0.094 mL, 1.930 mmol) prepared at the embient temperature in ethanol (4 mL) was heated at reflux for 16 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The precipitates were collected by filtration, washed by water, and dried to give N-cyclohexyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.180 g, 85.7%).


[Step 3] Compound 11351



embedded image


Triethylamine (0.077 mL, 0.551 mmol) was added to a solution of N-cyclohexyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.090 g, 0.276 mmol) in tetrahydrofuran (1 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.045 mL, 0.414 mmol), heated at reflux for 6 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-cyclohexyl-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.070 g, 65.7%).



1H NMR (400 MHz, CDCl3) δ 9.21 (dd, 1H, J=2.3, 0.8 Hz), 8.36 (dd, 1H, J=8.3, 2.2 Hz), 7.80 (dd, 1H, J=8.3, 0.8 Hz), 6.93 (t, 1H, J=51.6 Hz), 4.59 (s, 2H), 3.86-3.69 (m, 1H), 3.00 (s, 3H), 1.84-1.66 (m, 4H), 1.59 (d, 1H, J=13.6 Hz), 1.31 (td, 4H, J=9.4, 2.8 Hz), 1.07-0.88 (m, 1H); LRMS (ES) m/z 387.0 (M++1).


EXAMPLE 95
Compound 11352: N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] Methyl 6-((N-(3-chlorophenyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.294 g, 1.276 mmol) and potassium iodide (0.040 g, 0.243 mmol) in N,N-dimethylformide (4 mL) was stirred at the room temperature for 20 min, and mixed with N-(3-chlorophenyl)methanesulfonamide (0.250 g, 1.216 mmol) and potassium carbonate (0.202 g, 1.459 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(3-chlorophenyl)methylsulfonamido)methyl)nicotinate as light yellow solid (0.292 g, 67.7%).


[Step 2] (N-(3-chlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(3-chlorophenyl)methylsulfonamido)methyl)nicotinate (0.292 g, 0.823 mmol) and hydrazine hydrate (0.087 mL, 2.469 mmol) in ethanol (6 mL) preapared at ambient temperature was heated at reflux for 16 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(3-chlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide, 0.250 g, 85.6%, white solid).


[Step 3] N-(3-chlorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


Triethylamine (0.112 mL, 0.803 mmol) was added to a solution of N-(3-chlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.190 g, 0.535 mmol) in tetrahydrofuran (3 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.070 mL, 0.643 mmol), heated at reflux for 16 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-chlorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.210 g, 90.6%).


[Step 4] Compound 11352



embedded image


A mixture of N-(3-chlorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.110 g, 0.254 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.073 g, 0.305 mmol) in tetrahydrofuran (6 mL) was heated at 130° C. for 30 min under the microwaves. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.080 g, 75.9%).



1H NMR (400 MHz, CDCl3) δ 9.27 (dd, 1H, J=2.3, 0.8 Hz), 8.41 (dd, 1H, J=8.2, 2.2 Hz), 7.67 (dd, 1H, J=8.2, 0.9 Hz), 7.47 (dt, 1H, J=2.6, 1.1 Hz), 7.36-7.26 (m, 4H), 6.95 (t, 1H, J=51.6 Hz), 5.14 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 417.0 (M++1).


EXAMPLE 96
Compound 11353: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(pyridin-3-yl)methanesulfonamide
[Step 1] methyl 6-((N-(pyridin-3-yl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.168 g, 0.732 mmol) and potassium iodide (0.023 g, 0.139 mmol) in N,N-dimethylformide (2 mL) was stirred at the room temperature for 20 min, and mixed with N-(pyridin-3-yl)methanesulfonamide (0.120 g, 0.697 mmol) and potassium carbonate (0.116 g, 0.836 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-((N-(pyridin-3-yl)methylsulfonamido)methyl)nicotinate as yellow solid (0.140 g, 62.5%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(pyridin-3-yl)methylsulfonamido)methyl)nicotinate (0.140 g, 0.436 mmol) and hydrazine hydrate (0.064 mL, 1.307 mmol) in ethanol (4 mL) prepared at the ambient temperature was heated at reflux for 16 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(pyridin-3-yl)methanesulfonamide, 0.135 g, 96.4%, light yellow oil).


[Step 3] N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


Triethylamine (0.117 mL, 0.840 mmol) was added to a solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(pyridin-3-yl)methanesulfonamide (0.135 g, 0.420 mmol) in tetrahydrofuran (1 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.069 mL, 0.630 mmol), heated at reflux for 6 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(pyridin-3-yl)methanesulfonamide as yellow oil (0.070 g, 43.7%).


[Step 4] Compound 11353



embedded image


A mixture of N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(pyridin-3-yl)methanesulfonamide (0.070 g, 0.184 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.052 g, 0.220 mmol) in tetrahydrofuran (2 mL) was heated at 130° C. for 30 min under the microwaves. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(pyridin-3-yl)methanesulfonamide as light yellow oil (0.025 g, 35.7%).



1H NMR (400 MHz, CDCl3) δ 9.28 (d, J=1.7 Hz, 1H), 8.89 (d, J=2.1 Hz, 1H), 8.57 (dd, J=5.0, 1.2 Hz, 1H), 8.42 (dd, J=8.2, 2.2 Hz, 1H), 8.15 (d, J=9.0 Hz, 1H), 7.54 (m, 1H), 6.94 (t, J=51.6 Hz, 1H), 5.19 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 382.27 (M++1).


EXAMPLE 97
Compound 11354: N-(3-bromophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] methyl 6-((N-(3-bromophenyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.193 g, 0.840 mmol) and potassium iodide (0.027 g, 0.160 mmol) in N,N-dimethylformide (3 mL) was stirred at the room temperature for 20 min, and mixed with N-(3-bromophenyl)methanesulfonamide (0.200 g, 0.800 mmol) and potassium carbonate (0.144 g, 1.040 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(3-bromophenyl)methylsulfonamido)methyl)nicotinate as white solid (0.270 g, 84.6%).


[Step 2] N-(3-bromophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(3-bromophenyl)methylsulfonamido)methyl)nicotinate (0.270 g, 0.676 mmol) and hydrazine monohydrate (0.099 mL, 2.029 mmol) in ethanol (6 mL) prepared at the ambient temperature was heated at reflux for 8 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The precipitates were collected by filtration, washed by water, and dried to give N-(3-bromophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.250 g, 92.6%).


[Step 3] Compound 11354



embedded image


Triethylamine (0.042 mL, 0.304 mmol) was added to a solution of N-(3-bromophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.061 g, 0.152 mmol) in tetrahydrofuran (2 mL) at the room temperature, and the mixture was stirred for 20 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.025 mL, 0.228 mmol), heated at reflux for 8 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-bromophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.055 g, 78.8%).



1H NMR (400 MHz, CDCl3) δ 9.26 (d, J=1.7 Hz, 1H), 8.40 (dd, J=8.2, 2.1 Hz, 1H), 7.67 (d, J=8.2 Hz, 1H), 7.61 (m, 1H), 7.44˜7.37 (m, 2H), 7.24 (t, J=8.0 Hz, 1H), 6.95 (t, J=51.6 Hz, 1H), 5.13 (s, 2H), 3.09 (s, 3H); LRMS (ES) m/z 491.06 (M++1).


EXAMPLE 98
Compound 11355: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)methanesulfonamide
[Step 1] 6-((N-(m-tolyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.196 g, 0.850 mmol) and potassium iodide (0.027 g, 0.162 mmol) in N,N-dimethylformide (3 mL) was stirred at the room temperature for 20 min, and mixed with N-(m-tolyl)methanesulfonamide (0.150 g, 0.810 mmol) and potassium carbonate (0.145 g, 1.053 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-((N-(m-tolyl)methylsulfonamido)methyl)nicotinate as white solid (0.200 g, 73.9%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(m-tolyl)methylsulfonamido)methyl)nicotinate (0.200 g, 0.598 mmol) and hydrazine monohydrate (0.087 mL, 1.794 mmol) in ethanol (3 mL) prepared at the ambient temperature was heated at reflux for 8 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrates, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)methanesulfonamide, 0.190 g, 95.0%, white solid).


[Step 3] Compound 11355



embedded image


Triethylamine (0.055 mL, 0.391 mmol) was added to a solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)methanesulfonamide (0.065 g, 0.196 mmol) in tetrahydrofuran (2 mL) at the room temperature, and the mixture was stirred for 20 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.032 mL, 0.293 mmol), heated at reflux for 8 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and the aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)methane sulfonamide as white solid (0.048 g, 62.2%).



1H NMR (400 MHz, CDCl3) δ 9.23 (d, J=2.0 Hz, 1H), 8.39 (dd, J=8.3, 2.2 Hz, 1H), 7.75 (d, J=8.3 Hz, 1H), 7.28˜7.18 (m, 3H), 6.95 (t, J=51.6 Hz, 1H), 5.14 (s, 2H), 3.07 (s, 3H); LRMS (ES) m/z 394.99 (M++1).


EXAMPLE 99
Compound 11366: N-(3-bromophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] N-(3-bromophenyl)ethanesulfonamide



embedded image


A solution of 3-bromoaniline (3.000 g, 17.439 mmol), pyridine (1.545 mL, 19.183 mmol) and ethanesulfonyl chloride (2.148 mL, 22.670 mmol) in dichloromethane (100 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-bromophenyl)ethanesulfonamide as colorless oil (4.000 g, 86.8%).


[Step 2] methyl 6-((N-(3-bromophenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.479 g, 2.082 mmol) and potassium iodide (0.063 g, 0.379 mmol) in N,N-dimethylformide (30 mL) was stirred at the room temperature for 30 min, and mixed with N-(3-bromophenyl)ethanesulfonamide (0.500 g, 1.893 mmol) and potassium carbonate (0.392 g, 2.839 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 6-((N-(3-bromophenyl)ethylsulfonamido)methyl)nicotinate as yellwo solid (0.582 g, 74.4%).


[Step 3] N-(3-bromophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A mixture of methyl 6-((N-(3-bromophenyl)methylsulfonamido)methyl)nicotinate (0.582 g, 1.458 mmol) and hydrazine hydrate (0.730 g, 14.577 mmol) in ethanol (40 mL) was heated at reflux for 5 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-bromophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide, 0.500 g, 85.9%, colorless oil).


[Step 4] Compound 11366



embedded image


A mixture of N-(3-bromophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.500 g, 1.210 mmol), triethylamine (0.843 mL, 6.049 mmol) and difluoroacetic anhydride (0.329 mL, 3.025 mmol) in tetrahydrofuran (10 mL) preapared at ambient temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(3-bromophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as colorless oil (0.430 g, 74.8%).



1H NMR (400 MHz, CDCl3) δ 9.25 (d, 1H, J=1.8 Hz), 8.40 (dd, 1H, J=8.2, 2.3 Hz), 7.70 (d, 1H, J=8.3 Hz), 7.63-7.62 (m, 1H), 7.43-7.37 (m, 2H), 7.24-7.20 (m, 1H), 7.07 (s, 0.2H), 6.95 (s, 0.5H), 6.82 (s, 0.8H), 5.16 (s, 2H), 3.21 (q, 2H, J=7.4 Hz), 1.48-1.41 (m, 3H); LRMS (ES) m/z 473.0 (M++1).


EXAMPLE 100
Compound 11367: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-methyl-N-phenylpiperidine-4-sulfonamide
[Step 1] tert-butyl 4-(N-phenylsulfamoyl)piperidine-1-carboxylate



embedded image


Triethylamine (1.946 mL, 13.959 mmol) was added to a solution of aniline (0.980 mL, 10.738 mmol) in dichloromethane (10 mL) at the room temperature, and the mixture was stirred at the same temperature for 20 min. The reaction mixture was treated with tert-butyl 4-(chlorosulfonyl)piperidine-1-carboxylate (3.199 g, 11.275 mmol), and stirred for additional 16 hr at the same temperature. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (tert-butyl 4-(N-phenylsulfamoyl)piperidine-1-carboxylate, 3.600 g, 98.5%, white solid).


[Step 2] methyl 6-(((1-(tert-butoxycarbonyl)-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.710 g, 3.084 mmol) and potassium iodide (0.098 g, 0.587 mmol) in N,N-dimethylformide (6 mL) was stirred at the room temperature for 30 min, and mixed with tert-butyl 4-(N-phenylsulfamoyl)piperidine-1-carboxylate (1.000 g, 2.937 mmol) and potassium carbonate (0.487 g, 3.525 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. The reaction mixture was diluted with water, and stirred at the ambient temperature. The resulting precipitates were collected by filtration, washed by water solution, and dried to give methyl 6-(((1-(tert-butoxycarbonyl)-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate as brown solid (1.350 g, 93.9%).


[Step 3] methyl 6-((N-phenylpiperidine-4-sulfonamido)methyl)nicotinate hydrochloride



embedded image


A solution of methyl 6-(((1-(tert-butoxycarbonyl)-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate (0.436 g, 0.891 mmol) and hydrochloric acid (4.00 M solution in 1,4-dioxane, 0.891 mL, 3.562 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 1 hr, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (methyl 6-((N-phenylpiperidine-4-sulfonamido)methyl)nicotinate hydrochloride, 0.350 g, 92.3%, yellow solid).


[Step 4] methyl 6-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate



embedded image


Acetic acid (0.032 mL, 0.563 mmol) was added to a solution of methyl 6-((N-phenylpiperidine-4-sulfonamido)methyl)nicotinate hydrochloride (0.200 g, 0.470 mmol) and formaldehyde (0.141 g, 4.696 mmol) in dichloromethane (10 mL) at the room temperature, and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with sodium triacetoxyborohydride (0.199 g, 0.939 mmol), and stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate as yellow oil (0.142 g, 74.9%).


[Step 5] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-methyl-N-phenylpiperidine-4-sulfonamide



embedded image


A mixture of methyl 6-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate (0.142 g, 0.352 mmol) and hydrazine monohydrate (0.171 mL, 3.519 mmol) in ethanol (10 mL) prepared at the ambient temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-methyl-N-phenylpiperidine-4-sulfonamide, 0.130 g, 91.5%, yellow solid).


[Step 6] Compound 11367



embedded image


A mixture of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-methyl-N-phenylpiperidine-4-sulfonamide (0.130 g, 0.322 mmol), difluoroacetic anhydride (0.062 g, 0.354 mmol) and triethylamine (0.054 mL, 0.387 mmol) in tetrahydrofuran (10 mL) prepaed at the ambient temperature was heated at reflux for 5 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-methyl-N-phenylpiperidine-4-sulfonamide as yellow solid (0.094 g, 62.9%).



1H NMR (400 MHz, CDCl3) δ 9.29-9.20 (m, 1H), 8.41-8.37 (m, 1H), 7.60-7.47 (m, 2H), 7.36-7.29 (m, 4H), 7.08 (s, 0.2H), 6.95 (s, 0.5H), 6.82(s, 0.2H), 5.14 (s, 2H), 3.68-3.65 (m, 2H), 3.45-3.35 (m, 3H), 3.17-3.10 (m, 2H), 2.84 (s, 3H), 2.64-2.49 (m, 2H); LRMS (ES) m/z 464.4 (M++1).


EXAMPLE 101
Compound 11368: N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-ethyl-N-phenylpiperidine-4-sulfonamide
[Step 1] methyl 6-(((1-ethyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate



embedded image


Acetic acid (0.032 mL, 0.563 mmol) was added to a solution of methyl 6-((N-phenylpiperidine-4-sulfonamido)methyl)nicotinate hydrochloride (0.200 g, 0.470 mmol) and acetaldehyde (0.207 g, 4.696 mmol) in dichloromethane (10 mL) at the room temperature, and the mixture was stirred at the same temperature for 30 min. The reaction mixture was treated with sodium triacetoxyborohydride (0.199 g, 0.939 mmol), and stirred for additional 12 hr at the same temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-(((1-ethyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate as yellow oil (0.139 g, 70.9%).


[Step 2] 1-ethyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide



embedded image


A mixture of methyl 6-(((1-ethyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate (0.139 g, 0.333 mmol) and hydrazine monohydrate (0.162 mL, 3.329 mmol) in ethanol (10 mL) prepared at the ambient temperature was heated at reflux for 12 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (1-ethyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide, 0.120 g, 86.3%, white solid).


[Step 3] Compound 11368



embedded image


A mixture of 1-ethyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide (0.120 g, 0.287 mmol), difluoroacetic anhydride (0.055 g, 0.316 mmol) and triethylamine (0.048 mL, 0.345 mmol) in tetrahydrofuran (10 mL) prepared at the ambient temperature was heated at reflux for 5 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-ethyl-N-phenylpiperidine-4-sulfonamide as white solid (0.082 g, 59.7%).



1H NMR (400 MHz, CDCl3) δ 9.30-9.20 (m, 1H), 8.40-8.34 (m, 1H), 7.55-7.54 (m, 1H), 7.47-7.45 (m, 1H), 7.41-7.29 (m, 4H), 7.08 (s, 0.2H), 6.95 (s, 0.5H), 6.82 (s, 0.2H), 5.14 (s, 2H), 3.80-3.65 (m, 2H), 3.45-3.31 (m, 2H), 3.29-3.07 (m, 3H), 2.70-2.61 (m, 2H), 2.55-2.50 (m, 2H), 1.41-1.26 (m, 3H); LRMS (ES) m/z 478.4 (M++1).


EXAMPLE 102
Compound 11372: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide
[Step 1] tert-butyl 4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate



embedded image


A solution of methyl 4-(bromomethyl)-3-fluorobenzoate (0.610 g, 2.467 mmol) and potassium iodide (0.039 g, 0.235 mmol) in N,N-dimethylformide (8 mL) was stirred at the room temperature for 30 min, and mixed with tert-butyl 4-(N-phenylsulfamoyl)piperidine-1-carboxylate (0.800 g, 2.350 mmol) and potassium carbonate (0.422 g, 3.055 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 70%) to give tert-butyl 4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate as white solid (1.100 g, 92.4%).


[Step 2] methyl 3-fluoro-4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride



embedded image


A solution of tert-butyl 4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate (1.100 g, 2.171 mmol) in dichloromethane (10 mL) was mixed at the room temperature with hydrochloric acid (0.158 g, 4.343 mmol). The reaction mixture was stirred at the same temperature for 5 hr. The precipitates were collected by filtration, washed by dichloromethane, and dried to give methyl 3-fluoro-4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride as white solid (0.850 g, 88.4%).


[Step 3] methyl 3-fluoro-4-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate



embedded image


A solution of methyl 3-fluoro-4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride (0.100 g, 0.226 mmol), formaldehyde (0.034 g, 1.129 mmol) and acetic acid (0.006 mL, 0.113 mmol) in methanol (2 mL) was stirred at the room temperature for 20 min, and mixed with sodium cyanoborohydride (0.043 g, 0.677 mmol). The reaction mixture was stirred at the same temperature for additional 5 hr, and concentrated under the reduced pressure to remove the solvent. Then, saturated aqueous sodium bicarbonate solution was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give methyl 3-fluoro-4-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate as white solid (0.080 g, 84.3%).


[Step 4] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide



embedded image


A mixture of methyl 3-fluoro-4-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate (0.080 g, 0.190 mmol) and hydrazine monohydrate (0.028 mL, 0.571 mmol) in ethanol (3 mL) prepared at the ambient temperature was heated at reflux for 16 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide as white solid (0.075 g, 93.8%).


[Step 5] Compound 11372



embedded image


Triethylamine (0.046 mL, 0.327 mmol) was added to solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide (0.069 g, 0.164 mmol) in tetrahydrofuran (2 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.027 mL, 0.245 mmol), heated at reflux for 5 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide as white solid (0.055 g, 70.0%).



1H NMR (400 MHz, CDCl3) δ 7.85 (dd, 1H, J=8.0, 1.6 Hz), 7.69 (d, 1H, J=16.4 Hz), 7.62 (t, 1H, J=7.4 Hz), 7.37-7.26 (m, 5H), 7.02 (s, 0.25H), 6.89 (s, 0.5H), 6.76 (s, 0.25H), 5.06 (s, 2H), 3.19 (m, 3H), 2.51-2.42 (m, 4H), 2.28-2.04 (m, 5H); LRMS (ES) m/z 481.21 (M++1).


EXAMPLE 103
Compound 11373: N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-ethyl-N-phenylpiperidine-4-sulfonamide
[Step 1] methyl 4-(((1-ethyl-N-phenylpiperidine)-4-sulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 3-fluoro-4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride (0.100 g, 0.226 mmol) and acetaldehyde (0.038 mL, 0.677 mmol) in methanol (2 mL) was stirred at the room temperature for 20 min, and mixed with sodium cyanoborohydride (0.043 g, 0.677 mmol). The reaction mixture was stirred at the same temperature for additional 5 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 100%) to give methyl 4-(((1-ethyl-N-phenylpiperidine)-4-sulfonamido)methyl)-3-fluorobenzoate as white solid (0.080 g, 81.5%).


[Step 2] 1-ethyl-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylpiperidine-4-sulfonamide



embedded image


A mixture of methyl 4-(((1-ethyl-N-phenylpiperidine)-4-sulfonamido)methyl)-3-fluorobenzoate (0.080 g, 0.184 mmol) and hydrazine monohydrate (0.045 mL, 0.921 mmol) in ethanol (3 mL) prepared at the ambient temperature was heated at reflux for 18 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give 1-ethyl-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylpiperidine-4-sulfonamide as whtie solid (0.070 g, 87.5%).


[Step 3] Compound 11373



embedded image


Triethylamine (0.040 mL, 0.289 mmol) was added to solution of 1-ethyl-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-phenylpiperidine-4-sulfonamide (0.063 g, 0.145 mmol) in tetrahydrofuran (2 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.024 mL, 0.217 mmol), heated at reflux for 5 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-ethyl-N-phenylpiperidine-4-sulfonamide as white solid (0.055 g, 77.0%).



1H NMR (400 MHz, CDCl3) δ 7.85 (dd, 1H, J=8.1, 1.6 Hz), 7.69 (dd, 1H, J=9.8, 1.4 Hz), 7.64 (t, 1H, J=6.7 Hz), 7.33-7.02 (m, 5H), 7.02 (s, 0.25H), 6.89 (s, 0.5H), 6.76 (s, 0.25H), 5.06 (s, 2H), 3.21 (m, 3H), 2.65 (m, 3H), 2.24 (m, 5H), 1.24 (m, 3H); LRMS (ES) m/z 495.18 (M++1).


EXAMPLE 104
Compound 11377, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(2-hydroxy-2-methylpropyl)-N-phenylpiperidine-4-sulfonamide
[Step 1] ethyl 3-fluoro-4-(((1-(2-hydroxy-2-methylpropyl)-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate



embedded image


A mixture of methyl 3-fluoro-4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride (0.090 g, 0.203 mmol), 2,2-dimethyloxirane (0.073 g, 1.016 mmol) and potassium carbonate (0.056 g, 0.406 mmol) in ethanol (6 mL) was heated at 120° C. for 30 min under the microwaves. Then, the reaction mixture was concentrated under the reduced pressure to remove the solvent. The precipitates were collected by filtration, washed by water, and dried to give ethyl 3-fluoro-4-(((1-(2-hydroxy-2-methylpropyl)-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate as white solid (0.080 g, 79.9%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-(2-hydroxy-2-methylpropyl)-N-phenylpiperidine-4-sulfonamide



embedded image


A mixture of ethyl 3-fluoro-4-(((1-(2-hydroxy-2-methylpropyl)-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate (0.080 g, 0.162 mmol) and hydrazine monohydrate (0.039 mL, 0.812 mmol) in ethanol (2 mL) prepared at the ambient temperature was heated at reflux for 16 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-(2-hydroxy-2-methylpropyl)-N-phenylpiperidine-4-sulfonamide as white solid (0.065 g, 83.6%).


[Step 3] Compound 11377



embedded image


Triethylamine (0.025 mL, 0.180 mmol) was added to solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-(2-hydroxy-2-methylpropyl)-N-phenylpiperidine-4-sulfonamide (0.043 g, 0.090 mmol) in tetrahydrofuran (3 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.015 mL, 0.135 mmol), heated at reflux for 5 hr, and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 70%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(2-hydroxy-2-methylpropyl)-N-phenylpiperidine-4-sulfonamide as white solid (0.015 g, 31.0%).



1H NMR (400 MHz, CDCl3) δ 7.85 (dd, 1H, J=8.0, 1.5 Hz), 7.70 (dd, 1H, J=9.9, 1.5 Hz), 7.63 (t, 1H, J=7.6 Hz), 7.35-7.27 (m, 5H), 7.02 (s, 0.25H), 6.89 (s, 0.5H), 6.76 (s, 0.25H), 5.05 (s, 2H), 3.24 (m, 2H), 3.14 (m, 1H), 2.63-2.54 (m, 4H), 2.23-2.16 (m, 4H), 1.25 (S, 6H); LRMS (ES) m/z 539.54 (M++1).


EXAMPLE 105
Compound 11386, N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] tert-butyl 4-(4-nitrobenzyl)piperazine-1-carboxylate



embedded image


A solution of 1-(bromomethyl)-4-nitrobenzene (1.000 g, 4.629 mmol), N,N-diisopropylethylamine (1.209 mL, 6.943 mmol) and tert-butyl piperazine-1-carboxylate (0.948 g, 5.092 mmol) in acetonitrile (50 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give tert-butyl 4-(4-nitrobenzyl)piperazine-1-carboxylate as yellow oil (1.100 g, 73.9%).


[Step 2] tert-butyl 4-(4-aminobenzyl)piperazine-1-carboxylate



embedded image


A solution of tert-butyl 4-(4-nitrobenzyl)piperazine-1-carboxylate (1.100 g, 3.423 mmol), ammonium chloride (0.915 g, 17.114 mmol) and Zn dust (1.119 g, 17.114 mmol) in tetrahydrofuran (20 mL)/water (20 mL) was stirred at the room temperature for 12 hr. The reaction mixture was filtered to remove solids. Then, water was added to the filtrate, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (tert-butyl 4-(4-aminobenzyl)piperazine-1-carboxylate, 0.900 g, 90.2%, yellow solid).


[Step 3] tert-butyl 4-(4-(ethylsulfonamido)benzyl)piperazine-1-carboxylate



embedded image


A solution of tert-butyl 4-(4-aminobenzyl)piperazine-1-carboxylate (0.900 g, 3.089 mmol), pyridine (0.299 mL, 3.706 mmol) and ethanesulfonyl chloride (0.477 g, 3.706 mmol) in dichloromethane (30 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give tert-butyl 4-(4-(ethylsulfonamido)benzyl)piperazine-1-carboxylate as yellow solid (0.800 g, 67.5%).


[Step 4] tert-butyl 4-(4-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.528 g, 2.295 mmol) and potassium iodide (0.069 g, 0.417 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 30 min, and mixed with tert-butyl 4-(4-(ethylsulfonamido)benzyl)piperazine-1-carboxylate (0.800 g, 2.086 mmol) and potassium carbonate (0.432 g, 3.129 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give tert-butyl 4-(4-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate as yellow solid (0.623 g, 56.1%).


[Step 5] methyl 6-((N-(4-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)nicotinate hydrochloride



embedded image


A solution of tert-butyl 4-(4-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate (0.623 g, 1.170 mmol) and hydrochloric acid (4.00 M solution in 1,4-dioxane, 1.170 mL, 4.678 mmol) in dichloromethane (30 mL) was stirred at the room temperature for 5 hr. The reaction mixture was concentrated under the reduced pressure to remove the solvent, and then, the title compound was used without further purification (methyl 6-((N-(4-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)nicotinate hydrochloride, 0.500 g, 91.2%, yellow solid).


[Step 6] methyl 6-((N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-((N-(4-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)nicotinate hydrochloride (0.150 g, 0.320 mmol), triethylamine (0.067 mL, 0.480 mmol) and acetic anhydride (0.042 g, 0.416 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-((N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate as yellow oil (0.090 g, 59.3%).


[Step 7] N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate (0.090 g, 0.190 mmol) and hydrazine hydrate (0.095 g, 1.896 mmol) in ethanol (5 mL) was stirred at 90° C. for 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.071 g, 78.9%, white solid).


[Step 8] Compound 11386



embedded image


A mixture of N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.072 g, 0.152 mmol), triethylamine (0.085 mL, 0.607 mmol) and 2,2-difluoroacetic anhydride (0.033 mL, 0.303 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 5 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as yellow solid (0.026 g, 32.1%).



1H NMR (400 MHz, CDCl3) δ 9.23 (dd, 1H, J=2.2, 0.9 Hz), 8.39 (dd, 1H, J=8.2, 2.2 Hz), 7.77 (d, 1H, J=8.3 Hz), 7.39 (s, 4H), 6.95 (m, 1H), 5.18 (s, 2H), 3.62 (s, 3H), 3.50 (s, 3H), 3.22 (q, 2H, J=7.4 Hz), 2.43 (s, 4H), 2.09 (s, 3H), 1.47 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 535.34 (M++1).


EXAMPLE 106
Compound 11387, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide
[Step 1] methyl 6-((N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-((N-(4-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)nicotinate hydrochloride (0.150 g, 0.320 mmol), triethylamine (0.067 mL, 0.480 mmol) and methanesulfonyl chloride (0.032 mL, 0.416 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-((N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate as yellow oil (0.094 g, 57.6%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate (0.094 g, 0.184 mmol) and hydrazine hydrate (0.092 g, 1.841 mmol) in ethanol (5 mL) was stirred at 90° C. for 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide, 0.069 g, 73.4%, white solid).


[Step 3] Compound 11387



embedded image


A mixture of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide (0.090 g, 0.176 mmol), triethylamine (0.098 mL, 0.705 mmol) and 2,2-difluoroacetic anhydride (0.038 mL, 0.353 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 5 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide as yellow solid (0.031 g, 30.8%).



1H NMR (400 MHz, CDCl3) δ 9.22 (td, 1H, J=2.2, 0.9 Hz), 8.39 (dd, 1H, J=8.2, 2.2 Hz), 7.70 (ddd, 1H, J=8.2, 4.7, 0.9 Hz), 7.53-7.44 (m, 2H), 7.46-7.37 (m, 2H), 7.11-6.80 (m, 1H), 5.17 (s, 2H), 3.72 (s, 1H), 3.55-3.50 (m, 3H), 3.22 (q, 2H, J=7.4 Hz), 3.06 (s, 4H), 2.84 (s, 3H), 1.44 (s, 5H); LRMS (ES) m/z 571.37 (M++1).


EXAMPLE 107
Compound 11388, N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] tert-butyl 4-(3-nitrobenzyl)piperazine-1-carboxylate



embedded image


A solution of 1-(bromomethyl)-3-nitrobenzene (1.000 g, 4.629 mmol), N,N-diisopropylethylamine (1.209 mL, 6.943 mmol) and tert-butyl piperazine-1-carboxylate (0.948 g, 5.092 mmol) in acetonitrile (20 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give tert-butyl 4-(3-nitrobenzyl)piperazine-1-carboxylate as yellow oil (1.050 g, 70.6%).


[Step 2] tert-butyl 4-(3-aminobenzyl)piperazine-1-carboxylate



embedded image


A solution of tert-butyl 4-(3-nitrobenzyl)piperazine-1-carboxylate (1.050 g, 3.267 mmol), ammonium chloride (0.874 g, 16.336 mmol) and Zinc dust (1.068 g, 16.336 mmol) in tetrahydrofuran (20 mL)/water (20 mL) was stirred at the room temperature for 12 hr. The reaction mixture was filtered to remove solids. Then, water was added to the filtrate, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (tert-butyl 4-(3-aminobenzyl)piperazine-1-carboxylate, 0.940 g, 98.7%, yellow solid).


[Step 3] tert-butyl 4-(3-(ethylsulfonamido)benzyl)piperazine-1-carboxylate



embedded image


A solution of tert-butyl 4-(3-aminobenzyl)piperazine-1-carboxylate (0.940 g, 3.226 mmol), pyridine (0.312 mL, 3.871 mmol) and ethanesulfonyl chloride (0.456 g, 3.548 mmol) in dichloromethane (30 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, separated, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give tert-butyl 4-(3-(ethylsulfonamido)benzyl)piperazine-1-carboxylate as yellow solid (1.080 g, 87.3%).


[Step 4] tert-butyl 4-(3-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.713 g, 3.098 mmol) and potassium iodide (0.093 g, 0.563 mmol) in N,N-dimethylformide (30 mL) was stirred at the room temperature for 30 min, and mixed with tert-butyl 4-(3-(ethylsulfonamido)benzyl)piperazine-1-carboxylate (1.080 g, 2.816 mmol) and potassium carbonate (0.584 g, 4.224 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give tert-butyl 4-(3-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate as yellow solid (0.616 g, 41.1%).


[Step 5] methyl 6-((N-(3-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)nicotinate hydrochloride



embedded image


A solution of tert-butyl 4-(3-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate (0.616 g, 1.156 mmol) and hydrochloric acid (4.00 M solution in 1,4-dioxane, 1.156 mL, 4.626 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 5 hr, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (methyl 6-((N-(3-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)nicotinate hydrochloride, 0.520 g, 95.9%, yellow solid).


[Step 6] methyl 6-((N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-((N-(3-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)nicotinate hydrochloride (0.150 g, 0.320 mmol), triethylamine (0.067 mL, 0.480 mmol) and acetic anhydride (0.039 g, 0.384 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-((N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.094 g, 61.9%).


[Step 7] N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)nicotinate (0.094 g, 0.198 mmol) and hydrazine hydrate (0.099 g, 1.981 mmol) in ethanol (10 mL) was stirred at 90° C. for 5 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.064 g, 68.1%, white solid).


[Step 8] Compound 11388



embedded image


A mixture of N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.061 g, 0.129 mmol), triethylamine (0.072 mL, 0.514 mmol) and 2,2-difluoroacetic anhydride (0.028 mL, 0.257 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 5 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as yellow solid (0.018 g, 26.2%).



1H NMR (400 MHz, CDCl3) δ 9.21 (d, 1H, J=2.2 Hz), 8.38 (dd, 1H, J=8.2, 2.2 Hz), 7.76 (d, 1H, J=8.2 Hz), 7.44 (s, 1H), 7.35-7.23 (m, 3H), 7.13-6.77 (m, 1H), 5.18 (s, 2H), 3.88-3.33 (m, 6H), 3.21 (q, 2H, J=7.4 Hz), 2.40 (s, 4H), 2.08 (s, 3H), 1.46 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 535.47 (M++1).


EXAMPLE 108
Compound 11389, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanesulfonamide
[Step 1] (tert-butyl (4-cyanobenzyl)carbamate



embedded image


Triethylamine (4.932 mL, 35.583 mmol) was added to solution of 4-(aminomethyl)benzonitrile hydrochloride (5.000 g, 29.652 mmol) in dichloromethane (20 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated at the same temperature with Di-tert-butyl dicarbonate (6.795 g, 31.135 mmol) and stirred for additional 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (tert-butyl (4-cyanobenzyl)carbamate, 6.850 g, 99.5%, whtie solid).


[Step 2] tert-butyl (Z)-4-(N′-hydroxycarbamimidoyl)benzylcarbamate



embedded image


A mixture of tert-butyl 4-cyanobenzylcarbamate (6.800 g, 29.275 mmol), NH2OH (6.103 g, 87.825 mmol), Na2CO3 (9.309 g, 87.825 mmol) and NH2OH (50.00% solution in water, 5.372 mL, 87.825 mmol) in ethanol (20 mL) prepared at the room temperature was heated at reflux for 14 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give tert-butyl (Z)-4-(N′-hydroxycarbamimidoyl)benzylcarbamate as white solid (7.500 g, 96.6%).


[Step 3] tert-butyl (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)carbamate



embedded image


Triethylamine (5.298 mL, 38.219 mmol) was added to solution of tert-butyl (Z)-(4-(N′-hydroxycarbamimidoyl)benzyl)carbamate (7.800 g, 29.400 mmol) in N,N-dimethylformide (25 mL) at 0° C., and the mixture was stirred at the same temperature. The reaction mixture was treated at 80° C. with Trifluoroacetic anhydride (TFAA, 4.305 mL, 32.340 mmol), stirred for additioanl 2 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to terminate the reaction. Then, aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with brine, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 80 g cartridge; ethyl acetate/hexane=0% to 30%) to give tert-butyl (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)carbamate as colorlessness oil (5.240 g, 51.9%).


[Step 4] (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanamine hydrochloride



embedded image


A solution of tert-butyl (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)carbamate (5.240 g, 15.263 mmol) in dichloromethane (20 mL) prepared at the room temperature was mixed with HCl (4.00 M solution, 4.197 mL, 16.789 mmol). The reaction mixture was stirred at the same temperature for 1 hr. The precipitates were collected by filtration, washed by dichloromethane, and dried to give (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanamine hydrochloride as white solid (3.900 g, 91.4%).


[Step 5] N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanesulfonamide



embedded image


Triethylamine (0.060 mL, 0.429 mmol) was added to solution of (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanamine hydrochloride (0.100 g, 0.358 mmol) in dichloromethane (4 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated at the same temperature with methanesulfonyl chloride (0.028 mL, 0.358 mmol) and stirred for additional 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The title compound was used without further purification (N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanesulfonamide, 0.110 g, 95.7%, white solid).


[Step 6] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanesulfonamide



embedded image


A solution of 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.043 g, 0.141 mmol) and potassium iodide (0.004 g, 0.027 mmol) in N,N-dimethylformide (2 mL) was stirred at the room temperature for 30 min, and mixed with N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanesulfonamide (0.043 g, 0.134 mmol) and potassium carbonate (0.028 g, 0.201 mmol). The reaction mixture was stirred at the same temperature for additional 8 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 35%) to give N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanesulfonamide as yellow solid (0.050 g, 66.1%).


[Step 7] Compound 11389



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanesulfonamide (0.050 g, 0.088 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.063 g, 0.265 mmol) in tetrahydrofuran (4 mL) was heated at 130° C. for 30 min under the microwaves. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 25%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanesulfonamide as white solid (0.025 g, 51.6%).



1H NMR (400 MHz, DMSO-D6) δ 7.94 (d, 2H, J=8.3 Hz), 7.78 (dd, 1H, J=25.9, 17.9 Hz), 7.70-7.67 (m, 1.25H), 7.62 (t, 5H, J=7.8 Hz), 7.56 (s, 0.5H), 7.50 (d, 1H, J=8.3 Hz), 7.43 (s, 0.25H), 4.60 (s, 2H), 4.55 (s, 2H), 3.17 (s, 3H); LRMS (ES) m/z 548.38 (M++1).


EXAMPLE 109
Compound 11390, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-pyran-4-sulfonamide
[Step 1] N-phenyltetrahydro-2H-pyran-4-sulfonamide



embedded image


A solution of aniline (0.294 mL, 3.221 mmol) and triethylamine (0.539 mL, 3.866 mmol) in dichloromethane (8 mL) was stirred at 0° C. for 10 min, and mixed with tetrahydro-2H-pyran-4-sulfonyl chloride (0.624 g, 3.382 mmol). The reaction mixture was stirred at the room temperature for additional 6 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-phenyltetrahydro-2H-pyran-4-sulfonamide as light yellow oil (0.650 g, 83.6%).


[Step 2] methyl 6-(((N-phenyltetrahydro-2H-pyran)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.497 g, 2.158 mmol) and potassium iodide (0.068 g, 0.411 mmol) in N,N-dimethylformide (8 mL) was stirred at the room temperature for 20 min, and mixed with N-phenyltetrahydro-2H-pyran-4-sulfonamide (0.496 g, 2.055 mmol) and potassium carbonate (0.369 g, 2.672 mmol). The reaction mixture was stirred at the same temperature for additional 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-(((N-phenyltetrahydro-2H-pyran)-4-sulfonamido)methyl)nicotinate as yellow soild (0.650 g, 81.0%).


[Step 3] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-pyran-4-sulfonamide



embedded image


A mixture of methyl 6-(((N-phenyltetrahydro-2H-pyran)-4-sulfonamido)methyl)nicotinate (0.650 g, 1.665 mmol) and hydrazine monohydrate (0.405 mL, 8.324 mmol) in ethanol (10 mL) prepared at the room temperature was heated at reflux for 8 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-pyran-4-sulfonamide as white solid (0.580 g, 89.2%).


[Step 4] Compound 11390



embedded image


Triethylamine (0.039 mL, 0.277 mmol) was added to solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-pyran-4-sulfonamide (0.054 g, 0.138 mmol) in tetrahydrofuran (2 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.023 mL, 0.207 mmol), heated at reflux for 3 hr, and cooled down to the room temperature to terminate the reaction. Then, aqueous saturated sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-pyran-4-sulfonamide as white solid (0.055 g, 88.3%).



1H NMR (400 MHz, CDCl3) δ 9.18 (d, 1H, J=2.2 Hz), 8.38 (dd, 1H, J=8.2, 2.2 Hz), 7.75 (d, 1H, J=8.2 Hz), 7.40 (m, 2 Hz), 7.35 (m, 2H), 7.25 (m, 1Hz), 7.05 (s, 0.25H), 6.92 (s, 0.5H), 6.79 (s, 0.25H), 5.20 (s, 2H), 4.11-4.07 (m, 2H), 3.39-3.30 (m, 3H), 2.20-1.99 (m, 4H); LRMS (ES) m/z 451.35 (M++1).


EXAMPLE 110
Compound 11392, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)ethanesulfonamide
[Step 1] 4-(3-nitrobenzyl)thiomorpholine 1,1-dioxide



embedded image


A solution of 1-(bromomethyl)-3-nitrobenzene (2.400 g, 11.110 mmol), thiomorpholine 1,1-dioxide (1.427 g, 10.554 mmol) and N,N-diisopropylethylamine (2.516 mL, 14.442 mmol) in acetonitrile (16 mL) was stirred at the room temperature for 24 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give 4-(3-nitrobenzyl)thiomorpholine 1,1-dioxide as yellow solid (2.800 g, 93.2%).


[Step 2] 4-(3-aminobenzyl)thiomorpholine 1,1-dioxide



embedded image


A solution of 4-(3-nitrobenzyl)thiomorpholine 1,1-dioxide (2.750 g, 10.174 mmol), zinc (2.661 g, 40.696 mmol) and ammonium chloride (2.177 g, 40.696 mmol) in tetrahydrofuran (10 mL)/water (5 mL) was stirred at the room temperature for 16 hr. The reaction mixture was filtered by paper filter to remove solids. Then, saturated aqueous sodium bicarbonate solution was added to filtrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give 4-(3-aminobenzyl)thiomorpholine 1,1-dioxide as yellow solid (2.100 g, 85.9%).


[Step 3] N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)ethanesulfonamide



embedded image


A solution of 4-(3-aminobenzyl)thiomorpholine 1,1-dioxide (1.000 g, 4.161 mmol) and pyridine (0.402 mL, 4.993 mmol) in dichloromethane (20 mL) was mixed at 0° C. with ethanesulfonyl chloride (0.387 mL, 4.369 mmol), and stirred at the same temperature for 20 min. The reaction mixture was stirred at the room temperature for additional 16 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)ethanesulfonamide as light yellow solid (1.200 g, 86.8%).


[Step 4] methyl 4-((N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 4-(bromomethyl)-3-fluorobenzoate (0.531 g, 2.148 mmol) and potassium iodide (0.068 g, 0.409 mmol) in N,N-dimethylformide (8 mL) was stirred at the room temperature for 20 min, and mixed with N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)ethanesulfonamide (0.680 g, 2.046 mmol) and potassium carbonate (0.368 g, 2.659 mmol). The reaction mixture was stirred at the same temperature for additional 8 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 70%) to give methyl 4-((N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate as white solid (0.880 g, 86.3%).


[Step 5] N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide



embedded image


A mixture of methyl 4-((N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate (0.880 g, 1.765 mmol) and hydrazine monohydrate (0.257 mL, 5.295 mmol) in ethanol (8 mL) prepared at the room temperature was heated at reflux for 14 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide as white solid (0.850 g, 96.6%).


[Step 6] Compound 11392



embedded image


Triethylamine (0.028 mL, 0.201 mmol) was added to solution of N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide (0.050 g, 0.100 mmol) in tetrahydrofuran (2 mL) at the room temperature, and the mixture was stirred for 10 min at the same temperature. The reaction mixture was treated with 2,2-difluoroacetic anhydride (0.016 mL, 0.150 mmol), heated at reflux for 5 hr, and cooled down to the room temperature to terminate the reaction. Then, aqueous saturated sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 80%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-((1,1-dioxidothiomorpholino)methyl)phenyl)ethanesulfonamide as white solid (0.045 g, 80.3%).



1H NMR (400 MHz, CDCl3) δ 7.86 (dd, 1H, J=8.1, 1.5 Hz), 7.84-7.66 (m, 2H), 7.32-7.28 (m, 2 Hz), 7.25-7.21 (m, 2 Hz), 7.02 (s, 0.25H), 6.89 (s, 0.5H), 6.77 (s, 0.25H), 5.03 (s, 2H), 3.62 (m, 2H), 3.13 (q, 2H, J=7.4 Hz), 3.02 (m, 4H), 2.87 (m, 4H), 1.45 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 560.47 (M++1).


EXAMPLE 111
Compound 11402: N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)ethanesulfonamide
[Step 1] tert-butyl 4-(4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate



embedded image


A solution of methyl 4-(bromomethyl)-3-fluorobenzoate (0.454 g, 1.836 mmol) and potassium iodide (0.055 g, 0.334 mmol) in N,N-dimethylformide (30 mL) was stirred at the room temperature for 30 min, and mixed with tert-butyl 4-(4-(ethylsulfonamido)benzyl)piperazine-1-carboxylate (0.640 g, 1.669 mmol) and potassium carbonate (0.346 g, 2.503 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give tert-butyl 4-(4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate as yellow solid (0.780 g, 85.0%).


[Step 2] methyl 3-fluoro-4-((N-(4-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride



embedded image


A solution of tert-butyl 4-(4-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate (0.780 g, 1.419 mmol) and hydrochloric acid (4.00 M solution in 1,4-dioxane, 1.419 mL, 5.676 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (methyl 3-fluoro-4-((N-(4-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride, 0.680 g, 98.6%, white solid).


[Step 3] methyl 4-((N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 3-fluoro-4-((N-(4-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride (0.200 g, 0.412 mmol), triethylamine (0.086 mL, 0.617 mmol) and acetic anhydride (0.047 mL, 0.494 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (methyl 4-((N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate, 0.130 g, 64.3%, yellow oil).


[Step 4] N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide



embedded image


A solution of methyl 4-((N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate (0.130 g, 0.264 mmol) and hydrazine monohydrate (0.129 mL, 2.645 mmol) in ethanol (5 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compoundwas used without further purification (N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide, 0.096 g, 73.8%, yellow solid).


[Step 5] Compound 11402



embedded image


A mixture of N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide (0.096 g, 0.195 mmol), triethylamine (0.109 mL, 0.781 mmol) and 2,2-difluoroacetic anhydride (0.042 mL, 0.391 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 5 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)ethanesulfonamide as yellow oil (0.021 g, 19.5%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.0, 1.7 Hz), 7.76-7.66 (m, 2H), 7.30 (t, 4H, J=4.7 Hz), 7.10-6.72 (m, 1H), 5.05 (s, 2H), 3.62 (s, 2H), 3.52-3.42 (m, 4H), 3.20-3.08 (m, 2H), 2.41 (s, 4H), 2.08 (d, 3H, J=1.5 Hz), 1.51-1.39 (m, 3H); LRMS (ES) m/z 552.45 (M++1).


EXAMPLE 112
Compound 11403, N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)ethanesulfonamide
[Step 1] tert-butyl 4-(3-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate



embedded image


A solution of methyl 4-(bromomethyl)-3-fluorobenzoate (0.454 g, 1.836 mmol) and potassium iodide (0.055 g, 0.334 mmol) in N,N-dimethylformide (30 mL) was stirred at the room temperature for 30 min, and mixed with tert-butyl 4-(3-(ethylsulfonamido)benzyl)piperazine-1-carboxylate (0.640 g, 1.669 mmol) and potassium carbonate (0.346 g, 2.503 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give tert-butyl 4-(3-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate as yellow solid (0.780 g, 85.0%).


[Step 2] methyl 3-fluoro-4-((N-(3-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride



embedded image


A solution of tert-butyl 4-(3-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)benzyl)piperazine-1-carboxylate (0.780 g, 1.419 mmol) and hydrochloric acid (4.00 M solution in 1,4-dioxane, 1.419 mL, 5.676 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (methyl 3-fluoro-4-((N-(3-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride, 0.680 g, 98.6%, white solid).


[Step 3] methyl 4-((N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 3-fluoro-4-((N-(3-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride (0.200 g, 0.412 mmol), triethylamine (0.086 mL, 0.617 mmol) and acetic anhydride (0.050 mL, 0.535 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-((N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate as yellow oil (0.160 g, 79.1%).


[Step 4] N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide



embedded image


A solution of methyl 4-((N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)-3-fluorobenzoate (0.160 g, 0.325 mmol) and hydrazine monohydrate (0.158 mL, 3.255 mmol) in ethanol (5 mL) was stirred at 90° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide, 0.096 g, 60.0%, yellow solid).


[Step 5] Compound 11403



embedded image


A mixture of N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide (0.096 g, 0.195 mmol), triethylamine (0.109 mL, 0.781 mmol) and 2,2-difluoroacetic anhydride (0.042 mL, 0.391 mmol) in tetrahydrofuran (10 mL) preapared at the room temperature was heated at reflux for 5 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)ethanesulfonamide as white solid (0.021 g, 19.5%).



1H NMR (400 MHz, CDCl3) δ 7.85 (dd, 1H, J=8.0, 1.6 Hz), 7.73-7.63 (m, 2H), 7.34-7.25 (m, 2H), 7.27-7.18 (m, 2H), 7.11-6.77 (m, 1H), 5.05 (s, 2H), 3.57 (d, 2H, J=6.2 Hz), 3.51-3.39 (m, 4H), 3.15 (q, 2H, J=7.4 Hz), 2.33 (t, 4H, J=10.2 Hz), 2.06 (s, 3H), 1.45 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 552.51 (M++1).


EXAMPLE 113
Compound 11404, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide
[Step 1] methyl 3-fluoro-4-((N-(3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 3-fluoro-4-((N-(3-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride (0.200 g, 0.412 mmol), triethylamine (0.086 mL, 0.617 mmol) and methanesulfonyl chloride (0.041 mL, 0.535 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 3-fluoro-4-((N-(3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)benzoate as yellow oil (0.130 g, 59.9%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide



embedded image


A solution of methyl 3-fluoro-4-((N-(3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)benzoate (0.130 g, 0.246 mmol) and hydrazine monohydrate (0.120 mL, 2.464 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide, 0.092 g, 70.8%, yellow solid).


[Step 3] Compound 11404



embedded image


A mixture of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide (0.160 g, 0.303 mmol), triethylamine (0.169 mL, 1.213 mmol) and 2,2-difluoroacetic anhydride (0.066 mL, 0.606 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)ethanesulfonamide as yellow oil (0.110 g, 61.7%).



1H NMR (400 MHz, CDCl3) δ 7.86 (dd, 1H, J=8.0, 1.7 Hz), 7.73-7.63 (m, 2H), 7.36-7.16 (m, 4H), 7.11-6.75 (m, 1H), 5.04 (s, 2H), 3.52 (s, 2H), 3.21-3.10 (m, 6H), 2.78 (s, 3H), 2.45 (s, 4H), 1.51-1.40 (m, 3H); LRMS (ES) m/z 588.48 (M++1).


EXAMPLE 114
Compound 11405, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)ethanesulfonamide
[Step 1] methyl 3-fluoro-4-((N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 3-fluoro-4-((N-(3-(piperazin-1-ylmethyl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride (0.200 g, 0.412 mmol), formaldehyde (0.037 g, 1.235 mmol) and acetic acid (0.026 mL, 0.453 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 30 min, and mixed with sodium triacetoxyborohydride (0.131 g, 0.617 mmol). The reaction mixture was stirred at the same temperature for additional 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 3-fluoro-4-((N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)benzoate as yellow oil (0.120 g, 62.9%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)ethanesulfonamide



embedded image


A solution of methyl 3-fluoro-4-((N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)ethylsulfonamido)methyl)benzoate (0.120 g, 0.259 mmol) and hydrazine monohydrate (0.126 mL, 2.589 mmol) in ethanol (5 mL) was stirred at 90° C. for 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)ethanesulfonamide, 0.089 g, 74.2%, yellow solid).


[Step 3] Compound 11405



embedded image


A mixture of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)ethanesulfonamide (0.150 g, 0.324 mmol), triethylamine (0.180 mL, 1.294 mmol) and 2,2-difluoroacetic anhydride (0.070 mL, 0.647 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)ethanesulfonamide as yellow oil (0.090 g, 53.1%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.1, 1.7 Hz), 7.75-7.65 (m, 2H), 7.34-7.18 (m, 4H), 7.12-6.73 (m, 1H), 5.06 (s, 2H), 3.50 (s, 2H), 3.15 (q, 2H, J=7.4 Hz), 2.71-2.40 (m, 8H), 2.37 (s, 3H), 1.47 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 524.50 (M++1).


EXAMPLE 115
Compound 11406, N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)ethanesulfonamide



embedded image


A mixture of N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethanesulfonamide (0.052 g, 0.106 mmol), triethylamine (0.059 mL, 0.423 mmol) and trifluoroacetic anhydride (0.030 mL, 0.212 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 100%) to give N-(3-((4-acetylpiperazin-1-yl)methyl)phenyl)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)ethanesulfonamide as yellow solid (0.021 g, 34.9%).



1H NMR (400 MHz, CDCl3) δ 7.88 (dd, 1H, J=8.0, 1.6 Hz), 7.77-7.68 (m, 2H), 7.61 (s, 1H), 7.48-7.32 (m, 3H), 5.07 (s, 2H), 4.18 (s, 2H), 3.85 (s, 2H), 3.18 (q, 3H, J=7.4 Hz), 3.07 (s, 5H), 2.13 (s, 3H), 1.46 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 570.56 (M++1).


EXAMPLE 116
Compound 11411, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] N-(3-chloro-4-fluorophenyl)ethanesulfonamide



embedded image


A solution of 3-chloro-4-fluoroaniline (2.000 g, 13.740 mmol), pyridine (1.328 mL, 16.488 mmol) and ethanesulfonyl chloride (1.943 g, 15.114 mmol) in dichloromethane (100 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)ethanesulfonamide, 2.100 g, 64.3%, black solid).


[Step 2] methyl 6-((N-(3-chloro-4-fluorophenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.658 g, 2.861 mmol) and potassium iodide (0.086 g, 0.520 mmol) in N,N-dimethylformide (30 mL) was mixed at 50° C. with N-(3-chloro-4-fluorophenyl)ethanesulfonamide (0.600 g, 2.601 mmol) and potassium carbonate (0.539 g, 3.902 mmol). The reaction mixture was stirred at the same temperature for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(3-chloro-4-fluorophenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.510 g, 50.7%).


[Step 3] N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(3-chloro-4-fluorophenyl)ethylsulfonamido)methyl)nicotinate (0.510 g, 1.318 mmol) and hydrazine monohydrate (0.641 mL, 13.184 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.300 g, 58.8%, white solid).


[Step 4] Compound 11411



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.150 g, 0.388 mmol), triethylamine (0.216 mL, 1.551 mmol) and 2,2-difluoroacetic anhydride (0.084 mL, 0.776 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as white solid (0.092 g, 53.1%).



1H NMR (400 MHz, CDCl3) δ 9.26 (dd, 1H, J=2.3, 0.9 Hz), 8.42 (ddd, 1H, J=8.3, 2.3, 0.7 Hz), 7.70 (dd, 1H, J=8.2, 0.9 Hz), 7.54 (ddd, 1H, J=6.5, 2.7, 0.7 Hz), 7.38-7.26 (m, 1H), 7.16-7.09 (m, 1H), 7.09-6.81 (m, 1H), 5.13 (s, 2H), 3.21 (qd, 2H, J=7.4, 0.7 Hz), 1.45 (td, 3H, J=7.4, 0.8 Hz); LRMS (ES) m/z 447.44 (M++1).


EXAMPLE 117
Compound 11412, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethanesulfonamide
[Step 1] N-phenylethanesulfonamide



embedded image


Triethylamine (1.946 mL, 13.959 mmol) was added to solution of aniline (0.980 mL, 10.738 mmol) in dichloromethane (12 mL) prepared at 0° C., and the mixture was stirred for 20 min at the same temperature. The reaction mixture was treated with ethanesulfonyl chloride (1.119 mL, 11.811 mmol and stirred for additional 24 hr at the room temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 15%) to give N-phenylethanesulfonamide as yellow oil (1.400 g, 70.4%).


[Step 2] methyl 6-((N-phenylethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.710 g, 3.088 mmol) and potassium iodide (0.093 g, 0.561 mmol) in N,N-dimethylformide (30 mL) was mixed at the room temperature with N-phenylethanesulfonamide (0.520 g, 2.807 mmol) and potassium carbonate (0.582 g, 4.211 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 100%) to give methyl 6-((N-phenylethylsulfonamido)methyl)nicotinate as yellow solid (0.500 g, 53.3%).


[Step 3] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylethanesulfonamide



embedded image


A solution of methyl 6-((N-phenylethylsulfonamido)methyl)nicotinate (0.300 g, 0.897 mmol) and hydrazine monohydrate (0.436 mL, 8.972 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylethanesulfonamide, 0.220 g, 73.3%, white solid).


[Step 4] Compound 11412



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylethanesulfonamide (0.220 g, 0.658 mmol), triethylamine (0.367 mL, 2.632 mmol) and 2,2-difluoroacetic anhydride (0.143 mL, 1.316 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethanesulfonamide as white solid (0.120 g, 46.2%).



1H NMR (400 MHz, CDCl3) δ 9.23 (dd, 1H, J=2.2, 0.8 Hz), 8.42 (dd, 1H, J=8.3, 2.2 Hz), 7.80 (dd, 1H, J=8.3, 0.8 Hz), 7.48-7.24 (m, 5H), 7.09-6.80 (m, 1H), 5.22 (s, 2H), 3.21 (q, 2H, J=7.4 Hz), 1.46 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 395.43 (M++1).


EXAMPLE 118
Compound 11426, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(methylsulfonyl)-N-phenylpiperidine-4-sulfonamide
[Step 1] methyl 6-(((1-(methylsulfonyl)-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-((N-phenylpiperidine-4-sulfonamido)methyl)nicotinate hydrochloride (0.165 g, 0.387 mmol), triethylamine (0.081 mL, 0.581 mmol) and methanesulfonyl chloride (0.036 mL, 0.465 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give methyl 6-(((1-(methylsulfonyl)-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate as yellow solid (0.110 g, 60.7%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(methylsulfonyl)-N-phenylpiperidine-4-sulfonamide



embedded image


A solution of methyl 6-(((1-(methylsulfonyl)-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate (0.110 g, 0.235 mmol) and hydrazine monohydrate (0.118 g, 2.353 mmol) in ethanol (10 mL) was stirred at the room temperature for 12 hr and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(methylsulfonyl)-N-phenylpiperidine-4-sulfonamide, 0.086 g, 78.2%, yellow solid).


[Step 3] Compound 11426



embedded image


A mixture of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(methylsulfonyl)-N-phenylpiperidine-4-sulfonamide (0.086 g, 0.184 mmol), triethylamine (0.103 mL, 0.736 mmol) and 2,2-difluoroacetic anhydride (0.040 mL, 0.368 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(methylsulfonyl)-N-phenylpiperidine-4-sulfonamide as yellow solid (0.053 g, 54.6%).



1H NMR (400 MHz, CDCl3) δ 9.23 (s, 1H), 8.40 (dd, 1H, J=8.3, 2.2 Hz), 7.71 (d, 1H, J=8.2 Hz), 7.46-7.32 (m, 3H), 7.34-7.26 (m, 2H), 7.11-6.78 (m, 1H), 5.21 (s, 2H), 3.96-3.88 (m, 2H), 3.31-3.21 (m, 1H), 2.86-2.76 (m, 5H), 2.32-2.23 (m, 2H), 2.15-2.01 (m, 2H); LRMS (ES) m/z 528.51 (M++1).


EXAMPLE 119
Compound 11427, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-(1-methylpiperidin-4-yl)phenyl)ethanesulfonamide
[Step 1] tert-butyl 4-(3-(ethylsulfonamido)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate



embedded image


A mixture of N-(3-bromophenyl)ethanesulfonamide (1.000 g, 3.786 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.288 g, 4.164 mmol), [1,1′-Bis(di-tert-butylphosphino)-ferrocene]palladium(II)Dichloride (0.247 g, 0.379 mmol) and sodium carbonate (0.602 g, 5.679 mmol) in 1,4-dioxane (50 mL)/water (10 mL) prepared at the room temperature was heated at reflux for 12 hr, cooled down to the ambient temperature and filtered through a celite pad to remove solids. Then, water was added to the filtrate, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 30%) to give tert-butyl 4-(3-(ethylsulfonamido)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate as yellow solid (1.300 g, 93.7%).


[Step 2] tert-butyl 4-(3-(ethylsulfonamido)phenyl)piperidine-1-carboxylate



embedded image


A solution of tert-butyl 4-(3-(ethylsulfonamido)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (0.900 g, 2.456 mmol) in Pd/C (50 mg) and methanol (20 mL) was stirred at the room temperature for 12 hr under the presence of H2 gas and filtered through a celite pad to remove solids. Then, water was added to the filtrate, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (tert-butyl 4-(3-(ethylsulfonamido)phenyl)piperidine-1-carboxylate, 0.820 g, 90.6%, yellow solid).


[Step 3] tert-butyl 4-(3-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)phenyl)piperidine-1-carboxylate



embedded image


A solution of methyl 4-(bromomethyl)-3-fluorobenzoate (0.605 g, 2.448 mmol) and potassium iodide (0.074 g, 0.445 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 30 min, and mixed with tert-butyl 4-(3-(ethylsulfonamido)phenyl)piperidine-1-carboxylate (0.820 g, 2.225 mmol) and potassium carbonate (0.461 g, 3.338 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give tert-butyl 4-(3-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)phenyl)piperidine-1-carboxylate as yellow solid (0.900 g, 75.6%).


[Step 4] methyl 3-fluoro-4-((N-(3-(piperidin-4-yl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride



embedded image


A solution of tert-butyl 4-(3-(N-(2-fluoro-4-(methoxycarbonyl)benzyl)ethylsulfonamido)phenyl)piperidine-1-carboxylate (0.900 g, 1.683 mmol) and hydrochloric acid (4.00 M solution in 1,4-dioxane, 1.683 mL, 6.734 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (methyl 3-fluoro-4-((N-(3-(piperidin-4-yl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride, 0.750 g, 94.6%, yellow solid).


[Step 5] methyl 3-fluoro-4-((N-(3-(1-methylpiperidin-4-yl)phenyl)ethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 3-fluoro-4-((N-(3-(piperidin-4-yl)phenyl)ethylsulfonamido)methyl)benzoate hydrochloride (0.300 g, 0.637 mmol), formaldehyde (0.057 g, 1.911 mmol) and acetic acid (0.044 mL, 0.764 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 30 min, and mixed with sodium triacetoxyborohydride (0.202 g, 0.955 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 3-fluoro-4-((N-(3-(1-methylpiperidin-4-yl)phenyl)ethylsulfonamido)methyl)benzoate as yellow solid (0.264 g, 92.4%).


[Step 6] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-(1-methylpiperidin-4-yl)phenyl)ethanesulfonamide



embedded image


A solution of methyl 3-fluoro-4-((N-(3-(1-methylpiperidin-4-yl)phenyl)ethylsulfonamido)methyl)benzoate (0.264 g, 0.589 mmol) and hydrazine monohydrate (0.286 mL, 5.886 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-(1-methylpiperidin-4-yl)phenyl)ethanesulfonamide, 0.176 g, 66.7%, yellow solid).


[Step 7] Compound 11427



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(3-(1-methylpiperidin-4-yl)phenyl)ethanesulfonamide (0.176 g, 0.392 mmol), triethylamine (0.219 mL, 1.569 mmol) and 2,2-difluoroacetic anhydride (0.085 mL, 0.785 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-(1-methylpiperidin-4-yl)phenyl)ethanesulfonamide as yellow solid (0.098 g, 49.1%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.0, 1.7 Hz), 7.76-7.64 (m, 2H), 7.29 (d, 1H, J=15.5 Hz), 7.24-7.11 (m, 3H), 7.08-6.73 (m, 1H), 5.05 (s, 2H), 3.14 (q, 4H, J=7.4 Hz), 2.54 (tt, 1H, J=11.9, 3.8 Hz), 2.48 (s, 3H), 2.35-2.24 (m, 2H), 2.07-1.91 (m, 2H), 1.89-1.81 (m, 2H), 1.46 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 509.40 (M++1).


EXAMPLE 120
Compound 11428, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenyltetrahydrofuran-3-sulfonamide
[Step 1] N-phenyltetrahydrofuran-3-sulfonamide



embedded image


A solution of aniline (0.147 mL, 1.611 mmol), triethylamine (0.337 mL, 2.416 mmol) and tetrahydrofuran-3-sulfonyl chloride (0.330 g, 1.933 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-phenyltetrahydrofuran-3-sulfonamide as yellow solid (0.300 g, 82.0%).


[Step 2] methyl 6-(((N-phenyltetrahydrofuran)-3-sulfonamido)methyl)nicotinate



embedded image


A solution of N-phenyltetrahydrofuran-3-sulfonamide (0.300 g, 1.320 mmol), potassium carbonate (0.274 g, 1.980 mmol), methyl 6-(bromomethyl)nicotinate (0.334 g, 1.452 mmol) and potassium iodide (0.110 g, 0.660 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 70%) to give methyl 6-(((N-phenyltetrahydrofuran)-3-sulfonamido)methyl)nicotinate as yellow solid (0.120 g, 24.2%).


[Step 3] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydrofuran-3-sulfonamide



embedded image


A solution of methyl 6-(((N-phenyltetrahydrofuran)-3-sulfonamido)methyl)nicotinate (0.120 g, 0.319 mmol) and hydrazine monohydrate (0.155 mL, 3.188 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hrcooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydrofuran-3-sulfonamide, 0.082 g, 68.3%, white solid).


[Step 4] Compound 11428



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydrofuran-3-sulfonamide (0.082 g, 0.218 mmol), triethylamine (0.121 mL, 0.871 mmol) and 2,2-difluoroacetic anhydride (0.047 mL, 0.436 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenyltetrahydrofuran-3-sulfonamide as yellow solid (0.051 g, 53.6%).



1H NMR (400 MHz, CDCl3) δ 9.23 (dd, 1H, J=2.3, 0.9 Hz), 8.39 (dd, 1H, J=8.3, 2.2 Hz), 7.72 (dd, 1H, J=8.2, 0.8 Hz), 7.47-7.25 (m, 5H), 7.11-6.77 (m, 1H), 5.28-5.13 (m, 2H), 4.20-3.91 (m, 4H), 3.85 (ddd, 1H, J=8.8, 7.3, 6.1 Hz), 2.45-2.20 (m, 2H); LRMS (ES) m/z 437.41 (M++1).


EXAMPLE 121
Compound 11429, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.068 g, 0.176 mmol), triethylamine (0.098 mL, 0.703 mmol) and trifluoroacetic anhydride (0.050 mL, 0.352 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as yellow solid (0.042 g, 51.4%).



1H NMR (400 MHz, CDCl3) δ 9.26 (dd, 1H, J=2.3, 0.8 Hz), 8.42 (dd, 1H, J=8.2, 2.2 Hz), 7.70 (dd, 1H, J=8.3, 0.8 Hz), 7.54 (dd, 1H, J=6.4, 2.7 Hz), 7.34 (ddd, 1H, J=8.9, 4.1, 2.7 Hz), 7.12 (t, 1H, J=8.6 Hz), 5.13 (s, 2H), 3.20 (q, 2H, J=7.4 Hz), 1.45 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 465.30 (M++1).


EXAMPLE 122
Compound 11430, N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylethanesulfonamide (0.056 g, 0.167 mmol), triethylamine (0.093 mL, 0.670 mmol) and trifluoroacetic anhydride (0.047 mL, 0.335 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as yellow solid (0.036 g, 52.1%).



1H NMR (400 MHz, CDCl3) δ 9.22 (dd, 1H, J=2.2, 0.8 Hz), 8.38 (dd, 1H, J=8.3, 2.2 Hz), 7.78 (dt, 1H, J=8.3, 0.7 Hz), 7.47-7.40 (m, 2H), 7.45-7.32 (m, 2H), 7.36-7.24 (m, 1H), 5.20 (s, 2H), 3.20 (q, 2H, J=7.4 Hz), 1.50-1.41 (m, 3H); LRMS (ES) m/z 413.0 (M++1).


EXAMPLE 123
Compound 11431, N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)tetrahydro-2H-pyran-4-sulfonamide



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyltetrahydro-2H-pyran-4-sulfonamide (0.095 g, 0.243 mmol), triethylamine (0.136 mL, 0.973 mmol) and trifluoroacetic anhydride (0.069 mL, 0.487 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)tetrahydro-2H-pyran-4-sulfonamide as white solid (0.056 g, 49.1%).



1H NMR (400 MHz, CDCl3) δ 9.20 (dt, 1H, J=2.1, 1.0 Hz), 8.39 (dt, 1H, J=8.3, 2.0 Hz), 7.78 (dt, 1H, J=8.3, 1.1 Hz), 7.43 (ddd, 2H, J=8.3, 1.8, 0.8 Hz), 7.44-7.32 (m, 2H), 7.36-7.21 (m, 1H), 5.22 (d, 2H, J=1.5 Hz), 4.19-4.07 (m, 2H), 3.46-3.28 (m, 3H), 2.10-1.96 (m, 4H); LRMS (ES) m/z 469.30 (M++1).


EXAMPLE 124
Compound 11432, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] N-(3-chloro-4-fluorophenyl)methanesulfonamide



embedded image


A solution of 3-chloro-4-fluoroaniline (2.000 g, 13.740 mmol), pyridine (1.217 mL, 15.114 mmol) and methanesulfonyl chloride (1.276 mL, 16.488 mmol) in dichloromethane (80 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)methanesulfonamide, 2.600 g, 84.6%, black solid).


[Step 2] methyl 6-((N-(3-chloro-4-fluorophenyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.339 g, 1.476 mmol) and potassium iodide (0.111 g, 0.671 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 30 min, and mixed with N-(3-chloro-4-fluorophenyl)methanesulfonamide (0.300 g, 1.341 mmol) and potassium carbonate (0.278 g, 2.012 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-((N-(3-chloro-4-fluorophenyl)methylsulfonamido)methyl)nicotinate as yellow solid (0.290 g, 58.0%).


[Step 3] N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A solution of methyl 6-((N-(3-chloro-4-fluorophenyl)methylsulfonamido)methyl)nicotinate (0.100 g, 0.268 mmol) and hydrazine monohydrate (0.130 mL, 2.682 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide, 0.071 g, 71.0%, yellow solid).


[Step 4] Compound 11432



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.071 g, 0.190 mmol), triethylamine (0.106 mL, 0.762 mmol) and trifluoroacetic anhydride (0.054 mL, 0.381 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as yellow solid (0.036 g, 41.9%).



1H NMR (400 MHz, CDCl3) δ 9.29 (dd, 1H, J=2.3, 0.8 Hz), 8.43 (dd, 1H, J=8.2, 2.2 Hz), 7.67 (dt, 1H, J=8.3, 0.7 Hz), 7.54 (dd, 1H, J=6.4, 2.7 Hz), 7.41-7.26 (m, 1H), 7.14 (t, 1H, J=8.6 Hz), 5.11 (s, 2H), 3.09 (d, 3H, J=0.4 Hz); LRMS (ES) m/z 451.38 (M++1).


EXAMPLE 125
Compound 11433, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.070 g, 0.188 mmol), triethylamine (0.105 mL, 0.751 mmol) and 2,2-difluoroacetic anhydride (0.047 mL, 0.376 mmol) in tetrahydrofuran (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as yellow solid (0.046 g, 56.6%).



1H NMR (400 MHz, CDCl3) δ 9.29 (d, 1H, J=2.1 Hz), 8.42 (dd, 1H, J=8.2, 2.2 Hz), 7.65 (dd, 1H, J=8.1, 0.8 Hz), 7.54 (dd, 1H, J=6.5, 2.7 Hz), 7.34 (ddd, 1H, J=8.8, 4.1, 2.7 Hz), 7.14 (t, 1H, J=8.7 Hz), 7.10-6.81 (m, 1H), 5.10 (s, 2H), 3.09 (s, 3H); LRMS (ES) m/z 433.40 (M++1).


EXAMPLE 126
Compound 11447, 1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)piperidine-4-sulfonamide
[Step 1] tert-butyl 4-(N-(3-chloro-4-fluorophenyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of 3-chloro-4-fluoroaniline (2.200 g, 15.114 mmol) and tert-butyl 4-(chlorosulfonyl)piperidine-1-carboxylate (4.289 g, 15.114 mmol) in dichloromethane (20 mL) was treated at the room temperature with triethylamine (2.528 mL, 18.137 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=10% to 30%) to give tert-butyl 4-(N-(3-chloro-4-fluorophenyl)sulfamoyl)piperidine-1-carboxylate as pale purple solid (2.940 g, 49.5%).


[Step 2] tert-butyl 4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-(3-chloro-4-fluorophenyl)sulfamoyl)piperidine-1-carboxylate (1.500 g, 3.818 mmol), methyl 4-(bromomethyl)-3-fluorobenzoate (1.132 g, 4.582 mmol), potassium carbonate (0.792 g, 5.727 mmol) and potassium iodide (0.951 g, 5.727 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 16 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate as white solid (1.860 g, 87.1%).


[Step 3] methyl 4-((N-(3-chloro-4-fluorophenyl)piperidine-4-sulfonamido)methyl)-3-fluorobenzoate hydrochloride



embedded image


A solution of tert-butyl 4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate (1.860 g, 3.327 mmol) in 1,4-dioxane (8 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 8.318 mL, 33.273 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (10 mL) and hexane (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give methyl 4-((N-(3-chloro-4-fluorophenyl)piperidine-4-sulfonamido)methyl)-3-fluorobenzoate hydrochloride as beige solid (1.620 g, 98.3%).


[Step 4] tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate



embedded image


A mixture of methyl 4-((N-(3-chloro-4-fluorophenyl)piperidine-4-sulfonamido)methyl)-3-fluorobenzoate hydrochloride (1.300 g, 2.624 mmol), tert-butyl 3-oxoazetidine-1-carboxylate (0.674 g, 3.937 mmol) and N,N-diisopropylethylamine (0.686 mL, 3.937 mmol) in dichloromethane (50 mL) was treated at the room temperature with sodium triacetoxyborohydride (1.112 g, 5.249 mmol) and stirred at the same temperature for 16 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=40% to 70%) to give tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate as white solid (1.178 g, 73.1%).


[Step 5] tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate



embedded image


tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate (1.178 g, 1.918 mmol) and hydrazine monohydrate (0.932 mL, 19.183 mmol) were mixed at the room temperature in ethanol (20 mL), stirred at 110° C. for 2 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (100 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate as white solid (1.149 g, 97.5%).


[Step 6] tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate



embedded image


A solution of tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate (1.149 g, 1.871 mmol) in tetrahydrofuran (30 mL) was mixed at 70° C. with 2,2-difluoroacetic anhydride (0.244 mL, 2.245 mmol) and N,N-diisopropylethylamine (0.489 mL, 2.807 mmol), stirred at the same temperature for 1 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=30% to 60%) to give tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)-2-fluorobenzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate as white solid (1.058 g, 81.7%).


[Step 7] tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate



embedded image


A solution of tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(4-(2-(2,2-difluoroac etyl)hydrazine-1-carbonyl)-2-fluorobenzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate (1.000 g, 1.445 mmol) in dichloromethane (30 mL) was mixed at the room temperature with methanesulfonyl chloride (0.134 mL, 1.734 mmol) and N,N-diisopropylethylamine (0.377 mL, 2.167 mmol) and stirred at the same temperature for 1 hr. Then, saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=40% to 70%) to give tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate as light yellow solid (0.680 g, 69.8%).


[Step 8] 1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)piperidine-4-sulfonamide dihydrochloride



embedded image


A solution of tert-butyl 3-(4-(N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate (0.680 g, 1.009 mmol) in 1,4-dioxane (10 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 5.044 mL, 20.175 mmol) and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (10 mL) and hexane (70 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)piperidine-4-sulfonamide dihydrochloride as white solid (0.620 g, 95.0%).


[Step 9] Compound 11447



embedded image


A slurry of 1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.077 mmol) in dichloromethane (5 mL) was mixed at the room temperature with acetyl chloride (0.008 mL, 0.116 mmol) and N,N-diisopropylethylamine (0.047 mL, 0.271 mmol) and stirred at the same temperature for 3 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give 1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)piperidine-4-sulfonamide as beige solid (0.023 g, 48.3%).



1H NMR (400 MHz, DMSO-d6) δ 7.88 (dd, 2H, J=7.9, 1.6 Hz), 7.83-7.75 (m, 2H), 7.71-7.62 (m, 1.25H), 7.54 (s, 0.5H), 7.51-7.47 (m, 1H), 7.44-7.36 (m, 1.25H), 5.12 (s, 2H), 4.10 (t, 1H, J=7.9 Hz), 3.92 (dd, 1H, J=8.6, 5.0 Hz), 3.82 (t, 1H, J=8.5 Hz), 3.63 (m, 1H), 3.12-3.06 (m, 1H), 2.89 (t, 2H, J=12.8 Hz), 2.11 (d, 2H, J=11.2 Hz), 2.01-1.89 (m, 2H), 1.89 (s, 3H), 1.75-1.71 (m, 2H); LRMS (ES) m/z 616.5 (M++1).


EXAMPLE 127
Compound 11448, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine-4-sulfonamide



embedded image


A slurry of 1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.077 mmol) in dichloromethane (5 mL) was mixed at the room temperature with methanesulfonyl chloride (0.009 mL, 0.116 mmol) and N,N-diisopropylethylamine (0.047 mL, 0.271 mmol) and stirred at the same temperature for 3 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=50% to 80 %) to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine-4-sulfonamide as light yellow solid (0.026 g, 51.6%).



1H NMR (400 MHz, DMSO-d6) δ 7.88 (dd, 1H, J=8.0, 1.7 Hz), 7.83-7.75 (m, 2H), 7.70-7.61 (m, 1.25H), 7.54 (s, 0.5H), 7.49 (m, 1H), 7.44-7.36 (m, 1.25H), 5.12 (s, 2H), 3.85 (t, 2H, J=7.7 Hz), 3.75 (dd, 2H, J=8.4, 6.0 Hz), 3.16 (q, 1H, J=6.5 Hz), 3.00 (s, 3H), 2.87 (d, 2H, J=11.0 Hz), 2.10 (d, 2H, J=12.1 Hz), 1.97-1.86 (m, 2H), 1.76-1.62 (m, 2H); LRMS (ES) m/z 652.4 (M++1).


EXAMPLE 128
Compound 11451, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(1-methylazetidin-3-yl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)piperidine-4-sulfonamide dihydrochloride (0.100 g, 0.155 mmol) and formaldehyde (37.00% solution in water, 0.023 mL, 0.309 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.066 g, 0.309 mmol) and stirred at the same temperature for 3 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 15%) to give the crude product, and then the crude product was dissolved in ethyl acetate (1 mL) and hexane (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(1-methylazetidin-3-yl)piperidine-4-sulfonamide as light yellow solid (0.022 g, 24.2%).



1H NMR (400 MHz, DMSO-d6) δ 7.87 (dd, 2H, J=8.0, 1.7 Hz), 7.83-7.74 (m, 2H), 7.70-7.61 (m, 1.25H), 7.54 (s, 0.5H), 7.48 (m, 1H), 7.45-7.35 (m, 1.25H), 5.11 (s, 2H), 3.50-3.47 (m, 2H), 2.92-2.86 (m, 3H), 2.79 (d, 2H, J=11.2 Hz), 2.31 (s, 3H), 2.08-2.04 (m, 2H), 1.83 (t, 2H, J=11.5 Hz), 1.67 (dt, 2H, J=12.2, 6.3 Hz); LRMS (ES) m/z 588.6 (M++1).


EXAMPLE 129
Compound 11452, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(1-(2-hydroxyacetyl)azetidin-3-yl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)piperidine-4-sulfonamide dihydrochloride (0.100 g, 0.155 mmol), 2-hydroxyacetic acid (0.013 g, 0.170 mmol) and 1H-benzo[d][1,2,3]triazol-1-ol (HOBt, 0.031 g, 0.232 mmol) in dichloromethane (5 mL) was treated at the room temperature with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 0.036 g, 0.232 mmol) and N,N-diisopropylethylamine (0.121 mL, 0.696 mmol) and stirred at the same temperature for 16 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give the crude product, and then the crude product was dissolved in ethyl acetate (1 mL) and hexane (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(1-(2-hydroxyacetyl)azetidin-3-yl)piperidine-4-sulfonamide as light yellow solid (0.041 g, 42.0%).



1H NMR (400 MHz, DMSO-d6) δ 7.87 (dd, 1H, J=8.0, 1.7 Hz), 7.83-7.75 (m, 2H), 7.70-7.62 (m, 1.25H), 7.54 (s, 0.5H), 7.49 (m, 1H), 7.44-7.35 (m, 1.25H), 5.12 (s, 2H), 4.88 (t, 1H, J=6.0 Hz), 4.16 (m, 1H), 3.98 (m, 1H), 3.91-3.87 (m, 2H), 3.69 (dd, 1H, J=10.0, 5.1 Hz), 3.37 (m, 1H), 3.14 (dq, 1H, J=12.4, 6.6, 5.9 Hz), 2.92-2.84 (m, 2H), 2.10 (d, 2H, J=12.0 Hz), 1.93-1.86 (m, 2H), 1.77-1.62 (m, 2H); LRMS (ES) m/z 632.6 (M++1).


EXAMPLE 130
Compound 11460, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3-fluoro-4-methylphenyl)ethanesulfonamide
[Step 1] N-(3-fluoro-4-methylphenyl)ethanesulfonamide



embedded image


A solution of 3-fluoro-4-methylaniline (0.457 mL, 3.995 mmol), pyridine (0.483 mL, 5.993 mmol) and ethanesulfonyl chloride (0.453 mL, 4.794 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous 1M-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give N-(3-fluoro-4-methylphenyl)ethanesulfonamide as yellow solid (0.623 g, 71.8%).


[Step 2] Methyl 6-((N-(3-fluoro-4-methylphenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of N-(3-fluoro-4-methylphenyl)ethanesulfonamide (0.250 g, 1.151 mmol), methyl 6-(bromomethyl)nicotinate (0.318 g, 1.381 mmol), potassium carbonate (0.239 g, 1.726 mmol) and potassium iodide (0.019 g, 0.115 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 100%) to give methyl 6-((N-(3-fluoro-4-methylphenyl)ethylsulfonamido)methyl)nicotinate as white solid (0.290 g, 68.8%).


[Step 3] N-(3-fluoro-4-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


Methyl 6-4N-(3-fluoro-4-methylphenyl)ethylsulfonamido)methyl)nicotinate (0.290 g, 0.791 mmol) and hydrazine monohydrate (1.154 mL, 23.744 mmol) were mixed at the room temperature in ethanol (8 mL)/water (2 mL), stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(3-fluoro-4-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.259 g, 89.3%, yellow solid).


[Step 4] N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3-fluoro-4-methylphenyl)ethanesulfonamide



embedded image


A solution of N-(3-fluoro-4-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.080 g, 0.218 mmol) and triethylamine (0.046 mL, 0.328 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.029 mL, 0.262 mmol), stirred at 50° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3-fluoro-4-methylphenyl)ethanesulfonamide, 0.087 g, 89.7%, yellow oil).


[Step 5] Compound 11460



embedded image


A mixture of N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3-fluoro-4-methylphenyl)ethanesulfonamide (0.090 g, 0.203 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.145 g, 0.608 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, cooled down to the room temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 100%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3-fluoro-4-methylphenyl)ethanesulfonamide as yellow solid (0.050 g, 57.9%).



1H NMR (400 MHz, CDCl3) δ 9.21 (dd, 1H, J=2.2, 0.9 Hz), 8.37 (dd, 1H, J=8.2, 2.2 Hz), 7.75-7.66 (m, 1H), 7.16-7.07 (m, 3H), 6.86 (d, 1H, J=51.6 Hz), 5.14 (s, 2H), 3.18 (q, 2H, J=7.4 Hz), 2.20 (d, 3H, J=1.9 Hz), 1.42 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 427.3 (M++1).


EXAMPLE 131
Compound 11461, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(4-fluoro-3-methylphenyl)ethanesulfonamide
[Step 1] N-(4-fluoro-3-methylphenyl)ethanesulfonamide



embedded image


A solution of 4-fluoro-3-methylaniline (0.500 g, 3.995 mmol), pyridine (0.483 mL, 5.993 mmol) and ethanesulfonyl chloride (0.453 mL, 4.794 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous 1M-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give N-(4-fluoro-3-methylphenyl)ethanesulfonamide as yellow solid (0.633 g, 72.9%).


[Step 2] methyl 6-4N-(4-fluoro-3-methylphenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of N-(4-fluoro-3-methylphenyl)ethanesulfonamide (0.250 g, 1.151 mmol), methyl 6-(bromomethyl)nicotinate (0.318 g, 1.381 mmol), potassium carbonate (0.239 g, 1.726 mmol) and potassium iodide (0.019 g, 0.115 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 100%) to give methyl 6-((N-(4-fluoro-3-methylphenyl)ethylsulfonamido)methyl)nicotinate as white solid (0.230 g, 54.6%).


[Step 3] N-(4-fluoro-3-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


Methyl 6-((N-(4-fluoro-3-methylphenyl)ethylsulfonamido)methyl)nicotinate (0.230 g, 0.628 mmol) and hydrazine monohydrate (0.915 mL, 18.831 mmol) were mixed at the room temperature in ethanol (8 mL)/water (2 mL), stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(4-fluoro-3-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.222 g, 96.5%, yellow solid).


[Step 4] N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(4-fluoro-3-methylphenyl)ethanesulfonamide



embedded image


A solution of N-(4-fluoro-3-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.080 g, 0.218 mmol) and triethylamine (0.046 mL, 0.328 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.029 mL, 0.262 mmol), stirred at 50° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(4-fluoro-3-methylphenyl)ethanesulfonamide, 0.088 g, 94.5%, yellow oil).


[Step 5] Compound 11461



embedded image


A mixture of N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(4-fluoro-3-methylphenyl)ethanesulfonamide (0.090 g, 0.203 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.145 g, 0.608 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 100%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(4-fluoro-3-methylphenyl)ethanesulfonamide as yellow solid (0.070 g, 81.1%).



1H NMR (400 MHz, CDCl3) δ 9.21 (dd, 1H, J=2.2, 0.8 Hz), 8.39 (dd, 1H, J=8.3, 2.2 Hz), 7.74 (dd, 1H, J=8.3, 0.9 Hz), 7.25-7.12 (m, 2H), 7.07-6.78 (m, 2H), 5.12 (s, 2H), 3.17 (q, 2H, J=7.4 Hz), 2.22 (d, 3H, J=2.0 Hz), 1.44 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 427.3 (M++1)


EXAMPLE 132
Compound 11462, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3,4-difluorophenyl)ethanesulfonamide
[Step 1] N-(3,4-difluorophenyl)ethanesulfonamide



embedded image


A solution of 3,4-difluoroaniline (0.384 mL, 3.873 mmol), pyridine (0.468 mL, 5.809 mmol) and ethanesulfonyl chloride (0.439 mL, 4.647 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous 1M-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give N-(3,4-difluorophenyl)ethanesulfonamide as yellow solid (0.670 g, 78.2%).


[Step 2] Methyl 64(N-(3,4-difluorophenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of N-(3,4-difluorophenyl)ethanesulfonamide (0.250 g, 1.130 mmol), methyl 6-(bromomethyl)nicotinate (0.312 g, 1.356 mmol), potassium carbonate (0.234 g, 1.695 mmol) and potassium iodide (0.019 g, 0.113 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 100%) to give methyl 6-((N-(3,4-difluorophenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.151 g, 36.1%).


[Step 3] N-(3,4-difluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


Methyl 6-((N-(3,4-difluorophenyl)ethylsulfonamido)methyl)nicotinate (0.160 g, 0.432 mmol) and hydrazine monohydrate (0.630 mL, 12.960 mmol) were mixed at the room temperature in ethanol (8 mL)/water (2 mL), stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(3,4-difluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.152 g, 95.0%, yellow solid).


[Step 4] N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3,4-difluorophenyl)ethanesulfonamide



embedded image


A solution of N-(3,4-difluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.080 g, 0.216 mmol) and triethylamine (0.045 mL, 0.324 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.028 mL, 0.259 mmol), stirred at 50° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3,4-difluorophenyl)ethanesulfonamide, 0.090 g, 92.9%, yellow oil).


[Step 5] Compound 11462



embedded image


A mixture of N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3,4-difluorophenyl)ethanesulfonamide (0.090 g, 0.201 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.143 g, 0.602 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 100%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3,4-difluorophenyl)ethanesulfonamide as yellow solid (0.053 g, 61.4%).



1H NMR (400 MHz, CDCl3) δ 9.24 (dd, 1H, J=2.2, 0.8 Hz), 8.42 (dd, 1H, J=8.2, 2.2 Hz), 7.69 (dd, 1H, J=8.2, 0.8 Hz), 7.32 (ddd, 1H, J=11.0, 7.0, 2.6 Hz), 7.22-7.08 (m, 2H), 6.93 (t, 1H, J=51.6 Hz), 5.13 (s, 2H), 3.18 (q, 2H, J=7.4 Hz), 1.42 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 431.3 (M++1).


EXAMPLE 133
Compound 11463, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3,5-difluorophenyl)ethanesulfonamide
[Step 1] N-(3,5-difluorophenyl)ethanesulfonamide



embedded image


A solution of 3,5-difluoroaniline (0.500 g, 3.873 mmol), pyridine (0.468 mL, 5.809 mmol) and ethanesulfonyl chloride (0.439 mL, 4.647 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous 1M-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give N-(3,5-difluorophenyl)ethanesulfonamide as yellow solid (0.611 g, 71.3%).


[Step 2] Methyl 6-((N-(3,5-difluorophenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of N-(3,5-difluorophenyl)ethanesulfonamide (0.250 g, 1.130 mmol), methyl 6-(bromomethyl)nicotinate (0.312 g, 1.356 mmol), potassium carbonate (0.234 g, 1.695 mmol) and potassium iodide (0.019 g, 0.113 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 100%) to give methyl 6-((N-(3,5-difluorophenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.175 g, 41.8%).


[Step 3] N-(3,5-difluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


Methyl 6-((N-(3,5-difluorophenyl)ethylsulfonamido)methyl)nicotinate (0.180 g, 0.486 mmol) and hydrazine monohydrate (0.709 mL, 14.580 mmol) were mixed at the room temperature in ethanol (8 mL)/water (2 mL), stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(3,5-difluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.177 g, 98.3%, yellow solid).


[Step 4] N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3,5-difluorophenyl)ethanesulfonamide



embedded image


A solution of N-(3,5-difluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.080 g, 0.216 mmol) and triethylamine (0.045 mL, 0.324 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.028 mL, 0.259 mmol), stirred at 50° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3,5-difluorophenyl)ethanesulfonamide, 0.092 g, 95.0%, yellow oil).


[Step 5] Compound 11463



embedded image


A mixture of N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3,5-difluorophenyl)ethanesulfonamide (0.090 g, 0.201 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.143 g, 0.602 mmol) in tetrahydrofuran (10 mL) was heated at 150° C. for 30 min under the microwaves, cooled down to the room temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 100%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3,5-difluorophenyl)ethanesulfonamide as yellow solid (0.046 g, 53.2%).



1H NMR (400 MHz, CDCl3) δ 9.25 (dd, 1H, J=2.2, 0.9 Hz), 8.39 (dd, 1H, J=8.3, 2.2 Hz), 7.65 (d, 1H, J=8.2 Hz), 7.10-7.00 (m, 2H), 6.87 (d, 1H, J=51.6 Hz), 6.70 (tt, 1H, J=8.6, 2.3 Hz), 5.16 (s, 2H), 3.22 (q, 2H, J=7.4 Hz), 1.41 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 431.2 (M++1).


EXAMPLE 134
Compound 11497, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide
[Step 1] N-(3-chloro-4-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide



embedded image


A solution of 3-chloro-4-fluoroaniline (0.300 g, 2.061 mmol), triethylamine (0.575 mL, 4.122 mmol) and tetrahydro-2H-thiopyran-4-sulfonyl chloride 1,1-dioxide (0.528 g, 2.267 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-(3-chloro-4-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as yellow solid (0.265 g, 37.6%).


[Step 2] methyl 6-(((N-(3-chloro-4-fluorophenyl)-1,1-dioxidotetrahydro-2H-thiopyran)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of N-(3-chloro-4-fluorophenyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide (0.265 g, 0.775 mmol), potassium carbonate (0.161 g, 1.163 mmol), methyl 6-(bromomethyl)nicotinate (0.196 g, 0.853 mmol) and potassium iodide (0.064 g, 0.388 mmol) in N,N-dimethylformide (15 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 60%) to give methyl 6-(((N-(3-chloro-4-fluorophenyl)-1,1-dioxidotetrahydro-2H-thiopyran)-4-sulfonamido)methyl)nicotinate as yellow solid (0.370 g, 97.2%).


[Step 3] N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide



embedded image


A solution of methyl 6-(((N-(3-chloro-4-fluorophenyl)-1,1-dioxidotetrahydro-2H-thiopyran)-4-sulfonamido)methyl)nicotinate (0.370 g, 0.754 mmol) and hydrazine monohydrate (0.377 g, 7.536 mmol) in ethanol (5 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (20 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as white solid (0.220 g, 59.5%).


[Step 4] N-(3-chloro-4-fluorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide (0.220 g, 0.448 mmol), triethylamine (0.250 mL, 1.792 mmol) and 2,2-difluoroacetic anhydride (0.111 mL, 0.896 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide, 0.140 g, 54.9%, yellow solid).


[Step 5] Compound 11497



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide (0.140 g, 0.246 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.176 g, 0.738 mmol) in tetrahydrofuran (15 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)tetrahydro-2H-thiopyran-4-sulfonamide 1,1-dioxide as white solid (0.095 g, 70.1%).



1H NMR (400 MHz, CDCl3) δ 9.30 (dd, 1H, J=2.2, 0.9 Hz), 8.42 (dd, 1H, J=8.2, 2.2 Hz), 7.57-7.48 (m, 2H), 7.35-7.27 (m, 1H), 7.13 (t, 1H, J=8.6 Hz), 7.10-6.82 (m, 1H), 5.09 (s, 2H), 3.49-3.31 (m, 3H), 3.07-2.95 (m, 2H), 2.70-2.61 (m, 4H); LRMS (ES) m/z 551.45 (M++1).


EXAMPLE 135
Compound 11501, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide
[Step 1] methyl 6-(((1-(tert-butoxycarbonyl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


tert-butyl 4-(N-(3-chloro-4-fluorophenyl)sulfamoyl)piperidine-1-carboxylate (1.440 g, 3.665 mmol), methyl 6-(bromomethyl)nicotinate (1.012 g, 4.398 mmol), potassium carbonate (0.760 g, 5.498 mmol) and potassium iodide (0.913 g, 5.498 mmol) were mixed at the room temperature in N,N-dimethylformide (30 mL) and then stirred at the same temperature for 16 hr. Then, saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 80 g cartridge; ethyl acetate/hexane=20% to 50%) to give methyl 6-(((1-(tert-butoxycarbonyl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate as beige solid (1.920 g, 96.6%).


[Step 2] methyl 6-((N-(3-chloro-4-fluorophenyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride



embedded image


A solution of methyl 6-(((1-(tert-butoxycarbonyl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate (1.920 g, 3.542 mmol) in 1,4-dioxane (10 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 8.856 mL, 35.423 mmol), stirred at the same temperature for 3 hr, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with ethyl acetate (20 mL) and hexane (20 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give methyl 6-((N-(3-chloro-4-fluorophenyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride as brown solid (1.760 g, 96.5%).


[Step 3] methyl 6-(((N-(3-chloro-4-fluorophenyl)-1-(oxetan-3-yl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A mixture of methyl 6-((N-(3-chloro-4-fluorophenyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride (0.300 g, 0.583 mmol), oxetan-3-one (0.084 g, 1.165 mmol) and N,N-diisopropylethylamine (0.254 mL, 1.457 mmol) in dichloromethane (20 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.247 g, 1.165 mmol), and stirred at the same temperature for 16 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=50% to 80%) to give methyl 6-(((N-(3-chloro-4-fluorophenyl)-1-(oxetan-3-yl)piperidine)-4-sulfonamido)methyl)nicotinate as beige solid (0.286 g, 98.6%).


[Step 4] N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide



embedded image


A slurry of methyl 6-(((N-(3-chloro-4-fluorophenyl)-1-(oxetan-3-yl)piperidine)-4-sulfonamido)methyl)nicotinate (0.286 g, 0.574 mmol) in ethanol (5 mL) was mixed at the room temperature with hydrazine monohydrate (0.558 mL, 11.487 mmol), stirred at 110° C. for 16 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with ethyl acetate (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide as white solid (0.243 g, 85.0%).


[Step 5] Compound 11501



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide (0.243 g, 0.488 mmol) in tetrahydrofuran (10 mL) was mixed at 70° C. with 2,2-difluoroacetic anhydride (0.152 mL, 1.220 mmol) and N,N-diisopropylethylamine (0.255 mL, 1.464 mmol). The reaction mixture was stirred at the same temperature for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=60% to 90%) to give the crude product, and then the crude product was dissolved in dichloromethane (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide as white solid (0.126 g, 46.3%).



1H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 1H), 8.42 (m, 1H), 7.83 (m, 1H), 7.73-7.69 (m, 1.25H), 7.56-7.54 (m, 1.5H), 7.46-7.36 (m, 1.25H), 5.18 (s, 2H), 4.53 (t, 2H, J=6.5 Hz), 4.42 (t, 2H, J=6.1 Hz), 3.44 (m, 1H), 2.80 (d, 2H, J=10.9 Hz), 2.11 (d, 2H, J=11.9 Hz), 1.86 (t, 2H, J=11.7 Hz), 1.72 (t, 2H, J=12.1 Hz); LRMS (ES) m/z 558.5 (M++1).


EXAMPLE 136
Compound 11502, 1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide
[Step 1] methyl 6-(((1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A mixture of methyl 6-((N-(3-chloro-4-fluorophenyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride (1.600 g, 3.108 mmol), tert-butyl 3-oxoazetidine-1-carboxylate (0.798 g, 4.662 mmol) and N,N-diisopropylethylamine (1.353 mL, 7.770 mmol) in dichloromethane (50 mL) was treated at the room temperature with sodium triacetoxyborohydride (1.317 g, 6.216 mmol) and stirred at the same temperature for 16 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=30% to 60%) to give methyl 6-(((1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate as beige solid (1.520 g, 81.9%).


[Step 2] methyl 6-(((1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate trihydrochloride



embedded image


A solution of methyl 6-(((1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate (1.520 g, 2.546 mmol) in 1,4-dioxane (20 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 9.546 mL, 38.185 mmol), stirred at the same temperature for 3 hr, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with ethyl acetate (20 mL) and hexane (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give methyl 6-(((1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate trihydrochloride as beige solid (1.420 g, 92.0%).


[Step 3] Methyl 6-(((1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate trihydrochloride (0.300 g, 0.604 mmol) and N,N-diisopropylethylamine (0.210 mL, 1.207 mmol) in dichloromethane (10 mL) was mixed at the room temperature with acetic anhydride (0.085 mL, 0.905 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 15%) to give methyl 6-(((1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate as colorless oil (0.320 g, 98.3%).


[Step 4] 1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)piperidine-4-sulfonamide



embedded image


Methyl 6-(((1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate (0.330 g, 0.612 mmol) and hydrazine monohydrate (0.893 mL, 18.367 mmol) were mixed at the room temperature in ethanol (8 mL)/water (2 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)piperidine-4-sulfonamide, 0.288 g, 87.3%, white solid).


[Step 5] Compound 11502



embedded image


A solution of 1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)piperidine-4-sulfonamide (0.288 g, 0.534 mmol) and triethylamine (0.223 mL, 1.603 mmol) in tetrahydrofuran (10 mL) was mixed at room temperature with 2,2-difluoroacetic anhydride (0.199 mL, 1.603 mmol). The reaction mixture was stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 20%) to give 1-(1-acetylazetidin-3-yl)-N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide as white solid (0.020 g, 6.2%).



1H NMR (400 MHz, CDCl3) δ 9.20 (dd, 1H, J=2.2, 0.8 Hz), 8.37 (dd, 1H, J=8.2, 2.2 Hz), 7.63 (dd, 1H, J=8.2, 0.8 Hz), 7.49 (dd, 1H, J=6.4, 2.7 Hz), 7.29 (ddd, 1H, J=8.9, 4.1, 2.7 Hz), 7.12-7.03 (m, 1H), 6.86 (d, 1H, J=51.6 Hz), 5.09 (d, 2H, J=1.6 Hz), 4.12 (t, 1H, J=7.8 Hz), 4.05-3.91 (m, 2H), 3.84 (dd, 1H, J=10.0, 5.3 Hz), 3.20-3.06 (m, 2H), 3.00-2.89 (m, 1H), 2.16 (d, 1H, J=13.5 Hz), 1.95 (td, 6H, J=12.7, 10.8, 5.1 Hz), 1.86 (s, 3H); LRMS (ES) m/z 599.5 (M++1).


EXAMPLE 137
Compound 11503, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine-4-sulfonamide
[Step 1] methyl 6-(((N-(3-chloro-4-fluorophenyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((1-(azetidin-3-yl)-N-(3-chloro-4-fluorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate trihydrochloride (0.300 g, 0.604 mmol) and N,N-diisopropylethylamine (0.210 mL, 1.207 mmol) in dichloromethane (10 mL) was mixed at the room temperature with methanesulfonyl chloride (0.070 mL, 0.905 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 15%) to give methyl 6-(((N-(3-chloro-4-fluorophenyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine)-4-sulfonamido)methyl)nicotinate as yellow solid (0.280 g, 80.7%).


[Step 2] N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine-4-sulfonamide



embedded image


methyl 6-(((N-(3-chloro-4-fluorophenyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine)-4-sulfonamido)methyl)nicotinate (0.280 g, 0.487 mmol) and hydrazine monohydrate (0.710 mL, 14.607 mmol) were mixed at the room temperature in ethanol (8 mL)/water (2 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine-4-sulfonamide, 0.245 g, 87.5%, white solid).


[Step 3] Compound 11503



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine-4-sulfonamide (0.245 g, 0.426 mmol) and triethylamine (0.178 mL, 1.278 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.159 mL, 1.278 mmol), stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 20%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-(methylsulfonyl)azetidin-3-yl)piperidine-4-sulfonamide as white solid (0.120 g, 44.4%).



1H NMR (400 MHz, CDCl3) δ 9.19 (dd, 1H, J=2.3, 0.8 Hz), 8.35 (dd, 1H, J=8.2, 2.2 Hz), 7.61 (dd, 1H, J=8.3, 0.9 Hz), 7.48 (dd, 1H, J=6.4, 2.7 Hz), 7.33-7.27 (m, 2H), 7.10-7.05 (m, 2H), 7.05-6.78 (m, 1H), 5.07 (s, 2H), 3.85 (ddd, 4H, J=30.8, 8.0, 6.6 Hz), 3.18 (q, 1H, J=6.6 Hz), 3.10 (s, 1H), 2.87 (s, 3H), 2.12 (s, 2H), 1.93 (t, 4H, J=9.7 Hz); LRMS (ES) m/z 635.5 (M++1).


EXAMPLE 138
Compound 11504, N-(4-chloro-3-methylphenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] N-(4-chloro-3-methylphenyl)ethanesulfonamide



embedded image


A solution of 4-chloro-3-methylaniline (0.500 g, 3.531 mmol) and pyridine (0.427 mL, 5.297 mmol) in dichloromethane (20 mL) was mixed at the room temperature with ethanesulfonyl chloride (0.400 mL, 4.237 mmol) and stirred at the same temperature for 12 hr. Then, aqueous 1M-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=5% to 50%) to give N-(4-chloro-3-methylphenyl)ethanesulfonamide as beige solid (0.440 g, 53.3%).


[Step 2] methyl 6-((N-(4-chloro-3-methylphenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of N-(4-chloro-3-methylphenyl)ethanesulfonamide (0.200 g, 0.856 mmol), potassium carbonate (0.177 g, 1.284 mmol), methyl 6-(bromomethyl)nicotinate (0.217 g, 0.941 mmol) and potassium iodide (0.071 g, 0.428 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(4-chloro-3-methylphenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.150 g, 45.8%).


[Step 3] N-(4-chloro-3-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(4-chloro-3-methylphenyl)ethylsulfonamido)methyl)nicotinate (0.150 g, 0.392 mmol) and hydrazine monohydrate (0.190 mL, 3.918 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-chloro-3-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.077 g, 51.3%, yellow oil).


[Step 4] Compound 11504



embedded image


A solution of N-(4-chloro-3-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.077 g, 0.201 mmol), triethylamine (0.112 mL, 0.804 mmol) and 2,2-difluoroacetic anhydride (0.050 mL, 0.402 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-(4-chloro-3-methylphenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as yellow solid (0.035 g, 39.3%).



1H NMR (400 MHz, CDCl3) δ 9.23 (dd, 1H, J=2.2, 0.9 Hz), 8.41 (dd, 1H, J=8.2, 2.2 Hz), 7.75 (dd, 1H, J=8.2, 0.9 Hz), 7.35-7.26 (m, 2H), 7.19 (ddd, 1H, J=8.6, 2.7, 0.7 Hz), 7.10-6.80 (m, 1H), 5.16 (s, 2H), 3.20 (q, 2H, J=7.4 Hz), 2.35 (s, 3H), 1.46 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 443.3 (M++1).


EXAMPLE 139
Compound 11505, N-(3-chloro-4-methylphenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] N-(3-chloro-4-methylphenyl)ethanesulfonamide



embedded image


A solution of 3-chloro-4-methylaniline (0.500 g, 3.531 mmol), ethanesulfonyl chloride (0.501 mL, 5.297 mmol) and pyridine (0.341 mL, 4.237 mmol) in dichloromethane (15 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous 1M-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give N-(3-chloro-4-methylphenyl)ethanesulfonamide as red solid (0.528 g, 64.0%).


[Step 2] methyl 6-((N-(3-chloro-4-methylphenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.217 g, 0.941 mmol) and potassium iodide (0.071 g, 0.428 mmol) in N,N-dimethylformide (10 mL) was mixed at the room temperature with N-(3-chloro-4-methylphenyl)ethanesulfonamide (0.200 g, 0.856 mmol) and potassium carbonate (0.177 g, 1.284 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-((N-(3-chloro-4-methylphenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.140 g, 42.7%).


[Step 3] N-(3-chloro-4-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(3-chloro-4-methylphenyl)ethylsulfonamido)methyl)nicotinate (0.140 g, 0.366 mmol) and hydrazine monohydrate (0.178 mL, 3.657 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.088 g, 62.9%, yellow oil).


[Step 4] Compound 11505



embedded image


A solution of N-(3-chloro-4-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.088 g, 0.230 mmol), triethylamine (0.128 mL, 0.919 mmol) and 2,2-difluoroacetic anhydride (0.057 mL, 0.460 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 20%) to give the title compound as yellow oil (0.055 g, 54.0%).



1H NMR (400 MHz, CDCl3) δ 9.23 (dd, 1H, J=2.2, 0.9 Hz), 8.40 (dd, 1H, J=8.3, 2.2 Hz), 7.73 (dd, 1H, J=8.3, 0.9 Hz), 7.44 (d, 1H, J=2.1 Hz), 7.33-7.16 (m, 2H), 7.10-6.80 (m, 1H), 5.14 (s, 2H), 3.20 (q, 2H, J=7.4 Hz), 2.33 (s, 3H), 1.45 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 443.43 (M++1).


EXAMPLE 140
Compound 11506, N-(3,5-dichlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] N-(3,5-dichlorophenyl)ethanesulfonamide



embedded image


A solution of 3,5-dichloroaniline (0.500 g, 3.086 mmol) and pyridine (0.298 mL, 3.703 mmol) in dichloromethane (15 mL) was mixed at the room temperature with ethanesulfonyl chloride (0.437 mL, 4.629 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(3,5-dichlorophenyl)ethanesulfonamide as white solid (0.638 g, 81.3%)


[Step 2] methyl 6-((N-(3,5-dichlorophenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.199 g, 0.866 mmol) and potassium iodide (0.065 g, 0.393 mmol) in N,N-dimethylformide (10 mL) was mixed at the room temperature with N-(3,5-dichlorophenyl)ethanesulfonamide (0.200 g, 0.787 mmol) and potassium carbonate (0.163 g, 1.180 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(3,5-dichlorophenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.160 g, 50.4%).


[Step 3] N-(3,5-dichlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(3,5-dichlorophenyl)ethylsulfonamido)methyl)nicotinate (0.160 g, 0.397 mmol) and hydrazine monohydrate (0.193 mL, 3.968 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3,5-dichlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.087 g, 54.4%, yellow oil).


[Step 4] Compound 11506



embedded image


A solution of N-(3,5-dichlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.087 g, 0.216 mmol), triethylamine (0.120 mL, 0.863 mmol) and 2,2-difluoroacetic anhydride (0.054 mL, 0.431 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-(3,5-dichlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as yellow oil (0.039 g, 39.0%).



1H NMR (400 MHz, CDCl3) δ 9.28 (dd, 1H, J=2.2, 0.9 Hz), 8.43 (dd, 1H, J=8.2, 2.2 Hz), 7.67 (dt, 1H, J=8.2, 0.7 Hz), 7.41 (d, 2H, J=1.8 Hz), 7.28 (d, 1H, J=1.8 Hz), 7.10-6.81 (m, 1H), 5.15 (s, 2H), 3.23 (q, 2H, J=7.4 Hz), 1.45 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 463.35 (M++1).


EXAMPLE 141
Compound 11507, N-(3,4-dichlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] N-(3,4-dichlorophenyl)ethanesulfonamide



embedded image


A solution of 3,4-dichloroaniline (0.500 g, 3.086 mmol) and pyridine (0.373 mL, 4.629 mmol) in dichloromethane (20 mL) was mixed at the room temperature with ethanesulfonyl chloride (0.350 mL, 3.703 mmol) and stirred at the same temperature for 12 hr. Then, aqueous 1M-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=5% to 50%) to give N-(3,4-dichlorophenyl)ethanesulfonamide as red solid (0.430 g, 54.8%).


[Step 2] methyl 6-4N-(3,4-dichlorophenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.199 g, 0.866 mmol) and potassium iodide (0.065 g, 0.393 mmol) in N,N-dimethylformide (10 mL) was mixed at the room temperature with N-(3,4-dichlorophenyl)ethanesulfonamide (0.200 g, 0.787 mmol) and potassium carbonate (0.163 g, 1.180 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-((N-(3,4-dichlorophenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.110 g, 34.7%).


[Step 3] N-(3,4-dichlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(3,4-dichlorophenyl)ethylsulfonamido)methyl)nicotinate (0.110 g, 0.273 mmol) and hydrazine monohydrate (0.133 mL, 2.728 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3,4-dichlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.046 g, 41.8%, yellow oil).


[Step 4] N-(3,4-dichlorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of N-(3,4-dichlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.046 g, 0.114 mmol), triethylamine (0.064 mL, 0.456 mmol) and 2,2-difluoroacetic anhydride (0.028 mL, 0.228 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromathane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3,4-dichlorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.029 g, 52.8%, yellow oil).


[Step 5] Compound 11507



embedded image


A solution of N-(3,4-dichlorophenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.029 g, 0.060 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.029 g, 0.121 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3,4-dichlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as yellow solid (0.012 g, 43.0%).



1H NMR (400 MHz, CDCl3) δ 9.26 (dd, 1H, J=2.2, 0.9 Hz), 8.41 (dd, 1H, J=8.2, 2.2 Hz), 7.68 (dd, 1H, J=8.2, 0.9 Hz), 7.60 (d, 1H, J=2.5 Hz), 7.42 (d, 1H, J=8.7 Hz), 7.36-7.25 (m, 1H), 7.16-6.77 (m, 1H), 5.15 (s, 2H), 3.21 (q, 2H, J=7.4 Hz), 1.49-1.38 (m, 3H); LRMS (ES) m/z 463.35 (M++1).


EXAMPLE 142
Compound 11508, N-(3-chloro-5-methylphenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide
[Step 1] N-(3-chloro-5-methylphenyl)ethanesulfonamide



embedded image


A solution of 3-chloro-5-methylaniline (0.500 g, 3.531 mmol) and pyridine (0.427 mL, 5.297 mmol) in dichloromethane (20 mL) was mixed at the room temperature with ethanesulfonyl chloride (0.400 mL, 4.237 mmol), and stirred at the same temperature for 12 hr. Then, aqueous 1M-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=5% to 50%) to give N-(3-chloro-5-methylphenyl)ethanesulfonamide as beige solid (0.380 g, 46.0%).


[Step 2] methyl 6-((N-(3-chloro-5-methylphenyl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.217 g, 0.941 mmol) and potassium iodide (0.071 g, 0.428 mmol) in N,N-dimethylformide (10 mL) was mixed at the room temperature with N-(3-chloro-5-methylphenyl)ethanesulfonamide (0.200 g, 0.856 mmol) and potassium carbonate (0.177 g, 1.284 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-((N-(3-chloro-5-methylphenyl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.130 g, 39.7%).


[Step 3] N-(3-chloro-5-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(3-chloro-5-methylphenyl)ethylsulfonamido)methyl)nicotinate (0.130 g, 0.340 mmol) and hydrazine monohydrate (0.165 mL, 3.395 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-5-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.063 g, 48.5%, yellow oil).


[Step 4] N-(3-chloro-5-methylphenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)ethanesulfonamide



embedded image


A solution of N-(3-chloro-5-methylphenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.063 g, 0.165 mmol), triethylamine (0.092 mL, 0.658 mmol) and 2,2-difluoroacetic anhydride (0.041 mL, 0.329 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-5-methylphenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)ethanesulfonamide, 0.034 g, 44.8%, yellow oil).


[Step 5] Compound 11508



embedded image


A solution of N-(3-chloro-5-methylphenyl)-N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)ethanesulfonamide (0.034 g, 0.074 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.035 g, 0.148 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-chloro-5-methylphenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)ethanesulfonamide as yellow solid (0.026 g, 79.6%).



1H NMR (400 MHz, CDCl3) δ 9.25 (dd, 1H, J=2.2, 0.9 Hz), 8.41 (dd, 1H, J=8.2, 2.2 Hz), 7.73 (dd, 1H, J=8.2, 0.8 Hz), 7.26 (td, 1H, J=2.0, 0.6 Hz), 7.16 (ddt, 1H, J=2.3, 1.5, 0.8 Hz), 7.12-7.06 (m, 1H), 7.02-6.79 (m, 1H), 5.15 (s, 2H), 3.21 (q, 2H, J=7.4 Hz), 2.32 (s, 3H), 1.46 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 443.36 (M++1).


EXAMPLE 143
Compound 11514, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(pyrrolidin-1-yl)ethane-1-sulfonamide
[Step 1] N-(3-chloro-4-fluorophenyl)ethenesulfonamide



embedded image


A solution of 3-chloro-4-fluoroaniline (3.000 g, 20.610 mmol) and 2-chloroethane-1-sulfonyl chloride (2.369 mL, 22.671 mmol) in dichloromethane (14 mL) was mixed at the room temperature with pyridine (2.158 mL, 26.793 mmol) and stirred at the same temperature for 6 hr. Then, aqueous 0.1N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-(3-chloro-4-fluorophenyl)ethenesulfonamide as gray solid (3.800 g, 78.2%).


[Step 2] methyl 4-((N-(3-chloro-4-fluorophenyl)vinylsulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of N-(3-chloro-4-fluorophenyl)ethenesulfonamide (2.000 g, 8.487 mmol), methyl 4-(bromomethyl)-3-fluorobenzoate (3.145 g, 12.730 mmol) and potassium carbonate (1.290 g, 9.335 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 16 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-((N-(3-chloro-4-fluorophenyl)vinylsulfonamido)methyl)-3-fluorobenzoate as light yellow soild (2.700 g, 91.1%).


[Step 3] methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(pyrrolidin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 4-((N-(3-chloro-4-fluorophenyl)vinylsulfonamido)methyl)-3-fluorobenzoate (0.200 g, 0.498 mmol), N,N-diisopropylethylamine (0.104 mL, 0.597 mmol) and pyrrolidine (0.071 g, 0.995 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 60%) to give methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(pyrrolidin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate as yellow solid (0.150 g, 63.7%).


[Step 4] N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(pyrrolidin-1-yl)ethane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(pyrrolidin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate (0.150 g, 0.317 mmol) and hydrazine monohydrate (0.154 mL, 3.172 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (10 mL) and water (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(pyrrolidin-1-yl)ethane-1-sulfonamide as white solid (0.100 g, 66.7%).


[Step 5] Compound 11514



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(pyrrolidin-1-yl)ethane-1-sulfonamide (0.100 g, 0.211 mmol), triethylamine (0.147 mL, 1.057 mmol) and 2,2-difluoroacetic anhydride (0.079 mL, 0.634 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(pyrrolidin-1-yl)ethane-1-sulfonamide as yellow oil (0.045 g, 39.9%).



1H NMR (400 MHz, CDCl3) δ 7.90 (dd, 1H, J=8.1, 1.6 Hz), 7.75 (dd, 1H, J=9.9, 1.7 Hz), 7.67 (dd, 1H, J=8.0, 7.2 Hz), 7.51 (dd, 1H, J=6.4, 2.6 Hz), 7.25 (ddd, 1H, J=8.8, 4.2, 2.7 Hz), 7.10 (t, 1H, J=8.6 Hz), 7.06-6.77 (m, 1H), 5.04 (s, 2H), 3.32 (dd, 2H, J=7.4, 6.5 Hz), 3.05 (dd, 2H, J=7.4, 6.4 Hz), 2.75-2.49 (m, 4H), 1.96-1.84 (m, 4H); LRMS (ES) m/z 533.40 (M++1).


EXAMPLE 144
Compound 11518, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)methyl)-N-phenylmethanesulfonamide
[Step 1] methyl 5-(bromomethyl)pyrazine-2-carboxylate



embedded image


A mixture of methyl 5-methylpyrazine-2-carboxylate (3.000 g, 19.717 mmol), 1-bromopyrrolidine-2,5-dione (NBS, 3.685 g, 20.703 mmol) and Azobisisobutyronitrile (AIBN, 1.295 g, 7.887 mmol) in carbon tetrachloride (20 mL) prepared at the room temperature was heated at reflux for 10 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 15%) to give methyl 5-(bromomethyl)pyrazine-2-carboxylate as gray solid (1.500 g, 32.9%).


[Step 2] methyl 5-((N-phenylmethylsulfonamido)methyl)pyrazine-2-carboxylate



embedded image


A solution of methyl 5-(bromomethyl)pyrazine-2-carboxylate (0.567 g, 2.453 mmol) and potassium iodide (0.039 g, 0.234 mmol) in N,N-dimethylformide (6 mL) was stirred at the room temperature for 30 min, and mixed with N-phenylmethanesulfonamide (0.400 g, 2.336 mmol) and potassium carbonate (0.420 g, 3.037 mmol). The reaction mixture was stirred at the same temperature for additional 8 hr. The reaction mixture was diluted with water and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give methyl 5-((N-phenylmethylsulfonamido)methyl)pyrazine-2-carboxylate as white solid (0.710 g, 94.6%).


[Step 3] N-((5-(hydrazinecarbonyl)pyrazin-2-yl)methyl)-N-phenylmethanesulfonamide



embedded image


A solution of methyl 5-((N-phenylmethylsulfonamido)methyl)pyrazine-2-carboxylate (0.400 g, 1.245 mmol) and potassium carbonate (0.860 g, 6.224 mmol) in ethanol (4 mL) was mixed at the room temperature with hydrazine monohydrate (0.605 mL, 12.447 mmol). The reaction mixture was heated at reflux for 2 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyrazin-2-yl)methyl)-N-phenylmethanesulfonamide, 0.350 g, 87.5%, white solid).


[Step 4] Compound 11518



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyrazin-2-yl)methyl)-N-phenylmethanesulfonamide (0.100 g, 0.311 mmol) and triethylamine (0.130 mL, 0.934 mmol) in tetrahydrofuran (5 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.085 mL, 0.685 mmol). The reaction mixture was heated at reflux for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)methyl)-N-phenylmethanesulfonamide as white solid (0.070 g, 59.0%).



1H NMR (400 MHz, CDCl3) δ 9.39 (d, 1H, J=1.4 Hz), 8.90 (d, 1H, J=1.4 Hz), 7.41-7.35 (m, 4 Hz), 7.32 (m, 1Hz), 7.07 (s, 0.25H), 6.94 (s, 0.5H), 6.81 (s, 0.25H), 5.19 (s, 2H), 3.05 (s, 3H); LRMS (ES) m/z 382.34 (M++1).


EXAMPLE 145
Compound 11520, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide
[Step 1] N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide



embedded image


A solution of 1-methyl-1H-indazol-4-amine (0.300 g, 2.038 mmol), pyridine (0.197 mL, 2.446 mmol) and ethanesulfonyl chloride (0.231 mL, 2.446 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide, 0.350 g, 71.8%, yellow oil).


[Step 2] methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-4-yl)ethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(bromomethyl)-3-fluorobenzoate (0.216 g, 0.873 mmol) and potassium iodide (0.066 g, 0.397 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 30 min, and mixed with N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide (0.190 g, 0.794 mmol) and potassium carbonate (0.165 g, 1.191 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-4-yl)ethylsulfonamido)methyl)benzoate as yellow solid (0.250 g, 77.7%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide



embedded image


A solution of methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-4-yl)ethylsulfonamido)methyl)benzoate (0.250 g, 0.617 mmol) and hydrazine monohydrate (0.300 mL, 6.166 mmol) in ethanol (15 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide, 0.200 g, 80.0%, yellow oil).


[Step 4] Compound 11520



embedded image


A mixture of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide (0.200 g, 0.493 mmol), triethylamine (0.344 mL, 2.466 mmol) and 2,2-difluoroacetic anhydride (0.184 mL, 1.480 mmol) in tetrahydrofuran (15 mL) preapared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide as white solid (0.110 g, 47.9%).



1H NMR (400 MHz, CDCl3) δ 8.01 (d, 1H, J=0.9 Hz), 7.82 (dt, 1H, J=8.1, 1.5 Hz), 7.71-7.62 (m, 2H), 7.42-7.30 (m, 2H), 7.13 (dd, 1H, J=7.0, 1.1 Hz), 7.07-6.74 (m, 1H), 5.17 (s, 2H), 4.08 (s, 3H), 3.20 (q, 2H, J=7.4 Hz), 1.48 (td, 3H, J=7.4, 1.1 Hz); LRMS (ES) m/z 466.42 (M++1).


EXAMPLE 146
Compound 11521, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide
[Step 1] N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide



embedded image


A solution of 1-methyl-1H-indazol-6-amine (0.300 g, 2.038 mmol), pyridine (0.197 mL, 2.446 mmol) and ethanesulfonyl chloride (0.231 mL, 2.446 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide, 0.360 g, 73.8%, yellow oil).


[Step 2] methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-6-yl)ethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(bromomethyl)-3-fluorobenzoate (0.261 g, 1.057 mmol) and potassium iodide (0.080 g, 0.481 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 30 min, and mixed with N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide (0.230 g, 0.961 mmol) and potassium carbonate (0.199 g, 1.442 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-6-yl)ethylsulfonamido)methyl)benzoate as yellow oil (0.200 g, 51.3%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide



embedded image


A solution of methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-6-yl)ethylsulfonamido)methyl)benzoate (0.200 g, 0.493 mmol) and hydrazine monohydrate (0.240 mL, 4.933 mmol) in ethanol (20 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide, 0.180 g, 90.0%, white solid).


[Step 4] Compound 11521



embedded image


A mixture of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide (0.180 g, 0.444 mmol), triethylamine (0.309 mL, 2.220 mmol) and 2,2-difluoroacetic anhydride (0.166 mL, 1.332 mmol) in tetrahydrofuran (15 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide as yellow oil (0.130 g, 62.9%).



1H NMR (400 MHz, CDCl3) δ 7.96 (d, 1H, J=1.0 Hz), 7.88 (dd, 1H, J=8.0, 1.6 Hz), 7.77-7.66 (m, 3H), 7.42 (dt, 1H, J=1.8, 0.8 Hz), 7.11 (dd, 1H, J=8.6, 1.8 Hz), 7.06-6.76 (m, 1H), 5.16 (s, 2H), 4.04 (s, 3H), 3.17 (q, 2H, J=7.4 Hz), 1.49 (d, 3H, J=7.3 Hz); LRMS (ES) m/z 466.30 (M++1).


EXAMPLE 147
Compound 11522, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide
[Step 1] N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide



embedded image


A solution of 1-methyl-1H-indazol-7-amine (0.500 g, 3.397 mmol), pyridine (0.328 mL, 4.077 mmol) and ethanesulfonyl chloride (0.385 mL, 4.077 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide, 0.550 g, 67.7%, yellow solid).


[Step 2] methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-7-yl)ethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(bromomethyl)-3-fluorobenzoate (0.227 g, 0.919 mmol) and potassium iodide (0.069 g, 0.418 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 30 min, and mixed with N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide (0.200 g, 0.836 mmol) and potassium carbonate (0.173 g, 1.254 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-7-yl)ethylsulfonamido)methyl)benzoate as yellow oil (0.240 g, 70.8%).


[Step 3] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide



embedded image


A solution of methyl 3-fluoro-4-((N-(1-methyl-1H-indazol-7-yl)ethylsulfonamido)methyl)benzoate (0.240 g, 0.592 mmol) and hydrazine monohydrate (0.288 mL, 5.919 mmol) in ethanol (20 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide, 0.200 g, 83.3%, yellow oil).


[Step 4] Compound 11522



embedded image


A mixture of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide (0.200 g, 0.493 mmol), triethylamine (0.344 mL, 2.466 mmol) and 2,2-difluoroacetic anhydride (0.184 mL, 1.480 mmol) in tetrahydrofuran (15 mL) was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide as yellow oil (0.150 g, 65.3%).



1H NMR (400 MHz, CDCl3) δ7.98 (d, 1H, J=1.5 Hz), 7.80 (dd, 1H, J=8.0, 1.7 Hz), 7.78-7.71 (m, 2H), 7.42 (t, 1H, J=7.6 Hz), 7.27-7.20 (m, 1H), 7.12 (dd, 1H, J=8.0, 7.4 Hz), 7.07-6.76 (m, 1H), 5.07 (d, 2H, J=1.0 Hz), 4.13 (s, 3H), 3.29 (qd, 2H, J=7.4, 1.8 Hz), 1.52 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 466.42 (M++1).


EXAMPLE 148
Compound 11539, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide
[Step 1] methyl 6-((N-(1-methyl-1H-indazol-4-yl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.159 g, 0.690 mmol) and potassium iodide (0.052 g, 0.313 mmol) in N,N-dimethylformide (15 mL) was mixed at the room temperature with N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide (0.150 g, 0.627 mmol) and potassium carbonate (0.130 g, 0.940 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(1-methyl-1H-indazol-4-yl)ethylsulfonamido)methyl)nicotinate as yellow oil (0.190 g, 78.0%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(1-methyl-1H-indazol-4-yl)ethylsulfonamido)methyl)nicotinate (0.190 g, 0.489 mmol) and hydrazine monohydrate (0.245 g, 4.891 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide as white solid (0.150 g, 78.9%).


[Step 3] Compound 11539



embedded image


A mixture of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide (0.080 g, 0.206 mmol), triethylamine (0.144 mL, 1.030 mmol) and 2,2-difluoroacetic anhydride (0.077 mL, 0.618 mmol) in tetrahydrofuran (5 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-4-yl)ethanesulfonamide as yellow oil (0.056 g, 60.6%).



1H NMR (400 MHz, CDCl3) δ 9.17 (dd, 1H, J=2.2, 0.9 Hz), 8.35 (dd, 1H, J=8.3, 2.3 Hz), 8.08 (d, 1H, J=0.8 Hz), 7.78 (dd, 1H, J=8.3, 0.9 Hz), 7.42-7.26 (m, 2H), 7.21 (dd, 1H, J=6.6, 1.5 Hz), 7.10-6.76 (m, 1H), 5.28 (s, 2H), 4.08 (s, 3H), 3.26 (q, 2H, J=7.4 Hz), 1.48 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 449.40 (M++1).


EXAMPLE 149
Compound 11540, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide
[Step 1] methyl 6-((N-(1-methyl-1H-indazol-6-yl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.212 g, 0.919 mmol) and potassium iodide (0.069 g, 0.418 mmol) in N,N-dimethylformide (15 mL) was mixed at 50° C. with N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide (0.200 g, 0.836 mmol) and potassium carbonate (0.173 g, 1.254 mmol). The reaction mixture was stirred at the same temperature for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(1-methyl-1H-indazol-6-yl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.220 g, 67.8%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(1-methyl-1H-indazol-6-yl)ethylsulfonamido)methyl)nicotinate (0.200 g, 0.515 mmol) and hydrazine monohydrate


(0.258 g, 5.149 mmol) in ethanol (20 mL) was stirred at 90° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide as yellow solid (0.170 g, 85.0%).


[Step 3] Compound 11540



embedded image


A mixture of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide (0.100 g, 0.257 mmol), triethylamine (0.179 mL, 1.287 mmol) and 2,2-difluoroacetic anhydride (0.096 mL, 0.772 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-6-yl)ethanesulfonamide as white solid (0.089 g, 77.1%).



1H NMR (400 MHz, CDCl3) δ 9.22 (dd, 1H, J=2.2, 0.9 Hz), 8.38 (dd, 1H, J=8.2, 2.2 Hz), 7.95 (d, 1H, J=1.0 Hz), 7.78 (dd, 1H, J=8.3, 0.9 Hz), 7.70 (dd, 1H, J=8.6, 0.7 Hz), 7.54 (dt, 1H, J=1.7, 0.9 Hz), 7.19 (dd, 1H, J=8.6, 1.8 Hz), 7.10-6.75 (m, 1H), 5.27 (s, 2H), 4.06 (s, 3H), 3.23 (q, 2H, J=7.4 Hz), 1.47 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 449.34 (M++1).


EXAMPLE 150
Compound 11541, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide
[Step 1] methyl 6-((N-(1-methyl-1H-indazol-7-yl)ethylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(bromomethyl)nicotinate (0.212 g, 0.919 mmol) and potassium iodide (0.069 g, 0.418 mmol) in N,N-dimethylformide (15 mL) was mixed at 50° C. with N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide (0.200 g, 0.836 mmol) and potassium carbonate (0.173 g, 1.254 mmol). The reaction mixture was stirred at the same temperature for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 6-((N-(1-methyl-1H-indazol-7-yl)ethylsulfonamido)methyl)nicotinate as yellow solid (0.230 g, 70.8%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide



embedded image


A solution of methyl 6-((N-(1-methyl-1H-indazol-7-yl)ethylsulfonamido)methyl)nicotinate (0.230 g, 0.592 mmol) and hydrazine monohydrate


(0.296 g, 5.921 mmol) in ethanol (20 mL) was stirred at 90° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide as yellow solid (0.180 g, 78.3%).


[Step 3] Compound 11541



embedded image


A mixture of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide (0.050 g, 0.129 mmol), triethylamine (0.090 mL, 0.644 mmol) and 2,2-difluoroacetic anhydride (0.048 mL, 0.386 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(1-methyl-1H-indazol-7-yl)ethanesulfonamide as yellow oil (0.039 g, 67.6%).



1H NMR (400 MHz, CDCl3) δ 9.34 (dd, 1H, J=2.2, 0.8 Hz), 8.33 (dd, 1H, J=8.1, 2.3 Hz), 8.01 (s, 1H), 7.71 (dd, 1H, J=8.0, 1.0 Hz), 7.36 (dd, 1H, J=8.1, 0.9 Hz), 7.17 (dd, 1H, J=7.4, 1.0 Hz), 7.02 (dd, 1H, J=8.0, 7.4 Hz), 6.97-6.81 (m, 1H), 5.39 (d, 1H, J=15.1 Hz), 4.91 (d, 1H, J=15.1 Hz), 4.33 (s, 3H), 3.61 (dq, 1H, J=13.6, 7.5 Hz), 3.42 (dq, 1H, J=13.5, 7.4 Hz), 1.51 (t, 3H, J=7.4 Hz); LRMS (ES) m/z 449.46 (M++1).


EXAMPLE 151
Compound 11552, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(4-methylpiperazin-1-yl)ethane-1-sulfonamide
[Step 1] tert-butyl 4-(2-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)ethyl)piperazine-1-carboxylate



embedded image


A solution of methyl 4-((N-(3-chloro-4-fluorophenyl)vinylsulfonamido)methyl)-3-fluorobenzoate (1.000 g, 2.489 mmol), N,N-diisopropylethylamine (0.650 mL, 3.733 mmol) and tert-butyl piperazine-1-carboxylate (0.603 g, 3.235 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give tert-butyl 4-(2-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)ethyl)piperazine-1-carboxylate as white solid (1.300 g, 88.8%).


[Step 2] methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride



embedded image


A solution of tert-butyl 4-(2-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)ethyl)piperazine-1-carboxylate (1.300 g, 2.211 mmol) and hydrogen chloride (4.00 M solution in 1,4-dioxane, 1.105 mL, 4.421 mmol) in dichloromethane (50 mL) was stirred at the room temperature for 5 hr. The precipitates were collected by filtration, washed by dichloromethane, and dried to give methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride as white solid (1.150 g, 99.2%).


[Step 3] methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-methylpiperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride (0.200 g, 0.381 mmol), formaldehyde (0.023 g, 0.763 mmol) and acetic acid (0.024 mL, 0.420 mmol) in dichloromethane (10 mL) was mixed at the room temperature with sodium triacetoxyborohydride (0.162 g, 0.763 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-methylpiperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate as yellow oil (0.150 g, 78.4%).


[Step 4] N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-methylpiperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate (0.150 g, 0.299 mmol) and hydrazine monohydrate (0.145 mL, 2.988 mmol) in ethanol (20 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperazin-1-yl)ethane-1-sulfonamide as white solid (0.120 g, 80.0%).


[Step 5] Compound 11552



embedded image


A mixture of N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperazin-1-yl)ethane-1-sulfonamide (0.080 g, 0.159 mmol), triethylamine (0.111 mL, 0.797 mmol) and 2,2-difluoroacetic anhydride (0.059 mL, 0.478 mmol) in tetrahydrofuran (10 mL) was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(4-methylpiperazin-1-yl)ethane-1-sulfonamide as white solid (0.056 g, 62.5%).



1H NMR (400 MHz, CDCl3) δ 7.91 (dd, 1H, J=7.9, 1.6 Hz), 7.76 (dd, 1H, J=9.9, 1.6 Hz), 7.66 (t, 1H, J=7.6 Hz), 7.50 (dd, 1H, J=6.5, 2.6 Hz), 7.24 (ddd, 1H, J=8.8, 4.1, 2.7 Hz), 7.11 (t, 1H, J=8.6 Hz), 7.07-6.74 (m, 1H), 5.03 (s, 2H), 3.28 (t, 2H, J=6.9 Hz), 2.94 (t, 2H, J=6.9 Hz), 2.59 (s, 8H), 2.36 (s, 3H); LRMS (ES) m/z 562.47 (M++1).


EXAMPLE 152
Compound 11553, 2-(4-acetylpiperazin-1-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)ethane-1-sulfonamide
[Step 1] methyl 4-(((2-(4-acetylpiperazin-1-yl)-N-(3-chloro-4-fluorophenyl)ethyl)sulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride (0.200 g, 0.381 mmol), triethylamine (0.080 mL, 0.572 mmol) and acetic anhydride (0.047 mL, 0.496 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give methyl 4-(((2-(4-acetylpiperazin-1-yl)-N-(3-chloro-4-fluorophenyl)ethyl)sulfonamido)methyl)-3-fluorobenzoate as yellow oil (0.160 g, 79.2%).


[Step 2] 2-(4-acetylpiperazin-1-yl)-N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethane-1-sulfonamide



embedded image


A solution of methyl 4-(((2-(4-acetylpiperazin-1-yl)-N-(3-chloro-4-fluorophenyl)ethyl)sulfonamido)methyl)-3-fluorobenzoate (0.160 g, 0.302 mmol) and hydrazine monohydrate (0.147 mL, 3.019 mmol) in ethanol (20 mL) was stirred at 90° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give 2-(4-acetylpiperazin-1-yl)-N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethane-1-sulfonamide as white solid (0.130 g, 81.2%).


[Step 3] Compound 11553



embedded image


A mixture of 2-(4-acetylpiperazin-1-yl)-N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)ethane-1-sulfonamide (0.080 g, 0.151 mmol), triethylamine (0.105 mL, 0.755 mmol) and 2,2-difluoroacetic anhydride (0.056 mL, 0.453 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give 2-(4-acetylpiperazin-1-yl)-N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)ethane-1-sulfonamide as yellow solid (0.051 g, 57.3%).



1H NMR (400 MHz, CDCl3) δ 7.91 (dd, 1H, J=8.1, 1.7 Hz), 7.77 (dd, 1H, J=9.9, 1.6 Hz), 7.64 (t, 1H, J=7.6 Hz), 7.45 (dd, 1H, J=6.4, 2.6 Hz), 7.22 (ddd, 1H, J=8.9, 4.2, 2.6 Hz), 7.12 (t, 1H, J=8.6 Hz), 7.08-6.77 (m, 1H), 5.01 (s, 2H), 3.68 (t, 2H, J=5.1 Hz), 3.57-3.49 (m, 2H), 3.29 (dd, 2H, J=8.1, 6.1 Hz), 2.94 (dd, 2H, J=8.0, 6.1 Hz), 2.57-2.45 (m, 4H), 2.12 (s, 3H); LRMS (ES) m/z 590.42 (M++1).


EXAMPLE 153
Compound 11554, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(4-(methylsulfonyl)piperazin-1-yl)ethane-1-sulfonamide
[Step 1] methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride (0.200 g, 0.381 mmol), triethylamine (0.106 mL, 0.763 mmol) and methanesulfonyl chloride (0.038 mL, 0.496 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate as yellow solid (0.180 g, 83.4%).


[Step 2] N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(methylsulfonyl)piperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate (0.180 g, 0.318 mmol) and hydrazine monohydrate (0.155 mL, 3.180 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(methylsulfonyl)piperazin-1-yl)ethane-1-sulfonamide as white solid (0.130 g, 72.2%).


[Step 3] Compound 11554



embedded image


A mixture of N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(methylsulfonyl)piperazin-1-yl)ethane-1-sulfonamide (0.080 g, 0.141 mmol), triethylamine (0.098 mL, 0.707 mmol) and 2,2-difluoroacetic anhydride (0.053 mL, 0.424 mmol) in tetrahydrofuran (5 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(4-(methylsulfonyl)piperazin-1-yl)ethane-1-sulfonamide as yellow solid (0.034 g, 38.4%).



1H NMR (400 MHz, CDCl3) δ 7.95-7.86 (m, 1H), 7.81-7.73 (m, 1H), 7.63 (t, 1H, J=7.7 Hz), 7.44 (dt, 1H, J=6.5, 2.2 Hz), 7.27-7.16 (m, 1H), 7.17-7.07 (m, 1H), 7.08-6.75 (m, 1H), 5.01 (s, 2H), 3.34-3.25 (m, 6H), 2.98 (td, 2H, J=7.0, 1.7 Hz), 2.82 (s, 3H), 2.68-2.61 (m, 4H); LRMS (ES) m/z 626.39 (M++1).


EXAMPLE 154
Compound 11564, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)methyl)-N-phenylmethanesulfonamide
[Step 1] methyl 2-(bromomethyl)pyrimidine-5-carboxylate



embedded image


A mixture of methyl 2-methylpyrimidine-5-carboxylate (1.000 g, 6.572 mmol), 1-bromopyrrolidine-2,5-dione (NBS, 1.228 g, 6.901 mmol) and Azobisisobutyronitrile (AIBN, 0.432 g, 2.629 mmol) in carbon tetrachloride (6 mL) prepared at the room temperature was heated at reflux for 10 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 15%) to give methyl 2-(bromomethyl)pyrimidine-5-carboxylate as gray solid (0.390 g, 25.7%).


[Step 2] methyl 2-((N-phenylmethylsulfonamido)methyl)pyrimidine-5-carboxylate



embedded image


A solution of methyl 2-(bromomethyl)pyrimidine-5-carboxylate (0.383 g, 1.656 mmol) and potassium iodide (0.026 g, 0.158 mmol) in N,N-dimethylformide (4 mL) was mixed at the room temperature with N-phenylmethanesulfonamide (0.270 g, 1.577 mmol) and potassium carbonate (0.262 g, 1.892 mmol). The reaction mixture was stirred at the same temperature for 30 min. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give methyl 2-((N-phenylmethylsulfonamido)methyl)pyrimidine-5-carboxylate as white solid (0.370 g, 73.0%).


[Step 3] N-((5-(hydrazinecarbonyl)pyrimidin-2-yl)methyl)-N-phenylmethanesulfonamide



embedded image


A mixture of methyl 2-((N-phenylmethylsulfonamido)methyl)pyrimidine-5-carboxylate (0.200 g, 0.622 mmol) and hydrazine monohydrate (0.151 mL, 3.112 mmol) in ethanol (5 mL) prepared at the room temperature was heated at reflux for 5 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyrimidin-2-yl)methyl)-N-phenylmethanesulfonamide, 0.150 g, 75.0%, white solid).


[Step 4] Compound 11564



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyrimidin-2-yl)methyl)-N-phenylmethanesulfonamide (0.070 g, 0.218 mmol), triethylamine (0.152 mL, 1.089 mmol) and 2,2-difluoroacetic anhydride (0.081 mL, 0.653 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)methyl)-N-phenylmethanesulfonamide as yellow solid (0.049 g, 59.0%).



1H NMR (400 MHz, CDCl3) δ 9.43 (s, 2H), 7.54-7.46 (m, 2H), 7.43-7.27 (m, 3H), 7.17-6.79 (m, 1H), 5.30 (s, 2H), 3.24 (s, 3H); LRMS (ES) m/z 382.34 (M++1).


EXAMPLE 155
Compound 11565, N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)methyl)methanesulfonamide



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyrimidin-2-yl)methyl)-N-phenylmethanesulfonamide (0.056 g, 0.174 mmol), triethylamine (0.121 mL, 0.871 mmol) and trifluoroacetic anhydride (0.074 mL, 0.523 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)methyl)methanesulfonamide as white solid (0.031 g, 44.5%).



1H NMR (400 MHz, CDCl3) δ 9.44 (s, 2H), 7.55-7.46 (m, 2H), 7.43-7.27 (m, 3H), 5.31 (s, 2H), 3.23 (s, 3H); LRMS (ES) m/z 400.30 (M++1).


EXAMPLE 156
Compound 11566, N-((6-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)methyl)-N-phenylmethanesulfonamide
[Step 1] methyl 6-(bromomethyl)pyridazine-3-carboxylate



embedded image


A mixture of methyl 6-methylpyridazine-3-carboxylate (1.000 g, 6.572 mmol), 1-bromopyrrolidine-2,5-dione (NBS, 1.228 g, 6.901 mmol) and Azobisisobutyronitrile (AIBN, 0.432 g, 2.629 mmol) in carbon tetrachloride (6 mL) prepared at the room temperature was heated at reflux for 10 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 15%) to give methyl 6-(bromomethyl)pyridazine-3-carboxylate as white solid (0.490 g, 32.3%).


[Step 2] methyl 6-((N-phenylmethylsulfonamido)methyl)pyridazine-3-carboxylate



embedded image


A solution of methyl 6-(bromomethyl)pyridazine-3-carboxylate (0.468 g, 2.024 mmol) and potassium iodide (0.032 g, 0.193 mmol) in N,N-dimethylformide (5 mL) was stirred at the room temperature for 30 min, and mixed with N-phenylmethanesulfonamide (0.330 g, 1.927 mmol) and potassium carbonate (0.346 g, 2.506 mmol). The reaction mixture was stirred at the same temperature for additional 24 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 70%) to give methyl 6-((N-phenylmethylsulfonamido)methyl)pyridazine-3-carboxylate as white solid (0.450 g, 72.7%).


[Step 3] N-((6-(hydrazinecarbonyl)pyridazin-3-yl)methyl)-N-phenylmethanesulfonamide



embedded image


A mixture of methyl 6-((N-phenylmethylsulfonamido)methyl)pyridazine-3-carboxylate (0.200 g, 0.622 mmol) and hydrazine monohydrate (0.151 mL, 3.112 mmol) in ethanol (5 mL) prepared at the room temperature was heated at reflux for 3 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(((6-(hydrazinecarbonyl)pyridazin-3-yl)methyl)-N-phenylmethanesulfonamide, 0.150 g, 75.0%, white solid).


[Step 4] Compound 11566



embedded image


A solution of N-((6-(hydrazinecarbonyl)pyridazin-3-yl)methyl)-N-phenylmethanesulfonamide (0.080 g, 0.249 mmol), triethylamine (0.173 mL, 1.245 mmol) and 2,2-difluoroacetic anhydride (0.093 mL, 0.747 mmol) in dichloromethane (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-((6-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)methyl)-N-phenylmethanesulfonamide as white solid (0.059 g, 62.1%).



1H NMR (400 MHz, CDCl3) δ 8.42 (d, 1H, J=8.8 Hz), 8.01 (d, 1H, J=8.8 Hz), 7.47-7.41 (m, 2H), 7.42-7.36 (m, 2H), 7.35-7.29 (m, 1H), 7.14-6.82 (m, 1H), 5.40 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 381.90 (M++1).


EXAMPLE 157
Compound 11567, N-phenyl-N-((6-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)methyl)methanesulfonamide



embedded image


A solution of N-((6-(hydrazinecarbonyl)pyridazin-3-yl)methyl)-N-phenylmethanesulfonamide (0.067 g, 0.208 mmol), triethylamine (0.145 mL, 1.042 mmol) and trifluoroacetic anhydride (0.088 mL, 0.625 mmol) in dichloromethane (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-phenyl-N-((6-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)methyl)methanesulfonamide as white soild (0.042 g, 50.4%).



1H NMR (400 MHz, CDCl3) δ 8.44 (d, 1H, J=8.8 Hz), 8.03 (d, 1H, J=8.8 Hz), 7.48-7.34 (m, 4H), 7.37-7.28 (m, 1H), 5.40 (s, 2H), 3.10 (s, 3H); LRMS (ES) m/z 400.2(M++1).


EXAMPLE 158
Compound 11573, N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)methyl)methanesulfonamide



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyrazin-2-yl)methyl)-N-phenylmethanesulfonamide (0.080 g, 0.249 mmol) and triethylamine (0.104 mL, 0.747 mmol) in tetrahydrofuran (5 mL) was mixed at the room temperature with trifluoroacetic anhydride (0.077 mL, 0.548 mmol). The reaction mixture was heated at reflux for 5 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)methyl)methanesulfonamide as white solid (0.055 g, 55.3%).



1H NMR (400 MHz, CDCl3) δ 9.40 (d, 1H, J=1.4 Hz), 8.92 (d, 1H, J=1.5 Hz), 7.41-7.35 (m, 4H), 7.33-7.29 (m, 1H), 5.19 (s, 2H), 3.00 (s, 3H); LRMS (ES) m/z 400.32 (M++1).


EXAMPLE 159
Compound 11582, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(4-(1-(methylsulfonyl)azetidin-3-yl)piperazin-1-yl)ethane-1-sulfonamide
[Step 1] tert-butyl 3-(4-(2-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)ethyl)piperazin-1-yl)azetidine-1-carboxylate



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride (0.400 g, 0.763 mmol), tert-butyl 3-oxoazetidine-1-carboxylate (0.157 g, 0.915 mmol), acetic acid (0.065 mL, 1.144 mmol) and sodium triacetoxyborohydride (0.323 g, 1.526 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give tert-butyl 3-(4-(2-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)ethyl)piperazin-1-yl)azetidine-1-carboxylate as white solid (0.350 g, 71.3%).


[Step 2] methyl 4-(((2-(4-(azetidin-3-yl)piperazin-1-yl)-N-(3-chloro-4-fluorophenyl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride



embedded image


A solution of tert-butyl 3-(4-(2-(N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(methoxycarbonyl)benzyl)sulfamoyl)ethyl)piperazin-1-yl)azetidine-1-carboxylate (0.350 g, 0.544 mmol) and hydrogen chloride (4.00 M solution in 1,4-dioxane, 0.272 mL, 1.088 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 12 hr. The precipitates were collected by filtration, washed by dichloromethane, and dried to give methyl 4-(((2-(4-(azetidin-3-yl)piperazin-1-yl)-N-(3-chloro-4-fluorophenyl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride as white solid (0.300 g, 95.1%).


[Step 3] methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(1-(methylsulfonyl)azetidin-3-yl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 4-(((2-(4-(azetidin-3-yl)piperazin-1-yl)-N-(3-chloro-4-fluorophenyl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride (0.100 g, 0.173 mmol), triethylamine (0.036 mL, 0.259 mmol) and methanesulfonyl chloride (0.016 mL, 0.207 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(1-(methylsulfonyl)azetidin-3-yl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate as white solid (0.083 g, 77.4%).


[Step 4] N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(1-(methylsulfonyl)azetidin-3-yl)piperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(1-(methylsulfonyl)azetidin-3-yl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate (0.100 g, 0.161 mmol) and hydrazine monohydrate (0.078 mL, 1.610 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, and cooled down to the room temperature to terminate the reaction, and concentrated under the reduced pressure to remove the solvent. The concentrate was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(1-(methylsulfonyl)azetidin-3-yl)piperazin-1-yl)ethane-1-sulfonamide as white solid (0.083 g, 83.0%).


[Step 5] Compound 11582



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(1-(methylsulfonyl)azetidin-3-yl)piperazin-1-yl)ethane-1-sulfonamide (0.070 g, 0.113 mmol), triethylamine (0.079 mL, 0.563 mmol) and 2,2-difluoroacetic anhydride (0.042 mL, 0.338 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reactionThen, aqueous 1.0 N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(4-(1-(methylsulfonyl)azetidin-3-yl)piperazin-1-yl)ethane-1-sulfonamide as white solid (0.041 g, 53.4%).



1H NMR (400 MHz, CDCl3) δ 7.90 (dd, 1H, J=8.0, 1.6 Hz), 7.76 (dd, 1H, J=9.8, 1.6 Hz), 7.64 (t, 1H, J=7.6 Hz), 7.47 (dd, 1H, J=6.4, 2.6 Hz), 7.28-7.20 (m, 1H), 7.11 (t, 1H, J=8.6 Hz), 7.08-6.77 (m, 1H), 5.02 (s, 2H), 3.99-3.84 (m, 4H), 3.35-3.30 (m, 2H), 3.31-3.20 (m, 1H), 2.97 (t, 2H, J=7.1 Hz), 2.91 (s, 3H), 2.63 (s, 4H), 2.50 (s, 4H); LRMS (ES) m/z 681.52(M++1).


EXAMPLE 160
Compound 11583, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)ethane-1-sulfonamide
[Step 1] methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate hydrochloride (0.200 g, 0.381 mmol), oxetan-3-one (0.036 g, 0.496 mmol) and acetic acid (0.024 mL, 0.420 mmol) in dichloromethane (10 mL) was mixed at the room temperature with sodium triacetoxyborohydride (0.162 g, 0.763 mmol). The reaction mixture was stirred at the same temperature for 30 min. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate as yellow solid (0.150 g, 72.3%).


[Step 2] N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-(3-chloro-4-fluorophenyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)ethyl)sulfonamido)methyl)-3-fluorobenzoate (0.150 g, 0.276 mmol) and hydrazine monohydrate (0.134 mL, 2.757 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)ethane-1-sulfonamide as white solid (0.120 g, 80.0%).


[Step 3] Compound 11583



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)ethane-1-sulfonamide (0.070 g, 0.129 mmol), triethylamine (0.090 mL, 0.643 mmol) and 2,2-difluoroacetic anhydride (0.048 mL, 0.386 mmol) in tetrahydrofuran (10 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction Then, aqueous 1.0 N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-2-(4-(oxetan-3-yl)piperazin-1-yl)ethane-1-sulfonamide as white solid (0.040 g, 51.5%).



1H NMR (400 MHz, CDCl3) δ 7.91 (dd, 1H, J=8.1, 1.7 Hz), 7.77 (dd, 1H, J=9.9, 1.7 Hz), 7.65 (t, 1H, J=7.6 Hz), 7.48 (dd, 1H, J=6.4, 2.7 Hz), 7.27-7.21 (m, 1H), 7.11 (t, 1H, J=8.6 Hz), 7.07-6.77 (m, 1H), 5.02 (s, 2H), 4.68 (dt, 4H, J=22.2, 6.4 Hz), 3.64-3.53 (m, 1H), 3.34 (s, 2H), 2.99 (t, 2H, J=7.0 Hz), 2.68 (s, 4H), 2.50 (s, 4H); LRMS (ES) m/z 604.45 (M++1).


EXAMPLE 161
Compound 11588, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-3-morpholino-N-phenylpropane-1-sulfonamide
[Step 1] 3-chloro-N-phenylpropane-1-sulfonamide



embedded image


A solution of aniline (0.980 mL, 10.738 mmol), triethylamine (1.796 mL, 12.885 mmol) and 3-chloropropane-1-sulfonyl chloride (2.091 g, 11.811 mmol) in dichloromethane (30 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 5%) to give 3-chloro-N-phenylpropane-1-sulfonamide as yellow oil (2.000 g, 79.7%).


[Step 2] methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)-3-fluorobenzoate



embedded image


A solution of 3-chloro-N-phenylpropane-1-sulfonamide (2.000 g, 8.558 mmol), potassium carbonate (1.774 g, 12.836 mmol), methyl 4-(bromomethyl)-3-fluorobenzoate (2.326 g, 9.413 mmol) and potassium iodide (0.710 g, 4.279 mmol) in N,N-dimethylformide (5 mL) was stirred at the room temperature for 30 min and for additional 12 hr at 50° C., then, cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ammonium chloride. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)-3-fluorobenzoate as yellow oil (2.800 g, 81.8%).


[Step 3] methyl 3-fluoro-4-(((3-morpholino-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)-3-fluorobenzoate (0.200 g, 0.500 mmol), potassium iodide (0.042 g, 0.250 mmol), potassium carbonate (0.104 g, 0.750 mmol) and morpholine (0.056 mL, 0.650 mmol) in N,N-dimethylformide (10 mL) was stirred at 50° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, aqueous 1.0 N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 3-fluoro-4-(((3-morpholino-N-phenylpropyl)sulfonamido)methyl)benzoate as yellow oil (0.110 g, 48.8%).


[Step 4] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-3-morpholino-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl 3-fluoro-4-(((3-morpholino-N-phenylpropyl)sulfonamido)methyl)benzoate (0.100 g, 0.222 mmol) and hydrazine monohydrate (0.108 mL, 2.220 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (5 mL) and aqueous saturated sodium bicarbonate solution (3 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-3-morpholino-N-phenylpropane-1-sulfonamide as white solid (0.089 g, 89.0%).


[Step 5] Compound 11588



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-3-morpholino-N-phenylpropane-1-sulfonamide (0.089 g, 0.198 mmol), triethyl amine (0.138 mL, 0.988 mmol) and 2,2-difluoroacetic anhydride (0.074 mL, 0.593 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 18 hr Then, aqueous 1.0 N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-3-morpholino-N-phenylpropane-1-sulfonamide as yellow oil (0.040 g, 39.7%).



1H NMR (400 MHz, CDCl3) δ 7.85 (dd, 1H, J=8.0, 1.7 Hz), 7.73 (dd, 1H, J=9.9, 1.6 Hz), 7.59 (t, 1H, J=7.6 Hz), 7.41-7.27 (m, 5H), 7.07-6.75 (m, 1H), 5.04 (s, 2H), 4.01 (t, 4H, J=4.8 Hz), 3.31 (t, 4H, J=6.9 Hz), 3.21 (t, 4H, J=7.8 Hz), 2.51-2.31 (m, 2H); LRMS (ES) m/z 511.40 (M++1).


EXAMPLE 162
Compound 11589, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide
[Step 1] methyl 3-fluoro-4-(((3-(4-methylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)-3-fluorobenzoate (0.200 g, 0.500 mmol), potassium iodide (0.042 g, 0.250 mmol), potassium carbonate (0.104 g, 0.750 mmol) and 1-methylpiperazine (0.072 mL, 0.650 mmol) in N,N-dimethylformide (10 mL) was stirred at 50° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, aqueous 1.0 N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl methyl 3-fluoro-4-(((3-(4-methylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as yellow oil (0.160 g, 71.2%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl 3-fluoro-4-(((3-(4-methylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.088 g, 0.190 mmol) and hydrazine monohydrate (0.092 mL, 1.898 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (5 mL) and sodium bicarbonate (2 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide as white solid (0.070 g, 79.5%).


[Step 3] Compound 11589



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide (0.070 g, 0.151 mmol), triethylamine (0.105 mL, 0.755 mmol) and 2,2-difluoroacetic anhydride (0.079 g, 0.453 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 5 hr and cooled down to the room temperature to terminate the reaction Then, aqueous 1.0 N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide as white solid (0.031 g, 39.2%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.1, 1.6 Hz), 7.74 (dd, 1H, J=9.9, 1.6 Hz), 7.63 (t, 1H, J=7.6 Hz), 7.42-7.27 (m, 5H), 7.08-6.76 (m, 1H), 5.06 (s, 2H), 3.28-3.19 (m, 4H), 3.07-3.02 (m, 4H), 2.80-2.72 (m, 5H), 2.21-2.08 (m, 4H); LRMS (ES) m/z 524.44 (M++1).


EXAMPLE 163
Compound 11605, N-((2-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-5-yl)methyl)-N-phenylmethanesulfonamide
[Step 1] methyl 5-(bromomethyl)pyrimidine-2-carboxylate



embedded image


A mixture of methyl 5-methylpyrimidine-2-carboxylate (0.500 g, 3.286 mmol), 1-bromopyrrolidine-2,5-dione (NBS, 0.643 g, 3.615 mmol) and Azobisisobutyronitrile (AIBN, 0.216 g, 1.314 mmol) in carbon tetrachloride (4 mL) prepared at the room temperature was heated at reflux for 10 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 5-(bromomethyl)pyrimidine-2-carboxylate as white solid (0.380 g, 50.0%).


[Step 2] methyl 5-((N-phenylmethylsulfonamido)methyl)pyrimidine-2-carboxylate



embedded image


A solution of methyl 5-(bromomethyl)pyrimidine-2-carboxylate (0.270 g, 1.168 mmol) and potassium iodide (0.019 g, 0.117 mmol) in N,N-dimethylformide (5 mL) was stirred at the room temperature for 20 min, and mixed with N-phenylmethanesulfonamide (0.200 g, 1.168 mmol) and potassium carbonate (0.194 g, 1.402 mmol). The reaction mixture was stirred at the same temperature for additional 8 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give methyl 5-((N-phenylmethylsulfonamido)methyl)pyrimidine-2-carboxylate as light yellow solid (0.220 g, 58.6%).


[Step 3] N-((2-(hydrazinecarbonyl)pyrimidin-5-yl)methyl)-N-phenylmethanesulfonamide



embedded image


A mixture of methyl 5-((N-phenylmethylsulfonamido)methyl)pyrimidine-2-carboxylate (0.220 g, 0.685 mmol) and hydrazine monohydrate (0.166 mL, 3.423 mmol) in ethanol (4 mL) prepared at the room temperature was heated at reflux for 5 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. Then, saturated aqueous sodium bicarbonate solution was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((2-(hydrazinecarbonyl)pyrimidin-5-yl)methyl)-N-phenylmethanesulfonamide, 0.190 g, 86.4%, white solid).


[Step 4] Compound 11605



embedded image


A solution of N-((2-(hydrazinecarbonyl)pyrimidin-5-yl)methyl)-N-phenylmethanesulfonamide (0.045 g, 0.140 mmol) and triethylamine (0.059 mL, 0.420 mmol) in tetrahydrofuran (1.5 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.038 mL, 0.308 mmol), stirred at 60° C. for 2 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-((2-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-5-yl)methyl)-N-phenylmethanesulfonamide as white solid (0.040 g, 74.9%).



1H NMR (400 MHz, CDCl3) δ 8.87 (s, 2H), 7.41-7.34 (m, 3H), 7.31 (d, 2H, J=9.8 Hz), 7.07 (s, 0.25H), 6.94 (s, 0.5H), 6.81 (s, 0.25H), 5.00 (s, 2H), 3.01 (s, 3H); LRMS (ES) m/z 382.34 (M++1).


EXAMPLE 164
Compound 11606, N-phenyl-N-((2-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-5-yl)methyl)methanesulfonamide



embedded image


A solution of N-((2-(hydrazinecarbonyl)pyrimidin-5-yl)methyl)-N-phenylmethanesulfonamide (0.030 g, 0.093 mmol) and triethylamine (0.039 mL, 0.280 mmol) in tetrahydrofuran (1.5 mL) was mixed at the room temperature with trifluoroacetic anhydride (0.029 mL, 0.205 mmol), stirred at 60° C. for 2 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-phenyl-N-((2-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-5-yl)methyl)methanesulfonamide as white solid (0.028 g, 75.1%).



1H NMR (400 MHz, CDCl3) δ 8.89 (s, 2H), 7.42-7.28 (m, 5H), 5.00 (s, 2H), 3.01 (s, 3H); LRMS (ES) m/z 400.38 (M++1).


EXAMPLE 165
Compound 11625, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(oxetan-3-yl)-N-phenylpiperidine-4-sulfonamide
[Step 1] methyl 3-fluoro-4-(((1-(oxetan-3-yl)-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate



embedded image


A solution of methyl 3-fluoro-4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride (0.100 g, 0.226 mmol), oxetan-3-one (0.020 g, 0.271 mmol) and acetic acid (0.014 mL, 0.248 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 30 min, and mixed with sodium triacetoxyborohydride (0.096 g, 0.452 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 60%) to give methyl 3-fluoro-4-(((1-(oxetan-3-yl)-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate as white solid (0.090 g, 86.2%).


[Step 2] N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-(oxetan-3-yl)-N-phenylpiperidine-4-sulfonamide



embedded image


A solution of methyl 3-fluoro-4-(((1-(oxetan-3-yl)-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate (0.100 g, 0.216 mmol) and hydrazine monohydrate (0.105 mL, 2.162 mmol) in ethanol (10 mL) was stirred at the room temperature for 18 hr, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-(oxetan-3-yl)-N-phenylpiperidine-4-sulfonamide as white solid (0.089 g, 89.0%).


[Step 3] compound 11625



embedded image


A solution of N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)-1-(oxetan-3-yl)-N-phenylpiperidine-4-sulfonamide (0.050 g, 0.108 mmol), triethylamine (0.075 mL, 0.540 mmol) and 2,2-difluoroacetic anhydride (0.040 mL, 0.324 mmol) in tetrahydrofuran (10 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 70%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-(oxetan-3-yl)-N-phenylpiperidine-4-sulfonamide as white solid (0.023 g, 40.7%).



1H NMR (400 MHz, CDCl3) δ 7.87 (dd, 1H, J=8.1, 1.6 Hz), 7.73 (dd, 1H, J=9.9, 1.6 Hz), 7.60 (t, 1H, J=7.6 Hz), 7.41-7.27 (m, 5H), 7.10-6.75 (m, 1H), 5.07 (s, 2H), 4.98-4.91 (m, 2H), 4.74 (t, 2H, J=7.2 Hz), 3.93 (s, 1H), 3.37-3.16 (m, 3H), 2.65-2.60 (m, 2H), 2.48-2.43 (m, 2H), 2.40-2.31 (m, 2H); LRMS (ES) m/z 523.38 (M++1).


EXAMPLE 166
Compound 11628, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)methanesulfonamide
[Step 1] methyl 4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate



embedded image


N-(pyridin-3-yl)methanesulfonamide (1.000 g, 5.807 mmol), methyl 4-(bromomethyl)benzoate (1.995 g, 8.711 mmol), potassium carbonate (1.204 g, 8.711 mmol) and potassium iodide (0.096 g, 0.581 mmol) were mixed at the room temperature in N,N-dimethylformide (20 mL), stirred at 50° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 80%) to give methyl 4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate as red solid (1.510 g, 81.2%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide



embedded image


Methyl 4-((N-(pyridin-3-yl)methylsulfonamido)methyl)benzoate (1.500 g, 4.682 mmol) and hydrazine monohydrate (5.689 mL, 117.056 mmol) were mixed at the room temperature in ethanol (20 mL)/water (5 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide, 1.120 g, 74.7%, yellow solid).


[Step 3] Compound 11628



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-(pyridin-3-yl)methanesulfonamide (0.200 g, 0.624 mmol) and triethylamine (0.261 mL, 1.873 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.233 mL, 1.873 mmol), stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2 plate, 20×20×1 mm; methanol/dichloromethane=10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)methanesulfonamide as white solid (0.023 g, 9.7%).



1H NMR (400 MHz, DMSO-d6) δ 8.57 (d, 1H, J=2.4 Hz), 8.43 (dd, J=4.8, 1.1 Hz, 1H), 7.98 (d, 2H, J=8.2 Hz), 7.90 (d, 1H, J=8.2 Hz), 7.65-7.38 (m, 4H), 5.03 (s, 2H), 3.20 (s, 3H); LRMS (ES) m/z 380.9 (M++1).


EXAMPLE 167
Compound 11629, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(piperidin-1-yl)ethane-1-sulfonamide
[Step 1] N-phenylethenesulfonamide



embedded image


A solution of aniline (0.980 mL, 10.738 mmol), 2-chloroethane-1-sulfonyl chloride (1.233 mL, 11.811 mmol) and pyridine (1.730 mL, 21.475 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 20%) to give N-phenylethenesulfonamide as yellow oil (0.945 g, 48.0%).


[Step 2] methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate



embedded image


A solution of N-phenylethenesulfonamide (0.945 g, 5.157 mmol), methyl 4-(bromomethyl)benzoate (1.300 g, 5.673 mmol), potassium iodide (0.428 g, 2.579 mmol) and potassium carbonate (1.069 g, 7.736 mmol) in N,N-dimethylformide (50 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 20%) to give methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate as light green solid (1.500 g, 87.8%).


[Step 3] methyl 4-(((N-phenyl-2-(piperidin-1-yl)ethyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.300 g, 0.905 mmol), piperdine (0.179 mL, 1.811 mmol) and N,N-Diisopropylethylamine (0.189 mL, 1.086 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=20% to 80%) to give methyl 4-(((N-phenyl-2-(piperidin-1-yl)ethyl)sulfonamido)methyl)benzoate as white solid (0.334 g, 88.7%).


[Step 4] N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-(piperidin-1-yl)ethane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-phenyl-2-(piperidin-1-yl)ethyl)sulfonamido)methyl)benzoate (0.334 g, 0.803 mmol) and hydrazine hydrate (0.402 g, 8.028 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (10 mL) and water (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-(piperidin-1-yl)ethane-1-sulfonamide as white solid (0.273 g, 81.7%).


[Step 5] Compound 11629



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-(piperidin-1-yl)ethane-1-sulfonamide (0.100 g, 0.240 mmol), triethylamine (0.167 mL, 1.200 mmol) and 2,2-difluoroacetic anhydride (0.090 mL, 0.720 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(piperidin-1-yl)ethane-1-sulfonamide as white solid (0.035 g, 30.8%).



1H NMR (400 MHz, CDCl3) δ8.02 (d, 2H, J=8.4 Hz), 7.46 (d, 2H, J=8.4 Hz), 7.47˜7.28 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 5.00 (s, 2H), 3.58˜3.56 (m, 2H), 3.06 (t, 2H, J=7.1 Hz), 2.70 (brs, 4H), 1.79 (brs, 4H), 1.55 (brs, 2H); LRMS (ES) m/z 477.3 (M++1).


EXAMPLE 168
Compound 11630, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-methylpiperazin-1-yl)-N-phenylethane-1-sulfonamide
[Step 1] methyl 4-(((2-(4-methylpiperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.300 g, 0.905 mmol), 1-methylpiperazine (0.202 mL, 1.811 mmol) and N,N-Diisopropylethylamine (0.189 mL, 1.086 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=20% to 80%) to give methyl 4-(((2-(4-methylpiperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate as white solid (0.362 g, 92.7%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperazin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of methyl 4-(((2-(4-methylpiperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate (0.362 g, 0.840 mmol) and hydrazine hydrate (0.420 g, 8.395 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (10 mL) and water (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperazin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.237 g, 65.5%).


[Step 3] Compound 11630



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperazin-1-yl)-N-phenylethane-1-sulfonamide (0.100 g, 0.232 mmol), triethylamine (0.161 mL, 1.159 mmol) and 2,2-difluoroacetic anhydride (0.086 mL, 0.695 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-methylpiperazin-1-yl)-N-phenylethane-1-sulfonamide as colorless oil (0.033 g, 28.7%).



1H NMR (400 MHz, CDCl3) δ8.04 (d, 2H, J=8.4 Hz), 7.47 (d, 2H, J=8.6 Hz), 7.36˜7.30 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.29 (dd, 2H, J=8.3, 6.2 Hz), 3.01 (dd, 2H, J=8.2, 6.3 Hz), 2.79 (brs, 8H), 2.57 (s, 3H); LRMS (ES) m/z 492.3 (M++1).


EXAMPLE 169
Compound 11631, tert-butyl 4-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate
[Step 1] tert-butyl 4-(2-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.300 g, 0.905 mmol), tert-butyl piperazine-1-carboxylate (0.337 g, 1.811 mmol) and N,N-Diisopropylethylamine (0.189 mL, 1.086 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=20% to 80%) to give tert-butyl 4-(2-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate as white solid (0.411 g, 87.7%).


[Step 2] tert-butyl 4-(2-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate



embedded image


A solution of tert-butyl 4-(2-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate (0.411 g, 0.794 mmol) and hydrazine hydrate (0.397 g, 7.936 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (10 mL) and water (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give tert-butyl 4-(2-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate as white solid (0.344 g, 83.8%).


[Step 3] Compound 11631



embedded image


A solution of tert-butyl 4-(2-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate (0.240 g, 0.464 mmol), triethylamine (0.323 mL, 2.318 mmol) and 2,2-difluoroacetic anhydride (0.173 mL, 1.391 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give tert-butyl 4-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate as yellow oil (0.199 g, 74.3%).



1H NMR (400 MHz, CDCl3) δ8.03 (d, 2H, J=8.5 Hz), 7.46 (d, 2H, J=8.6 Hz), 7.37˜7.28 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 3.54 (brs, 4H), 3.41 (brs, 2H), 3.00 (t, 2H, J=7.3 Hz), 2.56 (brs, 4H), 1.48 (s, 9H); LRMS (ES) m/z 578.3 (M++1).


EXAMPLE 170
Compound 11632, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide
[Step 1] methyl 4-(((2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.300 g, 0.905 mmol), (2S,6R)-2,6-dimethylpiperazine (0.207 g, 1.811 mmol) and N,N-Diisopropylethylamine (0.189 mL, 1.086 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give methyl 4-(((2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate as white solid (0.403 g, 99.9%).


[Step 2] 2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of methyl 4-(((2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate (0.403 g, 0.904 mmol) and hydrazine hydrate (0.453 g, 9.042 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (10 mL) and water (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give 2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylethane-1-sulfonamide as yellow solid (0.263 g, 65.3%).


[Step 3] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of 2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylethane-1-sulfonamide (0.100 g, 0.224 mmol), triethylamine (0.156 mL, 1.122 mmol) and 2,2-difluoroacetic anhydride (0.084 mL, 0.673 mmol) in tetrahydrofuran (5 mL) was stirred at 90° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide, 0.125 g, 106.4%, yellow oil).


[Step 4] Compound 11632



embedded image


A mixture of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide (0.125 g, 0.239 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.171 g, 0.716 mmol) in tetrahydrofuran (2 mL) was heated at 150° C. for 0.5 hr under the microwaves, cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide as yellow solid (0.015 g, 12.0%).



1H NMR (400 MHz, CDCl3+CD3OD) δ7.99˜7.97 (m, 2H), 7.42 (d, 2H, J=8.1 Hz), 7.31˜7.28 (m, 5H), 6.88 (t, 1H, J=51.9 Hz), 4.93 (s, 2H), 3.39˜3.36 (m, 4H), 3.12˜2.96 (m, 4H), 2.74˜2.46 (m, 4H), 1.37 (s, 6H). ; LRMS (ES) m/z 506.4 (M++1).


EXAMPLE 171
Compound 11633, 2-(4-acetylpiperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide
[Step 1] N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(piperazin-1-yl)ethane-1-sulfonamide hydrochloride



embedded image


A solution of tert-butyl 4-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)piperazine-1-carboxylate (0.150 g, 0.290 mmol) and hydrogen chloride (4.00 M solution in 1,4-dioxane, 0.362 mL, 1.449 mmol) in 1,4-dioxane (5 mL) was stirred at the room temperature for 2 hr, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with diethylether (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by diethylether, and dried to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(piperazin-1-yl)ethane-1-sulfonamide hydrochloride as white solid (0.146 g, 98.0%).


[Step 2] Compound 11633



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(piperazin-1-yl)ethane-1-sulfonamide hydrochloride (0.050 g, 0.097 mmol), acetic anhydride (0.014 mL, 0.146 mmol) and triethylamine (0.041 mL, 0.292 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=30% to 100%) to give 2-(4-acetylpiperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.033 g, 65.3%).



1H NMR (400 MHz, CDCl3) δ8.04 (d, 2H, J=8.1 Hz), 7.46 (d, 2H, J=8.2 Hz), 7.37˜7.31 (m, 5H), 6.92 (t, 1H, J=51.8 Hz), 4.99 (s, 2H), 3.75˜3.70 (m, 4H), 3.63˜3.49 (m, 2H), 3.10˜3.05 (m, 2H), 2.72˜2.50 (m, 4H), 2.12 (s, 3H); LRMS (ES) m/z 520.3 (M++1).


EXAMPLE 172
Compound 11634, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(piperazin-1-yl)ethane-1-sulfonamide hydrochloride (0.050 g, 0.097 mmol), methanesulfonyl chloride (0.011 mL, 0.146 mmol) and triethylamine (0.041 mL, 0.292 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=30% to 80%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.041 g, 75.3%).



1H NMR (400 MHz, CDCl3) δ8.4 Hz, 2H), 7.46 (d, 2H, J=8.5 Hz), 7.38˜7.29 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 3.40˜3.37 (m, 6H), 3.06˜3.05 (m, 2H), 2.83 (s, 3H), 2.74 (brs, 4H); LRMS (ES) m/z 556.3 (M++1).


EXAMPLE 173
Compound 11636, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide
[Step 1] methyl 4-((N-(pyrimidin-5-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(pyrimidin-5-yl)methanesulfonamide (0.300 g, 1.732 mmol) and potassium carbonate (0.359 g, 2.598 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 30 min, and mixed with methyl 4-(bromomethyl)benzoate (0.436 g, 1.905 mmol) and potassium iodide (0.144 g, 0.866 mmol). The reaction mixture was stirred at 50° C. for additional 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-((N-(pyrimidin-5-yl)methylsulfonamido)methyl)benzoate as white solid (0.350 g, 62.9%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(pyrimidin-5-yl)methylsulfonamido)methyl)benzoate (0.350 g, 1.089 mmol) and hydrazine monohydrate (0.529 mL, 10.892 mmol) in ethanol (20 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (10 mL) and sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide as white solid (0.290 g, 82.9%).


[Step 3] Compound 11636



embedded image


A mixture of N-(4-(hydrazinecarbonyl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide (0.100 g, 0.311 mmol), triethylamine (0.217 mL, 1.556 mmol) and 2,2-difluoroacetic anhydride (0.116 mL, 0.934 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 60%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyrimidin-5-yl)methanesulfonamide as white solid (0.073 g, 61.5%).



1H NMR (400 MHz, MeOD) δ 9.00 (s, 1H), 8.86 (s, 2H), 8.08 (d, 2H, J=6.6 Hz), 7.62 (d, 2H, J=8.4 Hz), 7.34 (s, 0.3H), 7.21 (s, 0.5H), 7.08 (s, 0.3H), 5.14 (s, 2H), 3.20 (s, 3H); LRMS (ES) m/z 382.2 (M++1).


EXAMPLE 174
Compound 11637, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide
[Step 1] tert-butyl 4-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate



embedded image


tert-butyl 4-(N-phenylsulfamoyl)piperidine-1-carboxylate (0.600 g, 1.763 mmol), methyl 4-(bromomethyl)benzoate (0.606 g, 2.644 mmol), potassium carbonate (0.487 g, 3.526 mmol) and potassium iodide (0.029 g, 0.176 mmol) were mixed at the room temperature in N,N-dimethylformide (15 mL), stirred at 50° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give tert-butyl 4-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate as white solid (0.855 g, 99.3%).


[Step 2] methyl 4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride



embedded image


A solution of tert-butyl 4-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate (0.855 g, 1.750 mmol) in dichloromethane (15 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution, 1.750 mL, 7.000 mmol). The reaction mixture was stirred at the same temperature for 18 hr, and concentrated under the reduced pressure to remove the solvent. The precipitates were collected by filtration, washed by dichloromethane, and dried to give methyl 4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride as white solid (0.558 g, 75.0%).


[Step 3] methyl 4-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride (0.100 g, 0.235 mmol) and paraformaldehyde (0.011 g, 0.353 mmol) in dichloromethane (10 mL) was mixed at the room temperature with sodium triacetoxyborohydride (0.100 g, 0.471 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 15%) to give methyl 4-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate as white solid (0.067 g, 70.7%).


[Step 4] N-(4-(hydrazinecarbonyl)benzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide



embedded image


Methyl 4-(((1-methyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate (0.067 g, 0.166 mmol) and hydrazine monohydrate (0.243 mL, 4.994 mmol) were mixed at the room temperature in ethanol (16 mL)/water (4 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)benzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide, 0.050 g, 74.6%, white solid).


[Step 5] Compound 11637



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide (0.050 g, 0.124 mmol) and triethylamine (0.035 mL, 0.248 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.046 mL, 0.373 mmol), stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 15%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-methyl-N-phenylpiperidine-4-sulfonamide as white solid (0.017 g, 29.6%).



1H NMR (400 MHz, CDCl3) δ 8.00 (d, 2H, J=8.4 Hz), 7.42 (d, 2H, J=8.4 Hz), 7.42-7.23 (m, 5H), 7.01 (s, 0.25H), 6.88 (s, 0.5H), 6.75 (s, 0.25H), 4.98 (s, 2H), 3.20-3.0 (m, 3H), 2.51-2.38 (m, 3H), 2.38-2.10 (m, 6H); LRMS (ES) m/z 463.3 (M++1).


EXAMPLE 175
Compound 11638, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-isopropyl-N-phenylpiperidine-4-sulfonamide
[Step 1] Methyl 4-(((1-isopropyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride (0.100 g, 0.235 mmol) and propan-2-one (0.021 mL, 0.282 mmol) in dichloromethane (10 mL) was mixed at the room temperature with sodium triacetoxyborohydride (0.100 g, 0.471 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 15%) to give methyl 4-(((1-isopropyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate as white solid (0.078 g, 77.0%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-1-isopropyl-N-phenylpiperidine-4-sulfonamide



embedded image


Methyl 4-(((1-isopropyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate (0.078 g, 0.181 mmol) and hydrazine monohydrate (0.264 mL, 5.435 mmol) were mixed at the room temperature in ethanol (16 mL)/water (4 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)benzyl)-1-isopropyl-N-phenylpiperidine-4-sulfonamide, 0.061 g, 78.2%, white solid).


[Step 3] Compound 11638



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-1-isopropyl-N-phenylpiperidine-4-sulfonamide (0.061 g, 0.142 mmol) and triethylamine (0.039 mL, 0.283 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.053 mL, 0.425 mmol), stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-isopropyl-N-phenylpiperidine-4-sulfonamide as white solid (0.044 g, 63.3%).



1H NMR (400 MHz, CDCl3) δ 8.00 (d, 2H, J=8.2 Hz), 7.42 (d, 2H, J=8.2 Hz), 7.30-7.24 (m, 5H), 7.01 (s, 0.25H), 6.88 (s, 0.5H), 6.75 (s, 0.25H), 4.99 (s, 2H), 3.45-2.88 (m, 4H), 2.65-1.82 (m, 6H), 1.53-0.89 (m, 6H); LRMS (ES) m/z 491.3 (M++1).


EXAMPLE 176
Compound 11639, 1-cyclobutyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperidine-4-sulfonamide
[Step 1] methyl 4-(((1-cyclobutyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylpiperidine-4-sulfonamido)methyl)benzoate hydrochloride (0.100 g, 0.235 mmol) and cyclobutanone (0.021 mL, 0.282 mmol) in dichloromethane (10 mL) was mixed at the room temperature with sodium triacetoxyborohydride (0.100 g, 0.471 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 15%) to give methyl 4-(((1-cyclobutyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate as white solid (0.084 g, 80.7%).


[Step 2] 1-cyclobutyl-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpiperidine-4-sulfonamide



embedded image


Methyl 4-(((1-cyclobutyl-N-phenylpiperidine)-4-sulfonamido)methyl)benzoate (0.084 g, 0.190 mmol) and hydrazine monohydrate (0.277 mL, 5.694 mmol) were mixed at the room temperature in ethanol (16 mL)/water (4 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (1-cyclobutyl-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpiperidine-4-sulfonamide, 0.078 g, 92.9%, white solid).


[Step 3] Compound 11639



embedded image


A solution of 1-cyclobutyl-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpiperidine-4-sulfonamide (0.078 g, 0.176 mmol) and triethylamine (0.049 mL, 0.352 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.066 mL, 0.529 mmol), stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 15%) to give 1-cyclobutyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperidine-4-sulfonamide as white solid (0.058 g, 65.5%).



1H NMR (400 MHz, CDCl3) δ 7.99 (d, 2H, J=8.4 Hz), 7.42 (d, 2H, J=8.4 Hz), 7.32-7.21 (m, 5H), 7.01 (s, 0.25H), 6.88 (s, 0.5H), 6.75 (s, 0.25H), 4.97 (s, 2H), 3.18-2.91 (m, 3H), 2.83-2.62 (m, 2H), 2.25-1.85 (m, 8H), 1.85-1.60 (m, 4H); LRMS (ES) m/z 503.2 (M++1).


EXAMPLE 177
Compound 11645, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(pyrrolidin-1-yl)ethane-1-sulfonamide
[Step 1] methyl 4-(((N-phenyl-2-(pyrrolidin-1-yl)ethyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.200 g, 0.604 mmol), pyrrolidine (0.086 g, 1.207 mmol) and N,N-Diisopropylethylamine (0.126 mL, 0.724 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=20% to 80%) to give methyl 4-(((N-phenyl-2-(pyrrolidin-1-yl)ethyl)sulfonamido)methyl)benzoate as white solid (0.173 g, 71.1%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-(pyrrolidin-1-yl)ethane-1-sulfonamide as white solid



embedded image


A solution of methyl 4-(((N-phenyl-2-(pyrrolidin-1-yl)ethyl)sulfonamido)methyl)benzoate (0.173 g, 0.429 mmol) and hydrazine hydrate (0.215 g, 4.288 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with aqueous saturated sodium bicarbonate solution (10 mL) and water (5 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-(pyrrolidin-1-yl)ethane-1-sulfonamide as white solid (0.173 g, 99.9%).


[Step 3] Compound 11645



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-(pyrrolidin-1-yl)ethane-1-sulfonamide (0.650 g, 1.615 mmol), triethylamine (1.125 mL, 8.074 mmol) and 2,2-difluoroacetic anhydride (0.602 mL, 4.845 mmol) in tetrahydrofuran (2 mL) was stirred at 90° C. for 0.5 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the concentrate, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(pyrrolidin-1-yl)ethane-1-sulfonamide as white solid (0.020 g, 2.7%).



1H NMR (400 MHz, CDCl3) δ8.03 (d, 2H, J=8.3 Hz), 7.47 (d, 2H, J=8.2 Hz), 7.35˜7.28 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.99 (s, 2H), 3.51 (brs, 2H), 3.15 (t, 2H, J=7.4 Hz), 2.78 (brs, 4H), 1.94 (brs, 4H); LRMS (ES) m/z 463.3 (M++1).


EXAMPLE 178
Compound 11646, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethane-1-sulfonamide
[Step 1] methyl 4-(((N-phenyl-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((2-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate (0.500 g, 1.122 mmol) and formaldehyde (0.413 mL, 11.221 mmol) in acetonitrile (5 mL) was mixed at the room temperature with sodium triacetoxyborohydride (1.189 g, 5.611 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((N-phenyl-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethyl)sulfonamido)methyl)benzoate as white solid (0.309 g, 59.9%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-phenyl-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethyl)sulfonamido)methyl)benzoate (0.160 g, 0.348 mmol) and hydrazine hydrate (0.174 g, 3.481 mmol) in ethanol (3 mL) was stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (20 mL) and water (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethane-1-sulfonamide as white solid (0.078 g, 48.8%).


[Step 3] Compound 11646



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethane-1-sulfonamide (0.078 g, 0.170 mmol), triethylamine (0.118 mL, 0.849 mmol) and 2,2-difluoroacetic anhydride (0.063 mL, 0.509 mmol) in tetrahydrofuran (3 mL) was stirred at 90° C. for 1 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, aqueous N-sodium bicarbonate solution was added to the concentrate, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethane-1-sulfonamide as yellow oil (0.068 g, 76.7%).



1H NMR (400 MHz, CDCl3) δ8.04 (d, 2H, J=8.4 Hz), 7.47 (d, 2H, J=8.4 Hz), 7.38˜7.29 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.32 (t, 2H, J=7.0 Hz), 3.14 (brs, 2H), 3.06 (t, 2H, J=7.0 Hz), 2.88˜2.85 (m, 4H), 2.80 (s, 3H), 1.47 (d, 6H, J=5.8 Hz); LRMS (ES) m/z 520.3 (M++1).


EXAMPLE 179
Compound 11647, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide
[Step 1] 3-chloro-N-phenylpropane-1-sulfonamide



embedded image


A solution of aniline (1.961 mL, 21.475 mmol), 3-chloropropane-1-sulfonyl chloride (2.865 mL, 23.623 mmol) and pyridine (3.460 mL, 42.951 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, aqueous N-hydrochloric acid solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 30%) to give 3-chloro-N-phenylpropane-1-sulfonamide as yellow oil (3.160 g, 63.0%).


[Step 2] methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of 3-chloro-N-phenylpropane-1-sulfonamide (3.160 g, 13.521 mmol), methyl 4-(bromomethyl)benzoate (3.407 g, 14.873 mmol), potassium iodide (1.122 g, 6.761 mmol) and potassium carbonate (2.803 g, 20.282 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 80 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate as yellow solid (3.200 g, 62.0%).


[Step 3] methyl 4-(((N-phenyl-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.500 g, 1.309 mmol), pyrrolidine (0.186 g, 2.619 mmol) and N,N-Diisopropylethylamine (0.274 mL, 1.571 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 18 hr and then for additional 2 hr at 90° C., and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give methyl 4-(((N-phenyl-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)benzoate as ivory solid (0.340 g, 62.3%).


[Step 4] N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-phenyl-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)benzoate (0.200 g, 0.480 mmol) and hydrazine hydrate (0.240 g, 4.801 mmol) in ethanol (3 mL) was stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (20 mL) and water (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide as white solid (0.181 g, 90.5%).


[Step 5] Compound 11647



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide (0.092 g, 0.221 mmol), triethylamine (0.154 mL, 1.104 mmol) and 2,2-difluoroacetic anhydride (0.082 mL, 0.663 mmol) in tetrahydrofuran (3 mL) was stirred at 90° C. for 1 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide as yellow oil (0.071 g, 67.3%).



1H NMR (400 MHz, CDCl3) δ8.01 (d, 2H, J=8.5 Hz), 7.45 (d, 2H, J=8.6 Hz), 7.36˜7.25 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 3.80˜3.79 (m, 2H), 3.33˜3.26 (m, 4H), 2.80×2.79 (m, 2H), 2.42×2.35 (m, 2H), 2.10×2.05 (m, 4H); LRMS (ES) m/z 447.1 (M++1).


EXAMPLE 180
Compound 11648, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylpropane-1-sulfonamide
[Step 1] tert-butyl 4-(3-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)propyl)piperazine-1-carboxylate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.978 g, 2.561 mmol), tert-butyl piperazine-1-carboxylate (0.954 g, 5.122 mmol) and potassium carbonate (0.531 g, 3.842 mmol) in N,N-dimethylformide (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give tert-butyl 4-(3-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)propyl)piperazine-1-carboxylate as white solid (1.190 g, 87.4%).


[Step 2] methyl 4-(((N-phenyl-3-(piperazin-1-yl)propyl)sulfonamido)methyl)benzoate hydrochloride



embedded image


A solution of tert-butyl 4-(3-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)propyl)piperazine-1-carboxylate (1.190 g, 2.238 mmol) and hydrochloric acid (4.00 M solution, 2.798 mL, 11.191 mmol) in 1,4-dioxane (5 mL) was stirred at the room temperature for 2 hr, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with diethylether (20 mL) and stirred. The resulting precipitates were collected by filtration, washed by diethylether, and dried to give methyl 4-(((N-phenyl-3-(piperazin-1-yl)propyl)sulfonamido)methyl)benzoate hydrochloride as white solid (0.932 g, 89.0%).


[Step 3] methyl 4-(((3-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((N-phenyl-3-(piperazin-1-yl)propyl)sulfonamido)methyl)benzoate hydrochloride (0.300 g, 0.641 mmol), methanesulfonyl chloride (0.074 mL, 0.962 mmol) and triethylamine (0.268 mL, 1.923 mmol) in dichloromethane (2 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((3-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as white solid (0.131 g, 40.2%).


[Step 4] N-(4-(hydrazinecarbonyl)benzyl)-3-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl 4-(((3-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.131 g, 0.257 mmol) and hydrazine hydrate (0.129 g, 2.57 mmol) in ethanol (3 mL) was stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (20 mL) and water (10 mL), and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-3-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylpropane-1-sulfonamide as white solid (0.056 g, 42.7%).


[Step 5] Compound 11648



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-3-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylpropane-1-sulfonamide (0.056 g, 0.110 mmol), triethylamine (0.077 mL, 0.549 mmol) and 2,2-difluoroacetic anhydride (0.041 mL, 0.330 mmol) in tetrahydrofuran (3 mL) was stirred at 90° C. for 1 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, aqueous N-sodium bicarbonate solution was added to the concentrate, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(4-(methylsulfonyl)piperazin-1-yl)-N-phenylpropane-1-sulfonamide as white solid (0.059 g, 93.6%).



1H NMR (400 MHz, CDCl3) δ8.02 (d, 2H, J=8.4 Hz), 7.44 (d, 2H, J=8.5 Hz), 7.35˜7.27 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 4.96 (s, 2H), 3.59 (brs, 4H), 3.26 (t, 2H, J=7.1 Hz), 3.22˜3.12 (m, 6H), 2.87 (s, 3H), 2.37˜2.30 (m, 2H); LRMS (ES) m/z 570.3 (M++1).


EXAMPLE 181
Compound 11655, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-morpholino-N-phenylethanesulfonamide
[Step 1] methyl 4-((2-morpholino-N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.300 g, 0.905 mmol), morpholine (0.078 mL, 0.905 mmol) and N,N-Diisopropylethylamine (0.312 mL, 1.811 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-((2-morpholino-N-phenylethylsulfonamido)methyl)benzoate as white solid (0.250 g, 66.0%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-2-morpholino-N-phenylethanesulfonamide



embedded image


A solution of methyl 4-((2-morpholino-N-phenylethylsulfonamido)methyl)benzoate (0.250 g, 0.597 mmol) and hydrazine (0.375 mL, 11.947 mmol) in ethanol (10 mL) was stirred at 80° C. for 6 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The concentrate was crystallized at the room temperature using water (10 mL). The resulting precipitates were filtered and dried to give N-(4-(hydrazinecarbonyl)benzyl)-2-morpholino-N-phenylethanesulfonamide as white solid (0.180 g, 72.0%).


[Step 3] Compound 11655



embedded image


A mixture of N-(4-(hydrazinecarbonyl)benzyl)-2-morpholino-N-phenylethanesulfonamide (0.180 g, 0.430 mmol), 2,2-difluoroacetic anhydride (0.160 mL, 1.290 mmol) and triethylamine (0.300 mL, 2.150 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-morpholino-N-phenylethanesulfonamide as white solid (0.179 g, 87.0%).



1H NMR (400 MHz, CDCl3) δ 7.99(d, 2H, J=8.3 Hz), 7.54-7.52 (m, 2H), 7.45-7.33 (m, 4H), 7.26 (t, 1H, J=7.3 Hz), 6.21 (t, 1H, J=53.5 Hz), 5.04 (s, 2H), 3.64-3.61 (m, 4H), 3.53-3.49 (m, 2H), 2.89-2.85 (m, 2H), 2.60-2.56 (m, 4H); LRMS (ES) m/z 479.0 (M++1).


EXAMPLE 182
Compound 11656, 3-(4-acetylpiperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpropane-1-sulfonamide
[Step 1] methyl 4-(((3-(4-acetylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((N-phenyl-3-(piperazin-1-yl)propyl)sulfonamido)methyl)benzoate hydrochloride (0.300 g, 0.641 mmol), acetic anhydride (0.091 mL, 0.962 mmol) and triethylamine (0.268 mL, 1.923 mmol) in dichloromethane (2 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((3-(4-acetylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as coloeless oil (0.201 g, 66.2%).


[Step 2] 3-(4-acetylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide



embedded image


A solution methyl 4-(((3-(4-acetylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.118 g, 0.249 mmol) and hydrazine hydrate (0.116 g, 2.315 mmol) in ethanol (3 ml) were stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The concentrate was diluted aqueous N-sodium bicarbonate solution (20 ml) and water (10 ml), and stirred. The resulting precipitates were collected by filtration and dried to give 3-(4-acetylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide as white solid (0.078 g, 71.1%).


[Step 3] Compound 11656



embedded image


A solution of 3-(4-acetylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide (0.118 g, 0.249 mmol), triethylamine (0.174 mL, 1.246 mmol) and 2,2-difluoroacetic anhydride (0.093 mL, 0.747 mmol) in tetrahydrofuran (3 mL) was stirred at 90° C. for 1 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, aqueous N-sodium bicarbonate solution was added to the concentrate, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give 3-(4-acetylpiperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpropane-1-sulfonamide as yellow solid (0.020 g, 15.2%).



1H NMR (400 MHz, CDCl3) δ8.04 (d, 2H, J=8.2 Hz), 7.48 (d, 2H, J=8.1 Hz), 7.38˜7.28 (m, 5H), 6.92 (t, 1H, J=51.8 Hz), 5.00 (s, 2H), 3.73˜7.64 (m, 4H), 3.29 (m, 2H), 2.81˜2.60 (m, 6H), 2.28˜2.24 (m, 2H), 2.12 (s, 3H); LRMS (ES) m/z 534.2 (M++1).


EXAMPLE 183
Compound 11657, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-3-(piperidin-1-yl)propane-1-sulfonamide
[Step 1] methyl 4-(((N-phenyl-3-(piperidin-1-yl)propyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.500 g, 1.309 mmol), piperdine (0.259 mL, 2.619 mmol) and potassium carbonate (0.271 g, 1.964 mmol) in N,N-dimethylformide (3 mL) was stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give methyl 4-(((N-phenyl-3-(piperidin-1-yl)propyl)sulfonamido)methyl)benzoate as white solid (0.127 g, 22.5%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-(piperidin-1-yl)propane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-phenyl-3-(piperidin-1-yl)propyl)sulfonamido)methyl)benzoate (0.127 g, 0.295 mmol) and hydrazine hydrate (0.148 g, 2.950 mmol) in ethanol (3 mL) was stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (20 mL) and water (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-(piperidin-1-yl)propane-1-sulfonamide as white solid (0.123 g, 96.8%).


[Step 3] Compound 11657



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-(piperidin-1-yl)propane-1-sulfonamide (0.123 g, 0.286 mmol), triethylamine (0.198 mL, 1.43 mmol) and 2,2-difluoroacetic anhydride (0.107 mL, 0.858 mmol) in tetrahydrofuran (3 mL) was stirred at 90° C. for 1 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-3-(piperidin-1-yl)propane-1-sulfonamide as yellow oil (0.081 g, 58.0%).



1H NMR (400 MHz, CDCl3) δ8.03 (d, 2H, J=8.4 Hz), 7.47 (d, 2H, J=8.4 Hz), 7.36˜7.26 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.99 (s, 2H), 3.24˜3.17 (m, 2H), 2.64˜2.59 (m, 6H), 2.21˜2.15 (m, 2H), 1.70˜1.69 (m, 4H), 1.51-1.36 (m, 2H); LRMS (ES) m/z 491.3 (M++1).


EXAMPLE 184
Compound 11658, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide
[Step 1] methyl 4-(((3-(4-methylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.500 g, 1.309 mmol), 1-methylpiperazine (0.291 mL, 2.619 mmol) and potassium carbonate (0.271 g, 1.964 mmol) in N,N-dimethylformide (3 mL) was stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give methyl 4-(((3-(4-methylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as white solid (0.464 g, 79.6%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl 4-(((3-(4-methylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.200 g, 0.449 mmol) and hydrazine hydrate (0.225 g, 4.489 mmol) in ethanol (3 mL) was stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (20 mL) and water (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide as white solid (0.116 g, 58.0%).


[Step 3] Compound 11658



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide (0.116 g, 0.260 mmol), triethylamine (0.181 mL, 1.302 mmol) and 2,2-difluoroacetic anhydride (0.097 mL, 0.781 mmol) in tetrahydrofuran (3 mL) was stirred at 90° C. for 1 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(4-methylpiperazin-1-yl)-N-phenylpropane-1-sulfonamide as yellow oil (0.068 g, 51.6%).



1H NMR (400 MHz, CDCl3) δ8.04 (d, 2H, J=8.3 Hz), 7.47 (d, 2H, J=8.3 Hz), 7.37˜7.27 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 3.20˜3.13 (m, 2H), 2.61˜2.54 (m, 8H), 2.54˜2.49 (m, 2H), 2.44 (s, 3H), 2.09˜2.03 (m, 2H); LRMS (ES) m/z 506.4 (M++1).


EXAMPLE 185
Compound 11663, 2-(4-benzylpiperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethanesulfonamide
[Step 1] methyl 4-((2-(4-benzylpiperazin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.500 g, 1.509 mmol), 1-benzylpiperazine (0.258 mL, 1.509 mmol) and N,N-Diisopropylethylamine (0.520 mL, 3.018 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-((2-(4-benzylpiperazin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate as white solid (0.430 g, 56.1%).


[Step 2] 2-(4-benzylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylethanesulfonamide



embedded image


A solution of methyl 4-((2-(4-benzylpiperazin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate (0.200 g, 0.394 mmol) and hydrazine (0.247 mL, 7.880 mmol) in ethanol (10 mL) was stirred at 80° C. for 6 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The crude product was crystallized at the room temperature using water (20 mL). The resulting precipitates were filtered and dried to give 2-(4-benzylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylethanesulfonamide as white solid (0.160 g, 80.0%).


[Step 3] compound 11663



embedded image


A mixture of 2-(4-benzylpiperazin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylethanesulfonamide (0.160 g, 0.315 mmol), 2,2-Difluoroacetic anhydride (0.118 mL, 0.946 mmol) and triethylamine (0.220 mL, 1.576 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give 2-(4-benzylpiperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethanesulfonamide as white solid (0.060 g, 33.5%).



1H NMR (400 MHz, DMSO-d6) δ7.98 (d, 2H, J=8.3 Hz), 7.52 (d, 2H, J=8.4 Hz), 7.41-7.24 (m, 11H), 5.03 (s, 2H), 3.91-3.88 (m, 2H), 3.49 (t, 2H, J=7.0 Hz), 2.88-2.65 (m, 6H); LRMS (ES) m/z 568.1 (M++1).


EXAMPLE 186
Compound 11665, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-3-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)propane-1-sulfonamide
[Step 1] methyl 4-(((3-((3R,5S)-3,5-dimethylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.500 g, 1.309 mmol), (2R,6S)-2,6-dimethylpiperazine (0.299 g, 2.619 mmol) and potassium carbonate (0.271 g, 1.964 mmol) in N,N-dimethylformide (3 mL) was stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give methyl 4-(((3-((3R,5S)-3,5-dimethylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as white solid (0.515 g, 85.6%).


[Step 2] methyl 4-(((N-phenyl-3-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)propyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-((3R,5S)-3,5-dimethylpiperazin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.200 g, 0.435 mmol), paraformaldehyde (0.131 g, 4.352 mmol) and sodium triacetoxyborohydride (0.461 g, 2.176 mmol) in acetonitrile (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give methyl 4-(((N-phenyl-3-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)propyl)sulfonamido)methyl)benzoate as yellow solid (0.063 g, 30.3%).


[Step 3] N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)propane-1-sulfonamide



embedded image


A solution of methyl 4-(((N-phenyl-3-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)propyl)sulfonamido)methyl)benzoate (0.063 g, 0.133 mmol) and hydrazine hydrate (0.067 g, 1.330 mmol) in ethanol (5 mL) was stirred at 90° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (20 mL) and water (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)propane-1-sulfonamide as white solid (0.041 g, 64.4%).


[Step 4] Compound 11665



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-phenyl-3-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)propane-1-sulfonamide (0.041 g, 0.086 mmol), triethylamine (0.060 mL, 0.429 mmol) and 2,2-difluoroacetic anhydride (0.032 mL, 0.257 mmol) in tetrahydrofuran (3 mL) was stirred at 90° C. for 1 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-3-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)propane-1-sulfonamide as colorless oil (0.031 g, 67.3%).



1H NMR (400 MHz, CDCl3) δ8.04 (dt, 2H, J=8.5, 1.8 Hz), 7.47 (d, 2H, J=8.6 Hz), 7.37˜7.26 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 3.19˜3.15 (m, 2H), 2.72 (d, 2H, J=10.6 Hz), 2.42 (t, 2H, J=6.8 Hz), 2.35 (brs, 4H), 2.09˜2.01 (m, 4H), 1.16 (d, 6H, J=5.1 Hz); LRMS (ES) m/z 534.1 (M++1).


EXAMPLE 187
Compound 11668, N-((adamantan-1-yl)methyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] methyl 4-((((adamantan-1-yl)methyl)amino)methyl)benzoate



embedded image


A mixture of methyl 4-formylbenzoate (0.500 g, 3.046 mmol) and (adamantan-1-yl)methanamine (0.654 mL, 3.960 mmol) in dichloromethane (20 mL) was treated at the room temperature with sodium triacetoxyborohydride (1.291 g, 6.092 mmol), and stirred at the same temperature for 3 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=30% to 70%) to give methyl 4-((((adamantan-1-yl)methyl)amino)methyl)benzoate as colorless oil (0.860 g, 90.1%).


[Step 2] methyl 4-((N-((adamantan-1-yl)methyl)methylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((((adamantan-1-yl)methyl)amino)methyl)benzoate (0.860 g, 2.744 mmol) in dichloromethane (50 mL) was mixed at the room temperature with methanesulfonyl chloride (0.276 mL, 3.567 mmol) and triethylamine (0.574 mL, 4.116 mmol), and stirred at the same temperature for 1 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give methyl 4-((N-((adamantan-1-yl)methyl)methylsulfonamido)methyl)benzoate as beige solid (0.956 g, 89.0%).


[Step 3] N-((adamantan-1-yl)methyl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A solution of methyl 4-((N-((adamantan-1-yl)methyl)methylsulfonamido)methyl)benzoate (0.956 g, 2.442 mmol) in tetrahydrofuran (7 mL)/ethanol (7 mL) was mixed at the room temperature with hydrazine monohydrate (2.373 mL, 48.834 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was diluted with ethyl acetate (10 mL) and hexane (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((adamantan-1-yl)methyl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide as white solid (0.935 g, 97.8%).


[Step 4] Compound 11668



embedded image


A mixture of N-((adamantan-1-yl)methyl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.300 g, 0.766 mmol) and triethylamine (0.427 mL, 3.065 mmol) in tetrahydrofuran (20 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.286 mL, 2.299 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=20% to 50%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((adamantan-1-yl)methyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.262 g, 75.7%).



1H NMR (400 MHz, DMSO-d6) δ 8.07 (d, 2H, J=8.4 Hz), 7.68 (s, 0.25H), 7.65 (d, 2H, J=8.4 Hz), 7.55 (s, 0.5H), 7.42 (s, 0.25H), 4.51 (s, 2H), 2.97 (s, 3H), 2.93 (s, 2H), 1.86 (s, 3H), 1.64-1.56 (m, 3H), 1.53-1.47 (m, 3H), 1.47-1.41 (m, 6H); LRMS (ES) m/z 452.1 (M++1).


EXAMPLE 188
Compound 11669, N-((adamantan-1-yl)methyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide
[Step 1] methyl 6-((((adamantan-1-yl)methyl)amino)methyl)nicotinate



embedded image


A mixture of methyl 6-formylnicotinate (0.320 g, 1.938 mmol) and (adamantan-1-yl)methanamine (0.416 mL, 2.519 mmol) in dichloromethane (20 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.821 g, 3.875 mmol), and stirred at the same temperature for 3 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=30% to 70%) to give methyl 6-((((adamantan-1-yl)methyl)amino)methyl)nicotinate as yellow oil (0.530 g, 87.0%).


[Step 2] methyl 6-((N-((adamantan-1-yl)methyl)methylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-((((adamantan-1-yl)methyl)amino)methyl)nicotinate (0.530 g, 1.686 mmol) in dichloromethane (50 mL) was mixed at the room temperature with methanesulfonyl chloride (0.170 mL, 2.191 mmol) and triethylamine (0.352 mL, 2.528 mmol), and stirred at the same temperature for 1 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=30% to 70%) to give methyl 6-((N-((adamantan-1-yl)methyl)methylsulfonamido)methyl)nicotinate as yellow solid (0.510 g, 77.1%).


[Step 3] N-((adamantan-1-yl)methyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A solution of methyl 6-((N-((adamantan-1-yl)methyl)methylsulfonamido)methyl)nicotinate (0.510 g, 1.299 mmol) in tetrahydrofuran (7 mL)/ethanol (7 mL) was mixed at the room temperature with hydrazine monohydrate (1.263 mL, 25.987 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was diluted with ethyl acetate (10 mL) and hexane (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((adamantan-1-yl)methyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.365 g, 71.6%).


[Step 4] Compound 11669



embedded image


A mixture of N-((adamantan-1-yl)methyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methanesulfonamide (0.300 g, 0.764 mmol) and triethylamine (0.426 mL, 3.057 mmol) in tetrahydrofuran (20 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.285 mL, 2.293 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=30% to 60%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((adamantan-1-yl)methyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.241 g, 69.7%).



1H NMR (400 MHz, DMSO-d6) δ 9.17 (dd, 1H, J=2.2, 0.8 Hz), 8.50 (dd, 1H, J=8.3, 2.3 Hz), 7.83 (dd, 1H, J=8.3, 0.9 Hz), 7.58 (t, 1H, J=51.3 Hz), 4.61 (s, 2H), 3.01 (s, 3H), 2.96 (s, 2H), 1.88 (s, 3H), 1.66-1.58 (m, 3H), 1.57-1.51 (m, 3H), 1.50-1.45 (m, 6H); LRMS (ES) m/z 453.3 (M++1).


EXAMPLE 189
Compound 11675, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-methylpiperidin-1-yl)-N-phenylethanesulfonamide
[Step 1] methyl 4-((2-(4-methylpiperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.200 g, 0.604 mmol), 4-methylpiperidine (0.060 g, 0.604 mmol) and N,N-Diisopropylethylamine (0.208 mL, 1.207 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give methyl 4-((2-(4-methylpiperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate as white solid (0.230 g, 88.5%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperidin-1-yl)-N-phenylethanesulfonamide



embedded image


A mixture of methyl 4-((2-(4-methylpiperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate (0.230 g, 0.534 mmol) and hydrazine (0.335 mL, 10.684 mmol) in ethanol (5 mL) prepared at the room temperature was heated at reflux for 6 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (20 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperidin-1-yl)-N-phenylethanesulfonamide as white solid (0.160 g, 69.6%).


[Step 3] Compound 11675



embedded image


A mixture of N-(4-(hydrazinecarbonyl)benzyl)-2-(4-methylpiperidin-1-yl)-N-phenylethanesulfonamide (0.160 g, 0.372 mmol), 2,2-difluoroacetic anhydride (0.139 mL, 1.115 mmol) and triethylamine (0.259 mL, 1.858 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-methylpiperidin-1-yl)-N-phenylethanesulfonamide as white solid (0.060 g, 32.9%).



1H NMR (400 MHz, CDCl3) δ 8.00 (d, 2H, J=8.1 Hz), 7.43 (d, 2H, J=8.0 Hz), 7.33-7.27 (m, 5H), 6.91 (t, 1H, J=51.9 Hz), 4.96 (s, 2H), 3.84-3.75 (m, 2H), 3.58-3.48 (m, 2H), 3.40-3.36 (m, 2H), 2.66 (m, 2H), 1.86-1.84 (m, 2H), 1.65 (m, 2H), 1.27 (t, 1H, J=1.3 Hz), 1.03-1.02 (m, 3H); LRMS (ES) m/z 491.8 (M++1).


EXAMPLE 190
Compound 11676, (1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-Phenylsulfamoyl)ethyl)piperidin-4-yl)methyl 2,2-difluoroacetate
[Step 1] methyl 4-((2-(4-(hydroxymethyl)piperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.200 g, 0.604 mmol), piperidin-4-ylmethanol (0.070 g, 0.604 mmol) and N,N-Diisopropylethylamine (0.208 mL, 1.207 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give methyl 4-((2-(4-(hydroxymethyl)piperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate as white solid (0.180 g, 66.8%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(hydroxymethyl)piperidin-1-yl)-N-phenylethanesulfonamide



embedded image


A mixture of methyl 4-((2-(4-(hydroxymethyl)piperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate (0.180 g, 0.403 mmol) and hydrazine (0.253 mL, 8.062 mmol) in ethanol (5 mL) prepared at the room temperature was heated at reflux for 6 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (20 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(hydroxymethyl)piperidin-1-yl)-N-phenylethanesulfonamide as white solid (0.100 g, 55.6%).


[Step 3] Compound 11676



embedded image


A mixture of N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(hydroxymethyl)piperidin-1-yl)-N-phenylethanesulfonamide (0.100 g, 0.224 mmol), 2,2-difluoroacetic anhydride (0.084 mL, 0.672 mmol) and triethylamine (0.156 mL, 1.120 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give (1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-Phenylsulfamoyl)ethyl)piperidin-4-yl)methyl 2,2-difluoroacetate as white solid (0.050 g, 38.2%).



1H NMR (400 MHz, CDCl3) δ 8.02 (d, 2H, J=8.3 Hz), 7.44 (d, 2H, J=8.0 Hz), 7.37-7.28 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 5.96 (t, 1H, J=53.1 Hz), 4.97 (d, 2H), 4.22 (d, 2H, J=6.1 Hz), 3.84-3.81 (m, 2H), 3.69-3.65 (m, 2H), 3.44-3.40 (m, 2H), 2.77 (m, 2H), 2.02-1.78 (m, 5H); LRMS (ES) m/z 585.9 (M++1).


EXAMPLE 191
Compound 11677, tert-butyl 2,2-difluoroacetyl(1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)piperidin-4-yl)carbamate
[Step 1] methyl 4-((2-(4-(tert-butoxycarbonylamino)piperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.200 g, 0.604 mmol), tert-butyl piperidin-4-ylcarbamate (0.121 g, 0.604 mmol) and N,N-Diisopropylethylamine (0.208 mL, 1.207 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give methyl 4-((2-(4-(tert-butoxycarbonylamino)piperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate as white solid (0.220 g, 68.6%).


[Step 2] tert-butyl 1-(2-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperidin-4-ylcarbamate



embedded image


A mixture of methyl 4-((2-(4-(tert-butoxycarbonylamino)piperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate (0.220 g, 0.414 mmol) and hydrazine (0.260 mL, 8.276 mmol) in ethanol (5 mL) prepared at the room temperature was heated at reflux for 6 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (20 mL) and stirred. The resulting precipitates were collected by filtration and dried to give tert-butyl 1-(2-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperidin-4-ylcarbamate as white solid (0.120 g, 54.5%).


[Step 3] Compound 11677



embedded image


A mixture of give tert-butyl 1-(2-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)ethyl)piperidin-4-ylcarbamate (0.120 g, 0.226 mmol), 2,2-difluoroacetic anhydride (0.084 mL, 0.677 mmol) and triethylamine (0.157 mL, 1.129 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give tert-butyl 2,2-difluoroacetyl(1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)piperidin-4-yl)carbamate as white solid (0.050 g, 33.1%).



1H NMR (400 MHz, CDCl3) δ 8.01 (d, 2H, J=8.2 Hz), 7.43 (d, 2H, J=8.2 Hz), 7.33-7.28 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 5.87 (t, 1H, J=54.6 Hz), 4.95 (d, 2H), 4.60 (m, 1H), 3.79-3.70 (m, 4H), 3.47-3.44 (m, 2H), 2.95-2.84 (m, 4H), 1.89 (m, 2H), 1.58-1.44 (m, 9H); LRMS (ES) m/z 670.4 (M++1).


EXAMPLE 192
Compound 11678, 2-(5-(2,2-difluoroacetyl)-1H-imidazol-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide
[Step 1] methyl 4-((2-(1H-imidazol-1-yl)-N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.200 g, 0.604 mmol), 1H-imidazole (0.041 g, 0.604 mmol) and N,N-Diisopropylethylamine (0.208 mL, 1.207 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give methyl 4-((2-(1H-imidazol-1-yl)-N-phenylethylsulfonamido)methyl)benzoate as white solid (0.210 g, 87.1%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-2-(1H-imidazol-1-yl)-N-phenylethanesulfonamide



embedded image


A mixture of methyl 4-((2-(1H-imidazol-1-yl)-N-phenylethylsulfonamido)methyl)benzoate (0.210 g, 0.526 mmol) and hydrazine (0.330 mL, 10.514 mmol) in ethanol (5 mL) prepared at the room temperature was heated at reflux for 6 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (20 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-2-(1H-imidazol-1-yl)-N-phenylethanesulfonamide as white solid (0.130 g, 61.9%).


[Step 3] Compound 11678



embedded image


A mixture of N-(4-(hydrazinecarbonyl)benzyl)-2-(1H-imidazol-1-yl)-N-phenylethane sulfonamide (0.130 g, 0.325 mmol), 2,2-difluoroacetic anhydride (0.121 mL, 0.976 mmol) and triethylamine (0.227 mL, 1.627 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give 2-(5-(2,2-difluoroacetyl)-1H-imidazol-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.040 g, 22.9%).



1H NMR (400 MHz, DMSO-d6) δ7.99 (d,2H),7.97 (s, 1H),7.53-7.52 (m, 3H),7.43-7.29 (m, 5H),7.09(t, 1H, J=51.7 Hz), 6.25 (t, 1H, J=54.6 Hz), 5.03 (s, 1H), 4.88-4.84 (m, 2H), 3.85-3.82 (m, 2H); LRMS (ES) m/z 583.3 (M++1).


EXAMPLE 193
Compound 11679, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(3-hydroxypropyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide
[Step 1] methyl 4-((2-(4-(3-hydroxypropyl)piperazin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.200 g, 0.604 mmol), 3-(piperazin-1-yl)propan-1-ol (0.087 g, 0.604 mmol) and N,N-Diisopropylethylamine (0.208 mL, 1.207 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give methyl 4-((2-(4-(3-hydroxypropyl)piperazin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate as white solid (0.230 g, 80.1%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(3-hydroxypropyl)piperazin-1-yl)-N-phenylethanesulfonamide



embedded image


A mixture of methyl 4-((2-(4-(3-hydroxypropyl)piperazin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate (0.230 g, 0.484 mmol) and hydrazine (0.304 mL, 9.672 mmol) in ethanol (5 mL) prepared at the room temperature was heated at reflux for 6 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (20 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(3-hydroxypropyl)piperazin-1-yl)-N-phenylethanesulfonamide as white solid (0.140 g, 60.9%).


[Step 3] Compound 11679



embedded image


A mixture of N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(3-hydroxypropyl)piperazin-1-yl)-N-phenylethanesulfonamide (0.140 g, 0.294 mmol), 2,2-difluoroacetic anhydride (0.110 mL, 0.883 mmol) and triethylamine (0.205 mL, 1.472 mmol) in tetrahydrofuran (10 mL) prepared at the room temperature was heated at reflux for 12 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(3-hydroxypropyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.080 g, 50.7%).



1H NMR (400 MHz, DMSO-d6) δ8.03-7.98 (m, 2H), 7.55-7.53 (m, 2H), 7.44-7.24 (m, 5H),5.86(t, 1H, J=55.2 Hz), 5.04 (s, 2H), 3.51-3.39 (m, 6H), 3.38-3.20 (m, 4H), 2.94-2.91 (m, 4H), 2.68 (m, 2H), 1.99-1.78 (m, 2H); LRMS (ES) m/z 534.9 (M++1).


EXAMPLE 194
Compound 11680, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(oxetan-3-yl)-N-phenylpiperidine-4-sulfonamide
[Step 1] tert-butyl 4-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate



embedded image


tert-butyl 4-(N-(4-(methoxycarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate (0.830 g, 1.699 mmol) and hydrazine monohydrate (2.477 mL, 50.962 mmol) in tetrahydrofuran (7 mL)/ethanol (7 mL) was mixed at the room temperature, heated at 120° C. under the microwaves for 90 min, cooled down to the room temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with ethyl acetate (20 mL) and hexane (40 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give tert-butyl 4-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate as white solid (0.720 g, 86.7%).


[Step 2] tert-butyl 4-(N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-(4-(hydrazinecarbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate (0.720 g, 1.474 mmol) and triethylamine (1.027 mL, 7.368 mmol) in tetrahydrofuran (20 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.550 mL, 4.421 mmol), stirred at 70° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=30% to 60%) to give tert-butyl 4-(N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate as white solid (0.610 g, 73.1%).


[Step 3] tert-butyl 4-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate (0.610 g, 1.077 mmol) and triethylamine (0.450 mL, 3.230 mmol) in dichloromethane (30 mL) was treated at the room temperature with methanesulfonyl chloride (0.208 mL, 2.691 mmol), and stirred at the same temperature for 1 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate as white solid (0.360 g, 61.0%).


[Step 4] N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperidine-4-sulfonamide hydrochloride



embedded image


A solution of tert-butyl 4-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)piperidine-1-carboxylate (0.360 g, 0.656 mmol) in 1,4-dioxane (10 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 4.922 mL, 19.686 mmol), stirred at the same temperature for 1 hr, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with ethyl acetate (20 mL) and hexane (20 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperidine-4-sulfonamide hydrochloride as white solid (0.290 g, 91.1%).


[Step 5] Compound 11680



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperidine-4-sulfonamide hydrochloride (0.100 g, 0.206 mmol), oxetan-3-one (0.074 g, 1.031 mmol) and N,N-diisopropylethylamine (0.072 mL, 0.412 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.087 g, 0.412 mmol) and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(oxetan-3-yl)-N-phenylpiperidine-4-sulfonamide as white solid (0.062 g, 59.6%).



1H NMR (400 MHz, DMSO-d6) δ 8.00 (d, 2H, J=8.3 Hz), 7.65 (s, 0.25H), 7.55-7.47 (m, 2.5H), 7.47-7.39 (m, 2.25H), 7.33 (t, 2H, J=7.7 Hz), 7.23 (t, 1H, J=7.3 Hz), 5.08 (s, 2H), 4.53 (t, 2H, J=6.5 Hz), 4.42 (t, 2H, J=6.1 Hz), 3.44 (m, 1H), 3.29 (m, 1H), 2.79 (d, 2H, J=10.9 Hz), 2.08 (d, 2H, J=12.3 Hz), 1.84 (t, 2H, J=11.5 Hz), 1.80-1.66 (m, 2H); LRMS (ES) m/z 505.3 (M++1).


EXAMPLE 195
Compound 11681, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide
[Step 1] tert-butyl 4-(N-(3-chlorophenyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A solution of tert-butyl 4-(chlorosulfonyl)piperidine-1-carboxylate (3.000 g, 10.572 mmol) in dichloromethane (50 mL) was mixed at the room temperature with 3-chloroaniline (1.618 g, 12.686 mmol) and triethylamine (2.210 mL, 15.858 mmol), and stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (10 mL) and hexane (100 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give tert-butyl 4-(N-(3-chlorophenyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.860 g, 21.7%).


[Step 2] tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(methoxycarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-(3-chlorophenyl)sulfamoyl)piperidine-1-carboxylate (0.400 g, 1.067 mmol), methyl 4-(bromomethyl)benzoate (0.318 g, 1.387 mmol), potassium carbonate (0.295 g, 2.134 mmol) and potassium iodide (0.354 g, 2.134 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 6 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(methoxycarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate as beige solid (0.430 g, 77.0%).


[Step 3] tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A solution of tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(methoxycarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate (0.430 g, 0.822 mmol) in tetrahydrofuran (7 mL)/ethanol (7 mL) was mixed at the room temperature with hydrazine monohydrate (1.199 mL, 24.664 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.369 g, 85.8%).


[Step 4] tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate (0.369 g, 0.705 mmol) and triethylamine (0.393 mL, 2.822 mmol) in tetrahydrofuran (10 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.263 mL, 2.116 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.352 g, 85.6%).


[Step 5] N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide hydrochloride



embedded image


A solution of tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)sulfamoyl)piperidine-1-carboxylate (0.352 g, 0.604 mmol) in 1,4-dioxane (2 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 3.019 mL, 12.074 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (5 mL) and hexane (20 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide hydrochloride as white solid (0.290 g, 92.5%).


[Step 6] Compound 11681



embedded image


A mixture of N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide hydrochloride (0.100 g, 0.193 mmol), oxetan-3-one (0.069 g, 0.963 mmol) and N,N-diisopropylethylamine (0.067 mL, 0.385 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.082 g, 0.385 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide as white solid (0.068 g, 65.5%).



1H NMR (400 MHz, DMSO-d6) δ 8.00 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.59-7.53 (t, 1H, J=2.0 Hz), 7.53-7.48 (m, 2.5H), 7.44 (ddd, 1H, J=7.9, 2.1, 1.1 Hz), 7.40 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (ddd, 1H, J=8.1, 2.1, 1.2 Hz), 5.12 (s, 2H), 4.53 (t, 2H, J=6.5 Hz), 4.42 (t, 2H, J=6.1 Hz), 3.40 (m, 1H), 3.31 (m, 1H), 2.80 (d, 2H, J=11.1 Hz), 2.12-2.00 (m, 2H), 1.86 (t, 2H, J=11.4 Hz), 1.79-1.65 (m, 2H); LRMS (ES) m/z 539.2 (M++1).


EXAMPLE 196
Compound 11682, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(oxetan-3-yl)-N-(m-tolyl)piperidine-4-sulfonamide
[Step 1] tert-butyl 4-(N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A solution of tert-butyl 4-(chlorosulfonyl)piperidine-1-carboxylate (3.000 g, 10.572 mmol) in dichloromethane (50 mL) was mixed at the room temperature with m-toluidine hydrochloride (1.822 g, 12.686 mmol) and triethylamine (3.684 mL, 26.430 mmol), and stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (10 mL) and hexane (100 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give tert-butyl 4-(N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate as white solid (1.880 g, 50.2%).


[Step 2] tert-butyl 4-(N-(4-(methoxycarbonyl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate (0.880 g, 2.483 mmol), methyl 4-(bromomethyl)benzoate (0.739 g, 3.227 mmol), potassium carbonate (0.686 g, 4.965 mmol) and potassium iodide (0.824 g, 4.965 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 6 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-(4-(methoxycarbonyl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate as beige solid (0.930 g, 74.5%).


[Step 3] tert-butyl 4-(N-(4-(hydrazinecarbonyl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A solution of tert-butyl 4-(N-(4-(methoxycarbonyl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate (0.930 g, 1.850 mmol) in tetrahydrofuran (20 mL)/ethanol (20 mL) was mixed at the room temperature with hydrazine monohydrate (2.698 mL, 55.508 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give tert-butyl 4-(N-(4-(hydrazinecarbonyl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.866 g, 93.1%).


[Step 4] tert-butyl 4-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A reaction mixture of tert-butyl 4-(N-(4-(hydrazinecarbonyl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate (0.866 g, 1.723 mmol) and triethylamine (0.961 mL, 6.892 mmol) in tetrahydrofuran (20 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.643 mL, 5.169 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.823 g, 84.9%).


[Step 5] N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride



embedded image


A suspension of tert-butyl 4-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate (0.823 g, 1.463 mmol) in 1,4-dioxane (5 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 5.485 mL, 21.942 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (10 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride as white solid (0.723 g, 99.1%).


[Step 6] Compound 11682



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.100 g, 0.200 mmol), oxetan-3-one (0.072 g, 1.002 mmol) and N,N-diisopropylethylamine (0.070 mL, 0.401 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.085 g, 0.401 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(oxetan-3-yl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.072 g, 69.3%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.3 Hz), 7.66 (s, 0.25H), 7.56-7.47 (m, 2.5H), 7.40 (s, 0.25H), 7.27-7.17 (m, 3H), 7.04 (d, 1H, J=6.9 Hz), 5.06 (s, 2H), 4.53 (t, 2H, J=6.5 Hz), 4.42 (t, 2H, J=6.1 Hz), 3.40 (m, 1H), 3.25 (m, 1H), 2.80 (d, 2H, J=10.8 Hz), 2.25 (s, 3H), 2.14-2.02 (m, 2H), 1.81 (t, 2H, J=11.5 Hz), 1.79-1.69 (m, 2H); LRMS (ES) m/z 519.3 (M++1).


EXAMPLE 197
Compound 11683, N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide
[Step 1] methyl 6-(((1-(tert-butoxycarbonyl)-N-(3-chlorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A mixture of tert-butyl 4-(N-(3-chlorophenyl)sulfamoyl)piperidine-1-carboxylate (0.460 g, 1.227 mmol), methyl 6-(bromomethyl)nicotinate (0.367 g, 1.595 mmol), potassium carbonate (0.339 g, 2.454 mmol) and potassium iodide (0.407 g, 2.454 mmol) in N,N-dimethylformide (10 mL) was stirred at the room temperature for 6 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=30% to 60%) to give methyl 6-(((1-(tert-butoxycarbonyl)-N-(3-chlorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate as white solid (0.436 g, 67.8%).


[Step 2] tert-butyl 4-(N-(3-chlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A solution of methyl 6-(((1-(tert-butoxycarbonyl)-N-(3-chlorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate (0.436 g, 0.832 mmol) in tetrahydrofuran (7 mL)/ethanol (7 mL) was mixed at the room temperature with hydrazine monohydrate (1.213 mL, 24.960 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give tert-butyl 4-(N-(3-chlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.275 g, 63.1%).


[Step 3] tert-butyl 4-(N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A reaction mixture of tert-butyl 4-(N-(3-chlorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)sulfamoyl)piperidine-1-carboxylate (0.275 g, 0.525 mmol) and triethylamine (0.293 mL, 2.099 mmol) in tetrahydrofuran (10 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.196 mL, 1.574 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.230 g, 75.0%).


[Step 4] N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide dihydrochloride



embedded image


A solution of tert-butyl 4-(N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)sulfamoyl)piperidine-1-carboxylate (0.230 g, 0.394 mmol) in 1,4-dioxane (2 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 1.969 mL, 7.876 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (5 mL) and hexane (20 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide dihydrochloride as white solid (0.206 g, 93.9%).


[Step 5] Compound 11683



embedded image


A mixture of N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide dihydrochloride (0.100 g, 0.180 mmol), oxetan-3-one (0.065 g, 0.898 mmol) and N,N-diisopropylethylamine (0.094 mL, 0.539 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.076 g, 0.359 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)piperidine-4-sulfonamide as white solid (0.076 g, 78.4%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, 1H, J=2.2 Hz), 8.41 (m, 1H), 7.72-7.67 (m, 1.25H), 7.64 (t, 1H, J=2.1 Hz), 7.56 (s, 0.5H), 7.51 (m, 1H), 7.43 (s, 0.25H), 7.37 (t, 1H, J=8.0 Hz), 7.31 (m, 1H), 5.21 (s, 2H), 4.52 (t, 2H, J=6.5 Hz), 4.42 (t, 2H, J=6.1 Hz), 3.47-3.38 (m, 2H), 2.80 (d, 2H, J=11.1 Hz), 2.11 (d, 2H, J=12.5 Hz), 1.85 (t, 2H, J=11.4 Hz), 1.77-1.64 (m, 2H); LRMS (ES) m/z 540.2 (M++1).


EXAMPLE 198
Compound 11684, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)-N-(m-tolyl)piperidine-4-sulfonamide
[Step 1] methyl 6-(((1-(tert-butoxycarbonyl)-N-(m-tolyl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A mixture of tert-butyl 4-(N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate (1.000 g, 2.821 mmol), methyl 6-(bromomethyl)nicotinate (0.844 g, 3.667 mmol), potassium carbonate (0.780 g, 5.642 mmol) and potassium iodide (0.937 g, 5.642 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 6 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=30% to 60%) to give methyl 6-(((1-(tert-butoxycarbonyl)-N-(m-tolyl)piperidine)-4-sulfonamido)methyl)nicotinate as white solid (1.230 g, 86.6%).


[Step 2] tert-butyl 4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A solution of methyl 6-(((1-(tert-butoxycarbonyl)-N-(m-tolyl)piperidine)-4-sulfonamido)methyl)nicotinate (1.230 g, 2.442 mmol) in tetrahydrofuran (7 mL)/ethanol (7 mL) was mixed at the room temperature with hydrazine monohydrate (3.561 mL, 73.271 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give tert-butyl 4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.961 g, 78.1%).


[Step 3] tert-butyl 4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate (0.961 g, 1.908 mmol) and triethylamine (1.064 mL, 7.633 mmol) in tetrahydrofuran (20 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.712 mL, 5.725 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate as white solid (0.910 g, 84.6%).


[Step 4] N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride



embedded image


A solution of tert-butyl 4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidine-1-carboxylate (0.910 g, 1.615 mmol) in 1,4-dioxane (5 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 6.055 mL, 24.218 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (10 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride as white solid (0.843 g, 97.3%).


[Step 5] Compound 11684



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride (0.100 g, 0.186 mmol), oxetan-3-one (0.067 g, 0.932 mmol) and N,N-diisopropylethylamine (0.097 mL, 0.559 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.079 g, 0.373 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ammonium chloride. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(oxetan-3-yl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.049 g, 50.6%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (dd, 1H, J=2.1, 0.8 Hz), 8.41 (dd, 1H, J=8.3, 2.3 Hz), 7.71 (d, 1H, J=8.6 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.33 (s, 1H), 7.30 (d, 1H, J=8.0 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J=7.5 Hz), 5.15 (s, 2H), 4.52 (t, 2H, J=6.5 Hz), 4.42 (t, 2H, J=6.1 Hz), 3.40 (m, 1H), 3.26 (m, 1H), 2.79 (d, 2H, J=11.0 Hz), 2.26 (s, 3H), 2.11 (d, 2H, J=12.2 Hz), 1.84 (t, 2H, J=11.4 Hz), 1.79-1.64 (m, 2H); LRMS (ES) m/z 520.3 (M++1).


EXAMPLE 199
Compound 11685, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(dimethylamino)-N-phenylpropane-1-sulfonamide
[Step 1] methyl 4-(((3-(azetidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.250 g, 0.655 mmol), azetidine hydrochloride (0.122 g, 1.309 mmol) and potassium carbonate (0.136 g, 0.982 mmol) in N,N-dimethylformide (3 mL) was stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-(((3-(azetidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as white solid (0.108 g, 42.3%).


[Step 2] 3-(dimethylamino)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl 4-(((3-(dimethylamino)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.108 g, 0.277 mmol) and hydrazine monohydrate (0.134 mL, 2.766 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give 3-(dimethylamino)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide as white solid (0.099 g, 91.5%).


[Step 3] Compound 11685



embedded image


A solution of 3-(dimethylamino)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide (0.099 g, 0.253 mmol), 2,2-difluoroacetic anhydride (0.314 mL, 2.528 mmol) and triethylamine (0.176 mL, 1.264 mmol) in tetrahydrofuran (5 mL) was stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(dimethylamino)-N-phenylpropane-1-sulfonamide as white solid (0.023 g, 20.2%).



1H NMR (400 MHz, CD3OD) δ8.03 (d, 2H, J=8.4 Hz), 7.55 (d, 2H, J=8.4 Hz), 7.43˜7.26 (m, 5H), 7.21 (t, 1H, J=51.7 Hz), 5.05 (s, 2H), 3.28 (t, 2H, J=7.6 Hz), 2.60 (t, 2H, J=7.5 Hz), 2.36 (s, 6H), 2.11˜2.03 (m, 2H); LRMS (ES) m/z 451.3 (M++1).


EXAMPLE 200
Compound 11686, 1-(bicyclo[2.2.1]heptan-2-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.093 mmol), bicyclo[2.2.1]heptan-2-one (0.021 g, 0.186 mmol) and N,N-diisopropylethylamine (0.041 mL, 0.233 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.040 g, 0.186 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=50% to 80%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(bicyclo[2.2.1]heptan-2-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.039 g, 75.0%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (dd, 1H, J=2.4, 0.8 Hz), 8.42 (dd, 1H, J=8.3, 2.3 Hz), 7.71 (d, 1H, J=8.3 Hz), 7.56 (t, 1H, J=51.2 Hz), 7.33 (s, 1H), 7.29 (d, 1H, J=8.2 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J=7.5 Hz), 5.15 (s, 2H), 3.25 (m, 1H), 3.03-2.89 (m, 2H), 2.29-2.24 (m, 4H), 2.19 (m, 1H), 2.15-2.04 (m, 3H), 1.84-1.62 (m, 6H), 1.43 (m, 1H), 1.32 (m, 1H), 1.27-1.13 (m, 3H), 0.81 (m, 1H); LRMS (ES) m/z 558.3 (M++1).


EXAMPLE 201
Compound 11687, 1-(4,4-difluorocyclohexyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.093 mmol), 4,4-difluorocyclohexan-1-one (0.025 g, 0.186 mmol) and N,N-diisopropylethylamine (0.041 mL, 0.233 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.040 g, 0.186 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=50% to 80%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(4,4-difluorocyclohexyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.036 g, 66.4%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (m, 1H), 8.41 (dd, 1H, J=8.3, 2.3 Hz), 7.71 (d, 1H, J=8.2 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.33 (s, 1H), 7.29 (d, 1H, J=8.3 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J=7.6 Hz), 5.15 (s, 2H), 3.41 (m, 1H), 3.25 (m, 1H), 2.92 (d, 2H, J=11.1 Hz), 2.26 (s, 3H), 2.19 (t, 2H, J=11.4 Hz), 2.13-1.98 (m, 4H), 1.87-1.62 (m, 6H), 1.58-1.47 (m, 2H); LRMS (ES) m/z 582.3 (M++1).


EXAMPLE 202
Compound 11688, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-((1r,4r)-4-fluorocyclohexyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.093 mmol), 4-fluorocyclohexan-1-one (0.022 g, 0.186 mmol) and N,N-diisopropylethylamine (0.041 mL, 0.233 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.040 g, 0.186 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-((1r,4r)-4-fluorocyclohexyl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.008 g, 15.2%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (m, 1H), 8.41 (dd, 1H, J=8.3, 2.3 Hz), 7.71 (d, 1H, J=8.3 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.33 (s, 1H), 7.29 (d, 1H, J=8.0 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.05 (d, 1H, J=7.7 Hz), 5.14 (s, 2H), 4.63-4.36 (ddt, 1H, J=49.3, 10.0, 5.5 Hz), 3.21 (m, 1H), 2.91 (d, 2H, J=11.1 Hz), 2.33 (m, 1H), 2.26 (s, 3H), 2.23-2.12 (m, 2H), 2.12-1.99 (m, 4H), 1.77-1.69 (m, 2H), 1.69-1.58 (m, 2H), 1.47-1.26 (m, 4H); LRMS (ES) m/z 564.2 (M++1).


EXAMPLE 203
Compound 11689, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-((1s,4s)-4-fluorocyclohexyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.093 mmol), 4-fluorocyclohexan-1-one (0.022 g, 0.186 mmol) and N,N-diisopropylethylamine (0.041 mL, 0.233 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.040 g, 0.186 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-((1s,4s)-4-fluorocyclohexyl)-N-(m-tolyl)piperidine-4-sulfonamide as light yellow solid (0.011 g, 20.9%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, 1H, J=2.2 Hz), 8.41 (dd, 1H, J=8.2, 2.3 Hz), 7.71 (d, 1H, J=8.4 Hz), 7.56 (t, 1H, J=51.2 Hz), 7.37-7.27 (m, 2H), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J=7.6 Hz), 5.15 (s, 2H), 4.76 (d, 1H, J=48.7 Hz), 3.22 (m, 1H), 2.93 (d, 2H, J=11.1 Hz), 2.37 (m, 1H), 2.28-2.17 (m, 5H), 2.09 (d, 2H, J=12.0 Hz), 1.96-1.88 (m, 2H), 1.73-1.61 (m, 2H), 1.60-1.43 (m, 6H); LRMS (ES) m/z 564.2 (M++1).


EXAMPLE 204
Compound 11690, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)piperidine-4-sulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.093 mmol), 4-(trifluoromethyl)cyclohexan-1-one (0.031 g, 0.186 mmol) and N,N-diisopropylethylamine (0.041 mL, 0.233 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.040 g, 0.186 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)piperidine-4-sulfonamide as white solid (0.009 g, 15.7%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, 1H, J=2.2 Hz), 8.41 (dd, 1H, J=8.3, 2.3 Hz), 7.72 (d, 1H, J=8.2 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.33 (s, 1H), 7.29 (d, 1H, J=8.4 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J=7.5 Hz), 5.16 (s, 2H), 3.28 (m, 1H), 3.08 (d, 2H, J=11.3 Hz), 2.33 (m, 1H), 2.26 (s, 3H), 2.23 (m, 1H), 2.15-2.06 (m, 2H), 1.96-1.82 (m, 4H), 1.75-1.58 (m, 4H), 1.57-1.48 (m, 2H), 1.42 (t, 2H, J=12.6 Hz); LRMS (ES) m/z 614.3 (M++1).


EXAMPLE 205
Compound 11691, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)-1-((1s,4s)-4-(trifluoromethyl)cyclohexyl)piperidine-4-sulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.093 mmol), 4-(trifluoromethyl)cyclohexan-1-one (0.031 g, 0.186 mmol) and N,N-diisopropylethylamine (0.041 mL, 0.233 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.040 g, 0.186 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)-1-((1s,4s)-4-(trifluoromethyl)cyclohexyl)piperidine-4-sulfonamide as white solid (0.010 g, 17.5%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, 1H, J=2.3 Hz), 8.41 (dd, 1H, J=8.2, 2.3 Hz), 7.71 (d, 1H, J=8.2 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.33 (s, 1H), 7.29 (m, 1H), 7.22 (t, 1H, J=7.7 Hz), 7.05 (d, 1H, J=7.4 Hz), 5.15 (s, 2H), 3.21 (m, 1H), 2.90 (d, 2H, J=11.1 Hz), 2.33 (m, 1H), 2.30-2.18 (m, 6H), 2.08 (d, 2H, J=11.8 Hz), 1.91-1.86 (m, 2H), 1.84-1.76 (m, 2H), 1.72-1.58 (m, 2H), 1.37-1.13 (m, 4H); LRMS (ES) m/z 614.3 (M++1).


EXAMPLE 206
Compound 11692, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(tetrahydro-2H-pyran-4-yl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.093 mmol), tetrahydro-4H-pyran-4-one (0.019 g, 0.186 mmol) and N,N-diisopropylethylamine (0.041 mL, 0.233 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.040 g, 0.186 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=70% to 100%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(tetrahydro-2H-pyran-4-yl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.044 g, 86.2%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, 1H, J=2.2 Hz), 8.42 (dd, 1H, J=8.3, 2.2 Hz), 7.71 (d, 1H, J=8.1 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.33 (s, 1H), 7.30 (d, 1H, J=8.7 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J=7.5 Hz), 5.15 (s, 2H), 3.87 (d, 2H, J=8.7 Hz), 3.31-3.21 (m, 4H), 2.97 (d, 2H, J=11.2 Hz), 2.26 (s, 3H), 2.21-2.05 (m, 4H), 1.73-1.59 (m, 4H), 1.49-1.33 (m, 2H); LRMS (ES) m/z 548.0 (M++1).


EXAMPLE 207
Compound 11693, 1-(bicyclo[2.2.1]heptan-2-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.050 g, 0.100 mmol), bicyclo[2.2.1]heptan-2-one (0.022 g, 0.200 mmol) and N,N-diisopropylethylamine (0.026 mL, 0.150 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.042 g, 0.200 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=50% to 80%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(bicyclo[2.2.1]heptan-2-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.026 g, 46.6%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.3 Hz), 7.66 (s, 0.25H), 7.56-7.47 (m, 2.5H), 7.40 (s, 0.25H), 7.28-7.16 (m, 3H), 7.04 (d, 1H, J=6.6 Hz), 5.06 (s, 2H), 3.19 (m, 1H), 3.03-2.89 (m, 2H), 2.27-2.23 (m, 4H), 2.20 (m, 1H), 2.13 (m, 1H), 2.05 (d, 2H, J=11.0 Hz), 1.84-1.63 (m, 6H), 1.45 (m, 1H), 1.32 (m, 1H), 1.27-1.13 (m, 3H), 0.83 (m, 1H); LRMS (ES) m/z 557.0 (M++1).


EXAMPLE 208
Compound 11694, 1-(4,4-difluorocyclohexyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.050 g, 0.100 mmol), 4,4-difluorocyclohexan-1-one (0.027 g, 0.200 mmol) and N,N-diisopropylethylamine (0.026 mL, 0.150 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.042 g, 0.200 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=50% to 80%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(4,4-difluorocyclohexyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.037 g, 63.6%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.55-7.47 (m, 2.5H), 7.40 (s, 0.25H), 7.27-7.18 (m, 3H), 7.04 (d, 1H, J=6.7 Hz), 5.05 (s, 2H), 3.31 (m, 1H), 3.17 (m, 1H), 2.93 (d, 2H, J=11.1 Hz), 2.25 (s, 3H), 2.19 (t, 2H, J=11.4 Hz), 2.11-1.98 (m, 4H), 1.88-1.61 (m, 6H), 1.58-1.47 (m, 2H); LRMS (ES) m/z 581.2 (M++1).


EXAMPLE 209
Compound 11695, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-((1r,4r)-4-fluorocyclohexyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.050 g, 0.100 mmol), 4-fluorocyclohexan-1-one (0.023 g, 0.200 mmol) and N,N-diisopropylethylamine (0.026 mL, 0.150 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.042 g, 0.200 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-((1r,4r)-4-fluorocyclohexyl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.011 g, 19.5%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.55-7.47 (m, 2.5H), 7.40 (s, 0.25H), 7.27-7.15 (m, 3H), 7.04 (m, 1H), 5.05 (s, 2H), 4.49 (dt, 1H, J=10.3, 5.6 Hz), 3.16 (m, 1H), 2.91 (d, 2H, J=11.1 Hz), 2.35 (m, 1H), 2.25 (s, 3H), 2.22-2.12 (m, 2H), 2.09-1.98 (m, 4H), 1.77-1.58 (m, 4H), 1.50-1.26 (m, 4H); LRMS (ES) m/z 563.2 (M++1).


EXAMPLE 210
Compound 11696, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-((1s,4s)-4-fluorocyclohexyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.050 g, 0.100 mmol), 4-fluorocyclohexan-1-one (0.023 g, 0.200 mmol) and N,N-diisopropylethylamine (0.026 mL, 0.150 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.042 g, 0.200 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-((1s,4s)-4-fluorocyclohexyl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.013 g, 23.1%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.55-7.47 (m, 2.5H), 7.40 (s, 0.25H), 7.28-7.16 (m, 3H), 7.04 (m, 1H), 5.06 (s, 2H), 4.76 (d, 1H, J=49.0 Hz), 3.17 (m, 1H), 2.93 (d, 2H, J=11.1 Hz), 2.36 (m, 1H), 2.27-2.12 (m, 5H), 2.11-2.03 (m, 2H), 2.02-1.88 (m, 2H), 1.74-1.62 (m, 2H), 1.59-1.38 (m, 6H); LRMS (ES) m/z 563.3 (M++1).


EXAMPLE 211
Compound 11697, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.050 g, 0.100 mmol), 4-(trifluoromethyl)cyclohexan-1-one (0.033 g, 0.200 mmol) and N,N-diisopropylethylamine (0.026 mL, 0.150 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.042 g, 0.200 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)piperidine-4-sulfonamide as white solid (0.013 g, 21.2%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.55-7.47 (m, 2.5H), 7.40 (s, 0.25H), 7.29-7.15 (m, 3H), 7.04 (m, 1H), 5.06 (s, 2H), 3.21 (m, 1H), 3.09 (d, 2H, J=11.3 Hz), 2.34 (m, 1H), 2.27-2.20 (m, 4H), 2.07 (d, 2H, J=12.3 Hz), 1.96-1.85 (m, 4H), 1.75-1.58 (m, 4H), 1.57-1.48 (m, 2H), 1.42 (t, 2H, J=12.5 Hz); LRMS (ES) m/z 613.3 (M++1).


EXAMPLE 212
Compound 11698, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)-1-((1s,4s)-4-(trifluoromethyl)cyclohexyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.050 g, 0.100 mmol), 4-(trifluoromethyl)cyclohexan-1-one (0.033 g, 0.200 mmol) and N,N-diisopropylethylamine (0.026 mL, 0.150 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.042 g, 0.200 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)-1-((1s,4s)-4-(trifluoromethyl)cyclohexyl)piperidine-4-sulfonamide as white solid (0.016 g, 26.1%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.55-7.47 (m, 2.5H), 7.40 (s, 0.25H), 7.27-7.16 (m, 3H), 7.04 (d, 1H, J=6.8 Hz), 5.05 (s, 2H), 3.15 (m, 1H), 2.90 (d, 2H, J=11.0 Hz), 2.34 (m, 1H), 2.29-2.14 (m, 6H), 2.06 (d, 2H, J=11.8 Hz), 1.93-1.75 (m, 4H), 1.72-1.61 (m, 2H), 1.34-1.21 (m, 4H); LRMS (ES) m/z 613.3 (M++1).


EXAMPLE 213
Compound 11699, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(tetrahydro-2H-pyran-4-yl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.050 g, 0.100 mmol), tetrahydro-4H-pyran-4-one (0.020 g, 0.200 mmol) and N,N-diisopropylethylamine (0.026 mL, 0.150 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.042 g, 0.200 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=70% to 100%) to give the concentrate, and then the concentrate was dissolved in ethyl acetate (3 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(tetrahydro-2H-pyran-4-yl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.030 g, 54.8%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J J=8.4 Hz), 7.66 (s, 0.25H), 7.55-7.47 (m, 2.5H), 7.40 (s, 0.25H), 7.27-7.16 (m, 3H), 7.04 (d, 1H, J=6.6 Hz), 5.06 (s, 2H), 3.92-3.84 (m, 2H), 3.31-3.22 (m, 2H), 3.18 (m, 1H), 2.98 (d, 2H, J=11.0 Hz), 2.45 (m, 1H), 2.25 (s, 3H), 2.16 (t, 2H, J=11.4 Hz), 2.07 (d, 2H, J=12.4 Hz), 1.74-1.59 (m, 4H), 1.49-1.34 (qd, 2H, J=12.0, 4.4 Hz); LRMS (ES) m/z 547.3 (M++1).


EXAMPLE 214
Compound 11700, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxypiperidin-1-yl)-N-phenylethanesulfonamide
[Step 1] methyl 4-((2-(3-hydroxypiperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.200 g, 0.604 mmol), piperidin-3-ol (0.082 g, 0.604 mmol) and N,N-Diisopropylethylamine (0.208 mL, 1.207 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give methyl 4-((2-(3-hydroxypiperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate as white solid (0.220 g, 84.3%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-2-(3-hydroxypiperidin-1-yl)-N-phenylethanesulfonamide



embedded image


A mixture of methyl 4-((2-(3-hydroxypiperidin-1-yl)-N-phenylethylsulfonamido)methyl)benzoate (0.220 g, 0.509 mmol) and hydrazine (0.319 mL, 10.173 mmol) in ethanol (5 mL) prepared at the room temperature was heated at reflux for 6 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (20 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-2-(3-hydroxypiperidin-1-yl)-N-phenylethanesulfonamide as white solid (0.130 g, 59.1%).


[Step 3] Compound 11700



embedded image


A mixture of N-(4-(hydrazinecarbonyl)benzyl)-2-(3-hydroxypiperidin-1-yl)-N-phenylethanesulfonamide (0.130 g, 0.301 mmol), 2,2-difluoroacetic anhydride (0.112 mL, 0.902 mmol) and Triethylamine (0.209 mL, 1.503 mmol) in tetrahydrofuran (10 mL) was heated at reflux for 12 hr, cooled down to the ambient temperature, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxypiperidin-1-yl)-N-phenylethanesulfonamide as yellow solid (0.001 g, 0.7%).



1H NMR (400 MHz, CD3OD) δ8.03 (d, 2H, J=8.44 Hz), 7.56 (d, 2H, J=8.48 Hz), 7.45-7.29 (m, 5H), 7.21 (t, 1H, J=51.6 Hz), 5.07 (s, 2H), 3.75-3.65 (m, 2H), 3.44-3.40 (m, 2H), 2.93-2.89 (m, 1H), 2.23-2.12 (m, 1H), 2.14-2.01 (m, 1H), 1.95-1.85 (m, 1H), 1.91-1.86 (m, 1H), 1.86-1.78 (m, 1H), 1.82-1.77 (m, 1H), 1.64-1.50 (m, 1H), 1.32-1.24 (m, 1H); LRMS (ES) m/z 493.3 (M++1).


EXAMPLE 215
Compound 11705, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(3-fluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide
[Step 1] methyl (S)-4-(((3-(3-fluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.250 g, 0.655 mmol), (S)-3-fluoropyrrolidine hydrochloride (0.123 g, 0.982 mmol) and potassium carbonate (0.136 g, 0.982 mmol) in N,N-dimethylformide (3 mL) was stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl (S)-4-(((3-(3-fluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as colorless oil (0.162 g, 57.0%).


[Step 2] (S)-3-(3-fluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl (S)-4-(((3-(3-fluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.162 g, 0.373 mmol) and hydrazine monohydrate (0.181 mL, 3.730 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give (S)-3-(3-fluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide as white solid (0.106 g, 65.4%).


[Step 3] Compound 11705



embedded image


A solution of (S)-3-(3-fluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide (0.106 g, 0.244 mmol), 2,2-difluoroacetic anhydride (0.303 mL, 2.439 mmol) and triethylamine (0.170 mL, 1.220 mmol) in tetrahydrofuran (5 mL) was stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(3-fluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide as colorless oil (0.059 g, 49.0%).



1H NMR (400 MHz, CD3OD) δ8.00 (d, 2H, J=8.4 Hz), 7.54 (d, 2H, J=8.6 Hz), 7.43˜7.25 (m, 5H), 7.21 (t, 1H, J=51.7 Hz), 5.26˜5.09 (m, 1H), 5.05 (s, 2H), 3.31˜3.26 (m, 2H), 2.99˜2.88 (m, 2H), 2.69 (dd, 1H, J=11.7, 4.9 Hz), 2.65˜2.59 (m, 2H), 2.41 (q, 1H, J=8.0 Hz), 2.28˜2.14 (m, 1H), 2.12˜2.03 (m, 2H), 2.02˜1.93 (m, 1H); LRMS (ES) m/z 495.3 (M++1).


EXAMPLE 216
Compound 11706, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide
[Step 1] methyl 4-(((3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.250 g, 0.655 mmol), 3,3-difluoropyrrolidine hydrochloride (0.188 g, 1.309 mmol) and potassium carbonate (0.136 g, 0.982 mmol) in N,N-dimethylformide (3 mL) was stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as yellow oil (0.277 g, 93.5%).


[Step 2] 3-(3,3-difluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl 4-(((3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.277 g, 0.612 mmol) and hydrazine monohydrate (0.297 mL, 6.119 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give 3-(3,3-difluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide as white solid (0.139 g, 50.2%).


[Step 3] Compound 11706



embedded image


A solution of 3-(3,3-difluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide (0.139 g, 0.307 mmol), 2,2-difluoroacetic anhydride (0.382 mL, 3.072 mmol) and triethylamine (0.214 mL, 1.536 mmol) in tetrahydrofuran (5 mL) was stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide as colorless oil (0.079 g, 49.9%).



1H NMR (400 MHz, CD3OD) δ7.99 (d, 2H, J=8.5 Hz), 7.53 (d, 2H, J=8.5 Hz), 7.42˜7.26 (m, 5H), 7.20 (t, 1H, J=51.7 Hz), 5.05 (s, 2H), 4.22 (t, 2H, J=6.1 Hz), 3.68 (q, 2H, J=11.6 Hz), 3.61˜3.54 (m, 2H), 3.32˜3.30 (m, 2H), 2.44˜2.34 (m, 2H), 2.25˜2.18 (m, 2H); LRMS (ES) m/z 557.3 (M++1).


EXAMPLE 217
Compound 11707, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(2-methylpyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide
[Step 1] methyl (S)-4-(((3-(2-methylpyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.250 g, 0.655 mmol), (S)-2-methylpyrrolidine hydrochloride (0.076 g, 0.622 mmol) and potassium carbonate (0.136 g, 0.982 mmol) in N,N-dimethylformide (3 mL) was stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl (S)-4-(((3-(2-methylpyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as white solid (0.158 g, 56.0%).


[Step 2] (S)—N-(4-(hydrazinecarbonyl)benzyl)-3-(2-methylpyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl (S)-4-(((3-(2-methylpyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.158 g, 0.367 mmol) and hydrazine monohydrate (0.178 mL, 3.667 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give (S)—N-(4-(hydrazinecarbonyl)benzyl)-3-(2-methylpyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide as white solid (0.110 g, 69.7%).


[Step 3] Compound 11707



embedded image


A solution of (S)—N-(4-(hydrazinecarbonyl)benzyl)-3-(2-methylpyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide (0.110 g, 0.255 mmol), 2,2-difluoroacetic anhydride (0.318 mL, 2.555 mmol) and triethylamine (0.178 mL, 1.277 mmol) in tetrahydrofuran (5 mL) was stirred at 80° C. for 1 hr, and cooled down to the room temperature to terminate the reaction. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(2-methylpyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide as yellow solid (0.083 g, 66.4%).



1H NMR (400 MHz, CD3OD) δ8.00 (d, 2H, J=8.5 Hz), 7.54 (d, 2H, J=8.5 Hz), 7.43˜7.27 (m, 5H), 7.22 (t, 1H, J=51.7 Hz), 5.05 (s, 2H), 3.74 (brs, 1H), 3.55 (brs, 1H), 3.47˜3.39 (m, 3H), 3.16˜3.14 (m, 2H), 2.34˜2.26 (m, 3H), 2.11˜2.08 (m, 2H), 1.79˜1.76 (m, 1H), 1.45 (d, 3H, J=5.4 Hz); LRMS (ES) m/z 491.3 (M++1).


EXAMPLE 218
Compound 11708, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-hydroxy-N-phenylpropane-1-sulfonamide
[Step 1] methyl (R)-4-(((3-(3-fluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)benzoate (0.250 g, 0.655 mmol), (R)-3-fluoropyrrolidine hydrochloride (0.123 g, 0.982 mmol) and potassium carbonate (0.136 g, 0.982 mmol) in N,N-dimethylformide (3 mL) was stirred at 80° C. for 18 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl (R)-4-(((3-(3-fluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate as colorless oil (0.225 g, 79.1%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-3-hydroxy-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl (R)-4-(((3-(3-fluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.225 g, 0.518 mmol) and hydrazine monohydrate (0.252 mL, 5.178 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-3-hydroxy-N-phenylpropane-1-sulfonamide as white solid (0.180 g, 95.7%).


[Step 3] Compound 11708



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-3-hydroxy-N-phenylpropane-1-sulfonamide (0.100 g, 0.275 mmol), 2,2-difluoroacetic anhydride (0.342 mL, 2.752 mmol) and triethylamine (0.192 mL, 1.376 mmol) in tetrahydrofuran (5 mL) was stirred at 80° C. for 1 hr, and cooled down to the room temperature to terminate the reaction. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-hydroxy-N-phenylpropane-1-sulfonamide as colorless oil (0.036 g, 30.9%).



1H NMR (400 MHz, CD3OD) δ8.04 (d, 2H, J=8.5 Hz), 7.48 (d, 2H, J=8.6 Hz), 7.35˜7.28 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 3.82 (t, 2H, J=5.9 Hz), 3.27 (dd, 1H, J=8.8, 6.2 Hz), 2.29˜2.12 (m, 2H), 1.74 (brs, 1H); LRMS (ES) m/z 424.3 (M++1).


EXAMPLE 219
Compound 11709, 3-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)propyl 2,2-difluoroacetate



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-3-hydroxy-N-phenylpropane-1-sulfonamide (0.080 g, 0.220 mmol), 2,2-difluoroacetic anhydride (0.274 mL, 2.201 mmol) and triethylamine (0.153 mL, 1.101 mmol) in tetrahydrofuran (5 mL) was stirred at 80° C. for 1 hr, and cooled down to the room temperature to terminate the reaction. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=20% to 80%) to give 3-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)propyl 2,2-difluoroacetate as colorless oil (0.029 g, 26.5%).



1H NMR (400 MHz, CD3OD) δ8.02 (d, 2H, J=8.6 Hz), 7.54 (d, 2H, J=8.6 Hz), 7.42˜7.26 (m, 5H), 7.21 (t, 1H, J=51.6 Hz), 5.05 (s, 2H), 4.43 (t, 2H, J=6.3 Hz), 3.37˜3.35 (m, 2H), 2.32˜2.25 (m, 2H); LRMS (ES) m/z 502.1 (M++1).


EXAMPLE 220
Compound 11710, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide
[Step 1] methyl 6-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)nicotinate



embedded image


A solution of 3-chloro-N-phenylpropane-1-sulfonamide (2.000 g, 8.558 mmol) and potassium carbonate (1.774 g, 12.836 mmol) in N,N-dimethylformide (100 mL) was stirred at the room temperature for 30 min, and mixed with methyl 4-(bromomethyl)-3-fluorobenzoate (2.067 g, 8.985 mmol) and potassium iodide (0.710 g, 4.279 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 24 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 6-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)nicotinate as yellow solid (2.000 g, 61.0%).


[Step 2] methyl 6-(((N-phenyl-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)nicotinate (0.200 g, 0.522 mmol), N,N-Diisopropylethylamine (0.136 mL, 0.784 mmol) and pyrrolidine (0.074 g, 1.045 mmol) in tetrahydrofuran (10 mL) was stirred at 70° C. for 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-(((N-phenyl-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)nicotinate as yellow solid (0.130 g, 59.6%).


[Step 3] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide



embedded image


A solution of methyl 6-(((N-phenyl-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)nicotinate (0.130 g, 0.311 mmol) and hydrazine monohydrate (0.151 mL, 3.114 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (5 mL) and sodium bicarbonate (3 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide as white solid (0.098 g, 75.4%).


[Step 4] Compound 11710



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide (0.070 g, 0.168 mmol), triethylamine (0.117 mL, 0.838 mmol) and 2,2-difluoroacetic anhydride (0.063 mL, 0.503 mmol) in tetrahydrofuran (10 mL) was stirred at 70° C. for 12 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenyl-3-(pyrrolidin-1-yl)propane-1-sulfonamide as yellow solid (0.049 g, 61.2%).



1H NMR (400 MHz, CDCl3) δ 9.24 (s, 1H), 8.38-8.36 (m, 1H), 7.69 (d, 1H, J=8.3 Hz), 7.45-7.28 (m, 5H), 7.07 (s, 0.2H), 6.94 (s, 0.5H), 6.81 (s, 0.3H), 5.17 (s, 2H), 3.14-3.37 (m, 2H), 2.95-2.90 (m, 6H), 2.32-2.30 (m, 2H), 2.06-1.98 (m, 4H); LRMS (ES) m/z 478.3 (M++1).


EXAMPLE 221
Compound 11711, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3-morpholinopropane-1-sulfonamide
[Step 1] 3-chloro-N-(3-chloro-4-fluorophenyl)propane-1-sulfonamide



embedded image


A solution of 3-chloro-4-fluoroaniline (5.000 g, 34.350 mmol) and pyridine (5.534 mL, 68.700 mmol) in dichloromethane (50 mL) was mixed at the room temperature with 3-chloropropane-1-sulfonyl chloride (4.594 mL, 37.785 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 80 g cartridge; ethyl acetate/hexane=0% to 30%) to give 3-chloro-N-(3-chloro-4-fluorophenyl)propane-1-sulfonamide as brown solid (8.700 g, 88.5%).


[Step 2] Methyl 6-(((3-chloro-N-(3-chloro-4-fluorophenyl)propyl)sulfonamido)methyl)nicotinate



embedded image


3-chloro-N-(3-chloro-4-fluorophenyl)propane-1-sulfonamide (2.500 g, 8.737 mmol), methyl 6-(bromomethyl)nicotinate (2.010 g, 8.737 mmol), potassium carbonate (2.415 g, 17.474 mmol) and potassium iodide (0.725 g, 4.368 mmol) were mixed at the room temperature in N,N-dimethylformide (20 mL), stirred at 50° C. for 18 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=0% to 80%) to give methyl 6-(((3-chloro-N-(3-chloro-4-fluorophenyl)propyl)sulfonamido)methyl)nicotinate as res oil (3.800 g, 99.9%).


[Step 3] methyl 6-(((N-(3-chloro-4-fluorophenyl)-3-morpholinopropyl)sulfonamido)methyl)nicotinate



embedded image


Methyl 6-(((3-chloro-N-(3-chloro-4-fluorophenyl)propyl)sulfonamido)methyl)nicotinate (0.200 g, 0.459 mmol), morpholine (0.048 mL, 0.551 mmol), potassium carbonate (0.127 g, 0.919 mmol) and potassium iodide (0.008 g, 0.046 mmol) were mixed at the room temperature in N,N-dimethylformide (15 mL), stirred at 80° C. for 18 hr, and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give methyl 6-(((N-(3-chloro-4-fluorophenyl)-3-morpholinopropyl)sulfonamido)methyl)nicotinate as yellow oil (0.058 g, 26.0%).


[Step 4] N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-morpholinopropane-1-sulfonamide



embedded image


methyl 6-(((N-(3-chloro-4-fluorophenyl)-3-morpholinopropyl)sulfonamido)methyl)nicotinate (0.058 g, 0.119 mmol) and hydrazine monohydrate (0.174 mL, 3.581 mmol) were mixed at the room temperature in ethanol (10 mL), stirred at 70° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-morpholinopropane-1-sulfonamide, 0.057 g, 98.3%, white solid).


[Step 5] Compound 11711



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-morpholinopropane-1-sulfonamide (0.057 g, 0.117 mmol) and triethylamine (0.033 mL, 0.235 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.044 mL, 0.352 mmol), stirred at 80° C. for 2 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3-morpholinopropane-1-sulfonamide as yellow solid (0.025 g, 39.0%).



1H NMR (400 MHz, CDCl3) δ 9.23-9.22 (m, 1H), 8.38 (dd, 1H, J=8.2, 2.2 Hz), 7.63 (d, 1H, J=8.2 Hz), 7.52-7.50 (m, 1H), 7.33-7.29 (m, 1H), 7.11-7.06 (m, 1H), 7.06 (s, 0.25H), 6.93 (s, 0.5H), 6.80 (s, 0.25H), 5.07 (s, 2H), ; LRMS (ES) m/z 546.3 (M++1).


EXAMPLE 222
Compound 11712, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(2-methylisoindolin-4-yl)ethanesulfonamide
[Step 1] tert-butyl 4-(ethylsulfonamido)isoindoline-2-carboxylate



embedded image


A solution of tert-butyl 4-aminoisoindoline-2-carboxylate (2.000 g, 8.536 mmol) in dichloromethane (50 mL) was mixed at the room temperature with ethanesulfonyl chloride (0.887 mL, 9.390 mmol) and triethylamine (1.785 mL, 12.804 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=10% to 30%) to give tert-butyl 4-(ethylsulfonamido)isoindoline-2-carboxylate as white solid (2.770 g, 99.4%).


[Step 2] tert-butyl 4-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)isoindoline-2-carboxylate



embedded image


A mixture of tert-butyl 4-(ethylsulfonamido)isoindoline-2-carboxylate (1.380 g, 4.228 mmol), methyl 6-(bromomethyl)nicotinate (1.264 g, 5.496 mmol), potassium iodide (1.404 g, 8.456 mmol) and potassium carbonate (1.169 g, 8.456 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)isoindoline-2-carboxylate as brown solid (0.506 g, 25.2%).


[Step 3] methyl 6-((N-(isoindolin-4-yl)ethylsulfonamido)methyl)nicotinate dihydrochloride



embedded image


A solution of tert-butyl 4-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)ethylsulfonamido)isoindoline-2-carboxylate (0.506 g, 1.064 mmol) in 1,4-dioxane (5 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 5.320 mL, 21.280 mmol), stirred at the same temperature for 3 hr, and concentrated under the reduced pressure to remove the solvent. The residue was diluted with ethyl acetate (10 mL) and hexane (10 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give methyl 6-((N-(isoindolin-4-yl)ethylsulfonamido)methyl)nicotinate dihydrochloride as brown solid (0.420 g, 88.0%).


[Step 4] methyl 6-((N-(2-methylisoindolin-4-yl)ethylsulfonamido)methyl)nicotinate



embedded image


A mixture of methyl 6-((N-(isoindolin-4-yl)ethylsulfonamido)methyl)nicotinate dihydrochloride (0.200 g, 0.446 mmol), paraformaldehyde (0.067 g, 2.230 mmol) and N,N-diisopropylethylamine (0.194 mL, 1.115 mmol) in dichloromethane (10 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.189 g, 0.892 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give methyl 6-((N-(2-methylisoindolin-4-yl)ethylsulfonamido)methyl)nicotinate as brown solid (0.077 g, 44.3%).


[Step 5] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(2-methylisoindolin-4-yl)ethanesulfonamide



embedded image


methyl 6-((N-(2-methylisoindolin-4-yl)ethylsulfonamido)methyl)nicotinate (0.077 g, 0.198 mmol) and hydrazine monohydrate (0.480 mL, 9.885 mmol) were mixed at the room temperature in ethanol (5 mL), stirred at 110° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(2-methylisoindolin-4-yl)ethanesulfonamide, 0.077 g, 100.0%, brown solid).


[Step 6] Compound 11712



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(2-methylisoindolin-4-yl)ethanesulfonamide (0.077 g, 0.198 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.074 mL, 0.593 mmol) and triethylamine (0.110 mL, 0.791 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(2-methylisoindolin-4-yl)ethanesulfonamide as beige solid (0.046 g, 51.8%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (m, 1H), 8.42 (dd, 1H, J=8.2, 2.3 Hz), 7.73-7.65 (m, 1.25H), 7.56 (s, 0.5H), 7.43 (s, 0.25H), 7.32 (d, 1H, J=7.6 Hz), 7.21 (t, 1H, J=7.6 Hz), 7.16 (d, 1H, J=7.3 Hz), 5.00 (s, 2H), 3.85 (s, 2H), 3.76 (s, 2H), 3.48-3.40 (m, 2H), 2.41 (s, 3H), 1.31 (t, 3H, J=7.3 Hz); LRMS (ES) m/z 450.3 (M++1).


EXAMPLE 223
Compound 11717, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-N-phenylethanesulfonamide
[Step 1] Methyl 4-(((2-(4-(2-hydroxyethyl)piperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-phenylvinylsulfonamido)methyl)benzoate (0.300 g, 0.905 mmol), 2-(piperazin-1-yl)ethanol (0.122 mL, 0.996 mmol) and N,N-diisopropylethylamine (0.312 mL, 1.811 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give methyl 4-(((2-(4-(2-hydroxyethyl)piperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate as white solid (0.350 g, 83.8%).


[Step 2] N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-N-phenylethanesulfonamide



embedded image


A solution of methyl 4-(((2-(4-(2-hydroxyethyl)piperazin-1-yl)-N-phenylethyl)sulfonamido)methyl)benzoate (0.350 g, 0.758 mmol) and hydrazine (0.476 mL, 15.166 mmol) in ethanol (5 mL) prepared at the room temperature was heated at the reflux for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-N-phenylethanesulfonamide as white solid (0.130 g, 37.1%).


[Step 3] Compound 11717



embedded image


A mixture of N-(4-(hydrazinecarbonyl)benzyl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-N-phenylethanesulfonamide (0.130 g, 0.282 mmol), 2,2-difluoroacetic anhydride (0.105 mL, 0.845 mmol) and triethylamine (0.196 mL, 1.408 mmol) in tetrahydrofuran (5 mL) was heated at reflux for 6 hr, and cooled down to the ambient temperature. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-N-phenylethanesulfonamide as orange solid (0.070 g, 47.7%).



1H NMR (400 MHz, DMSO-d6) δ7.99(d, 2H, J=8.4 Hz), 7.54-7.52 (m, 2H), 7.43-7.24 (m, 6H), 5.04 (s, 2H), 3.77-3.76 (m, 2H), 3.49-3.45 (m, 4H), 3.18 (m, 2H), 3.04 (m, 4H), 2.84 (m, 2H), 2.50 (m, 2H); LRMS (ES) m/z 522.0 (M++1).


EXAMPLE 224
Compound 11718, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3-morpholino-N-phenylpropane-1-sulfonamide
[Step 1] methyl 6-(((3-morpholino-N-phenylpropyl)sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)nicotinate (0.150 g, 0.392 mmol), N,N-diisopropylethylamine (0.341 mL, 1.959 mmol) and morpholine (0.102 mL, 1.175 mmol) in tetrahydrofuran (10 mL) was stirred at 70° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-(((3-morpholino-N-phenylpropyl) sulfonamido)methyl)nicotinate as yellow solid (0.080 g, 47.1%).


[Step 2] N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-morpholino-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl 6-(((3-morpholino-N-phenylpropyl) sulfonamido)methyl)nicotinate (0.080 g, 0.185 mmol) and hydrazine monohydrate (0.090 mL, 1.845 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-morpholino-N-phenylpropane-1-sulfonamide, 0.069 g, 86.2%, white solid).


[Step 3] Compound 11718



embedded image


A solution of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-morpholino-N-phenylpropane-1-sulfonamide (0.100 g, 0.231 mmol), triethylamine (0.161 mL, 1.153 mmol) and 2,2-difluoroacetic anhydride (0.086 mL, 0.692 mmol) in tetrahydrofuran (10 mL) was stirred at 70° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3-morpholino-N-phenylpropane-1-sulfonamide as yellow solid (0.041 g, 36.0%).



1H NMR (400 MHz, CDCl3) δ 9.25-9.24 (m, 1H), 8.38-8.36 (m, 1H), 7.73-7.70 (m, 1H), 7.44-7.30 (m, 5H), 5.17 (s, 2H), 3.76-3.73 (m, 4H), 3.33-3.29 (m, 2H), 2.55-2.46 (m, 6H), 2.16-2.14 (m, 2H); LRMS (ES) m/z 494.3 (M++1).


EXAMPLE 225
Compound 11719, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide
[Step 1] methyl 6-(((3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((3-chloro-N-phenylpropyl)sulfonamido)methyl)nicotinate (0.150 g, 0.392 mmol), N,N-diisopropylethylamine (0.341 mL, 1.959 mmol) and 3,3-difluoropyrrolidine (0.126 g, 1.175 mmol) in tetrahydrofuran (10 mL) was stirred at 70° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-(((3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)nicotinate as yellow solid (0.049 g, 27.6%).


[Step 2] 3-(3,3-difluoropyrrolidin-1-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl 6-(((3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)nicotinate (0.049 g, 0.108 mmol) and hydrazine monohydrate (0.053 mL, 1.080 mmol) in ethanol (5 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (3-(3,3-difluoropyrrolidin-1-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpropane-1-sulfonamide, 0.023 g, 46.9%, yellow solid).


[Step 3] Compound 11719



embedded image


A solution of 3-(3,3-difluoropyrrolidin-1-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpropane-1-sulfonamide (0.057 g, 0.126 mmol), triethylamine (0.088 mL, 0.628 mmol) and 2,2-difluoroacetic anhydride (0.047 mL, 0.377 mmol) in tetrahydrofuran (10 mL) was stirred at 70° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3-(3,3-difluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide as yellow solid (0.019 g, 29.4%).



1H NMR (400 MHz, CDCl3) δ 9.23-9.22 (m, 1H), 8.38-8.36 (m, 1H), 7.72-7.70 (m, 1H), 7.44-7.27 (m, 5H), 7.07 (s, 0.2H), 6.94 (s, 0.5H), 6.81 (s, 0.2H), 5.16 (s, 2H), 3.31-3.28 (m, 2H), 2.97-2.91 (m, 2H), 2.79 (brs, 2H), 2.66 (brs, 2H), 2.35-2.25 (m, 2H), 2.11-2.04 (m, 2H); LRMS (ES) m/z 514.3 (M++1).


EXAMPLE 226
Compound 11721, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide
[Step 1] Methyl 6-(((N-(3-chloro-4-fluorophenyl)-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)nicotinate



embedded image


methyl 6-(((3-chloro-N-(3-chloro-4-fluorophenyl)propyl)sulfonamido)methyl)nicotinate (0.200 g, 0.459 mmol), pyrrolidine (0.057 mL, 0.689 mmol) and N,N-diisopropylethylamine (0.160 mL, 0.919 mmol) were mixed at the room temperature in tetrahydrofuran (10 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 20%) to give methyl 6-(((N-(3-chloro-4-fluorophenyl)-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)nicotinate as yellow solid (0.123 g, 57.0%).


[Step 2] N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide



embedded image


methyl 6-(((N-(3-chloro-4-fluorophenyl)-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)nicotinate (0.123 g, 0.262 mmol) and hydrazine monohydrate (0.382 mL, 7.852 mmol) were mixed at the room temperature in ethanol (10 mL), stirred at 70° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide, 0.121 g, 98.4%, colorless oil).


[Step 3] Compound 11721



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide (0.130 g, 0.277 mmol) and triethylamine (0.116 mL, 0.830 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.103 mL, 0.830 mmol), stirred at 70° C. for 2 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 20%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide as yellow solid (0.056 g, 38.2%).



1H NMR (400 MHz, CDCl3) δ 9.21-9.21 (m, 1H), 8.36 (dd, 1H, J=8.2, 2.2 Hz), 7.63 (d, 1H, J=8.2 Hz), 7.52-7.50 (m, 1H), 7.32-7.28 (m, 1H), 7.10-7.06 (m, 1H), 7.05 (s, 0.25H), 6.92 (s, 0.5H), 6.79 (s, 0.25H), 5.07 (s, 2H), 3.30-3.26 (m, 2H), 2.70-2.66 (m, 2H), 2.65-2.58 (m, 4H), 2.14-2.02 (m, 2H), 1.86-1.81 (m, 4H); LRMS (ES) m/z 530.2 (M++1).


EXAMPLE 227
Compound 11722, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide
[Step 1] Methyl 4-(((3-chloro-N-(3-chloro-4-fluorophenyl)propyl)sulfonamido)methyl)benzoate



embedded image


3-chloro-N-(3-chloro-4-fluorophenyl)propane-1-sulfonamide (3.000 g, 10.484 mmol), methyl 4-(bromomethyl)benzoate (2.522 g, 11.009 mmol), potassium iodide (0.870 g, 5.242 mmol) and potassium carbonate (2.898 g, 20.969 mmol) were mixed at the room temperature in N,N-dimethylformide (20 mL), stirred at 50° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 4-(((3-chloro-N-(3-chloro-4-fluorophenyl)propyl)sulfonamido)methyl)benzoate as yellow solid (4.500 g, 98.8%).


[Step 2] Methyl 4-(((N-(3-chloro-4-fluorophenyl)-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)benzoate



embedded image


Methyl 4-(((3-chloro-N-(3-chloro-4-fluorophenyl)propyl)sulfonamido)methyl)benzoate (0.200 g, 0.461 mmol), pyrrolidine (0.076 mL, 0.921 mmol) and N,N-diisopropylethylamine (0.160 mL, 0.921 mmol) were mixed at the room temperature in tetrahydrofuran (10 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 20%) to give methyl 4-(((N-(3-chloro-4-fluorophenyl)-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)benzoate as yellow solid (0.135 g, 62.5%).


[Step 3] N-(3-chloro-4-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide



embedded image


Methyl 4-(((N-(3-chloro-4-fluorophenyl)-3-(pyrrolidin-1-yl)propyl)sulfonamido)methyl)benzoate (0.135 g, 0.288 mmol) and hydrazine monohydrate (0.420 mL, 8.636 mmol) were mixed at the room temperature in ethanol (10 mL), stirred at 70° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide, 0.130 g, 96.3%, colorless oil).


[Step 4] Compound 11722



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide (0.130 g, 0.277 mmol) and triethylamine (0.116 mL, 0.832 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.103 mL, 0.832 mmol), stirred at 70° C. for 2 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 20%) to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(pyrrolidin-1-yl)propane-1-sulfonamide as yellow solid (0.063 g, 43.0%).



1H NMR (400 MHz, CDCl3) δ 8.02-8.00 (m, 2H), 7.43 (d, 2H, J=8.4 Hz), 7.37 (dd, 1H, J=6.4, 2.6 Hz), 7.18-7.14 (m, 1H), 7.07-7.03 (m, 1H), 7.02 (s, 0.25H), 6.89 (s, 0.5H), 6.76 (s, 0.25H), 4.90 (s, 2H), 3.23-3.19 (m, 2H), 2.65-2.62 (m, 2H), 2.60-2.50 (m, 4H), 2.13-2.02 (m, 2H), 1.86-1.77 (m, 4H); LRMS (ES) m/z 529.3 (M++1).


EXAMPLE 228
Compound 11723, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-morpholinopropane-1-sulfonamide
[Step 1] Methyl 4-(((N-(3-chloro-4-fluorophenyl)-3-morpholinopropyl)sulfonamido)methyl)benzoate



embedded image


Methyl 4-(((3-chloro-N-(3-chloro-4-fluorophenyl)propyl) sulfonamido)methyl)benzoate (0.200 g, 0.461 mmol), morpholine (0.060 mL, 0.691 mmol) and N,N-diisopropylethylamine (0.160 mL, 0.921 mmol) were mixed at the room temperature in tetrahydrofuran (10 mL), stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 20%) to give methyl 4-(((N-(3-chloro-4-fluorophenyl)-3-morpholinopropyl)sulfonamido)methyl)benzoate as yellow solid (0.031 g, 13.9%)


[Step 2] N-(3-chloro-4-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)-3-morpholinopropane-1-sulfonamide



embedded image


methyl 4-(((N-(3-chloro-4-fluorophenyl)-3-morpholinopropyl)sulfonamido)methyl)benzoate (0.031 g, 0.064 mmol) and hydrazine monohydrate (0.093 mL, 1.918 mmol) were mixed at the room temperature in ethanol (10 mL), stirred at 70° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(3-chloro-4-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)-3-morpholinopropane-1-sulfonamide, 0.030 g, 96.8%, colorless oil).


[Step 3] Compound 11723



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-N-(4-(hydrazinecarbonyl)benzyl)-3-morpholinopropane-1-sulfonamide (0.030 g, 0.062 mmol) and triethylamine (0.026 mL, 0.186 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.023 mL, 0.186 mmol), stirred at 70° C. for 2 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 20%) to give N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-morpholinopropane-1-sulfonamide as yellow oil (0.020 g, 59.3%).



1H NMR (400 MHz, CDCl3) δ 8.05-8.01 (m, 2H), 7.44 (d, 2H, J=8.4 Hz), 7.37 (dd, 1H, J=6.4, 2.6 Hz), 7.18-7.14 (m, 1H), 7.10-7.05 (m, 1H), 7.02 (s, 0.25H), 6.90 (s, 0.5H), 6.77 (s, 0.25H), 4.91 (s, 2H), 3.83-3.62 (m, 4H), 3.29-3.18 (m, 2H), 2.62-2.40 (m, 6H), 2.18-2.05 (m, 2H); LRMS (ES) m/z 545.2 (M++1).


EXAMPLE 229
Compound 11724, (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(3-fluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide
[Step 1] (R)-3-(3-fluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of methyl (R)-4-(((3-(3-fluoropyrrolidin-1-yl)-N-phenylpropyl)sulfonamido)methyl)benzoate (0.095 g, 0.219 mmol) and hydrazine monohydrate (0.106 mL, 2.186 mmol) in ethanol (2 mL) was stirred at 80° C. for 18 hr and cooled down to the room temperature to terminate the reaction. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The title compound was used without further purification ((R)-3-(3-fluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide, 0.078 g, 82.1%, yellow oil).


[Step 2] (R)—N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-3-(3-fluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide



embedded image


A solution of (R)-3-(3-fluoropyrrolidin-1-yl)-N-(4-(hydrazinecarbonyl)benzyl)-N-phenylpropane-1-sulfonamide (0.078 g, 0.180 mmol), 2,2-difluoroacetic anhydride (0.045 mL, 0.359 mmol) and triethylamine (0.050 mL, 0.359 mmol) in tetrahydrofuran (2 mL) was stirred at 80° C. for 0.5 hr and cooled down to the room temperature to terminate the reaction. Then, aqueous N-sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give (R)—N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-3-(3-fluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide as white solid (0.058 g, 63.0%).


[Step 3] Compound 11724



embedded image


A solution of (R)—N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)benzyl)-3-(3-fluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide (0.058 g, 0.113 mmol), methanesulfonyl chloride (0.026 mL, 0.339 mmol) and triethylamine (0.032 mL, 0.226 mmol) in dichloromethane (2 mL) was stirred at the room temperature for 0.5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3-(3-fluoropyrrolidin-1-yl)-N-phenylpropane-1-sulfonamide as yellow oil (0.008 g, 14.3%).



1H NMR (400 MHz, CD3OD) δ8.03 (d, 2H, J=8.5 Hz), 7.56 (d, 2H, J=8.6 Hz), 7.43˜7.26 (m, 5H), 7.21 (t, 1H, J=51.6 Hz), 5.30˜5.16 (m, 1H), 5.06 (s, 2H), 3.14˜3.02 (m, 2H), 2.91˜2.83 (m, 1H), 2.79˜2.72 (m, 2H), 2.63˜2.57 (m, 1H), 2.40˜2.17 (m, 2H), 2.15˜2.00 (m, 4H); LRMS (ES) m/z 495.3 (M++1).


EXAMPLE 230
Compound 11725, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-((1r,4r)-4-fluorocyclohexyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide hydrochloride (0.150 g, 0.289 mmol), 4-fluorocyclohexan-1-one (0.101 g, 0.866 mmol) and N,N-diisopropylethylamine (0.101 mL, 0.578 mmol) in dichloromethane (6 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.122 g, 0.578 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=80% to 100%) to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-((1r,4r)-4-fluorocyclohexyl)piperidine-4-sulfonamide as white solid (0.047 g, 27.9%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.57-7.47 (m, 3.5H), 7.44 (m, 1H), 7.40 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (m, 1H), 5.11 (s, 2H), 4.48 (m, 1H), 3.28 (m, 1H), 2.91 (d, 2H, J=11.1 Hz), 2.33 (m, 1H), 2.24-2.14 (m, 2H), 2.10-1.94 (m, 4H), 1.77-1.57 (m, 4H), 1.48-1.28 (m, 4H); LRMS (ES) m/z 583.2 (M++1).


EXAMPLE 231
Compound 11726, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-((1s,4s)-4-fluorocyclohexyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide hydrochloride (0.150 g, 0.289 mmol), 4-fluorocyclohexan-1-one (0.101 g, 0.866 mmol) and N,N-diisopropylethylamine (0.101 mL, 0.578 mmol) in dichloromethane (6 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.122 g, 0.578 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=80% to 100%) to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-((1s,4s)-4-fluorocyclohexyl)piperidine-4-sulfonamide as white solid (0.036 g, 21.4%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.58-7.48 (m, 3.5H), 7.46 (m, 1H), 7.40 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (m, 1H), 5.11 (s, 2H), 4.76 (d, 1H, J=48.8 Hz), 3.28 (m, 1H), 2.93 (d, 2H, J=11.1 Hz), 2.36 (m, 1H), 2.29-2.15 (m, 2H), 2.11-2.03 (d, 2H, J=11.4 Hz), 2.01-1.84 (m, 2H), 1.66 (qd, 2H, J=12.2, 3.9 Hz), 1.60-1.40 (m, 6H); LRMS (ES) m/z 583.3 (M++1).


EXAMPLE 232
Compound 11727, N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-((1r,4r)-4-fluorocyclohexyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide dihydrochloride (0.100 g, 0.180 mmol), 4-fluorocyclohexan-1-one (0.063 g, 0.539 mmol) and N,N-diisopropylethylamine (0.094 mL, 0.539 mmol) in dichloromethane (10 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.076 g, 0.359 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=80% to 100%) to give N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-((1r,4r)-4-fluorocyclohexyl)piperidine-4-sulfonamide as white solid (0.032 g, 30.5%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (dd, 1H, J=2.2, 0.8 Hz), 8.41 (dd, 1H, J=8.3, 2.3 Hz), 7.72-7.65 (m, 1.25H), 7.62 (t, 1H, J=2.1 Hz), 7.56 (s, 0.5H), 7.50 (ddd, 1H, J=8.0, 2.2, 1.1 Hz), 7.43 (s, 0.25H), 7.37 (t, 1H, J=8.0 Hz), 7.30 (ddd, 1H, J=8.1, 2.1, 1.1 Hz), 5.20 (s, 2H), 4.49 (m, 1H), 3.31 (m, 1H), 2.91 (d, 2H, J=11.2 Hz), 2.33 (m, 1H), 2.19 (t, 2H, J=11.4 Hz), 2.11-1.97 (m, 4H), 1.77-1.57 (m, 4H), 1.46-1.29 (m, 4H); LRMS (ES) m/z 584.3 (M++1).


EXAMPLE 233
Compound 11728, N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-((1s,4s)-4-fluorocyclohexyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide dihydrochloride (0.100 g, 0.180 mmol), 4-fluorocyclohexan-1-one (0.063 g, 0.539 mmol) and N,N-diisopropylethylamine (0.094 mL, 0.539 mmol) in dichloromethane (10 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.076 g, 0.359 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=80% to 100%) to give N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-((1s,4s)-4-fluorocyclohexyl)piperidine-4-sulfonamide as white solid (0.033 g, 31.5%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (dd, 1H, J=2.3, 0.9 Hz), 8.41 (dd, 1H, J=8.2, 2.3 Hz), 7.74-7.67 (m, 1.25H), 7.63 (t, 1H, J=2.0 Hz), 7.56 (s, 0.5H), 7.50 (ddd, 1H, J=8.1, 2.2, 1.2 Hz), 7.43 (s, 0.25H), 7.37 (t, 1H, J=8.0 Hz), 7.31 (ddd, 1H, J=8.1, 2.1, 1.1 Hz), 5.20 (s, 2H), 4.76 (d, 1H, J=48.9 Hz), 3.28 (m, 1H), 2.93 (d, 2H, J=11.2 Hz), 2.36 (m, 1H), 2.29-2.19 (m, 2H), 2.13-2.05 (m, 2H), 1.99-1.87 (m, 2H), 1.71-1.60 (m, 2H), 1.60-1.42 (m, 6H); LRMS (ES) m/z 584.2 (M++1).


EXAMPLE 234
Compound 11729, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-methylisoindolin-5-yl)methanesulfonamide
[Step 1] tert-butyl 5-(methylsulfonamido)isoindoline-2-carboxylate



embedded image


A solution of tert-butyl 5-aminoisoindoline-2-carboxylate (2.000 g, 8.536 mmol) in dichloromethane (50 mL) was mixed at the room temperature with methanesulfonyl chloride (0.661 mL, 8.536 mmol) and triethylamine (1.428 mL, 10.243 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 5-(methylsulfonamido)isoindoline-2-carboxylate as white solid (2.220 g, 83.3%).


[Step 2] tert-butyl 5-(N-(4-(methoxycarbonyl)benzyl)methylsulfonamido)isoindoline-2-carboxylate



embedded image


A mixture of tert-butyl 5-(methylsulfonamido)isoindoline-2-carboxylate (0.800 g, 2.561 mmol), methyl 4-(bromomethyl)benzoate (0.763 g, 3.329 mmol), potassium iodide (0.850 g, 5.122 mmol) and potassium carbonate (0.708 g, 5.122 mmol) in N,N-dimethylformide (15 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=30% to 60%) to give tert-butyl 5-(N-(4-(methoxycarbonyl)benzyl)methylsulfonamido)isoindoline-2-carboxylate as white solid (1.000 g, 84.8%)


[Step 3] tert-butyl 5-(N-(4-(hydrazinecarbonyl)benzyl)methylsulfonamido)isoindoline-2-carboxylate



embedded image


A solution of tert-butyl 5-(N-(4-(methoxycarbonyl)benzyl)methylsulfonamido)isoindoline-2-carboxylate (1.000 g, 2.171 mmol) in tetrahydrofuran (10 mL)/ethanol (10 mL) was mixed at the room temperature with hydrazine monohydrate (2.111 mL, 43.426 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (tert-butyl 5-(N-(4-(hydrazinecarbonyl)benzyl)methylsulfonamido)isoindoline-2-carboxylate, 0.914 g, 91.4%, white solid).


[Step 4] tert-butyl 5-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methylsulfonamido)isoindoline-2-carboxylate



embedded image


A solution of tert-butyl 5-(N-(4-(hydrazinecarbonyl)benzyl)methylsulfonamido)isoindoline-2-carboxylate (0.914 g, 1.985 mmol) in tetrahydrofuran (30 mL) was mixed at 50° C. with 2,2-difluoroacetic anhydride (0.987 mL, 7.938 mmol) and triethylamine (1.383 mL, 9.923 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 5-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methylsulfonamido)isoindoline-2-carboxylate as white solid (0.963 g, 93.2%).


[Step 5] N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(isoindolin-5-yl)methanesulfonamide hydrochloride



embedded image


A solution of tert-butyl 5-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methylsulfonamido)isoindoline-2-carboxylate (0.963 g, 1.850 mmol) in 1,4-dioxane (10 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 4.625 mL, 18.500 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(isoindolin-5-yl)methanesulfonamide hydrochloride as beige solid (0.835 g, 98.8%).


[Step 6] Compound 11729



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(isoindolin-5-yl)methanesulfonamide hydrochloride (0.050 g, 0.109 mmol), paraformaldehyde (0.016 g, 0.547 mmol) and N,N-diisopropylethylamine (0.038 mL, 0.219 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.046 g, 0.219 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-methylisoindolin-5-yl)methanesulfonamide as light yellow solid (0.013 g, 27.3%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.3 Hz), 7.67 (s, 0.25H), 7.58-7.51 (m, 2.5H), 7.41 (s, 0.25H), 7.31 (s, 1H), 7.24 (dd, 1H, J=8.0, 2.0 Hz), 7.19 (d, 1H, J=8.0 Hz), 4.96 (s, 2H), 3.81 (s, 2H), 3.80 (s, 2H), 3.12 (s, 3H), 2.48 (s, 3H); LRMS (ES) m/z 435.3 (M++1).


EXAMPLE 235
Compound 11730, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-isopropylisoindolin-5-yl)methanesulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(isoindolin-5-yl)methanesulfonamide hydrochloride (0.050 g, 0.109 mmol), acetone (0.040 mL, 0.547 mmol) and N,N-diisopropylethylamine (0.038 mL, 0.219 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.046 g, 0.219 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-isopropylisoindolin-5-yl)methanesulfonamide as beige solid (0.016 g, 31.6%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=7.9 Hz), 7.66 (s, 0.25H), 7.60-7.50 (m, 2.5H), 7.41 (s, 0.25H), 7.29 (s, 1H), 7.26-7.15 (m, 2H), 4.96 (s, 2H), 3.78 (s, 4H), 3.14 (s, 3H), 2.65 (p, 1H, J=6.2 Hz), 1.05 (d, 6H, J=6.2 Hz); LRMS (ES) m/z 463.3 (M++1).


EXAMPLE 236
Compound 11731, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-(oxetan-3-yl)isoindolin-5-yl)methanesulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(isoindolin-5-yl)methanesulfonamide hydrochloride (0.050 g, 0.109 mmol), oxetan-3-one (0.039 g, 0.547 mmol) and N,N-diisopropylethylamine (0.038 mL, 0.219 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.046 g, 0.219 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-(oxetan-3-yl)isoindolin-5-yl)methanesulfonamide as beige solid (0.027 g, 51.8%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=8.2 Hz), 7.66 (s, 0.25H), 7.59-7.51 (m, 2.5H), 7.31 (s, 0.25H), 7.26 (s, 1H), 7.28-7.15 (m, 2H), 4.96 (s, 2H), 4.61 (t, 2H, J=6.6 Hz), 4.52 (t, 2H, J=5.9 Hz), 3.93 (p, 1H, J=6.1 Hz), 3.81 (s, 4H), 3.12 (s, 3H); LRMS (ES) m/z 477.3 (M++1).


EXAMPLE 237
Compound 11732, N-(2-acetylisoindolin-5-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(isoindolin-5-yl)methanesulfonamide hydrochloride (0.050 g, 0.109 mmol) in dichloromethane (5 mL) was treated at the room temperature with acetyl chloride (0.023 mL, 0.328 mmol) and N,N-diisopropylethylamine (0.038 mL, 0.219 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(2-acetylisoindolin-5-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as white solid (0.038 g, 75.1%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=7.9 Hz), 7.66 (s, 0.25H), 7.59-7.51 (m, 2.5H), 7.47-7.36 (m, 1.25H), 7.36-7.25 (m, 2H), 4.98 (s, 2H), 4.76 (s, 2H), 4.55 (d, 2H, J=6.0 Hz), 3.14 (s, 3H), 2.02 (s, 3H); LRMS (ES) m/z 463.3 (M++1).


EXAMPLE 238
Compound 11733, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(2-methylisoindolin-5-yl)methanesulfonamide
[Step 1] tert-butyl 5-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate



embedded image


A mixture of tert-butyl 5-(methylsulfonamido)isoindoline-2-carboxylate (1.420 g, 4.546 mmol), methyl 6-(bromomethyl)nicotinate (1.360 g, 5.909 mmol), potassium iodide (1.509 g, 9.091 mmol) and potassium carbonate (1.256 g, 9.091 mmol) in N,N-dimethylformide (20 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=40% to 70%) to give tert-butyl 5-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate as brown solid (1.826 g, 87.0%).


[Step 2] tert-butyl 5-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate



embedded image


A solution of tert-butyl 5-(N-((5-(methoxycarbonyl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate (1.826 g, 3.956 mmol) in tetrahydrofuran (15 mL)/ethanol (15 mL) was mixed at the room temperature with hydrazine monohydrate (3.846 mL, 79.128 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (tert-butyl 5-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate, 1.757 g, 96.2%, beige solid).


[Step 3] tert-butyl 5-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate



embedded image


A solution of tert-butyl 5-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate (1.757 g, 3.807 mmol) in tetrahydrofuran (50 mL) was mixed at 50° C. with 2,2-difluoroacetic anhydride (1.893 mL, 15.227 mmol) and triethylamine (2.653 mL, 19.034 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=30% to 70%) to give tert-butyl 5-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate as white solid (1.518 g, 76.5%).


[Step 4] N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(isoindolin-5-yl)methanesulfonamide dihydrochloride



embedded image


A solution of tert-butyl 5-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methylsulfonamido)isoindoline-2-carboxylate (1.518 g, 2.911 mmol) in 1,4-dioxane (15 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 7.277 mL, 29.106 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (10 mL) and hexane (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(isoindolin-5-yl)methanesulfonamide dihydrochloride as beige solid (1.320 g, 91.7%).


[Step 5] Compound 11733



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(isoindolin-5-yl)methanesulfonamide dihydrochloride (0.050 g, 0.101 mmol), paraformaldehyde (0.015 g, 0.506 mmol) and N,N-diisopropylethylamine (0.035 mL, 0.202 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.043 g, 0.202 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(2-methylisoindolin-5-yl)methanesulfonamide as beige solid (0.018 g, 40.9%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, 1H, J=2.2 Hz), 8.41 (dd, 1H, J=8.2, 2.2 Hz), 7.75 (d, 1H, J J=8.3 Hz), 7.57 (t, 1H, J=51.2 Hz), 7.36 (s, 1H), 7.28 (dd, 1H, J=8.1, 1.9 Hz), 7.20 (d, 1H, J=8.0 Hz), 5.07 (s, 2H), 3.78 (s, 2H), 3.76 (s, 2H), 3.16 (s, 3H), 2.45 (s, 3H); LRMS (ES) m/z 436.0 (M++1).


EXAMPLE 239
Compound 11734, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(2-isopropylisoindolin-5-yl)methanesulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(isoindolin-5-yl)methanesulfonamide dihydrochloride (0.050 g, 0.101 mmol), acetone (0.037 mL, 0.506 mmol) and N,N-diisopropylethylamine (0.035 mL, 0.202 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.043 g, 0.202 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(2-isopropylisoindolin-5-yl)methanesulfonamide as white solid (0.039 g, 83.2%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, 1H, J=2.2 Hz), 8.40 (dd, 1H, J=8.2, 2.3 Hz), 7.74 (d, 1H, J=8.3 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.35 (s, 1H), 7.27 (dd, 1H, J=8.0, 2.0 Hz), 7.20 (d, 1H, J=8.1 Hz), 5.07 (s, 2H), 3.80 (s, 2H), 3.79 (s, 2H), 3.16 (s, 3H), 2.66 (p, 1H, J=6.2 Hz), 1.06 (d, 6H, J=6.2 Hz); LRMS (ES) m/z 464.1 (M++1).


EXAMPLE 240
Compound 11735, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(2-(oxetan-3-yl)isoindolin-5-yl)methanesulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(isoindolin-5-yl)methanesulfonamide dihydrochloride (0.050 g, 0.101 mmol), oxetan-3-one (0.036 g, 0.506 mmol) and N,N-diisopropylethylamine (0.035 mL, 0.202 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.043 g, 0.202 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(2-(oxetan-3-yl)isoindolin-5-yl)methanesulfonamide as brown solid (0.012 g, 24.8%).



1H NMR (400 MHz, DMSO-d6) δ 9.11 (d, 1H, J=2.2 Hz), 8.41 (dd, 1H, J=8.2, 2.3 Hz), 7.75 (d, 1H, J J=8.3 Hz), 7.57 (t, 1H, J=51.2 Hz), 7.38 (s, 1H), 7.30 (dd, 1H, J=8.0, 2.0 Hz), 7.23 (d, 1H, J=8.0 Hz), 5.08 (s, 2H), 4.62 (t, 2H, J=6.5 Hz), 4.53 (t, 2H, J=5.7 Hz), 3.94 (p, 1H, J=6.1 Hz), 3.83 (s, 2H), 3.82 (s, 2H), 3.17 (s, 3H); LRMS (ES) m/z 478.3 (M++1).


EXAMPLE 241
Compound 11736, N-(2-acetylisoindolin-5-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(isoindolin-5-yl)methanesulfonamide dihydrochloride (0.050 g, 0.101 mmol) in dichloromethane (5 mL) was treated at the room temperature with acetyl chloride (0.022 mL, 0.303 mmol) and N,N-diisopropylethylamine (0.035 mL, 0.202 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(2-acetylisoindolin-5-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)methanesulfonamide as white solid (0.036 g, 76.8%).



1H NMR (400 MHz, DMSO-d6) δ 9.11 (d, 1H, J=2.2 Hz), 8.41 (dd, 1H, J=8.2, 2.2 Hz), 7.75 (dd, 1H, J=8.3, 3.2 Hz), 7.70 (s, 0.25H), 7.57 (s, 0.5H), 7.52-7.42 (m, 1.25H), 7.39 (td, 1H, J=8.0, 2.1 Hz), 7.33 (t, 1H, J=8.4 Hz), 5.10 (s, 2H), 4.78 (d, 2H, J=5.3 Hz), 4.56 (d, 2H, J=5.2 Hz), 3.19 (s, 3H), 2.03 (s, 3H); LRMS (ES) m/z 464.3 (M++1).


EXAMPLE 242
Compound 11737, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-methyl-1,4-diazepan-1-yl)-N-phenylethanesulfonamide
[Step 1] 4-(chloromethyl)benzohydrazide



embedded image


A solution of 4-(chloromethyl)benzoyl chloride (7.200 g, 38.087 mmol) and hydrazine (11.954 mL, 380.872 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The precipitates were collected by filtration and dried to give 4-(chloromethyl)benzohydrazide as white solid (7.000 g, 99.5%).


[Step 2] 2-(4-(chloromethyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole



embedded image


A solution of 4-(chloromethyl)benzohydrazide (7.300 g, 39.541 mmol), 2,2-difluoroacetic anhydride (14.747 mL, 118.622 mmol) and triethylamine (27.556 mL, 197.703 mmol) in tetrahydrofuran (5 mL) was stirred at the room temperature for 18 hr, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=5% to 10%) to give 2-(4-(chloromethyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole as white solid (5.012 g, 51.8%).


[Step 3] N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide



embedded image


A solution of N-phenylethenesulfonamide (0.200 g, 1.092 mmol), 2-(4-(chloromethyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.267 g, 1.092 mmol), potassium carbonate (0.151 g, 1.092 mmol) and potassium iodide (0.018 g, 0.109 mmol) in N,N-dimethylformide (5 mL) was stirred at the room temperature for 18 hr, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 10%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide as white solid (0.220 g, 51.5%).


[Step 4] Compound 11737



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-methylhomopiperazine (0.035 mL, 0.281 mmol) and N,N-Diisopropylethylamine (0.088 mL, 0.511 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr, and concentrated under the reduced pressure to remove the solvent. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-methyl-1,4-diazepan-1-yl)-N-phenylethanesulfonamide as white solid (0.016 g, 12.4%).



1H NMR (400 MHz, DMSO-d6) δ 7.98(d, 2H, J=8.4 Hz), 7.54-7.52 (m, 2H), 7.45-7.25 (m, 6H), 5.04 (s, 2H), 3.42-3.39 (m, 2H), 2.94-2.90 (m, 2H), 2.70-2.67 (m, 4H), 2.57-2.56 (m, 4H), 2.27 (s, 3H), 1.71 (m, 2H); LRMS (ES) m/z 507.0 (M++1).


EXAMPLE 243
Compound 11738, 2-(azetidin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethanesulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), azetidine (0.026 g, 0.281 mmol) and N,N-diisopropylethylamine (0.088 mL, 0.511 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr, and concentrated under the reduced pressure to remove the solvent. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(azetidin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethanesulfonamide as white solid (0.045 g, 39.3%).



1H NMR (400 MHz, DMSO-d6) δ8.98 (d, 2H, J=8.4 Hz), 7.54-7.52 (m, 2H), 7.44-7.23 (m, 6H), 5.03 (s, 2H), 3.24-3.20 (m, 2H), 3.13 (t, 4H, J=6.9 Hz), 2.77-2.73 (m, 2H), 2.00-1.93 (m, 2H); LRMS (ES) m/z 449.2 (M++1).


EXAMPLE 244
Compound 11739, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(thiazol-2-yl)methanesulfonamide
[Step 1] N-(thiazol-2-yl)methanesulfonamide



embedded image


A solution of thiazol-2-amine (0.500 g, 4.993 mmol), pyridine (0.603 mL, 7.490 mmol) and methanesulfonyl chloride (0.502 mL, 6.491 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(thiazol-2-yl)methanesulfonamide, 0.390 g, 43.8%, yellow solid).


[Step 2] methyl 4-((N-(thiazol-2-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(thiazol-2-yl)methanesulfonamide (0.300 g, 1.683 mmol) and potassium carbonate (0.349 g, 2.525 mmol) in N,N-dimethylformide (20 mL) was mixed at the room temperature with methyl 4-(bromomethyl)benzoate (4.240 g, 1.852 mmol) and potassium iodide (0.140 g, 0.842 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 20%) to give methyl 4-((N-(thiazol-2-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.210 g, 38.2%).


[Step 3] N-(4-(hydrazinecarbonyl)benzyl)-N-(thiazol-2-yl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(thiazol-2-yl)methylsulfonamido)methyl)benzoate (0.210 g, 0.643 mmol) and hydrazine monohydrate (0.313 mL, 6.434 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)benzyl)-N-(thiazol-2-yl)methanesulfonamide, 0.130 g, 61.9%, white solid).


[Step 4] Compound 11739



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-(thiazol-2-yl)methanesulfonamide (0.130 g, 0.398 mmol), triethylamine (0.278 mL, 1.991 mmol) and 2,2-difluoroacetic anhydride (0.149 mL, 1.195 mmol) in tetrahydrofuran (10 mL) was stirred at 70° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(thiazol-2-yl)methanesulfonamide as white solid (0.059 g, 38.3%).



1H NMR (400 MHz, CDCl3) δ 8.10 (d, 2H, J=8.4 Hz), 7.67 (d, 2H, J=8.5 Hz), 7.51 (d, 1H, J=3.6 Hz), 7.06 (d, 1H, J=3.6 Hz), 7.05 (s, 0.3H), 6.92 (s, 0.5H), 6.79 (s, 0.3H), 5.28 (s, 2H), 3.11 (s, 3H); LRMS (ES) m/z 387.2 (M++1).


EXAMPLE 245
Compound 11740, N-(benzo[d]thiazol-2-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide
[Step 1] N-(benzo[d]thiazol-2-yl)methanesulfonamide



embedded image


A solution of benzo[d]thiazol-2-amine (0.500 g, 3.329 mmol), pyridine (0.402 mL, 4.993 mmol) and methanesulfonyl chloride (0.335 mL, 4.328 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 5 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous 1N-hydrochloric acid solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(benzo[d]thiazol-2-yl)methanesulfonamide, 0.390 g, 51.3%, yellow solid).


[Step 2] methyl 4-((N-(benzo[d]thiazol-2-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(benzo[d]thiazol-2-yl)methanesulfonamide (0.250 g, 1.095 mmol) and potassium carbonate (0.227 g, 1.643 mmol) in N,N-dimethylformide (20 mL) was mixed at the room temperature with methyl 4-(bromomethyl)benzoate (0.276 g, 1.205 mmol) and potassium iodide (0.091 g, 0.548 mmol). The reaction mixture was stirred at the same temperature for 12 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give methyl 4-((N-(benzo[d]thiazol-2-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.190 g, 46.1%).


[Step 3] N-(benzo[d]thiazol-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(benzo[d]thiazol-2-yl)methylsulfonamido)methyl)benzoate (0.190 g, 0.505 mmol) and hydrazine monohydrate (0.245 mL, 5.047 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(benzo[d]thiazol-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide, 0.090 g, 47.4%, yellow solid).


[Step 4] Compound 11740



embedded image


A solution of N-(benzo[d]thiazol-2-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.090 g, 0.239 mmol), triethylamine (0.167 mL, 1.195 mmol) and 2,2-difluoroacetic anhydride (0.089 mL, 0.717 mmol) in tetrahydrofuran (10 mL) was stirred at 70° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(benzo[d]thiazol-2-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)methanesulfonamide as yellow solid (0.039 g, 37.4%).



1H NMR (400 MHz, CDCl3) δ 8.11 (d, 2H, J=6.8 Hz), 7.86-7.84 (m, 1H), 7.76 (d, 3H, J=7.3 Hz), 7.48-7.46 (m, 1H), 7.44-7.32 (m, 1H), 7.04 (s, 0.2H), 6.92 (s, 0.4H), 6.79 (s, 0.2H), 5.45 (s, 2H), 3.14 (s, 3H); LRMS (ES) m/z 437.2 (M++1).


EXAMPLE 246
Compound 11741, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(oxazol-2-yl)methanesulfonamide
[Step 1] N-(oxazol-2-yl)methanesulfonamide



embedded image


A solution of oxazol-2-amine (0.300 g, 3.568 mmol), methanesulfonyl chloride (0.304 mL, 3.925 mmol) and triethylamine (0.746 mL, 5.352 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(oxazol-2-yl)methanesulfonamide as yellow oil (0.150 g, 25.9%).


[Step 2] methyl 4-((N-(oxazol-2-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(oxazol-2-yl)methanesulfonamide (0.200 g, 1.233 mmol), methyl 4-(bromomethyl)benzoate (0.339 g, 1.480 mmol), potassium carbonate (0.205 g, 1.480 mmol) and potassium iodide (0.102 g, 0.617 mmol) in N,N-dimethylformide (3 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-((N-(oxazol-2-yl)methylsulfonamido)methyl)benzoate as white solid (0.106 g, 27.7%).


[Step 3] N-(4-(hydrazinecarbonyl)benzyl)-N-(oxazol-2-yl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(oxazol-2-yl)methylsulfonamido)methyl)benzoate (0.106 g, 0.342 mmol) and hydrazine monohydrate (0.166 mL, 3.416 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-(oxazol-2-yl)methanesulfonamide as white solid (0.075 g, 70.8%).


[Step 4] Compound 11741



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-(oxazol-2-yl)methanesulfonamide (0.075 g, 0.242 mmol), 2,2-difluoroacetic anhydride (0.090 mL, 0.725 mmol) and triethylamine (0.101 mL, 0.725 mmol) in tetrahydrofuran (2 mL) was stirred at 80° C. for 0.5 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(oxazol-2-yl)methanesulfonamide as white solid (0.034 g, 38.0%).



1H NMR (400 MHz, CD3OD) δ8.11 (d, 2H, J=8.1 Hz), 7.74 (s, 1H), 7.64 (d, 2H, J=8.0 Hz), 7.10 (s, 1H), 7.23 (t, 1H, J=51.8 Hz), 5.13 (s, 2H), 3.38 (s, 3H); LRMS (ES) m/z 371.2 (M++1).


EXAMPLE 247
Compound 11742, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(1-isopropyl-1H-indazol-6-yl)methanesulfonamide
[Step 1] N-(1-isopropyl-1H-indazol-6-yl)methanesulfonamide



embedded image


A solution of 1-isopropyl-1H-indazol-6-amine (0.300 g, 1.712 mmol), methanesulfonyl chloride (0.146 mL, 1.883 mmol) and triethylamine (0.358 mL, 2.568 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(1-isopropyl-1H-indazol-6-yl)methanesulfonamide as orange solid (0.407 g, 93.8%).


[Step 2] methyl 4-((N-(1-isopropyl-1H-indazol-6-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(1-isopropyl-1H-indazol-6-yl)methanesulfonamide (0.200 g, 0.790 mmol), methyl 4-(bromomethyl)benzoate (0.217 g, 0.947 mmol), potassium carbonate (0.131 g, 0.947 mmol) and potassium iodide (0.066 g, 0.395 mmol) in N,N-dimethylformide (3 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-((N-(1-isopropyl-1H-indazol-6-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.251 g, 79.3%).


[Step 3] N-(4-(hydrazinecarbonyl)benzyl)-N-(1-isopropyl-1H-indazol-6-yl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(1-isopropyl-1H-indazol-6-yl)methylsulfonamido)methyl)benzoate (0.251 g, 0.625 mmol) and hydrazine monohydrate (0.304 mL, 6.252 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-(1-isopropyl-1H-indazol-6-yl)methanesulfonamide as white solid (0.242 g, 96.6%).


[Step 4] Compound 11741



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-(1-isopropyl-1H-indazol-6-yl)methanesulfonamide (0.080 g, 0.199 mmol), 2,2-difluoroacetic anhydride (0.074 mL, 0.598 mmol) and triethylamine (0.083 mL, 0.598 mmol) in tetrahydrofuran (2 mL) was stirred at 80° C. for 0.5 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(1-isopropyl-1H-indazol-6-yl)methanesulfonamide as white solid (0.075 g, 82.0%).



1H NMR (400 MHz, CD3OD) δ8.01 (d, 2H, J=8.3 Hz), 7.99 (s, 1H), 7.73 (d, 1H, J=8.6 Hz), 7.62 (s, 1H), 7.58 (d, 2H, J=8.2 Hz), 7.19 (t, 1H, J=51.7 Hz), 7.22 (dd, 1H, J=8.7, 1.3 Hz), 4.93-4.87 (m, 1H), 3.33 (s, 3H), 1.50 (d, 6H, J=6.6 Hz); LRMS (ES) m/z 462.2 (M++1).


EXAMPLE 248
Compound 11743, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(1-ethyl-1H-indazol-6-yl)methanesulfonamide
[Step 1] N-(1-ethyl-1H-indazol-6-yl)methanesulfonamide



embedded image


A solution of 1-ethyl-1H-indazol-6-amine (0.350 g, 2.171 mmol), methanesulfonyl chloride (0.185 mL, 2.388 mmol) and triethylamine (0.454 mL, 3.257 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(1-ethyl-1H-indazol-6-yl)methanesulfonamide as pink solid (0.508 g, 97.7%).


[Step 2] methyl 4-((N-(1-ethyl-1H-indazol-6-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(1-ethyl-1H-indazol-6-yl)methanesulfonamide (0.200 g, 0.836 mmol), methyl 4-(bromomethyl)benzoate (0.230 g, 1.003 mmol), potassium carbonate (0.139 g, 1.003 mmol) and potassium iodide (0.069 g, 0.418 mmol) in N,N-dimethylformide (3 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-((N-(1-ethyl-1H-indazol-6-yl)methylsulfonamido)methyl)benzoate as ivory solid (0.223 g, 68.9%).


[Step 3] N-(1-ethyl-1H-indazol-6-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(1-ethyl-1H-indazol-6-yl)methylsulfonamido)methyl)benzoate (0.223 g, 0.576 mmol) and hydrazine monohydrate (0.280 mL, 5.756 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(1-ethyl-1H-indazol-6-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide as white solid (0.205 g, 91.8%).


[Step 4] Compound 11743



embedded image


A solution of N-(1-ethyl-1H-indazol-6-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.080 g, 0.206 mmol), 2,2-difluoroacetic anhydride (0.077 mL, 0.619 mmol) and triethylamine (0.086 mL, 0.619 mmol) in tetrahydrofuran (2 mL) was stirred at 80° C. for 0.5 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(1-ethyl-1H-indazol-6-yl)methanesulfonamide as white solid (0.054 g, 58.9%).



1H NMR (400 MHz, CD3OD) δ8.01 (d, 2H, J=8.3 Hz), 7.92 (s, 1H), 7.74 (d, 1H, J=8.6 Hz), 7.63 (s, 1H), 7.59 (d, 2H, J=8.2 Hz), 7.19 (t, 1H, J=51.7 Hz), 7.23 (dd, 1H, J=8.6, 1.7 Hz), 5.10 (s, 2H), 4.42 (q, 2H, J=7.2 Hz), 3.13 (s, 3H), 1.41 (t, 3H, J=7.2 Hz); LRMS (ES) m/z 448.2 (M++1).


EXAMPLE 249
Compound 11744, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-isopropylbenzo[d]thiazol-6-yl)methanesulfonamide
[Step 1] N-(2-isopropylbenzo[d]thiazol-6-yl)methanesulfonamide



embedded image


A solution of 2-isopropylbenzo[d]thiazol-6-amine (0.250 g, 1.300 mmol), methanesulfonyl chloride (0.111 mL, 1.430 mmol) and triethylamine (0.272 mL, 1.950 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(2-isopropylbenzo[d]thiazol-6-yl)methanesulfonamide as orange solid (0.307 g, 87.2%).


[Step 2] methyl 4-((N-(2-isopropylbenzo[d]thiazol-6-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(2-isopropylbenzo[d]thiazol-6-yl)methanesulfonamide (0.300 g, 1.110 mmol), methyl 4-(bromomethyl)benzoate (0.305 g, 1.332 mmol), potassium carbonate (0.184 g, 1.332 mmol) and potassium iodide (0.092 g, 0.555 mmol) in N,N-dimethylformide (3 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-((N-(2-isopropylbenzo[d]thiazol-6-yl)methylsulfonamido)methyl)benzoate as pink solid (0.415 g, 89.3%).


[Step 3] N-(4-(hydrazinecarbonyl)benzyl)-N-(2-isopropylbenzo[d]thiazol-6-yl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(2-isopropylbenzo[d]thiazol-6-yl)methylsulfonamido)methyl)benzoate (0.415 g, 0.992 mmol) and hydrazine monohydrate (0.482 mL, 9.916 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(4-(hydrazinecarbonyl)benzyl)-N-(2-isopropylbenzo[d]thiazol-6-yl)methanesulfonamide as orange solid (0.307 g, 74.0%).


[Step 4] Compound 11744



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-(2-isopropylbenzo[d]thiazol-6-yl)methanesulfonamide (0.080 g, 0.191 mmol), 2,2-difluoroacetic anhydride (0.071 mL, 0.573 mmol) and triethylamine (0.080 mL, 0.573 mmol) in tetrahydrofuran (2 mL) was stirred at 80° C. for 0.5 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(2-isopropylbenzo[d]thiazol-6-yl)methanesulfonamide as ivory solid (0.057 g, 62.3%).



1H NMR (400 MHz, CD3OD) δ8.01 (d, 1H, J=1.8 Hz), 7.98 (d, 2H, J=8.3 Hz), 7.86 (d, 1H, J=8.7 Hz), 7.57˜7.53 (m, 3H), 7.19 (t, 1H, J=51.7 Hz), 5.07 (s, 2H), 3.43˜3.36 (m, 1H), 3.12 (s, 3H), 1.43 (d, 6H, J=6.9 Hz); LRMS (ES) m/z 479.3 (M++1).


EXAMPLE 250
Compound 11745, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl) methanesulfonamide
[Step 1] N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)methanesulfonamide



embedded image


A solution of 5-amino-1,3-dimethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (0.350 g, 1.975 mmol), methanesulfonyl chloride (0.168 mL, 2.173 mmol) and triethylamine (0.413 mL, 2.963 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)methanesulfonamide as pink solid (0.432 g, 85.6%).


[Step 2] methyl 4-((N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)methanesulfonamide (0.200 g, 0.783 mmol), methyl 4-(bromomethyl)benzoate (0.215 g, 0.940 mmol), potassium carbonate (0.130 g, 0.940 mmol) and potassium iodide (0.065 g, 0.392 mmol) in N,N-dimethylformide (3 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-((N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.291 g, 92.1%).


[Step 3] N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)methylsulfonamido)methyl)benzoate (0.291 g, 0.721 mmol) and hydrazine monohydrate (0.351 mL, 7.213 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide as yellow solid (0.188 g, 64.5%).


[Step 4] Compound 11745



embedded image


A solution of N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.080 g, 0.198 mmol), 2,2-difluoroacetic anhydride (0.074 mL, 0.595 mmol) and triethylamine (0.083 mL, 0.595 mmol) in tetrahydrofuran (2 mL) was stirred at 80° C. for 0.5 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl) methanesulfonamide as white solid (0.083 g, 90.6%).



1H NMR (400 MHz, CD3OD) δ7.99 (d, 2H, J=8.4 Hz), 7.55 (d, 2H, J=8.4 Hz), 7.20 (t, 1H, J=51.7 Hz), 7.19˜7.15 (m, 2H), 7.06 (d, 1H, J=8.3 Hz), 5.01 (s, 2H), 3.35 (s, 3H), 3.33 (s, 3H), 3.10 (s, 3H); LRMS (ES) m/z 464.2 (M++1).


EXAMPLE 251
Compound 11746, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(1,3-dimethyl-1H-indazol-5-yl)methanesulfonamide
[Step 1] N-(1,3-dimethyl-1H-indazol-5-yl)methanesulfonamide



embedded image


A solution of 1,3-dimethyl-1H-indazol-5-amine (0.250 g, 1.551 mmol), methanesulfonyl chloride (0.132 mL, 1.706 mmol) and triethylamine (0.324 mL, 2.326 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(1,3-dimethyl-1H-indazol-5-yl)methanesulfonamide as white solid (0.220 g, 59.3%).


[Step 2] methyl 4-((N-(1,3-dimethyl-1H-indazol-5-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of N-(1,3-dimethyl-1H-indazol-5-yl)methanesulfonamide (0.250 g, 1.045 mmol), methyl 4-(bromomethyl)benzoate (0.287 g, 1.254 mmol), potassium carbonate (0.173 g, 1.254 mmol) and potassium iodide (0.087 g, 0.522 mmol) in N,N-dimethylformide (3 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give methyl 4-((N-(1,3-dimethyl-1H-indazol-5-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.341 g, 84.2%).


[Step 3] N-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(1,3-dimethyl-1H-indazol-5-yl)methylsulfonamido)methyl)benzoate (0.341 g, 0.880 mmol) and hydrazine monohydrate (0.428 mL, 8.801 mmol) in ethanol (3 mL) was stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with sodium bicarbonate (5 mL) and stirred. The resulting precipitates were collected by filtration and dried to give N-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide as white solid (0.280 g, 82.0%).


[Step 4] Compound 11746



embedded image


A solution of N-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-(hydrazinecarbonyl)benzyl)methanesulfonamide (0.080 g, 0.206 mmol), 2,2-difluoroacetic anhydride (0.077 mL, 0.619 mmol) and triethylamine (0.086 mL, 0.619 mmol) in tetrahydrofuran (2 mL) was stirred at 80° C. for 0.5 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(1,3-dimethyl-1H-indazol-5-yl)methanesulfonamide as white solid (0.078 g, 84.5%).



1H NMR (400 MHz, CD3OD) δ7.97 (d, 2H, J=8.2 Hz), 7.75 (s, 1H), 7.54 (d, 2H, J=8.2 Hz), 7.42˜7.37 (m, 2H), 7.19 (t, 1H, J=51.7 Hz), 5.04 (s, 2H), 3.93 (s, 3H), 3.10 (s, 3H), 2.48 (s, 3H); LRMS (ES) m/z 448.3 (M++1).


EXAMPLE 252
Compound 11747, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2,3-dihydro-1H-inden-5-yl)methanesulfonamide
[Step 1] N-(2,3-dihydro-1H-inden-5-yl)methanesulfonamide



embedded image


A solution of 2,3-dihydro-1H-inden-5-amine (0.500 g, 3.754 mmol) and pyridine (0.605 mL, 7.508 mmol) in dichloromethane (20 mL) was mixed at the room temperature with methanesulfonyl chloride (0.320 mL, 4.129 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, aqueous 1M-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 80%) to give N-(2,3-dihydro-1H-inden-5-yl)methanesulfonamide as yellow solid (0.660 g, 83.2%).


[Step 2] Compound 11747



embedded image


N-(2,3-dihydro-1H-inden-5-yl)methanesulfonamide (0.200 g, 0.947 mmol), 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.320 g, 1.041 mmol), potassium carbonate (0.262 g, 1.893 mmol) and potassium iodide (0.047 g, 0.284 mmol) were mixed at the room temperature in N,N-dimethylformide (10 mL) and then stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2,3-dihydro-1H-inden-5-yl)methanesulfonamide as yellow solid (0.240 g, 58.0%).



1H NMR (400 MHz, CDCl3) δ 7.87-7.84 (m, 1H), 7.73-7.66 (m, 2H), 7.17-7.15 (m, 2H), 7.05-7.02 (m, 1H), 7.03 (s, 0.25H), 6.89(s, 0.5H), 6.76 (s, 0.25H), 4.98 (s, 2H), 2.99 (s, 3H), 2.88-2.83 (m, 4H), 2.11-1.02 (m, 2H); LRMS (ES) m/z 438.1 (M++1).


EXAMPLE 253
Compound 11748, (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide
[Step 1] (R)—N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide



embedded image


A solution of (R)-2,3-dihydro-1H-inden-1-amine (0.500 g, 3.754 mmol) and pyridine (0.605 mL, 7.508 mmol) in dichloromethane (20 mL) was mixed at the room temperature with methanesulfonyl chloride (0.320 mL, 4.129 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, aqueous 1M-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give (R)—N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide as white soid (0.407 g, 51.3%).


[Step 2] Compound 11748



embedded image


(R)—N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide (0.200 g, 0.947 mmol), 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.320 g, 1.041 mmol), potassium carbonate (0.262 g, 1.893 mmol) and potassium iodide (0.047 g, 0.284 mmol) were mixed at the room temperature in N,N-dimethylformide (10 mL) and then stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide as white solid (0.017 g, 4.1%).



1H NMR (400 MHz, CDCl3) δ 7.83-7.81 (m, 1H), 7.72-7.68 (m, 1H), 7.57 (dd, 1H, J=10.2, 1.6 Hz), 7.21-7.14 (m, 3H), 7.07-7.04 (m, 1H), 7.03 (s, 0.25H), 6.90 (s, 0.5H), 6.77 (s, 0.25H), 5.62-5.58 (m, 1H), 4.43-4.29 (m, 2H), 3.05 (s, 3H), 2.98-2.81 (m, 2H), 2.54-2.45 (m, 1H), 2.06-1.97 (m, 1H); LRMS (ES) m/z 438.3 (M++1).


EXAMPLE 254
Compound 11749, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide
[Step 1] (S)—N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide



embedded image


A solution of (S)-2,3-dihydro-1H-inden-1-amine (0.500 g, 3.754 mmol) and pyridine (0.605 mL, 7.508 mmol) in dichloromethane (20 mL) was mixed at the room temperature with methanesulfonyl chloride (0.320 mL, 4.129 mmol). The reaction mixture was stirred at the same temperature for 18 hr. Then, aqueous 1M-hydrochloric acid solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 50%) to give (S)—N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide as white solid (0.542 g, 68.3%).


[Step 2] Compound 11749



embedded image


(S)—N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide (0.200 g, 0.947 mmol), 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.320 g, 1.041 mmol), potassium carbonate (0.262 g, 1.893 mmol) and potassium iodide (0.047 g, 0.284 mmol) were mixed at the room temperature in N,N-dimethylformide (10 mL) and then stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(2,3-dihydro-1H-inden-1-yl)methanesulfonamide as white solid (0.011 g, 2.7%).



1H NMR (400 MHz, CDCl3) δ 7.83-7.81 (m, 1H), 7.72-7.68 (m, 1H), 7.59-7.56 (m, 1H), 7.21-7.18 (m, 2H), 7.16-7.15 (m, 1H), 7.07-7.04 (m, 1H), 7.03 (s, 0.25H), 6.90 (s, 0.5H), 6.77 (s, 0.25H), 5.62-5.59 (m, 1H), 4.43-4.29 (m, 2H), 3.05 (s, 3H), 2.98-2.81 (m, 2H), 2.54-2.45 (m, 1H), 2.06-1.97 (m, 1H); LRMS (ES) m/z 438.2 (M++1).


EXAMPLE 255
Compound 11750, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methanesulfonamide
[Step 1] tert-butyl 2-((4-(methoxycarbonyl)benzyl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate



embedded image


A solution of tert-butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (0.500 g, 1.958 mmol), methyl 4-formylbenzoate (0.354 g, 2.154 mmol) and acetic acid (0.135 mL, 2.350 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 30 min, and mixed with sodium triacetoxyborohydride (0.830 g, 3.916 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 40%) to give tert-butyl 2-((4-(methoxycarbonyl)benzyl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate as white solid (0.350 g, 44.3%).


[Step 2] tert-butyl 2-(N-(4-(methoxycarbonyl)benzyl)methylsulfonamido)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate



embedded image


A solution of tert-butyl 2-((4-(methoxycarbonyl)benzyl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (0.170 g, 0.421 mmol), TEA (0.056 g, 0.548 mmol), N,N-dimethylpyridin-4-amine (0.005 g, 0.042 mmol) and methanesulfonyl chloride (0.039 mL, 0.506 mmol) in dichloromethane (10 mL) was stirred at 50° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give tert-butyl 2-(N-(4-(methoxycarbonyl)benzyl)methylsulfonamido)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate as white solid (0.110 g, 54.2%).


[Step 3] methyl 4-((N-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methylsulfonamido)methyl)benzoate hydrochloride



embedded image


A solution of tert-butyl 2-(N-(4-(methoxycarbonyl)benzyl)methylsulfonamido)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (0.110 g, 0.228 mmol) and hydrogen chloride (4.00 M solution in 1,4-dioxane, 0.114 mL, 0.457 mmol) in dichloromethane (10 mL) was stirred at the room temperature for 5 hr, and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (methyl 4-((N-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methylsulfonamido)methyl)benzoate hydrochloride, 0.089 g, 93.2%, white solid).


[Step 4] methyl 4-((N-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methylsulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-((N-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methylsulfonamido)methyl)benzoate hydrochloride (0.089 g, 0.213 mmol), paraformaldehyde (0.013 g, 0.426 mmol) and acetic acid (0.015 mL, 0.256 mmol) in (10 mL) was stirred at the room temperature for 30 min, and mixed with sodium triacetoxyborohydride (0.090 g, 0.426 mmol). The reaction mixture was stirred at the same temperature for additional 12 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-((N-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methylsulfonamido)methyl)benzoate as yellow solid (0.073 g, 86.7%).


[Step 5] N-(4-(hydrazinecarbonyl)benzyl)-N-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methanesulfonamide



embedded image


A solution of methyl 4-((N-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methylsulfonamido)methyl)benzoate (0.035 g, 0.088 mmol) and hydrazine monohydrate (0.043 mL, 0.885 mmol) in ethanol (10 mL) was stirred at 90° C. for 12 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium bicarbonate solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The title compound was used without further purification (N-(4-(hydrazinecarbonyl)benzyl)-N-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methanesulfonamide, 0.021 g, 60.0%, white solid).


[Step 6] Compound 11750



embedded image


A solution of N-(4-(hydrazinecarbonyl)benzyl)-N-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methanesulfonamide (0.038 g, 0.096 mmol), TEA (0.049 g, 0.480 mmol) and 2,2-difluoroacetic anhydride (0.050 g, 0.288 mmol) in tetrahydrofuran (5 mL) was stirred at 70° C. for 12 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated ammonium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 40%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methanesulfonamide as white solid (0.010 g, 22.8%).



1H NMR (400 MHz, CDCl3) δ 8.09 (d, 2H, J=6.7 Hz), 7.63 (d, 2H, J=8.5 Hz), 7.05 (s, 0.2H), 6.92 (s, 0.5H), 6.80 (s, 0.3H), 5.19 (s, 2H), 3.54 (s, 2H), 3.09 (s, 3H), 2.84-2.78 (m, 4H), 2.49 (s, 3H); LRMS (ES) m/z 456.3 (M++1).


EXAMPLE 256
Compound 11751, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(2-morpholino-2-oxoethyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(morpholin-4-yl)-2-(piperazin-1-yl)ethan-1-one (0.109 g, 0.511 mmol) and N-,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(2-morpholino-2-oxoethyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.015 g, 9.7%).



1H NMR (400 MHz, CDCl3) δ 8.04-8.02 (m, 2H), 7.46 (d, 2H, J=8.3 Hz), 7.36-7.28 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 5.00 (s, 2H), 3.77-3.66 (m, 6H), 3.69-3.59 (m, 2H), 3.58-3.51 (m, 4H), 3.36-3.31 (m, 2H), 3.11-3.06 (m, 2H), 2.87-2.82 (m, 6H)); LRMS (ES) m/z 605.2 (M++1).


EXAMPLE 257
Compound 11752, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(1,4-oxazepan-4-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), Homomorpholine Hydrochloride (0.070 g, 0.511 mmol) and N-,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(1,4-oxazepan-4-yl)-N-phenylethane-1-sulfonamide as white solid (0.017 g, 13.5%).



1H NMR (400 MHz, CDCl3) δ 8.04-8.02 (m, 2H), 7.47 (d, 2H, J=8.4 Hz), 7.38-7.27 (m, 5H), 6.91 (t, 1H, J J=51.7 Hz), 4.99 (s, 2H), 3.84-3.71 (m, 4H), 3.40-3.31 (m, 2H), 3.17-3.09 (m, 2H), 2.86-2.75 (m, 4H), 2.00-1.97 (m, 2H); LRMS (ES) m/z 493.1 (M++1).


EXAMPLE 258
Compound 11753, (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-fluoropyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (R)-(−)3-fluoropyrrolidine hydrochloride (0.064 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-fluoropyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.089 g, 72.5%).



1H NMR (700 MHz, CDCl3) δ 7.98-7.97 (m, 2H), 7.45 (d, 2H, J=8.5 Hz), 7.34-7.23 (m, 5H), 6.90 (t, 1H, J=51.7 Hz), 5.23 (m, 1H), 4.99 (s, 2H), 3.32-3.30 (m, 2H), 3.07-2.95 (m, 4H), 2.70-2.63 (m, 1H), 2.42-2.41 (m, 1H), 2.23-2.18 (m, 2H); LRMS (ES) m/z 481.3 (M++1).


EXAMPLE 259
Compound 11754, (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(dimethylamino)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide
[Step 1] Compound 11754



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (R)-(+)-3-(dimethylamino)pyrrolidine dihydrochloride (0.096 g, 0.511 mmol) and N-,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(dimethylamino)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.082 g, 63.5%).



1H NMR (700 MHz, CDCl3) δ 8.00 (d, 2H, J=8.5 Hz), 7.44 (d, 2H, J=8.5 Hz), 7.33-7.24 (m, 5H), 6.90 (t, 1H, J=51.7 Hz), 4.96 (s, 2H), 3.28 (t, 2H, J J=7.5 Hz), 3.05-2.98 (m, 2H), 2.97-2.90 (m, 2H), 2.78-2.59 (m, 2H), 2.47 (m, 1H), 2.27 (s, 6H), 2.06-1.98 (m, 1H), 1.79 (m, 1H); LRMS (ES) m/z 506.4 (M++1).


EXAMPLE 260
Compound 11755, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(dimethylamino)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (S)-(−)-3-dimethylaminopyrrolidine dihydrochloride (0.096 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(dimethylamino)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.120 g, 92.9%).



1H NMR (700 MHz, CDCl3) δ 8.07-7.01 (m, 2H), 7.46-7.44 (m, 2H), 7.34-7.26 (m, 5H), 6.91 (t, 1H, J J=51.7 Hz), 4.97 (s, 2H), 3.28 (t, 2H, J=7.4 Hz), 3.05-3.00 (m, 2H), 2.98-2.84 (m, 1H), 2.84-2.79 (m, 1H), 2.74-2.68 (m, 1H), 2.65-2.59 (m, 1H), 2.55-2.50 (m, 1H), 2.29 (s, 6H), 2.08-1.99 (m, 1H), 1.85-1.77 (m, 1H); LRMS (ES) m/z 506.3 (M++1).


EXAMPLE 261
Compound 11756, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(isoindolin-2-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), isoindoline (0.061 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(isoindolin-2-yl)-N-phenylethane-1-sulfonamide as white solid (0.032 g, 24.5%).



1H NMR (700 MHz, CDCl3) δ 8.02 (d, 2H, J=8.5 Hz), 7.46 (d, 2H, J=8.5 Hz), 7.35-7.24 (m, 5H),), 6.91 (t, 1H, J=51.7 Hz), 5.01 (s, 2H), 4.11 (s, 4H), 3.51-3.46 (dd, 1H, J=9.1, 5.7 Hz), 3.37-3.32 (m, 1H); LRMS (ES) m/z 511.3 (M++1).


EXAMPLE 262
Compound 11757, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-ethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-ethylpiperazine (0.061 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-ethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.032 g, 24.5%).



1H NMR (700 MHz, CDCl3) δ 8.04-8.02 (m, 2H), 7.46 (d, 2H, J=8.5 Hz), 7.35-7.28 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.30-3.28 (m, 2H), 2.98-2.96 (m, 2H), 2.66-2.57 (m, 10H), 1.19 (t, 3H, J=7.2 Hz); LRMS (ES) m/z 506.1 (M++1).


EXAMPLE 263
Compound 11758, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(2-methoxyethyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(2-methoxyethyl)piperazine (0.074 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(2-methoxyethyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.040 g, 29.2%).



1H NMR (700 MHz, CDCl3) δ 8.01-8.00 (m, 2H), 7.45 (d, 2H, J=8.5 Hz), 7.34-7.26 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.96 (s, 2H), 3.55 (t, 3H, J=5.5 Hz), 3.36 (s, 3H), 3.29-3.27 (m, 2H), 2.94-2.93 (m, 2H), 2.65-2.60 (m, 10H); LRMS (ES) m/z 536.4 (M++1).


EXAMPLE 264
Compound 11759, 2-(4-acetyl-1,4-diazepan-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), N-acetylhomopiperazine (0.073 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(4-acetyl-1,4-diazepan-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.032 g, 23.5%).



1H NMR (700 MHz, CDCl3) δ 8.04-8.00 (m, 2H), 7.45 (d, 2H, J=8.3 Hz), 7.36-7.27 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.96 (s, 2H), 3.68-3.66 (m, 1H), 3.64-3.59 (m, 1H), 3.56-3.51 (m, 2H), 3.36-3.33 (m, 1H), 3.32-3.27 (m, 1H), 3.13-3.07 (m, 2H), 2.79-2.66 (m, 4H), 2.11-2.09 (m, 3H), 1.97 (m, 1H), 1.88-1.87 (m, 1H); LRMS (ES) m/z 534.3 (M++1).


EXAMPLE 265
Compound 11760, 2-(4-benzyl-1,4-diazepan-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-Benzylhomopiperazine (0.097 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(4-benzyl-1,4-diazepan-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.032 g, 21.5%).



1H NMR (700 MHz, CDCl3) δ 8.03-7.98 (m, 2H), 7.47-7.44 (m, 2H), 7.38-7.28 (m, 10H),), 6.92 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.82 (s, 2H), 3.30-3.28 (m, 2H), 3.13-3.11 (m, 2H), 2.85-2.80 (m, 8H), 1.96 (m, 2H); LRMS (ES) m/z 582.4 (M+1).


EXAMPLE 266
Compound 11761, 2-(4-(cyclopropanecarbonyl)piperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(c yclopropylcarbonyl)piperazine (0.079 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(4-(cyclopropanecarbonyl)piperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.034 g, 24.4%).



1H NMR (700 MHz, CDCl3) δ 8.03-8.02 (m, 2H), 7.47-7.45 (m, 2H), 7.36-7.30 (m, 2H), 7.33-7.275 (m, 3H), 6.91 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 3.77 (m, 2H), 3.73-3.71 (m, 2H), 3.40-3.35 (t, 2H, J=7.2 Hz), 3.01-2.99 (m, 2H), 2.63-2.55 (m, 4H), 1.75-1.71 (tt, 1H, J=8.0, 4.7 Hz), 1.01-0.99 (m, 2H), 0.81 (m, 2H); LRMS (ES) m/z 546.0 (M++1).


EXAMPLE 267
Compound 11762, 2-(4-benzylpiperidin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-benzylpiperidine (0.090 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(4-benzylpiperidin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.042 g, 29.0%).



1H NMR (700 MHz, CDCl3) δ 8.06-8.02 (m, 2H), 7.46 (d, 2H, J=8.5 Hz), 7.36-7.14 (m, 10H), 6.91 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.30-3.28 (m, 2H), 2.90-2.88 (m, 4H), 2.58-2.57 (m, 2H), 2.04-2.01 (m, 2H), 1.71-1.69 (m, 2H), 1.57-1.5\6 (m, 1H), 1.34-1.32 (m, 2H); LRMS (ES) m/z 567.0 (M++1).


EXAMPLE 268
Compound 11763, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-morpholinopiperidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-morpholinopiperidine (0.087 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-morpholinopiperidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.110 g, 76.7%).



1H NMR (700 MHz, CDCl3) δ 8.01-8.00 (m, 2H), 7.45 (d, 2H, J=8.5 Hz), 7.34-7.26 (m, 5H), 6.91 (t, 1H, J J=51.7 Hz), 4.96 (d, 2H), 3.75 (t, 4H, J=4.6 Hz), 3.29-3.27 (m, 2H), 2.97-2.95 (dt, 2H, J=11.3, 3.4 Hz), 2.90-2.88 (m, 2H), 2.58 (t, 4H, J=4.7 Hz), 2.23-2.22 (m, 1H), 2.10-2.07 (td, 1H, J=11.8, 2.3 Hz), 1.90-1.86 (dt, 1H, J J J=12.8, 3.0 Hz), 1.61-1.55 (td, 1H, J=12.1, 3.7 Hz); LRMS (ES) m/z 562.1 (M++1).


EXAMPLE 269
Compound 11764, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidine (0.085 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.115 g, 80.6%).



1H NMR (700 MHz, CDCl3) δ 8.02-8.00 (m, 2H), 7.46-7.45 (m, 2H), 7.34-7.27 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.33-3.31 (m, 2H), 2.96-2.93 (m, 5H), 2.38 (s, 3H), 2.29-2.27 (m, 2H), 2.15-2.13 (m, 2H), 1.98-1.93 (m, 2H); LRMS (ES) m/z 559.3 (M++1).


EXAMPLE 270
Compound 11765, 2-(benzyl(ethyl)amino)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), N-ethylbenzylamine (0.069 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(benzyl(ethyl)amino)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.018 g, 13.4%).



1H NMR (700 MHz, CDCl3) δ 8.04-7.93 (m, 2H), 7.45-7.24 (m, 10H), 7.34-7.21 (m, 2H), 6.91 (t, 1H, J=51.7 Hz), 4.82 (s, 2H), 3.64 (s, 2H), 3.26 (m, 2H), 3.05-3.02 (m, 2H), 2.64-2.59 (m, 2H), 1.13 (t, 3H, J=7.1 Hz); LRMS (ES) m/z 527.4 (M++1).


EXAMPLE 271
Compound 11766, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(4-phenylpiperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-phenylpiperazine (0.083 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(4-phenylpiperazin-1-yl)ethane-1-sulfonamide as white solid (0.021 g, 14.8%).



1H NMR (700 MHz, CDCl3) δ 8.05-7.97 (m, 2H), 7.49-7.41 (m, 2H), 7.38-7.28 (m, 8H), 7.00-6.88 (m, 2H), 6.91 (t, 1H, J=51.7 Hz), 5.01 (s, 2H), 3.47 (m, 2H), 3.32-3.25 (m, 4H), 3.09-3.05 (m, 2H), 2.91-2.80 (m, 4H); LRMS (ES) m/z 555.1 (M++1).


EXAMPLE 272
Compound 11767, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(4-(pyridin-2-yl)piperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(2-pyridyl)piperazine (0.083 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(4-(pyridin-2-yl)piperazin-1-yl)ethane-1-sulfonamide as white solid (0.025 g, 17.6%).



1H NMR (400 MHz, CDCl3) δ 8.22-8.16 (m, 1H), 8.04-7.97 (m, 2H), 7.51 (m, 1H), 7.49-7.38 (m, 2H), 7.41-7.25 (m, 5H), 6.91 (t, 1H, J J=51.7 Hz), 6.70-6.68 (m, 2H), 5.01 (s, 2H), 3.67 (t, 4H, J=5.0 Hz), 3.44 (t, 2H, J=7.4 Hz), 3.04 (dd, 2H, J=8.8, 6.1 Hz), 2.27-2.67 (m, 4H); LRMS (ES) m/z 555.2 (M++1).


EXAMPLE 273
Compound 11768, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(4-(pyridin-4-yl)piperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(4-pyridyl)piperazine (0.083 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(4-(pyridin-4-yl)piperazin-1-yl)ethane-1-sulfonamide as white solid (0.023 g, 16.2%).



1H NMR (400 MHz, CDCl3) δ 8.30-8.26 (m, 2H), 8.04-8.02 (m, 2H), 7.47-7.45 (m, 2H), 7.38-7.28 (m, 5H), 6.92 (t, 1H, J=51.7 Hz), 6.78-6.73 (m, 2H), 4.98 (s, 2H), 3.46 (t, 4H, J=5.1 Hz), 3.35-3.31 (m, 2H), 2.99-2.96 (m, 2H), 2.71-2.63 (m, 4H); LRMS (ES) m/z 555.2 (M++1).


EXAMPLE 274
Compound 11769, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(4-fluorophenyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(4-fluorophenyl)piperazine Dihydrochloride (0.129 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(4-fluorophenyl)piperazin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.110 g, 75.3%).



1H NMR (700 MHz, CDCl3) δ8.02-7.97 (m, 2H), 7.46-7.42 (m, 2H), 7.36-7.23 (m, 5H), 6.98-6.93 (m, 2H), 6.91-6.85 (m, 3H), 5.00 (s, 2H), 3.36-3.34 (m, 2H), 3.16-3.15 (m, 4H), 3.01-2.99 (m, 2H), 2.69-2.68 (m, 4H); LRMS (ES) m/z 572.1 (M++1).


EXAMPLE 275
Compound 11770, 2-(4-(3,4-dichlorophenyl)piperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(3,4-dichlorophenyl)piperazine (0.118 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(4-(3,4-dichlorophenyl)piperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.087 g, 54.8%).



1H NMR (700 MHz, CDCl3) δ 8.02-7.98 (m, 2H), 7.47-7.43 (m, 2H), 7.36-7.25 (m, 6H), 6.99 (s, 1H), 6.92 (t, 1H, J=51.7 Hz), 6.75-6.74 (dd, 2H, J=8.9, 2.9 Hz), 4.99 (s, 2H), 3.39-3.37 (t, 2H, J=7.3 Hz), 3.23-3.22 (t, 4H, J=5.0 Hz), 3.02-3.00 (m, 2H), 2.69-2.65 (t, 2H, J=4.8 Hz); LRMS (ES) m/z 622.3 (M++1).


EXAMPLE 276
Compound 11771, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-phenethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(2-phenylethyl)piperazine (0.097 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-phenethylpiperazin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.100 g, 67.3%).



1H NMR (700 MHz, CDCl3) δ 8.01-7.98 (m, 2H), 7.47-7.43 (d, 2H, J J=8.4 Hz), 7.37-7.21 (m, 10H), 6.91 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 3.32-3.30 (m, 2H), 2.97-2.95 (m, 2H), 2.86-2.83 (m, 2H), 2.67-2.61 (m, 10H); LRMS (ES) m/z 582.4 (M++1).


EXAMPLE 277
Compound 11772, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(4-(2-(pyridin-4-yl)ethyl)piperazin-1-yl)ethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1-(2-pyridin-4-yl-ethyl)piperazine (0.098 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(4-(2-(pyridin-4-yl)ethyl)piperazin-1-yl)ethane-1-sulfonamide as white solid (0.110 g, 73.9%).



1H NMR (700 MHz, CDCl3) δ 8.49-8.45 (m, 2H), 8.01-7.99 (m, 2H), 7.44 (d, 2H, J=8.4 Hz), 7.33-7.26 (m, 5H), 7.15-7.14 (m, 2H), 6.91 (t, 1H, J=51.7 Hz), 4.96 (s, 2H), 3.30-3.28 (m, 2H), 2.94-2.92 (m, 2H), 2.83-2.81 (dd, 2H, J=9.5, 6.4 Hz), 2.67-2.58 (m, 10H); LRMS (ES) m/z 583.1 (M++1).


EXAMPLE 278
Compound 11773, 2-(4-cinnamylpiperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), Trans-1-cinnamyl piperazine (0.103 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(4-cinnamylpiperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.120 g, 79.1%).



1H NMR (700 MHz, CDCl3) δ 8.02-7.97 (m, 2H), 7.47-7.42 (m, 2H), 7.40-7.36 (m, 2H), 7.33-7.30 (s, 3H), 7.36-7.21 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 6.57-6.52 (dd, 1H, J=15.9, 1.5 Hz), 6.31-6.24 (dt, 1H, J=15.9, 6.8 Hz), 4.97 (s, 2H), 3.31-3.29 (m, 2H), 3.20-3.19 (dd, 2H, J=6.9, 1.4 Hz), 2.95-2.93 (m, 2H), 2.58 (m, 8H); LRMS (ES) m/z 594.2 (M++1).


EXAMPLE 279
Compound 11774, N-(benzo[d]oxazol-6-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide
[Step 1] N-(benzo[d]oxazol-6-yl)methanesulfonamide



embedded image


A solution of benzo[d]oxazol-6-amine (0.500 g, 3.727 mmol), methanesulfonyl chloride (0.317 mL, 4.100 mmol) and triethylamine (0.779 mL, 5.591 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(benzo[d]oxazol-6-yl)methanesulfonamide as purple solid (0.351 g, 44.4%).


[Step 2] Compound 11774



embedded image


A solution of N-(benzo[d]oxazol-6-yl)methanesulfonamide (0.030 g, 0.141 mmol), 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.052 g, 0.170 mmol), potassium carbonate (0.039 g, 0.283 mmol) and potassium iodide (0.012 g, 0.071 mmol) in N,N-dimethylformide (2 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(benzo[d]oxazol-6-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as yellow oil (0.040 g, 64.5%).



1H NMR (400 MHz, CD3OD) δ8.50 (s, 1H), 7.86˜7.69 (m, 5H), 7.51 (dd, 1H, J=8.5, 1.9 Hz), 7.21 (t, 1H, J=51.6 Hz), 5.14 (s, 2H), 3.13 (s, 3H); LRMS (ES) m/z 439.2 (M++1).


EXAMPLE 280
Compound 11775, N-(benzo[d]thiazol-6-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide
[Step 1] N-(benzo[d]thiazol-6-yl)methanesulfonamide



embedded image


A solution of benzo[d]thiazol-6-amine (0.500 g, 3.329 mmol), methanesulfonyl chloride (0.283 mL, 3.662 mmol) and triethylamine (0.696 mL, 4.993 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(benzo[d]thiazol-6-yl)methanesulfonamide as light violet solid (0.320 g, 42.1%).


[Step 2] Compound 11775



embedded image


A solution of N-(benzo[d]thiazol-6-yl)methanesulfonamide (0.020 g, 0.088 mmol), 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.032 g, 0.105 mmol), potassium carbonate (0.024 g, 0.175 mmol) and potassium iodide (0.007 g, 0.044 mmol) in N,N-dimethylformide (2 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(benzo[d]thiazol-6-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)methanesulfonamide as yellow oil (0.021 g, 52.7%).



1H NMR (400 MHz, CD3OD) δ9.27 (s, 1H), 8.18 (d, 1H, J=1.9 Hz), 8.04 (d, 1H, J=8.7 Hz), 7.84 (dd, 1H, J=8.0, 1.1 Hz), 7.74˜7.70 (m, 2H), 7.63 (dd, 1H, J=8.7, 2.0 Hz), 7.20 (t, 1H, J=51.6 Hz), 5.16 (s, 2H), 3.14 (s, 3H); LRMS (ES) m/z 445.2 (M++1).


EXAMPLE 281
Compound 11776, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(1,3,4-thiadiazol-2-yl)methanesulfonamide
[Step 1] N-(1,3,4-thiadiazol-2-yl)methanesulfonamide



embedded image


A solution of 1,3,4-thiadiazol-2-amine (0.300 g, 2.966 mmol), methanesulfonyl chloride (0.253 mL, 3.263 mmol) and triethylamine (0.620 mL, 4.450 mmol) in dichloromethane (3 mL) was stirred at the room temperature for 3 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(1,3,4-thiadiazol-2-yl)methanesulfonamide as white solid (0.382 g, 71.8%).


[Step 2] Compound 11776



embedded image


A solution of N-(1,3,4-thiadiazol-2-yl)methanesulfonamide (0.030 g, 0.167 mmol), 2-(4-(bromomethyl)-3-fluorophenyl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.062 g, 0.201 mmol), potassium carbonate (0.046 g, 0.335 mmol) and potassium iodide (0.014 g, 0.084 mmol) in N,N-dimethylformide (2 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 4 g cartridge; ethyl acetate/hexane=0% to 50%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(1,3,4-thiadiazol-2-yl)methanesulfonamide as yellow oil (0.027 g, 39.3%).



1H NMR (400 MHz, CD3OD) δ8.64 (s, 1H), 8.00˜7.99 (m, 2H), 7.62˜7.57 (m, 1H), 7.24 (t, 1H, J=51.7 Hz), 5.55 (s, 2H), 3.02 (s, 3H); LRMS (ES) m/z 406.1 (M++1).


EXAMPLE 282
Compound 11777, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-ethylazetidin-3-yl)piperidine-4-sulfonamide
[Step 1] tert-butyl 3-(4-(N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate



embedded image


A mixture of N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide hydrochloride (0.760 g, 1.463 mmol), tert-butyl 3-oxoazetidine-1-carboxylate (0.752 g, 4.390 mmol) and N,N-diisopropylethylamine (0.510 mL, 2.927 mmol) in dichloromethane (20 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.620 g, 2.927 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=60% to 90%) to give tert-butyl 3-(4-(N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate as white solid (0.795 g, 85.1%).


[Step 2] 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride



embedded image


A solution of tert-butyl 3-(4-(N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate (0.795 g, 1.246 mmol) in 1,4-dioxane (6 mL) was mixed at the room temperature with hydrogen chloride (4.00 M solution in 1,4-dioxane, 3.115 mL, 12.458 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride as white solid (0.752 g, 98.8%).


[Step 3] Compound 11777



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.082 mmol), acetaldehyde (0.023 mL, 0.409 mmol) and N,N-diisopropylethylamine (0.043 mL, 0.246 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.035 g, 0.164 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-ethylazetidin-3-yl)piperidine-4-sulfonamide as beige solid (0.021 g, 45.3%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.55 (t, 1H, J=2.0 Hz), 7.54 (s, 0.5H), 7.51 (d, 2H, J=8.4 Hz), 7.44 (m, 1H), 7.41 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (m, 1H), 5.11 (s, 2H), 3.65-3.55 (m, 2H), 3.34 (m, 1H), 3.09 (s, 2H), 2.97 (q, 1H, J=6.6 Hz), 2.82 (d, 2H, J=11.0 Hz), 2.70-2.61 (m, 2H), 2.07 (d, 2H, J=12.2 Hz), 1.91-1.81 (m, 2H), 1.74-1.61 (m, 2H), 0.97-0.90 (t, 3H, J=7.1 Hz); LRMS (ES) m/z 566.1 (M++1).


EXAMPLE 283
Compound 11778, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-isopropylazetidin-3-yl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.082 mmol), acetone (0.030 mL, 0.409 mmol) and N,N-diisopropylethylamine (0.043 mL, 0.246 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.035 g, 0.164 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-isopropylazetidin-3-yl)piperidine-4-sulfonamide as white solid (0.026 g, 54.8%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.55 (t, 1H, J=2.0 Hz), 7.53 (s, 0.5H), 7.51 (d, 2H, J=8.4 Hz), 7.44 (ddd, 1H, J=8.0, 2.2, 1.2 Hz), 7.41 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (ddd, 1H, J=8.0, 2.1, 1.2 Hz), 5.11 (s, 2H), 3.43 (s, 2H), 3.10 (m, 1H), 2.93-2.73 (m, 5H), 2.34 (m, 1H), 2.11-2.03 (m, 2H), 1.89-1.78 (m, 2H), 1.67 (qd, 2H, J=11.9, 3.7 Hz), 0.86 (d, 6H, J=6.2 Hz); LRMS (ES) m/z 580.1 (M++1).


EXAMPLE 284
Compound 11779, 1-(1-acetylazetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.082 mmol) in dichloromethane (5 mL) was treated at the room temperature with acetyl chloride (0.017 mL, 0.246 mmol) and N,N-diisopropylethylamine (0.057 mL, 0.327 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give 1-(1-acetylazetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide as white solid (0.030 g, 63.2%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.56 (t, 1H, J=2.1 Hz), 7.53 (s, 0.5H), 7.51 (d, 2H, J=8.4 Hz), 7.45 (ddd, 1H, J=8.0, 2.1, 1.2 Hz), 7.40 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.28 (ddd, 1H, J=8.0, 2.0, 1.1 Hz), 5.12 (s, 2H), 4.09 (m, 1H), 3.91 (m, 1H), 3.82 (m, 1H), 3.62 (dd, 1H, J=9.9, 5.1 Hz), 3.37 (m, 1H), 3.09 (m, 1H), 2.89 (t, 2H, J=12.8 Hz), 2.09 (d, 2H, J=11.9 Hz), 1.96-1.83 (m, 2H), 1.79-1.66 (m, 5H); LRMS (ES) m/z 580.3 (M++1).


EXAMPLE 285
Compound 11780, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-propionylazetidin-3-yl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.082 mmol) in dichloromethane (5 mL) was treated at the room temperature with propionyl chloride (0.021 mL, 0.246 mmol) and N,N-diisopropylethylamine (0.057 mL, 0.327 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-propionylazetidin-3-yl)piperidine-4-sulfonamide as white solid (0.029 g, 59.6%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.56 (t, 1H, J=2.0 Hz), 7.53 (s, 0.5H), 7.51 (d, 2H, J=8.4 Hz), 7.45 (ddd, 1H, J=8.1, 2.1, 1.2 Hz), 7.40 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (ddd, 1H, J=8.0, 2.0, 1.1 Hz), 5.12 (s, 2H), 4.07 (t, 1H, J=9.7 Hz), 3.90 (m, 1H), 3.81 (m, 1H), 3.62 (dd, 1H, J=9.8, 5.1 Hz), 3.37 (m, 1H), 3.09 (m, 1H), 2.94-2.83 (m, 2H), 2.13-2.01 (m, 4H), 1.88 (q, 2H, J=10.9 Hz), 1.70 (q, 2H, J=12.1 Hz), 0.95 (t, 3H, J=7.5 Hz); LRMS (ES) m/z 594.3 (M++1).


EXAMPLE 286
Compound 11781, N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-isopropylazetidin-3-yl)piperidine-4-sulfonamide
[Step 1] tert-butyl 3-(4-(N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate



embedded image


A mixture of N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide dihydrochloride (0.490 g, 0.880 mmol), tert-butyl 3-oxoazetidine-1-carboxylate (0.452 g, 2.640 mmol) and N,N-diisopropylethylamine (0.460 mL, 2.640 mmol) in dichloromethane (15 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.373 g, 1.760 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=70% to 100%) to give tert-butyl 3-(4-(N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate as white solid (0.386 g, 68.6%).


[Step 2] 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide trihydrochloride



embedded image


A solution of tert-butyl 3-(4-(N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate (0.386 g, 0.604 mmol) in 1,4-dioxane (5 mL) was mixed at the room temperature with hydrogen chloride (4.00 M solution in 1,4-dioxane, 2.265 mL, 9.059 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide trihydrochloride as white solid (0.372 g, 95.0%).


[Step 3] Compound 11781



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide trihydrochloride (0.050 g, 0.077 mmol), acetone (0.028 mL, 0.386 mmol) and N,N-diisopropylethylamine (0.054 mL, 0.308 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.033 g, 0.154 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-isopropylazetidin-3-yl)piperidine-4-sulfonamide as white solid (0.020 g, 44.6%).



1H NMR (400 MHz, DMSO-d6) δ 9.11 (d, 1H, J=2.3 Hz), 8.42 (dd, 1H, J=8.3, 2.3 Hz), 7.73-7.63 (m, 2.25H), 7.57 (s, 0.5H), 7.51 (m, 1H), 7.44 (s, 0.25H), 7.38 (m, 1H), 7.32 (m, 1H), 5.21 (s, 2H), 4.10-4.02 (m, 2H), 3.85 (m, 1H), 3.61 (m, 1H), 3.45-3.42 (m, 2H), 3.16 (m, 1H), 3.02 (m, 1H), 2.84 (m, 1H), 2.18-2.12 (m, 2H), 2.00-1.89 (m, 2H), 1.72 (m, 2H), 1.19-1.08 (m, 6H); LRMS (ES) m/z 581.1 (M++1).


EXAMPLE 287
Compound 11782, N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-propionylazetidin-3-yl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide trihydrochloride (0.050 g, 0.077 mmol) in dichloromethane (5 mL) was treated at the room temperature with propionyl chloride (0.020 mL, 0.231 mmol) and N,N-diisopropylethylamine (0.054 mL, 0.308 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-propionylazetidin-3-yl)piperidine-4-sulfonamide as white solid (0.027 g, 58.8%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (dd, 1H, J=2.3, 0.8 Hz), 8.41 (dd, 1H, J=8.2, 2.3 Hz), 7.72-7.67 (m, 1.25H), 7.64 (t, 1H, J=2.0 Hz), 7.56 (s, 0.5H), 7.51 (ddd, 1H, J=8.0, 2.2, 1.2 Hz), 7.44 (s, 0.25H), 7.37 (t, 1H, J=8.0 Hz), 7.31 (ddd, 1H, J=8.1, 2.0, 1.1 Hz), 5.21 (s, 2H), 4.07 (t, 1H, J=7.9 Hz), 3.91 (m, 1H), 3.81 (m, 1H), 3.63 (m, 1H), 3.40 (m, 1H), 3.09 (m, 1H), 2.88 (t, 2H, J=12.9 Hz), 2.11 (d, 2H, J=12.0 Hz), 2.07-1.99 (m, 2H), 1.95-1.83 (m, 2H), 1.69 (q, 2H, J=12.1 Hz), 0.95 (t, 3H, J=7.5 Hz); LRMS (ES) m/z 595.1 (M++1).


EXAMPLE 288
Compound 11783, N-(3-chlorophenyl)-1-(1-(cyclopropanecarbonyl)azetidin-3-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.082 mmol) in dichloromethane (5 mL) was treated at the room temperature with cyclopropanecarbonyl chloride (0.026 g, 0.246 mmol) and N,N-diisopropylethylamine (0.057 mL, 0.327 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chlorophenyl)-1-(1-(cyclopropanecarbonyl)azetidin-3-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide as beige solid (0.039 g, 78.6%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.56 (t, 1H, J=2.0 Hz), 7.53 (s, 0.5H), 7.51 (d, 2H, J=8.4 Hz), 7.45 (ddd, 1H, J=8.0, 2.1, 1.2 Hz), 7.40 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (ddd, 1H, J=8.0, 2.0, 1.1 Hz), 5.12 (s, 2H), 4.24 (t, 1H, J=7.9 Hz), 4.03 (m, 1H), 3.83 (dd, 1H, J=9.8, 7.2 Hz), 3.65 (dd, 1H, J=9.8, 5.1 Hz), 3.38 (m, 1H), 3.14 (p, 1H, J=6.3 Hz), 2.90 (s, 2H), 2.09 (d, 2H, J=11.9 Hz), 1.94-1.85 (m, 2H), 1.72 (m, 2H), 1.50(m, 1H), 0.71-0.65 (m, 4H); LRMS (ES) m/z 606.1 (M++1).


EXAMPLE 289
Compound 11784, N-(3-chlorophenyl)-1-(1-(cyclopropanecarbonyl)azetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide trihydrochloride (0.050 g, 0.077 mmol) in dichloromethane (5 mL) was treated at the room temperature with cyclopropanecarbonyl chloride (0.024 g, 0.231 mmol) and N,N-diisopropylethylamine (0.054 mL, 0.308 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chlorophenyl)-1-(1-(cyclopropanecarbonyl)azetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperidine-4-sulfonamide as white solid (0.017 g, 36.3%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (dd, 1H, J=2.3, 0.8 Hz), 8.41 (dd, 1H, J=8.3, 2.3 Hz), 7.72-7.67 (m, 1.25H), 7.65 (t, 1H, J=2.0 Hz), 7.56 (s, 0.5H), 7.51 (ddd, 1H, J=8.1, 2.2, 1.2 Hz), 7.44 (s, 0.25H), 7.37 (t, 1H, J=8.0 Hz), 7.31 (ddd, 1H, J=8.0, 2.0, 1.1 Hz), 5.22 (s, 2H), 4.24 (t, 1H, J=7.9 Hz), 4.03 (dd, 1H, J=8.6, 4.9 Hz), 3.84 (m, 1H), 3.65 (dd, 1H, J=9.7, 5.1 Hz), 3.41 (m, 1H), 3.14 (m, 1H), 2.90 (s, 2H), 2.13 (d, 2H, J=12.2 Hz), 1.90 (m, 2H), 1.72-1.68 (m, 2H), 1.50 (m, 1H), 0.71-0.66 (m, 4H); LRMS (ES) m/z 607.1 (M++1).


EXAMPLE 290
Compound 11785, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-methylazetidin-3-yl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride (0.050 g, 0.082 mmol), paraformaldehyde (0.012 g, 0.409 mmol) and N,N-diisopropylethylamine (0.043 mL, 0.246 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.035 g, 0.164 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-methylazetidin-3-yl)piperidine-4-sulfonamide as white solid (0.016 g, 35.4%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.58-7.48 (m, 3.5H), 7.44 (m, 1H), 7.41 (s, 0.25H), 7.35 (t, 1H, J=7.9 Hz), 7.29 (m, 1H), 5.11 (s, 2H), 3.49-3.44 (m, 2H), 3.21 (m, 1H), 2.90-2.74 (m, 4H), 2.31-2.15 (m, 4H), 2.06 (d, 2H, J=12.3 Hz), 1.83 (t, 2H, J=11.6 Hz), 1.73-1.63 (m, 2H); LRMS (ES) m/z 552.3 (M++1).


EXAMPLE 291
Compound 11786, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-2-(4-fluoropiperidin-1-yl)ethane-1-sulfonamide
[Step 1] methyl 6-(((3-chloro-4-fluorophenyl)amino)methyl)nicotinate



embedded image


A mixture of methyl 6-formylnicotinate (1.000 g, 6.055 mmol) and 3-chloro-4-fluoroaniline (0.970 g, 6.661 mmol) in tetrahydrofuran (50 mL) was stirred at the room temperature for 30 min, and treated with sodium triacetoxyborohydride (1.925 g, 9.083 mmol). The reaction mixture was stirred at the same temperature for additional 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/dichloromethane=0% to 5%) to give methyl 6-(((3-chloro-4-fluorophenyl)amino)methyl)nicotinate as brown solid (0.510 g, 28.6%).


[Step 2] methyl 6-((N-(3-chloro-4-fluorophenyl)vinylsulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((3-chloro-4-fluorophenyl)amino)methyl)nicotinate (0.510 g, 1.731 mmol) in dichloromethane (10 mL) was mixed at the room temperature with 2-chloroethane-1-sulfonyl chloride (0.310 g, 1.904 mmol) and triethylamine (0.289 mL, 2.077 mmol), and stirred at the same temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=20% to 50%) to give methyl 6-((N-(3-chloro-4-fluorophenyl)vinylsulfonamido)methyl)nicotinate as brown solid (0.247 g, 37.1%).


[Step 3] methyl 6-(((N-(3-chloro-4-fluorophenyl)-2-(4-fluoropiperidin-1-yl)ethyl)sulfonamido)methyl)nicotinate



embedded image


A mixture of methyl 6-((N-(3-chloro-4-fluorophenyl)vinylsulfonamido)methyl)nicotinate (0.247 g, 0.642 mmol) and 4-fluoropiperidine hydrochloride (0.179 g, 1.284 mmol) in dichloromethane (10 mL) was treated at the room temperature with triethylamine (0.268 mL, 1.926 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=60% to 90%) to give methyl 6-(((N-(3-chloro-4-fluorophenyl)-2-(4-fluoropiperidin-1-yl)ethyl)sulfonamido)methyl)nicotinate as light yellow solid (0.250 g, 79.8%).


[Step 4] N-(3-chloro-4-fluorophenyl)-2-(4-fluoropiperidin-1-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethane-1-sulfonamide



embedded image


A solution of methyl 6-(((N-(3-chloro-4-fluorophenyl)-2-(4-fluoropiperidin-1-yl)ethyl)sulfonamido)methyl)nicotinate (0.250 g, 0.512 mmol) in tetrahydrofuran (7 mL)/ethanol (7 mL) was mixed at the room temperature with hydrazine monohydrate (0.498 mL, 10.247 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give N-(3-chloro-4-fluorophenyl)-2-(4-fluoropiperidin-1-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethane-1-sulfonamide as white solid (0.230 g, 92.0%).


[Step 5] Compound 11786



embedded image


A solution of N-(3-chloro-4-fluorophenyl)-2-(4-fluoropiperidin-1-yl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)ethane-1-sulfonamide (0.230 g, 0.471 mmol) in tetrahydrofuran (10 mL) was mixed at 50° C. with 2,2-difluoroacetic anhydride (0.176 mL, 1.414 mmol) and triethylamine (0.263 mL, 1.885 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=60% to 90%) to give N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-2-(4-fluoropiperidin-1-yl)ethane-1-sulfonamide as light yellow solid (0.146 g, 56.5%).



1H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 1H), 8.41 (d, 1H, J=8.3 Hz), 7.83 (d, 1H, J=5.4 Hz), 7.74 (d, 1H, J=8.3 Hz), 7.70 (s, 0.25H), 7.57 (s, 0.5H), 7.53 (s, 1H), 7.43 (d, 1H, J=8.2 Hz), 7.40 (s, 0.25H), 5.15 (s, 2H), 4.70 (d, 1H, J=49.1 Hz), 3.54 (t, 2H, J=7.2 Hz), 2.80-2.73 (m, 2H), 2.59 (s, 2H), 2.38 (s, 2H), 1.94-1.80 (m, 2H), 1.80-1.66 (m, 2H); LRMS (ES) m/z 548.2 (M++1).


EXAMPLE 292
Compound 11790, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-methoxypropan-2-yl)-N-phenylpiperidine-4-sulfonamide
[Step 1] tert-butyl 4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)piperidine-1-carboxylate



embedded image


A solution of methyl 6-(((1-(tert-butoxycarbonyl)-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate (1.000 g, 2.043 mmol) in tetrahydrofuran (7 mL)/ethanol (7 mL) was mixed at the room temperature with hydrazine monohydrate (2.978 mL, 61.276 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The residue was diluted with water (50 mL) and stirred. The resulting precipitates were collected by filtration, washed by water, and dried to give tert-butyl 4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)piperidine-1-carboxylate as white solid (0.899 g, 89.9%).


[Step 2] tert-butyl 4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)piperidine-1-carboxylate



embedded image


A mixture of tert-butyl 4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)piperidine-1-carboxylate (0.899 g, 1.836 mmol) and triethylamine (1.024 mL, 7.345 mmol) in tetrahydrofuran (20 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.685 mL, 5.509 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; ethyl acetate/hexane=20% to 50%) to give tert-butyl 4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)piperidine-1-carboxylate as white solid (0.882 g, 87.4%).


[Step 3] N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide dihydrochloride



embedded image


A solution of tert-butyl 4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)piperidine-1-carboxylate (0.882 g, 1.605 mmol) in 1,4-dioxane (5 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 6.018 mL, 24.072 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (10 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide dihydrochloride as white solid (0.760 g, 90.7%).


[Step 4] Compound 11790



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide dihydrochloride (0.050 g, 0.096 mmol), 1-methoxypropan-2-one (0.042 g, 0.479 mmol) and N,N-diisopropylethylamine (0.050 mL, 0.287 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.041 g, 0.191 mmol), and stirred at the same temperature for 6 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-methoxypropan-2-yl)-N-phenylpiperidine-4-sulfonamide as light yellow oil (0.009 g, 18.0%).



1H NMR (400 MHz, DMSO-d6) δ 9.08 (d, 1H, J=2.2 Hz), 8.41 (dd, 1H, J J=8.2, 2.3 Hz), 7.74-7.67 (m, 1.25H), 7.56 (s, 0.5H), 7.50 (d, 2H, J=7.5 Hz), 7.43 (s, 0.25H), 7.39-7.30 (m, 2H), 7.24 (t, 1H, J=7.3 Hz), 5.17 (s, 2H), 3.39 (m, 1H), 3.27-3.18 (m, 5H), 2.93-2.85 (m, 2H), 2.77 (p, 1H, J=6.4 Hz), 2.36-2.23 (m, 2H), 2.07 (d, 2H, J=12.0 Hz), 1.71-1.58 (m, 2H), 0.93 (d, 3H, J=6.7 Hz); LRMS (ES) m/z 522.4 (M++1).


EXAMPLE 293
Compound 11791, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-hydroxycyclobutyl)-N-phenylpiperidine-4-sulfonamide



embedded image


A mixture of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide dihydrochloride (0.090 g, 0.172 mmol), 3-hydroxycyclobutan-1-one (0.044 g, 0.517 mmol) and N,N-diisopropylethylamine (0.090 mL, 0.517 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.073 g, 0.345 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-hydroxycyclobutyl)-N-phenylpiperidine-4-sulfonamide as pale orange solid (0.039 g, 43.6%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, 1H, J=2.2 Hz), 8.41 (dd, 1H, J=8.2, 2.3 Hz), 7.72-7.68 (m, 1.25H), 7.56 (s, 0.5H), 7.49 (d, 2H, J=7.5 Hz), 7.43 (s, 0.25H), 7.38-7.31 (m, 2H), 7.25 (t, 1H, J=7.3 Hz), 5.17 (s, 2H), 4.93 (m, 1H), 4.18 (m, 0.5H), 3.78 (m, 0.5H), 3.00-2.80 (m, 2H), 2.34 (m, 1H), 2.15-2.03 (m, 4H), 2.00 (m, 1H), 1.90-1.54 (m, 6H); LRMS (ES) m/z 520.4 (M++1).


EXAMPLE 294
Compound 11792, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(3-hydroxycyclobutyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(m-tolyl)piperidine-4-sulfonamide hydrochloride (0.090 g, 0.180 mmol), 3-hydroxycyclobutan-1-one (0.047 g, 0.541 mmol) and N,N-diisopropylethylamine (0.063 mL, 0.361 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.076 g, 0.361 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(3-hydroxycyclobutyl)-N-(m-tolyl)piperidine-4-sulfonamide as light yellow solid (0.031 g, 32.3%).



1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, 2H, J=6.6 Hz), 7.66 (s, 0.25H), 7.53 (s, 0.5H), 7.50 (d, 2H, J=8.3 Hz), 7.40 (s, 0.25H), 7.27-7.16 (m, 3H), 7.04 (m, 1H), 5.05 (s, 2H), 4.93 (m, 1H), 4.14 (m, 0.5H), 3.75 (m, 0.5H), 3.19 (m, 1H), 2.93 (m, 1H), 2.91-2.78 (m, 2H), 2.33 (m, 1H), 2.25 (s, 3H), 2.13-2.02 (m, 3H), 1.86 (m, 1H), 1.77-1.53 (m, 5H); LRMS (ES) m/z 533.4 (M++1).


EXAMPLE 295
Compound 11793, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(3-hydroxycyclobutyl)piperidine-4-sulfonamide



embedded image


A mixture of N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide hydrochloride (0.050 g, 0.096 mmol), 3-hydroxycyclobutan-1-one (0.025 g, 0.289 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.193 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.041 g, 0.193 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(3-hydroxycyclobutyl)piperidine-4-sulfonamide as orange solid (0.021 g, 39.4%).



1H NMR (400 MHz, DMSO-d6) δ 8.04-7.95 (m, 2H), 7.65 (s, 0.25H), 7.56-7.42 (m, 3.5H), 7.41-7.38 (m, 1.25H), 7.37-7.27 (m, 2H), 5.11 (s, 2H), 4.93 (m, 1H), 4.20 (m, 1H), 3.03-2.88 (m, 2H), 2.34 (m, 1H), 2.16-2.05 (m, 4H), 2.04-1.97 (m, 2H), 1.92-1.85 (m, 2H), 1.79-1.58 (m, 3H); LRMS (ES) m/z 553.2 (M++1).


EXAMPLE 296
Compound 11794, 1-cyclobutyl-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide
[Step 1] methyl 6-(((1-c yclobutyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-((N-phenylpiperidine-4-sulfonamido)methyl)nicotinate hydrochloride (0.202 g, 0.474 mmol) and cyclobutanone (0.053 mL, 0.711 mmol) in dichloromethane (20 mL) was stirred at the room temperature for 10 min, and mixed with sodium triacetoxyborohydride (0.302 g, 1.423 mmol). The reaction mixture was stirred at the same temperature for additional 18 hr. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=0% to 30%) to give methyl 6-(((1-c yclobutyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate as white solid (0.100 g, 47.5%).


[Step 2] 1-cyclobutyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide



embedded image


Methyl 6-(((1-cyclobutyl-N-phenylpiperidine)-4-sulfonamido)methyl)nicotinate (0.100 g, 0.225 mmol) and hydrazine monohydrate (0.329 mL, 6.763 mmol) were mixed at the room temperature in ethanol (8 mL), stirred at 80° C. for 18 hr, cooled down to the room temperature to terminate the reaction, and oncentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (1-cyclobutyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide, 0.078 g, 78.0%, white solid).


[Step 3] Compound 11794



embedded image


A solution of 1-cyclobutyl-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide (0.058 g, 0.131 mmol) and triethylamine (0.091 mL, 0.654 mmol) in tetrahydrofuran (10 mL) was mixed at the room temperature with 2,2-difluoroacetic anhydride (0.049 mL, 0.392 mmol), stirred at 80° C. for 1 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 15%) to give 1-cyclobutyl-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylpiperidine-4-sulfonamide as white solid (0.032 g, 48.6%).



1H NMR (400 MHz, CDCl3) δ 9.17 (s, 1H), 8.34 (dd, 1H, J=8.2, 2.2 Hz), 7.70-7.65 (m, 1H), 7.41-7.39 (m, 2H), 7.34-7.30 (m, 2H), 7.26-7.23 (m, 1H), 7.04 (s, 0.25H), 6.91 (s, 0.5H), 6.78 (s, 0.25H), 5.16 (s, 2H), 3.18-2.74 (m, 4H), 2.47-1.23 (m, 13H); LRMS (ES) m/z 504.1 (M++1).


EXAMPLE 297
Compound 11795, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-fluoropyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (S)-(+)-3-fluoropyrrolidine, HCl (0.064 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-fluoropyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.015 g, 12.2%).



1H NMR (400 MHz, CDCl3) δ 8.03 (d, 2H, J=8.3 Hz), 7.47 (d, 2H, J=8.3 Hz), 7.36-7.26 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 5.32-5.19 (s, 1H), 5.01 (s, 2H), 3.42-3.41 (s, 2H), 3.18-3.11 (m, 2H), 3.08-2.97 (m, 3H), 2.68 (m, 1H), 2.31-2.15 (m, 2H); LRMS (ES) m/z 481.3 (M++1).


EXAMPLE 298
Compound 11796, 2-(dibenzylamino)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), dibenzylamine (0.101 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(dibenzylamino)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.054 g, 35.9%).



1H NMR (400 MHz, CDCl3) δ 8.00-7.98 (m, 2H), 7.41-7.24 (m, 15H), 6.95 (m, 2H), 6.91 (t, 1H, J=51.7 Hz), 4.71 (s, 2H), 3.66 (m, 4H), 3.23 (m, 2H), 3.06 (m, 2H); LRMS (ES) m/z 590.1 (M++1).


EXAMPLE 299
Compound 11797, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(dimethylamino)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), dimethyl amine (2.00 M in THF solution, 0.255 mL, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(dimethylamino)-N-phenylethane-1-sulfonamide as white solid (0.052 g, 46.6%).



1H NMR (700 MHz, CDCl3) δ 8.03-8.02 (m, 2H), 7.47-7.46 (m, 2H), 7.44-7.13 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.40-3.35 (m, 2H), 3.04-2.90 (m, 2H), 2.39 (s, 6H); LRMS (ES) m/z 437.3 (M++1).


EXAMPLE 300
Compound 11798, 2-(diethylamino)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), diethyl amine (0.056 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(diethylamino)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.064 g, 53.9%).



1H NMR (700 MHz, CDCl3) δ 8.03-8.02 (m, 2H), 7.47-7.43 (m, 2H), 7.35-7.26 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.99 (s, 2H), 3.36-3.31 (m, 2H), 3.07-3.02 (m, 2H), 2.65-2.59 (m, 4H), 1.10 (t, 6H, J=7.2 Hz); LRMS (ES) m/z 465.0 (M++1).


EXAMPLE 301
Compound 11799, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxyazetidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 3-hydroxyazetidine HCl (0.056 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxyazetidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.043 g, 36.2%).



1H NMR (400 MHz, CD3OD) δ 8.00 (d, 2H, J=8.3 Hz), 7.47 (d, 2H, J=8.3 Hz), 7.31-7.26 (m, 5H), 7.02 (t, 1H, J=51.7 Hz), 4.98 (s, 2H), 4.49 (m, 1H), 4.04-4.00 (m, 2H), 3.42-3.27 (m, 6H); LRMS (ES) m/z 465.1 (M++1).


EXAMPLE 302
Compound 11800, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxypyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (s)-3-pyrrolidinol (0.045 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxypyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.040 g, 32.7%).



1H NMR (700 MHz, CD3OD) δ 7.98-7.97 (m, 2H),7.45 (d, 2H, J=8.9 Hz), 7.32-7.25 (m, 5H), 6.97 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 4.42-4.38 (m, 1H), 3.48-3.46 (m, 2H), 3.23-3.21 (m, 2H), 3.09-3.05 (m, 1H), 3.02-3.00 (m, 1H), 2.87-2.84 (m, 2H), 2.17-2.14 (m, 1H), 1.87-1.85 (m, 1H); LRMS (ES) m/z 479.2 (M++1).


EXAMPLE 303
Compound 11801, (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxypyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (R)-3-pyrrolidinol (0.045 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxypyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.036 g, 29.4%).



1H NMR (700 MHz, CD3OD) δ 8.03-8.01(m,2H),7.55(d, 2H, J=8.5 Hz), 7.44-7.43 (m, 2H), 7.37-7.28 (m, 3H), 7.21 (t, 1H, J=51.7 Hz), 5.07 (s, 2H), 4.43-4.41 (m, 1H), 3.49-3.47 (m, 2H), 3.16-3.14 (m, 2H), 3.02-2.93 (m, 1H), 2.92-2.88 (dd, 1H, J=10.6, 5.5 Hz), 2.79-2.69 (m, 2H), 2.21-2.14 (ddt, 1H, J=13.7, 8.3, 6.9 Hz), 1.84 (ddddd, 1H, J=13.4, 8.0, 5.5, 2.8, 0.9 Hz); LRMS (ES) m/z 479.0 (M++1).


EXAMPLE 304
Compound 11802, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), L-prolinol (0.052 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.049 g, 38.9%).



1H NMR (700 MHz, CD3OD) δ 8.02-8.01 (m, 2H),7.54 (d, 2H, J=8.5 Hz), 7.42-7.38 (m, 2H), 7.37-7.32 (dd, 2H, J=8.6, 7.1 Hz), 7.30-7.25 (m, 1H), 7.21 (t, 1H, J=51.7 Hz), 5.06 (s, 2H), 3.67-3.62 (dd, 1H, J=11.5, 4.6 Hz), 3.60-3.50 (m, 4H), 3.33 (m, 1H), 3.12-3.11 (ddd, 1H, J=11.5, 8.6, 4.8 Hz), 3.02-2.95 (m, 1H), 2.66-2.59 (td, 1H, J=9.5, 7.4 Hz), 2.06-2.03 (m, 1H), 1.91 (m, 2H), 1.73 (dddd, 1H, J=12.6, 9.1, 6.7, 5.0 Hz); LRMS (ES) m/z 493.0 (M++1).


EXAMPLE 305
Compound 11803, (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (R)-(-)-prolinol (0.052 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.053 g, 42.1%).



1H NMR (700 MHz, CD3OD) δ 8.02-8.01 (m, 2H), 7.54 (d, 2H, J=8.5 Hz), 7.43-7.41 (m, 2H), 7.38-7.35 (m, 2H), 7.31-7.29 (m, 1H), 7.21 (t, 1H, J=51.7 Hz), 5.06 (s, 2H), 3.68-3.66 (dd, 1H, J=11.6, 4.5 Hz), 3.62-3.56 (m, 4H), 3.34 (m, 1H), 3.14-3.13 (ddt, 1H, J=9.8, 7.1, 4.8 Hz), 3.04 (dtd, 1H, J=8.7, 6.3, 4.8 Hz), 2.68-2.66 (td, 1H, J=9.5, 7.4 Hz), 2.07-2.04 (m, 1H), 1.92-1.85 (m, 2H), 1.74 (m, 1H); LRMS (ES) m/z 493.0 (M++1).


EXAMPLE 306
Compound 11804, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(hydroxymethyl)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (S)-pyrrolidin-3-ylmethanol (0.052 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(hydroxymethyl)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.035 g, 27.8%).



1H NMR (700 MHz, CD3OD) δ 8.02-8.01(m,2H),7.54(d, 2H, J=8.4 Hz), 7.43-7.42 (m, 2H), 7.38-7.35 (m, 2H), 7.31-7.29 (m, 1H), 7.21 (t, 1H, J=51.7 Hz), 5.06 (s, 2H), 3.59-3.57 (ddd, 3H, J=10.7, 5.6, 2.2 Hz), 3.54-3.51 (dd, 1H, J=10.7, 6.8 Hz), 3.33-3.30 (m, 2H), 3.15-3.13 (dd, 1H, J=10.4, 8.1 Hz), 3.04-3.02 (m, 2H), 2.85-2.84 (dd, 1H, J=10.4, 6.5 Hz), 2.54-2.51 (tt, 1H, J=8.4, 6.3 Hz), 2.12-2.05 (m, 1H), 1.74-1.71 (dtd, 1H, J=13.6, 7.5, 6.2 Hz); LRMS (ES) m/z 493.0 (M++1).


EXAMPLE 307
Compound 11805, (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(hydroxymethyl)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (R)-3-(hydroxymethyl)pyrrolidine (0.052 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (R)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(hydroxymethyl)pyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.040 g, 31.8%).



1H NMR (700 MHz, CD3OD) δ 8.04-8.03 (m, 2H),7.55 (d, 2H, J=8.5 Hz), 7.43-7.42 (m, 2H), 7.38-7.36 (m, 2H), 7.31-7.28 (m, 1H), 7.21 (t, 1H, J=51.7 Hz), 5.07 (s, 2H), 3.58-3.52 (dd, 1H, J=10.6, 5.9 Hz), 3.54-3.50 (m, 3H), 3.23-3.20 (m, 2H), 3.04-3.01 (dd, 1H, J J=10.1, 8.0 Hz), 2.92-2.90 (t, 2H, J=7.2 Hz), 2.73-2.71 (dd, 1H, J=10.1, 6.3 Hz), 2.50-2.48 (tdd, 1H, J=8.9, 6.4, 4.0 Hz), 2.09-2.05 (m, 1H), 1.69-1.67 (dtd, 1H, J=13.4, 7.3, 6.0 Hz); LRMS (ES) m/z 493.0 (M++1).


EXAMPLE 308
Compound 11806, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(2-methyl-1H-imidazol-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 2-methylimidazole (0.042 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(2-methyl-1H-imidazol-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.034 g, 28.1%).



1H NMR (700 MHz, CD3OD) δ 8.02-8.01 (m, 2H),7.52 (d, 2H, J=8.5 Hz), 7.39-7.35 (m, 4H), 7.32-7.28 (m, 2H), 7.21 (t, 1H, J=51.7 Hz), 7.11 (m, 1H), 5.01 (s, 2H), 4.52 (t, 2H, J=6.5 Hz), 3.76 (t, 2H, J=6.5 Hz), 2.50 (s, 3H); LRMS (ES) m/z 474.3 (M++1).


EXAMPLE 309
Compound 11807, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(5-methyl-1H-imidazol-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-methylimidazole (0.042 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(5-methyl-1H-imidazol-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.060 g, 49.6%).



1H NMR (700 MHz, CD3OD) δ 8.01-7.94 (m, 2H),7.52-7.51 (m, 2H),7.39-7.34 (m, 5H),7.29 (m, 1H),7.28 (m, 1H),7.21(t, 1H, J=51.7 Hz), 5.02 (d, 2H, J=8.3 Hz), 4.54-4.51 (td, 2H, J=6.7, 2.3 Hz), 3.76-3.72 (dt, 2H, J=19.3, 6.7 Hz), 2.29-2.28 (m, 3H); LRMS (ES) m/z 474.1 (M++1).


EXAMPLE 310
Compound 11808, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(hydroxymethyl)-1H-imidazol-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (1H-imidazole-4-yl)methanol (0.05 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(hydroxymethyl)-1H-imidazol-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.043 g, 34.4%).



1H NMR (400 MHz, CD3OD) δ 7.98 (d, 2H, J=8.3 Hz), 7.49 (dd, 2H, J=8.5, 2.3 Hz), 7.40-7.28 (m, 7H), 7.21 (t, 1H, J J=51.6 Hz), 5.01 (d, 2H, J=5.9 Hz), 4.66-4.55 (m, 4H), 3.88 (t, 1H, J=6.9 Hz), 3.76 (t, 1H, J=6.7 Hz); LRMS (ES) m/z 490.3 (M++1).


EXAMPLE 311
Compound 11809, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(1H-1,2,4-triazol-1-yl)ethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 1,2,4-1H-triazole (0.035 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2-(1H-1,2,4-triazol-1-yl)ethane-1-sulfonamide as white solid (0.030 g, 25.5%).



1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 8.05-8.01 (m, 3H), 7.41 (d, 2H, J=8.4 Hz), 7.37-7.23 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.85 (s, 2H), 4.69 (t, 2H, J=6.8 Hz), 3.71 (t, 2H, J=6.8 Hz); LRMS (ES) m/z 461.0 (M++1).


EXAMPLE 312
Compound 11810, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(hydroxymethyl)piperidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), piperidin-4-ylmethanol (0.059 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(hydroxymethyl)piperidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.100 g, 77.3%).



1H NMR (400 MHz, CDCl3) δ 8.00 (d, 2H, J=8.3 Hz), 7.45 (d, 2H, J=8.3 Hz), 7.35-7.24 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.51 (d, 2H, J J=6.4 Hz), 3.34-3.31 (m, 2H), 2.96-2.90 (m, 4H), 2.10 (td, 1H, J=11.7, 2.5 Hz), 1.97 (m, 1H), 1.81-1.78 (m, 2H), 1.56-1.49 (m, 1H), 1.37-1.33 (m, 2H); LRMS (ES) m/z 507.3 (M++1).


EXAMPLE 313
Compound 11811, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(hydroxymethyl)piperidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 3-piperidinemethanol (0.059 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-(hydroxymethyl)piperidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.090 g, 69.5%).



1H NMR (400 MHz, CDCl3) δ 8.01 (d, 2H, J=8.2 Hz), 7.45 (d, 2H, J=8.2 Hz), 7.35-7.24 (m, 5H), 6.91 (t, 1H, J=51.7 Hz), 4.97 (s, 2H), 3.62-3.47 (m, 2H) 3.34 (t, 2H, J=7.4 Hz), 2.92 (qt, 4H, J=7.4, 4.5 Hz), 2.75 (dd, 1H, J=10.2, 5.4 Hz), 2.17 (td, 1H, J=10.4, 2.6 Hz), 2.01 (t, 1H, J J=10.1 Hz), 1.87 (dd, 1H, J=11.7, 6.3 Hz), 1.76 (ddt, 1H, J=15.6, 8.6, 4.2 Hz), 1.74-1.55 (m, 1H), 1.08 (td, 1H, J=14.0, 12.7, 6.0 Hz)); LRMS (ES) m/z 507.4 (M++1).


EXAMPLE 314
Compound 11812, (S)-1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)pyrrolidine-2-carboxamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), L-prolinamide (0.058 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (S)-1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)pyrrolidine-2-carboxamide as white solid (0.120 g, 92.9%).



1H NMR (400 MHz, DMSO-d6) δ7.95 (d, 2H, J=8.0 Hz), 7.48 (d, 2H, J=8.1 Hz), 7.39-7.21 (m, 6H), 7.08 (br, 2H), 4.99 (s, 2H), 3.99 (q, 1H, J=5.3 Hz), 3.45 (m, 2H), 3.32-3.15 (m, 2H), 2.95-2.82 (m, 2H), 2.31 (m, 1H), 2.07 (m, 1H), 1.74-1.69 (m, 2H); LRMS (ES) m/z 506.3 (M++1).


EXAMPLE 315
Compound 11813, (R)-1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)pyrrolidine-2-carboxamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), D-(-)-prolinamide (0.058 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (R)-1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)pyrrolidine-2-carboxamide as white solid (0.120 g, 92.9%).



1H NMR (400 MHz, DMSO-d6) δ 7.96(d, 2H,J=8.4 Hz), 7.50 (d, 2H, J=8.3 Hz), 7.43-7.22 (m, 6H), 7.11 (br, 2H), 5.00 (s, 2H), 4.02 (q, 1H, J=5.2 Hz), 3.47 (m, 2H), 3.32 (s, 1H), 3.15-3.13 (m, 1H), 2.94-2.81 (m, 2H), 2.34-2.30 (m, 1H), 2.06 (m, 1H), 1.74-1.69 (m, 2H); LRMS (ES) m/z 506.1 (M++1).


EXAMPLE 316
Compound 11814, tert-butyl 7-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)-2,7-diazaspiro[3.5]nonane-2-carboxylate



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 2,7-diazaspiro[3,5]nonane-2-carboxylic acid tert-butyl ester (0.116 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give tert-butyl 7-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)-2,7-diazaspiro[3.5]nonane-2-carboxylate as white solid (0.040 g, 25.3%).



1H NMR (700 MHz, CD3OD) δ 8.01 (d, 2H, J=8.4 Hz), 7.54 (d, 2H, J=8.4 Hz), 7.43-7.41 (m, 2H), 7.37-7.34 (m, 2H), 7.30-7.28 (m, 1H), 7.21 (t, 1H, J=51.7 Hz), 5.05 (s, 2H), 3.64-3.63 (s, 4H), 3.43-3.41 (m, 2H), 2.90-2.87 (m, 2H), 2.49 (s, 4H), 1.85 (m, 4H), 1.46 (s, 9H); LRMS (ES) m/z 618.4 (M++1).


EXAMPLE 317
Compound 11815, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3,3-difluoropyrrolidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 3,3-difluoropyrrolidine hydrochloride (0.073 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3,3-difluoropyrrolidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.035 g, 27.5%).



1H NMR (700 MHz, CD3OD) δ 8.03-8.02 (m, 2H),7.55(d, 2H,J=8.5 Hz), 7.43-7.42 (m, 2H), 7.37-7.35 (m, 2H), 7.30-7.28 (m, 1H), 7.21 (t, 1H, J=51.7 Hz), 5.06 (s, 2H), 3.43-3.40 (m, 2H), 3.02-2.98 (m, 4H), 2.85-2.83 (t, 2H, J=7.0 Hz), 2.31 (tt, 2H, J=14.6, 7.0 Hz); LRMS (ES) m/z 499.1 (M++1).


EXAMPLE 318
Compound 11816, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(1H-imidazol-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), imidazole (0.035 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(1H-imidazol-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.042 g, 35.8%).



1H NMR (700 MHz, CD3OD) δ 8.03-8.02 (m, 2H),7.86 (s, 1H),7.53 (d, 2H, J=8.5 Hz), 7.39-7.35 (m, 4H), 7.31-7.28 (m, 2H), 7.21 (t, 1H, J=51.7 Hz), 7.06 (s, 1H), 5.01 (s, 2H), 4.57 (t, 2H, J=6.8 Hz), 3.75 (t, 2H, J=6.8 Hz); LRMS (ES) m/z 460.0 (M++1).


EXAMPLE 319
Compound 11817, (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxypiperidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (S)-3-hydroxypiperidine hydrochloride (0.070 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give (S)—N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(3-hydroxypiperidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.051 g, 40.5%).



1H NMR (700 MHz, CD3OD) δ 7.98 (d, 2H, J=8.3 Hz), 7.51 (d, 2H, J=8.3 Hz), 7.44-7.42 (m, 2H), 7.37-7.34 (m, 2H), 7.30-7.28 (m, 1H), 7.21 (t, 1H, J=51.6 Hz), 5.05 (s, 2H), 3.87 (tt, 1H, J=7.5, 3.4 Hz), 3.59 (td, 2H, J=6.9, 2.3 Hz), 3.21 (dd, 2H, J=8.3, 6.9 Hz), 3.07 (dd, 1H, J=11.4, 3.2 Hz), 2.92 (m, 1H), 2.66 (m, 1H), 2.58 (m, 1H), 1.92 (m, 2H), 1.74-1.59 (m, 1H), 1.47 (m, 1H); LRMS (ES) m/z 493.3 (M++1).


EXAMPLE 320
Compound 11818, 2-(4-cyanopiperidin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-cyanopiperidine (0.056 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give 2-(4-cyanopiperidin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.080 g, 62.4%).



1H NMR (700 MHz, CD3OD) δ 8.03 (d, 2H, J=8.3 Hz), 7.55 (d, 2H, J=8.3 Hz), 7.43-7.41 (m, 2H), 7.37-7.35 (m, 2H), 7.30-7.28 (m, 1H), 7.21 (t, 1H, J=51.7 Hz), 5.06 (s, 2H), 3.43-3.42 (m, 2H), 2.91-2.89 (m, 2H), 2.84-2.74 (m, 3H), 2.45 (m, 2H), 2.02-1.98 (m, 2H), 1.88-1.84 (m, 2H); LRMS (ES) m/z 502.3 (M++1).


EXAMPLE 321
Compound 11819, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(4-fluorophenyl)piperidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-(4-fluoro-phenyl)-piperidine hydrochloride (0.110 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(4-fluorophenyl)piperidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.040 g, 27.4%).



1H NMR (400 MHz, CDCl3) δ 7.74 (d, 2H, J=8.3 Hz), 7.23-7.20 (m, 2H), 7.15-7.03 (m, 4H), 6.98-6.96 (m, 2H), 6.83-6.68 (m, 4H), 4.76 (s, 2H), 3.65-3.59 (m, 2H), 3.43-3.41 (m, 2H), 3.29-3.27 (m, 2H), 2.84-2.81 (m, 2H), 2.59-2.55 (m, 1H), 1.97-1.92 (m, 2H), 1.84-1.80 (m, 2H); LRMS (ES) m/z 571.2 (M++1).


EXAMPLE 322
Compound 11820, methyl 1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)azetidine-3-carboxylate



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), methyl azetidine-3-carboxylate hydrochloride (0.077 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give methyl 1-(2-(N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)ethyl)azetidine-3-carboxylate as white solid (0.042 g, 32.5%).



1H NMR (400 MHz, CD3OD) δ 8.04-8.02 (m, 2H),7.55(d, 2H, J=8.5 Hz), 7.43-7.42 (m, 2H), 7.37-7.35 (m, 2H), 7.31-7.28 (m, 1H), 7.21 (t, 1H, J=51.7 Hz), 5.06 (s, 2H), 3.76-3.74 (m, 2H), 3.75 (s, 3H), 3.65-3.62 (m, 2H), 3.45-3.40 (m, 1H), 3.33-3.32 (m, 2H), 3.14-3.13 (t, 2H, J=7.1 Hz); LRMS (ES) m/z 507.3 (M++1).


EXAMPLE 323
Compound 11821, 2-(3,3-difluoroazetidin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 3,3-difluoroazetidine hydrochloride (0.066 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(3,3-difluoroazetidin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.065 g, 52.5%).



1H NMR (400 MHz, CD3OD) δ 8.02-8.00 (m, 2H),7.54(d, 2H, J=8.5 Hz), 7.43-7.41 (m, 2H), 7.42-7.33 (m, 2H), 7.30-7.28 (m, 1H), 7.21 (t, 1H, J=51.6 Hz), 5.05 (s, 2H), 3.69 (t, 4H, J=12.1 Hz), 3.37-3.30 (m, 4H), 3.11-3.07 (m, 2H)); LRMS (ES) m/z 485.3 (M++1).


EXAMPLE 324
Compound 11822, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-hydroxypiperidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-hydroxy piperidine (0.052 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, C18; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-hydroxypiperidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.046 g, 36.6%).



1H NMR (400 MHz, CD3OD) δ 8.00 (d, 2H, J=8.4 Hz), 7.53 (d, 2H, J=8.4 Hz), 7.43-7.42 (m, 2H), 7.37-7.34 (m, 2H), 7.31-7.29 (m, 1H), 7.21 (t, 1H, J=51.6 Hz), 5.05 (s, 2H), 3.73 (m, 1H), 3.52-3.37 (m, 2H), 3.07-2.97 (m, 4H), 2.53-2.50 (m, 2H), 1.96-1.91 (m, 2H), 1.68-1.63 (m, 2H); LRMS (ES) m/z 493.0 (M++1).


EXAMPLE 325
Compound 11836, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-(2-hydroxyacetyl)azetidin-3-yl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-sulfonamide dihydrochloride (0.080 g, 0.131 mmol), 2-hydroxyacetic acid (0.030 g, 0.393 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 0.081 g, 0.524 mmol) and 1H-benzo[d][1,2,3]triazol-1-ol (HOBt, 0.071 g, 0.524 mmol) in dichloromethane (5 mL) was treated at the room temperature with N,N-diisopropylethylamine (0.182 mL, 1.048 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give the concentrate, and then the concentrate was dissolved in diethylether (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(1-(2-hydroxyacetyl)azetidin-3-yl)piperidine-4-sulfonamide as white solid (0.059 g, 75.6%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.56 (t, 1H, J=2.0 Hz), 7.53 (s, 0.5H), 7.51 (d, 2H, J=8.4 Hz), 7.45 (m, 1H), 7.40 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (m, 1H), 5.12 (s, 2H), 4.89 (m, 1H), 4.19-4.13 (m, 2H), 3.97 (m, 1H), 3.90-3.85 (m, 2H), 3.69 (m, 1H), 3.38 (m, 1H), 3.13 (m, 1H), 2.93-2.84 (m, 2H), 2.11-2.07 (m, 2H), 1.91-1.87 (m, 2H), 1.75-1.68 (m, 2H); LRMS (ES) m/z 596.3 (M++1).


EXAMPLE 326
Compound 11837, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-isopropylazetidin-3-yl)-N-(m-tolyl)piperidine-4-sulfonamide
[Step 1] methyl 6-((N-(m-tolyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride



embedded image


A solution of methyl 6-(((1-(tert-butoxycarbonyl)-N-(m-tolyl)piperidine)-4-sulfonamido)methyl)nicotinate (0.510 g, 1.013 mmol) in 1,4-dioxane (5 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 5.063 mL, 20.254 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give methyl 6-((N-(m-tolyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride as white solid (0.460 g, 95.3%).


[Step 2] methyl 6-(((1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-N-(m-tolyl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A mixture of methyl 6-((N-(m-tolyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride (0.460 g, 0.966 mmol), tert-butyl 3-oxoazetidine-1-carboxylate (0.331 g, 1.931 mmol) and N,N-diisopropylethylamine (0.505 mL, 2.897 mmol) in dichloromethane (20 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.409 g, 1.931 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-(((1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-N-(m-tolyl)piperidine)-4-sulfonamido)methyl)nicotinate as beige solid (0.520 g, 96.4%).


[Step 3] tert-butyl 3-(4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate



embedded image


A solution of methyl 6-(((1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-N-(m-tolyl)piperidine)-4-sulfonamido)methyl)nicotinate (0.520 g, 0.931 mmol) in tetrahydrofuran (5 mL)/ethanol (10 mL) was mixed at the room temperature with hydrazine monohydrate (0.905 mL, 18.615 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was diluted with ethyl acetate (10 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give tert-butyl 3-(4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate as white solid (0.370 g, 71.2%).


[Step 4] tert-butyl 3-(4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate



embedded image


A mixture of tert-butyl 3-(4-(N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate (0.370 g, 0.662 mmol) and triethylamine (0.369 mL, 2.649 mmol) in tetrahydrofuran (10 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.247 mL, 1.987 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=70% to 100%) to give tert-butyl 3-(4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate as white solid (0.350 g, 85.4%).


[Step 5] 1-(azetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide trihydrochloride



embedded image


A solution of tert-butyl 3-(4-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)sulfamoyl)piperidin-1-yl)azetidine-1-carboxylate (0.350 g, 0.566 mmol) in 1,4-dioxane (5 mL) was mixed at the room temperature with hydrochloric acid (4.00 M solution in 1,4-dioxane, 2.829 mL, 11.314 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with diethylether (20 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(azetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide trihydrochloride as light yellow solid (0.310 g, 87.3%).


[Step 6] Compound 11837



embedded image


A mixture of 1-(azetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide trihydrochloride (0.080 g, 0.127 mmol), acetone (0.047 mL, 0.637 mmol) and N,N-diisopropylethylamine (0.089 mL, 0.510 mmol) in dichloromethane (5 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.054 g, 0.255 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 15%) to give the concentrate, and then the concentrate was dissolved in diethylether (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-isopropylazetidin-3-yl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.028 g, 39.2%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (dd, 1H, J=2.1, 0.8 Hz), 8.41 (dd, 1H, J J=8.3, 2.3 Hz), 7.71 (d, 1H, J=8.6 Hz), 7.57 (t, 1H, J=51.3 Hz), 7.33 (s, 1H), 7.30 (d, 1H, J=8.0 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J=7.5 Hz), 5.15 (s, 2H), 3.57-3.39 (m, 3H), 3.29-3.22 (m, 2H), 2.84-2.80 (m, 3H), 2.53 (m, 1H), 2.27 (s, 3H), 2.13-2.09 (m, 2H), 1.87-1.81 (m, 2H), 1.69-1.61 (m, 2H), 0.91 (d, 6H, J=4.2 Hz); LRMS (ES) m/z 561.1 (M++1).


EXAMPLE 327
Compound 11838, 1-(1-acetylazetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide trihydrochloride (0.080 g, 0.127 mmol) and N,N-diisopropylethylamine (0.089 mL, 0.510 mmol) in dichloromethane (5 mL) was treated at the room temperature with acetic anhydride (0.024 mL, 0.255 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give the concentrate, and then the concentrate was dissolved in diethylether (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give 1-(1-acetylazetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.036 g, 50.4%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (dd, 1H, J J=2.1, 0.8 Hz), 8.41 (dd, 1H, J=8.3, 2.3 Hz), 7.71 (d, 1H, J=8.6 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.34 (s, 1H), 7.30 (d, 1H, J=8.0 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J J=7.5 Hz), 5.16 (s, 2H), 4.09 (m, 1H), 3.91 (m, 1H), 3.81 (m, 1H), 3.63 (m, 1H), 3.30 (m, 1H), 3.09 (m, 1H), 2.92-2.85 (m, 2H), 2.27 (s, 3H), 2.16-2.10 (m, 2H), 1.90-1.84 (m, 2H), 1.76-1.67 (m, 5H); LRMS (ES) m/z 561.2 (M++1).


EXAMPLE 328
Compound 11839, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-(2-hydroxyacetyl)azetidin-3-yl)-N-(m-tolyl)piperidine-4-sulfonamide



embedded image


A mixture of 1-(azetidin-3-yl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(m-tolyl)piperidine-4-sulfonamide trihydrochloride (0.080 g, 0.127 mmol), 2-hydroxyacetic acid (0.029 g, 0.382 mmol), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 0.079 g, 0.510 mmol) and 1H-benzo[d][1,2,3]triazol-1-ol (HOBt, 0.069 g, 0.510 mmol) in dichloromethane (5 mL) was treated at the room temperature with N,N-diisopropylethylamine (0.178 mL, 1.019 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 10%) to give the concentrate, and then the concentrate was dissolved in diethylether (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1-(2-hydroxyacetyl)azetidin-3-yl)-N-(m-tolyl)piperidine-4-sulfonamide as white solid (0.031 g, 42.2%).



1H NMR (400 MHz, DMSO-d6) δ 9.09 (dd, 1H, J=2.1, 0.8 Hz), 8.41 (dd, 1H, J=8.3, 2.3 Hz), 7.71 (d, 1H, J=8.6 Hz), 7.56 (t, 1H, J=51.3 Hz), 7.33 (s, 1H), 7.30 (d, 1H, J=8.0 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.06 (d, 1H, J=7.5 Hz), 5.16 (s, 2H), 4.88 (m, 1H), 4.60 (m, 1H), 4.19-4.08 (m, 2H), 3.98 (m, 1H), 3.91-3.87 (m, 2H), 3.69 (m, 1H), 3.16 (m, 1H), 2.92-2.84 (m, 2H), 2.27 (s, 3H), 2.15-2.10 (m, 2H), 1.90-1.84 (m, 2H), 1.75-1.67 (m, 2H); LRMS (ES) m/z 577.3 (M++1).


EXAMPLE 329
Compound 11840, N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(3-fluorocyclobutyl)piperidine-4-sulfonamide
[Step 1] methyl 4-((N-(3-chlorophenyl)piperidine-4-sulfonamido)methyl)benzoate hydrochloride



embedded image


A solution of tert-butyl 4-(N-(3-chlorophenyl)-N-(4-(methoxycarbonyl)benzyl)sulfamoyl)piperidine-1-carboxylate (0.937 g, 1.791 mmol) in 1,4-dioxane (10 mL) was mixed at the room temperature with hydrogen chloride (4.00 M solution in 1,4-dioxane, 8.957 mL, 35.829 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (20 mL) and hexane (40 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give methyl 4-((N-(3-chlorophenyl)piperidine-4-sulfonamido)methyl)benzoate hydrochloride as white solid (0.790 g, 96.0%).


[Step 2] methyl 4-(((N-(3-chlorophenyl)-1-(3-hydroxycyclobutyl)piperidine)-4-sulfonamido)methyl)benzoate



embedded image


A mixture of methyl 4-((N-(3-chlorophenyl)piperidine-4-sulfonamido)methyl)benzoate hydrochloride (0.790 g, 1.720 mmol), 3-hydroxycyclobutan-1-one (0.296 g, 3.439 mmol) and N,N-diisopropylethylamine (0.599 mL, 3.439 mmol) in dichloromethane (20 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.729 g, 3.439 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((N-(3-chlorophenyl)-1-(3-hydroxycyclobutyl)piperidine)-4-sulfonamido)methyl)benzoate as beige solid (0.830 g, 97.9%).


[Step 3] methyl 4-(((N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)piperidine)-4-sulfonamido)methyl)benzoate



embedded image


A solution of methyl 4-(((N-(3-chlorophenyl)-1-(3-hydroxycyclobutyl)piperidine)-4-sulfonamido)methyl)benzoate (0.650 g, 1.318 mmol) in dichloromethane (30 mL) was mixed at the room temperature with Bis(2-methoxyethyl)aminosulfur trifluoride (0.365 mL, 1.978 mmol). The reaction mixture was heated at reflux for 18 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 4-(((N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)piperidine)-4-sulfonamido)methyl)benzoate as dark brown solid (0.530 g, 81.2%).


[Step 4] N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)-N-(4-(hydrazinecarbonyl)benzyl)piperidine-4-sulfonamide



embedded image


A solution of methyl 4-(((N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)piperidine)-4-sulfonamido)methyl)benzoate (0.530 g, 1.071 mmol) in tetrahydrofuran (5 mL)/ethanol (10 mL) was mixed at the room temperature with hydrazine monohydrate (1.041 mL, 21.414 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)-N-(4-(hydrazinecarbonyl)benzyl)piperidine-4-sulfonamide, 0.530 g, 100.0%, brown solid).


[Step 5] Compound 11840



embedded image


A mixture of N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)-N-(4-(hydrazinecarbonyl)benzyl)piperidine-4-sulfonamide (0.530 g, 1.071 mmol) and triethylamine (0.597 mL, 4.283 mmol) in tetrahydrofuran (10 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.399 mL, 3.212 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give the concentrate, and then the concentrate was dissolved in diethylether (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chlorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1-(3-fluorocyclobutyl)piperidine-4-sulfonamide as beige solid (0.049 g, 8.2%).



1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, 2H, J=8.4 Hz), 7.66 (s, 0.25H), 7.55 (t, 1H, J=2.0 Hz), 7.54 (s, 0.5H), 7.51 (d, 2H, J=8.4 Hz), 7.44 (m, 1H), 7.40 (s, 0.25H), 7.35 (t, 1H, J=8.0 Hz), 7.29 (m, 1H), 5.18 (m, 0.5H), 5.11 (s, 2H), 5.04 (m, 0.5H), 3.29 (m, 1H), 2.99-2.85 (m, 3H), 2.43 (m, 1H), 2.26-2.16 (m, 3H), 2.09-2.04 (m, 2H), 1.83-1.75 (m, 2H), 1.72-1.66 (m, 2H); LRMS (ES) m/z 555.3 (M++1).


EXAMPLE 330
Compound 11841, N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorocyclobutyl)piperidine-4-sulfonamide
[Step 1] methyl 6-((N-(3-chlorophenyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride



embedded image


A solution of methyl 6-(((1-(tert-butoxycarbonyl)-N-(3-chlorophenyl)piperidine)-4-sulfonamido)methyl)nicotinate (0.845 g, 1.613 mmol) in 1,4-dioxane (10 mL) was mixed at the room temperature with hydrogen chloride (4.00 M solution in 1,4-dioxane, 6.047 mL, 24.188 mmol), and stirred at the same temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (20 mL) and hexane (40 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give methyl 6-((N-(3-chlorophenyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride as beige solid (0.780 g, 97.4%).


[Step 2] methyl 6-(((N-(3-chlorophenyl)-1-(3-hydroxycyclobutyl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A mixture of methyl 6-((N-(3-chlorophenyl)piperidine-4-sulfonamido)methyl)nicotinate dihydrochloride (0.780 g, 1.570 mmol), 3-hydroxycyclobutan-1-one (0.270 g, 3.140 mmol) and N,N-diisopropylethylamine (0.820 mL, 4.710 mmol) in dichloromethane (20 mL) was treated at the room temperature with sodium triacetoxyborohydride (0.665 g, 3.140 mmol), and stirred at the same temperature for 18 hr. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-(((N-(3-chlorophenyl)-1-(3-hydroxycyclobutyl)piperidine)-4-sulfonamido)methyl)nicotinate as beige solid (0.710 g, 91.5%).


[Step 3] methyl 6-(((N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)piperidine)-4-sulfonamido)methyl)nicotinate



embedded image


A solution of methyl 6-(((N-(3-chlorophenyl)-1-(3-hydroxycyclobutyl)piperidine)-4-sulfonamido)methyl)nicotinate (0.580 g, 1.174 mmol) in dichloromethane (30 mL) was mixed at the room temperature with Bis(2-methoxyethyl)aminosulfur trifluoride (0.325 mL, 1.761 mmol). The reaction mixture was heated at reflux for 18 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 40 g cartridge; methanol/dichloromethane=0% to 5%) to give methyl 6-(((N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)piperidine)-4-sulfonamido)methyl)nicotinate as dark brown solid (0.420 g, 72.1%).


[Step 4] N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)piperidine-4-sulfonamide



embedded image


A solution of methyl 6-(((N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)piperidine)-4-sulfonamido)methyl)nicotinate (0.420 g, 0.847 mmol) in tetrahydrofuran (5 mL)/ethanol (10 mL) was mixed at the room temperature with hydrazine monohydrate (0.823 mL, 16.936 mmol). The reaction mixture was heated at reflux for 18 hr, cooled down to the room temperature to terminate the reaction and concentrated under the reduced pressure to remove the solvent. The title compound was used without further purification (N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)piperidine-4-sulfonamide, 0.420 g, 100.0%, brown solid).


[Step 5] Compound 11841



embedded image


A mixture of N-(3-chlorophenyl)-1-(3-fluorocyclobutyl)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)piperidine-4-sulfonamide (0.420 g, 0.847 mmol) and triethylamine (0.472 mL, 3.387 mmol) in tetrahydrofuran (10 mL) was treated at the room temperature with 2,2-difluoroacetic anhydride (0.316 mL, 2.540 mmol). The reaction mixture was heated at reflux for 1 hr and cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=0% to 5%) to give the concentrate, and then the concentrate was dissolved in diethylether (5 mL) and hexane (30 mL) and stirred. The resulting precipitates were collected by filtration, washed by hexane, and dried to give N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorocyclobutyl)piperidine-4-sulfonamide as beige solid (0.036 g, 7.6%).



1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, 1H, J=2.2 Hz), 8.41 (m, 1H), 7.72-7.67 (m, 1.25H), 7.63 (t, 1H, J=2.1 Hz), 7.56 (s, 0.5H), 7.51 (m, 1H), 7.43 (s, 0.25H), 7.37 (t, 1H, J=8.0 Hz), 7.31 (m, 1H), 5.21 (s, 2H), 5.11 (m, 1H), 3.40 (m, 1H), 2.97-2.86 (m, 3H), 2.55 (m, 1H), 2.28-2.17 (m, 3H), 2.12-2.08 (m, 2H), 1.78 (t, 2H, J=12.0 Hz), 1.71-1.64 (m, 2H); LRMS (ES) m/z 556.3 (M++1).


EXAMPLE 331
Compound 11842, 2-(4-(4-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine monohydrochloride (0.118 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(4-(4-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.070 g, 46.8%).



1H NMR (400 MHz, DMSO): δ 8.01-7.94 (m, 2H), 7.53 (d, 2H, J=8.1 Hz), 7.46 (dd, 4H, J=10.1, 8.0 Hz), 7.42-7.30 (m, 6H), 7.25 (t, 1H, J=7.3 Hz), 5.06 (s, 2H), 3.52 (t, 2H, J=7.3 Hz), 3.36 (d, 2H, J=9.4 Hz), 3.16 (q, 2H, J=3.0 Hz), 2.90 (t, 2H, J=7.3 Hz), 2.72 (t, 2H, J=5.6 Hz), 2.51-2.44 (m, 3H); LRMS (ES) m/z 586.3 (M++1).


EXAMPLE 332
Compound 11843, 2-(1H-benzo[de]isoquinolin-2(3H)-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 2,3-dihydro-lh-benz[De]Isoquinoline (0.086 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(1H-benzo[de]isoquinolin-2(3H)-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as orange color solid (0.040 g, 27.9%).



1H NMR (400 MHz, DMSO-d6): δ 7.94-7.87 (m, 2H), 7.78 (d, 2H, J=8.2 Hz), 7.53-7.17 (m, 12H), 4.98 (s, 2H), 4.05 (d, 4H, J=11.8 Hz), 3.62 (t, 2H, J=7.0 Hz), 3.16-3.04 (m, 2H); LRMS (ES) m/z 561.3 (M++1).


EXAMPLE 333
Compound 11844, 2-(4-(benzo[d]isoxazol-3-yl)piperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 3-(1-piperazinyl)-1,2-benzisoxazole, 96% (0.104 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=3% to 5%) to give 2-(4-(benzo[d]isoxazol-3-yl)piperazin-1-yl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethane-1-sulfonamide as white solid (0.030 g, 19.7%).



1H NMR (400 MHz, DMSO-d6): δ 7.98 (dd, 2H, J=8.6, 2.3 Hz), 7.63-7.48 (m, 5H), 7.46 (dd, 2H, J=7.6, 1.7 Hz), 7.35 (t, 2H, J=7.8 Hz), 7.35-7.21 (m, 2H), 5.07 (s, 2H), 3.52 (dd, 6H, J=6.1, 3.8 Hz), 2.87 (dd, 2H, J=8.4, 6.2 Hz), 2.67 (t, 4H, J=4.9 Hz); LRMS (ES) m/z 595.3 (M++1).


EXAMPLE 334
Compound 11845, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(2-methoxyphenyl)piperidin-1-yl)-N-phenylethane-1-sulfonamide



embedded image


A solution of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), 4-(2-methoxyphenyl)piperidine (0.098 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; acetonitrile/aqueous 0.1%-formic acid solution=10% to 90%) to give N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-2-(4-(2-methoxyphenyl)piperidin-1-yl)-N-phenylethane-1-sulfonamide as white solid (0.070 g, 47.0%).



1H NMR (400 MHz, CD3OD): δ 8.08-8.00 (m, 2H), 7.60-7.53 (m, 2H), 7.49-7.25 (m, 6H), 7.24-7.13 (m, 2H), 6.98-6.87 (m, 2H), 5.09 (s, 2H), 3.83 (s, 3H), 3.53-3.41 (m, 2H), 3.10 (d, 2H, J=11.3 Hz), 3.06-2.93 (m, 2H), 2.31 (td, 2H, J=11.3, 3.7 Hz), 1.86-1.72 (m, 5H); LRMS (ES) m/z 583.4 (M++1).


EXAMPLE 335
Compound 11847, (S)-1-(2-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)ethyl)pyrrolidine-2-carboxamide
[Step 1] 2-(difluoromethyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazole

A solution of 6-methylnicotinohydrazide (5.000 g, 33.075 mmol), 2,2-difluoroacetic anhydride (12.336 mL, 99.226 mmol) and triethylamine (23.050 mL, 165.377 mmol) in tetrahydrofuran (40 mL) was stirred at the room temperature for 6 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; dichloromethane/methanol=0% to 5%) to give 2-(difluoromethyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazole as brown solid (6.200 g, 88.8%).


[Step 2] 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole



embedded image


A mixture of 2-(difluoromethyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazole (6.200 g, 29.360 mmol), N-Bromosuccinimide (5.487 g, 30.828 mmol) and Azobisisobutyronitrile (0.482 g, 2.936 mmol) in chloroform (100 mL) was heated at reflux for 12 hr, and cooled down to the ambient temperature to terminate the reaction. Then, aqueous N-sodium thiosulfate (Na2S2O3) solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=10% to 20%) to give 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole as puple color solid (1.830 g, 21.5%).


[Step 3] N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethenesulfonamide



embedded image


A solution of N-phenylethenesulfonamide (1.830 g, 9.987 mmol), 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (2.897 g, 9.987 mmol), potassium carbonate (1.380 g, 9.987 mmol) and potassium iodide (0.166 g, 0.999 mmol) in N,N-dimethylformide (5 mL) was stirred at the room temperature for 6 hr, and concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl acetate/hexane=10% to 20%) to give N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethenesulfonamide as brown color solid (1.890 g, 48.2%).


[Step 4] Compound 11847



embedded image


A solution of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), L-Prolinamide (0.058 g, 0.510 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.019 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 24 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give (S)-1-(2-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)ethyl)pyrrolidine-2-carboxamide as white solid (0.040 g, 31.0%).



1H NMR (400 MHz, CD3OD): δ 9.17 (dd, 1H, J=2.2, 0.8 Hz), 8.44 (dd, 1H, J=8.2, 2.2 Hz), 7.76 (dd, 1H, J=8.3, 0.8 Hz), 7.52-7.45 (m, 2H), 7.45-7.29 (m, 3H), 7.34-7.20 (m, 2H), 5.17 (s, 1H), 3.55 (ddd, 2H, J=7.4, 6.2, 3.0 Hz), 3.33-3.22 (m, 2H), 3.26-3.11 (m, 1H), 3.14-2.99 (m, 1H), 2.99-2.80 (m, 1H), 2.40 (td, 1H, J=9.2, 6.7 Hz), 2.28-2.12 (m, 1H), 1.92-1.71 (m, 2H); LRMS (ES) m/z 507.1 (M++1).


EXAMPLE 336
Compound 11848, (R)-1-(2-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)ethyl)pyrrolidine-2-carboxamide



embedded image


A solution of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), D-(-)-Prolinamide (0.058 g, 0.510 mmol) and Diisopropylethylamine (0.176 mL, 1.019 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 24 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give (R)-1-(2-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)ethyl)pyrrolidine-2-carboxamide as white solid (0.045 g, 34.9%).



1H NMR (400 MHz, CD3OD): δ 9.17 (dd, 1H, J=2.2, 0.8 Hz), 8.43 (dd, 1H, J=8.3, 2.3 Hz), 7.76 (dd, 1H, J=8.2, 0.8 Hz), 7.55-7.44 (m, 2H), 7.46-7.35 (m, 1H), 7.40-7.19 (m, 3H), 5.17 (s, 2H), 3.63-3.46 (m, 2H), 3.32-2.76 (m, 3H), 2.65 (q, 1H, J=7.3 Hz), 2.45-2.28 (m, 1H), 2.30-2.12 (m, 1H), 1.92-1.71 (m, 3H); LRMS (ES) m/z 507.3 (M++1).


EXAMPLE 337
Compound 11849, (2S,4R)-1-(2-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide



embedded image


A solution of N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), (2s,4r)-4-hydroxypyrrolidine-2-carboxamide;hydrochloride (0.085 g, 0.510 mmol) and Diisopropylethylamine (0.176 mL, 1.019 mmol) in dichloromethane (5 mL) was stirred at the room temperature for 24 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (SiO2, 12 g cartridge; methanol/dichloromethane=5% to 10%) to give (2S,4R)-1-(2-(N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylsulfamoyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide as white solid (0.050 g, 37.5%).



1H NMR (400 MHz, CD3OD): δ 9.17 (dd, 1H, J=2.2, 0.8 Hz), 8.43 (dd, 1H, J=8.3, 2.3 Hz), 7.76 (dd, 1H, J=8.2, 0.8 Hz), 7.55-7.44 (m, 2H), 7.46-7.35 (m, 1H), 7.40-7.19 (m, 3H), 5.17 (s, 2H), 3.63-3.46 (m, 2H), 3.32-2.76 (m, 3H), 2.65 (q, 1H, J=7.3 Hz), 2.45-2.28 (m, 1H), 2.30-2.12 (m, 1H), 1.92-1.71 (m, 3H); LRMS (ES) m/z 523.3 (M++1).


Measurement of Activity of the Compounds of the Present Invention and Analysis Protocol


EXPERIMENTAL EXAMPLE 1
HDAC Enzyme Activity Inhibition Assays (In Vitro)

In order to examine the HDAC6 selectivity of the compounds of formula I of the present invention by HDAC1 and HDAC6 enzymatic activity inhibition assays, an experiment was performed using a conventional substance as a control.


HDAC enzyme activity was measured using a HDAC Fluorimetric Drug Discovery Kit (BML-AK511, 516, Enzo Life Science). For the HDAC1 enzyme activity test, human recombinant HDAC1 (BML-SE456) was used as an enzyme source, and Fluor de Lys®-“SIRT1 (BNL-KI177) was used as a substrate. A 5-fold dilution of the compound was seeded into a 96-well plate, and then 0.3 μg of the enzyme and 10 μM of the substrate were added to each well of the plate and allowed to react at 30° C. for 60 minutes. Then, Fluor de Lys®-Developer II (BML-KI176) was added thereto and allowed to react for 30 minutes, after which the fluorescence value (Ex 360, Em 460) was measured using a multi-plate reader (Flexstation 3, Molecular Device). The HDAC6 enzyme was tested using human recombinant HDAC6 (382180) (Calbiochem) according to the same protocol as the HDAC1 enzyme activity test method. Based on the resulting values, each IC50 value was calculated using GraphPad Prism4.0 program.









TABLE 2







Results of HDAC enzyme activity inhibition assays













HDAC1
HDAC6
HDAC6 selectivity


Ex.
Comp.
(nM)
(nM)
(fold)














1
11044
ND
331
302


2
11045
ND
158
633


3
11078
ND
3467
29


4
11088
51360
127
404


5
11089
47853
50
957


6
11120
ND
38
2631


7
11121
ND
2536
39


8
11128
ND
520
192


9
11129
ND
2101
48


10
11133
ND
345
290


11
11151
ND
135
741


12
11152
ND
58
1724


13
11153
ND
126
793


14
11154
ND
19
5263


15
11155
ND
80
1250


16
11156
ND
29
3448


17
11167
34219
38
900


18
11168
ND
23
4348


19
11169
41062
38
1081


20
11170
ND
14
7143


21
11171
26607
21
1267


22
11172
ND
9
11111


23
11173
28620
661
43


24
11174
ND
1310
76


25
11175
ND
179
559


26
11176
ND
28
3571


27
11177
18908
57
332


28
11178
ND
20
5000


29
11179
 7809
37
211


30
11180
ND
62
1613


31
11181
ND
33
3030


32
11182
ND
17
5882


33
11183
ND
235
426


34
11184
 2274
36
63


35
11186
ND
231
433


36
11190
19512
129
151


37
11191
ND
20
5000


38
11192
 7005
65
108


39
11193
ND
27
3704


40
11194
ND
65
1538


41
11195
ND
64
1563


42
11196
28672
65
441


43
11197
ND
15
6667


44
11216
27965
76
368


45
11217
ND
13
7692


46
11218
ND
233
429


47
11219
ND
94
1064


48
11220
26204
31
845


49
11221
ND
101
990


50
11222
ND
412
243


51
11225
ND
24
4167


52
11226
11576
39
297


53
11227
ND
23
4348


54
11229
ND
85
1176


55
11230
ND
33
3030


56
11231
ND
22
4545


57
11248
ND
112
893


58
11249
ND
37
2703


59
11250
ND
100
1000


60
11251
ND
64
1563


61
11252
ND
39
2564


62
11253
ND
666
150


63
11254
ND
29
3448


64
11255
ND
47
2128


65
11256
ND
13
7692


66
11271
ND
129
775


67
11272
ND
51
1961


68
11273
ND
79
1266


69
11274
ND
41
2439


70
11275
ND
73
1370


71
11276
ND
25
4000


72
11277
ND
187
535


73
11278
ND
52
1923


74
11279
ND
111
901


75
11280
ND
79
1266


76
11281
ND
44
2273


77
11282
ND
128
781


78
11283
ND
54
1852


79
11284
ND
27
3704


80
11287
ND
29
3448


81
11288
ND
47
2128


82
11289
ND
28
3571


83
11290
ND
49
2041


84
11291
ND
31
3226


85
11292
ND
56
1786


86
11323
ND
110
909


87
11324
ND
21
4762


88
11338
ND
513
195


89
11345
ND
28
3571


90
11346
ND
23
4348


91
11347
ND
103
971


92
11348
ND
132
758


93
11350
ND
10
10000


94
11351
ND
69
1449


95
11352
ND
8
12500


96
11353
ND
26
3846


97
11354
ND
8
12500


98
11355
ND
16
6250


99
11366
ND
11
9091


100
11367
ND
16
6250


101
11368
ND
15
6667


102
11372
ND
9
11111


103
11373
ND
10
10000


104
11377
ND
22
4545


105
11386
ND
76
1316


106
11387
ND
92
1087


107
11388
ND
75
1333


108
11389
ND
960
104


109
11390
ND
13
7692


110
11392
ND
100
1000


111
11402
ND
76
1316


112
11403
ND
78
1282


113
11404
ND
105
952


114
11405
ND
67
1493


115
11406
ND
230
435


116
11411
ND
7
14286


117
11412
ND
12
8333


118
11426
ND
13
7692


119
11427
ND
284
352


120
11428
ND
15
6667


121
11429
18704
65
288


122
11430
22220
42
529


123
11431
28088
62
453


124
11432
16510
61
271


125
11433
ND
12
8333


126
11447
ND
18
5556


127
11448
ND
21
4762


128
11451
27165
9
3018


129
11452
27515
8
3439


130
11460
27271
10
2727


131
11461
27690
10
2769


132
11462
21083
8
2635


133
11463
22309
8
2789


134
11497
21816
8
2727


135
11501
56678
15
3779


136
11502
78107
14
5579


137
11503
71875
15
4792


138
11504
86221
18
4790


139
11505
60400
13
4646


140
11506
59719
12
4977


141
11507
51403
14
3672


142
11508
49567
23
2155


143
11514
40350
43
938


144
11518
39843
68
586


145
11520
ND
32
3125


146
11521
43329
18
2407


147
11522
ND
24
4167


148
11539
ND
23
4348


149
11540
ND
10
10000


150
11541
ND
16
6250


151
11552
ND
14
7143


152
11553
ND
17
5882


153
11554
ND
23
4348


154
11564
ND
21
4762


155
11565
46512
149
312


156
11566
ND
89
1124


157
11567
30926
4326
7


158
11573
 2544
2290
1


159
11582
ND
23
4348


160
11583
ND
23
4348


161
11588
ND
44
2273


162
11589
ND
43
2326


163
11605
ND
ND
ND


164
11606
ND
1520
66


165
11625
ND
139
719


166
11628
ND
48
2083


167
11629
ND
96
1041


168
11630
ND
31
3225


169
11631
ND
229
436


170
11632
ND
63
1587


171
11633
ND
46
2173


172
11634
ND
48
2083


173
11636
ND
116
862


174
11637
66980
20
3349


175
11638
40912
23
1778


176
11639
77694
42
1849


177
11645
77906
61
1277


178
11646
108816 
15
7254


179
11647
79792
22
3626


180
11648
498032 
60
8300


181
11655
ND
58
1724


182
11656
ND
63
1587


183
11657
ND
82
1219


184
11658
ND
40
2500


185
11663
ND
173
578


186
11665
ND
19
5263


187
11668
ND
138
724


188
11669
ND
111
900


189
11675
ND
182
549


190
11676
ND
71
1408


191
11677
ND
57
1754


192
11678
54610
56
975


193
11679
61331
23
2666


194
11680
76400
29
2634


195
11681
ND
15
6667


196
11682
ND
22
4545


197
11683
ND
7
14285


198
11684
ND
16
6250


199
11685
ND
17
5882


200
11686
60296
92.1
654


201
11687
79144
106.7
741


202
11688
20214
47.7
423


203
11689
20008
46.6
429


204
11690
54825
224.5
244


205
11691
34216
80.5
425


206
11692
71655
54.7
1309


207
11693
ND
504.2
198


208
11694
ND
464
215


209
11695
61397
200.5
306


210
11696
51448
177.7
289


211
11697
ND
988.4
101


212
11698
ND
661
151


213
11699
ND
128.8
776


214
11700
ND
127.8
782


215
11705
ND
156.9
637


216
11706
ND
662.4
150


217
11707
42459
71.1
597


218
11708
65126
77.8
837


219
11709
80425
75.5
1065


220
11710
29435
50.9
578


221
11711
61289
70.1
874


222
11712
ND
377.9
264


223
11717
ND
113.7
879


224
11718
ND
73.9
1353


225
11719
ND
84.9
1177


226
11721
ND
21.1
4739


227
11722
41031
32.4
1266


228
11723
ND
78.6
1272


229
11724
ND
134.9
741


230
11725
ND
242.6
412


231
11726
ND
127.8
782


232
11727
33464
56.3
594


233
11728
21592
47.6
453


234
11729
ND
1763
56


235
11730
ND
2531
39


236
11731
ND
1752
57


237
11732
ND
542.3
184


238
11733
ND
490.4
203


239
11734
ND
754.9
132


240
11735
ND
809
123


241
11736
ND
461.2
216


242
11737
ND
69.4
1440


243
11738
ND
68.2
1466


244
11739
ND
674.9
148


245
11740
ND
530.9
188


246
11741
ND
1742
57


247
11742
ND
239.1
418


248
11743
ND
68.2
1466


249
11744
ND
531
188


250
11745
ND
231.2
432


251
11746
ND
127.4
784


252
11747
ND
95.2
1050


253
11748
ND
433.3
230


254
11749
ND
390.7
255


255
11750
ND
1294
77


256
11751
ND
85.4
1170


257
11752
ND
115.1
868


258
11753
ND
104.9
953


259
11754
ND
70.4
1420


260
11755
ND
72.6
1377


261
11756
ND
377.5
264


262
11757
ND
69.1
1447


263
11758
ND
96.2
1039


264
11759
ND
101.6
984


265
11760
ND
196.7
508


266
11761
ND
102.4
976


267
11762
ND
999.6
100


268
11763
ND
105.4
948


269
11764
ND
136.7
731


270
11765
ND
189.8
526


271
11766
ND
312.7
319


272
11767
ND
118.4
844


273
11768
ND
38.3
2610


274
11769
ND
278.3
359


275
11770
ND
886.3
112


276
11771
ND
321.1
311


277
11772
ND
48.6
2057


278
11773
ND
269.7
370


279
11774
ND
66.5
1503


280
11775
ND
34.4
2906


281
11776
ND
881.8
113


282
11777
ND
28.8
3472


283
11778
ND
36.7
2724


284
11779
ND
40.1
2493


285
11780
ND
52.8
1893


286
11781
ND
18.8
5319


287
11782
ND
24.8
4032


288
11783
ND
69.4
1440


289
11784
ND
31.7
3154


290
11785
ND
47.8
2092


291
11786
ND
54.7
1828


292
11790
ND
44.6
2227


293
11791
ND
47.3
2114


294
11792
ND
82.1
1218


295
11793
ND
58.2
1718


296
11794
ND
45.6
2192


297
11795
ND
68.2
1466


298
11796
ND
1777
56


299
11797
ND
121.7
821


300
11798
ND
185.8
538


301
11799
ND
193.6
516


302
11800
ND
44.4
2252


303
11801
ND
34.0
2941


304
11802
ND
35.1
2849


305
11803
ND
21.8
4587


306
11804
ND
32.1
3115


307
11805
ND
33.1
3021


308
11806
ND
25.0
4000


309
11807
ND
63.1
1584


310
11808
ND
34.7
2881


311
11809
ND
30.1
3222


312
11810
ND
35.8
2793


313
11811
ND
42.4
2358


314
11812
ND
32.9
3039


315
11813
ND
34.1
2932


316
11814
ND
1134
88


317
11815
ND
75.4
1326


318
11816
ND
37.1
2695


319
11817
ND
58.2
1718


320
11818
ND
60.7
1647


321
11819
ND
351
284


322
11820
ND
60.5
1652


323
11821
ND
133.8
747


324
11822
ND
73.28
1365


325
11836
ND
31.78
3147


326
11837
ND
24
4167


327
11838
ND
44.63
2241


328
11839
ND
44.73
2236


329
11840
ND
192.2
520


330
11841
ND
35.84
2790


331
11842
ND
825.9
121


332
11843
ND
993.7
101


333
11844
ND
580.6
172


334
11845
ND
973.4
103


335
11847
24519
55.12
445


336
11848
38926
58.9
661


337
11849
ND
62.3
1605









As can be seen in Table 2 above, the 1,3,4-oxadiazole sulfonamide derivative compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention showed superior selective HDAC6 inhibitory activities in the HDAC1 and HDAC6 activity inhibition assays.


EXPERIMENTAL EXAMPLE 2
Analysis of the Effect of HDAC6-Specific Inhibitors on Mitochondrial Axonal Transport (In Vitro)

The effect of HDAC6-specific inhibitors on mitochondrial axonal transport was analyzed. Specifically, in order to examine whether the compounds represented by formula I according to the present invention selectively inhibit HDAC6 activity to increase the acetylation of tubulin, which is a major substrate of HDAC6, thereby improving the mitochondrial axonal transport velocity reduced by amyloid-beta treatment in neuronal axons, a comparison experiment was performed using a compound that have already been developed as a control.


Hippocampal neurons from Sprague-Dawley (SD) rat embryos at embryonic day 17-18 (E17-18) were cultured in an extracellular matrix-coated dish for imaging for 7 days, and then treated with 1 M of an amyloid-beta peptides. After 24 hours, the neurons were treated with compounds for 3 hours on the 8th days in vitro and treated with MitoTracker Red CMXRos (Life Technologies, NY, USA) for the last 5 minutes to stain the mitochondria. Axonal transport of the stained mitochondria was imaged using a confocal microscope (Leica SP8; Leica Microsystems, UK) at 1-second intervals for 1 minute, and the transport velocity per second of each mitochondrion was determined using the IMARIS analysis software (BITPLANE, Zurich, Switzerland).


As a result, it was found that the 1,3,4-oxadiazole sulfonamide derivative compounds, stereoisomers thereof or pharmaceutically acceptable salts according to the present invention improved the velocity of mitochondrial axonal transport.

Claims
  • 1. An 1,3,4-oxadiazole sulfonamide derivative compound represented by the following formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
  • 2. The 1,3,4-oxadiazole sulfonamide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is —CX2H or —CX3;R2 is —(C1-C4 alkyl), —(C1-C4 alkyl)-O(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-O—C(═O)—(C1-C4 alkyl), —(C1-C4 alkyl)-NRARB, —(C1-C4 alkyl)-heteroaryl, -aryl, -heteroaryl,
  • 3. The 1,3,4-oxadiazole sulfonamide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 2, wherein R1 is —CX2H;R2 is —(C1-C4 alkyl), —(C1-C4 alkyl)-C(═O)—O(C1-C4 alkyl), —(C1-C4 alkyl)-NRARB, -heteroaryl,
  • 4. The 1,3,4-oxadiazole sulfonamide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 3, wherein R1 is —CF2H;R2 is —(C1-C4 alkyl), —(C1-C4 alkyl)-NRARB,
  • 5. The 1,3,4-oxadiazole sulfonamide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound represented by formula I is selected from the group consisting of compounds described in the following table:
  • 6. The 1,3,4-oxadiazole sulfonamide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 5, wherein the compound represented by formula I is selected from the group consisting of compounds described in the following table:
  • 7. The 1,3,4-oxadiazole sulfonamide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 6, wherein the compound represented by formula I is selected from the group consisting of compounds described in the following table:
  • 8. A pharmaceutical composition for preventing or treating histone deacetylase-mediated disease, comprising, as an active ingredient, the compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 1.
  • 9. The pharmaceutical composition of claim 8, wherein the histone deacetylase-mediated disease is selected from among infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.
  • 10. A method for treating histone deacetylase-mediated disease, comprising administering a therapeutically effective amount of the compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 1.
  • 11. (canceled)
Priority Claims (1)
Number Date Country Kind
10-2015-0105976 Jul 2015 KR national
PCT Information
Filing Document Filing Date Country Kind
PCT/KR2016/008214 7/27/2016 WO 00